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ABSTRACT 
 
The increasing prevalence of obesity has been accompanied by an increase in the number 
of individuals at the extreme end of the obesity spectrum. The detrimental impacts of 
extreme obesity, defined as BMI ≥40.0kg/m2, on affected individuals’ physical and 
psychological health have not been fully established. Furthermore, it remains unclear 
whether medical and behavioural interventions are effective at facilitating weight loss for 
individuals with extreme obesity. The efficacy of two treatment pathways within the Heart 
of England NHS Foundation Trust Specialist Weight Management Service were examined, 
with both demonstrated to facilitate clinically and statistically significant weight loss. A 
detailed profile of the characteristics of individuals entering the service highlighted the 
substantial physical and psychological co-morbidity associated with extreme obesity, 
revealing widespread impairment in quality of life and mental health. A systematic review 
of primary research examining the efficacy of medical and behavioural weight 
management interventions within lesser-researched extreme obese populations 
demonstrated the value of medically-supported programmes and also revealed the limited 
body of good quality research. This thesis has enhanced current understanding of extreme 
obesity, and recommendations generated from this work have been made in order to 
improve primary research examining weight management interventions and service 
provision for affected individuals. 
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CHAPTER ONE 
 
1.0 INTRODUCTION 
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1.1 INTRODUCTION TO THE THESIS 
 
1.1.1 Research setting 
1.1.1.1 Collaborations for Leadership in Applied Health Research and Care for 
Birmingham and Black Country (CLAHRC-BBC) 
The CLAHRC-BBC programme was one of nine pilot CLAHRCs established across 
England funded by the National Institute for Health Research (NIHR). The programme ran 
for five years from October 2008 to December 2013 and was a collaborative partnership 
between the University of Birmingham and healthcare service organisations across 
Birmingham and the Black Country. The aim of the programme was to conduct applied 
healthcare research across nine themes which addressed both national and local health 
policy initiatives, focusing on the needs of patients and supporting the translation of 
research evidence into clinical practice within the National Health Service (NHS) (1). 
 
1.1.1.2 CLAHRC-BBC Theme 8: Implementation of effective community care for diabetes  
This research project was conducted as part of a body of work under the CLAHRC-BBC 
Theme 8: Implementation of effective community care for diabetes. Theme 8 incorporated 
a range of research projects following the theme of care implementation for diabetes and 
weight management, conducted in partnership with Heart of England NHS Foundation 
Trust (HEFT) and the former South Birmingham Primary Care Trust (PCT). In particular 
this focussed on an evaluation of the efficacy of the Specialist Weight Management 
Service operated by HEFT.  
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1.1.2 Research project 
My research project was conducted to establish the efficacy of the Specialist Weight 
Management Service, whilst additionally gleaning a deeper understanding of the extreme 
obese (BMI ≥40.0kg/m2) patient population entering the service. The specific aims of the 
project were: 
 To explore the clinical, demographic and mental well-being characteristics of 
extreme obesity, specifically of those individuals entering the weight management 
service operated by HEFT, 
 To conduct a detailed examination of the psychological characteristics of 
individuals entering the service, incorporating an investigation of the relationship 
between adiposity and quality of life and mental health in extreme obesity, 
 To examine the physical and psychological outcomes following attendance at the 
two treatment pathways currently operating within the service; the Community 
Weight Management Service (CWMS) and the Specialist Lifestyle Management 
(SLiM) programme, 
 To better understand the physical and psychological impact of extreme obesity and 
the efficacy of this weight management service for the extreme obese patient 
population. 
 
1.1.3 Research design 
To achieve these aims, a pragmatic evaluation of the efficacy of the service was conducted. 
This pragmatic approach enables the researcher to investigate healthcare services within 
the complex real-world settings in which they currently operate. Indeed, one of the primary 
objectives of evaluations is to contribute to the knowledge base of currently operating 
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services, with the aim of providing feedback to improve care provision. However, this 
approach is not without limitation, and there has been much debate over the credibility and 
relevance when interpreting different types of evidence (2). Evidence-based practice has 
become a cornerstone of healthcare in the UK (3), with hierarchies of evidence developed 
to facilitate healthcare professionals, researchers and other stakeholders in the 
interpretation of studies and their findings. Figure 1.1 illustrates the hierarchy of evidence, 
which ranks a range of study designs in order of decreasing internal validity.  
 
Figure 1.1: Hierarchy of evidence 
 
Source: EBM Pyramid (4). 
 
Within the hierarchy of evidence the Randomised Controlled Trial (RCT) and systematic 
reviews of RCTs are traditionally considered to be the gold-standard for determining the 
effectiveness of interventions (5). However, it has been argued that the application of the 
hierarchy may be problematic when appraising public health research due to the fact that 
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healthcare interventions are often complex and context-dependent (6, 7). Indeed there are 
other types of research obtained from observational and qualitative methods which 
although further down the hierarchy of evidence can be valuable in understanding the 
efficacy of interventions (7). Furthermore, triangulation approaches are also adopted 
whereby data is gathered using multiple methods in order to provide the best quality 
evidence to address a research question (8). Strengths and limitations are present in each 
research design and methodology, and it seems likely that the debate will continue. 
However, it is essential that the limitations of research design and methodology are 
considered when evaluating evidence and interpreting findings. In light of this evidence 
debate, the pragmatic approach to the evaluation of the efficacy of the service was selected 
in the present research study, as the best method for the investigation of the efficacy of a 
service currently in operation in a ‘real-world’ setting.  
 
1.1.4 Research methods 
The evaluation involved a close collaboration with healthcare professionals and 
administrative staff responsible for the delivery, organisation and operation of the 
Specialist Weight Management Service.  
 
1.1.4.1 Data from the Community Weight Management Service (CWMS)  
Data obtained for those individuals attending the CWMS pathway was extracted from 
patient records stored electronically and on paper and from completed self-report 
questionnaires. This involved extracting clinical and demographic data as well as 
questionnaire responses, and collating this information in an anonymised database. The 
questionnaire items were also scored and processed according to standardised protocols 
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issued by the developers of each scale. The data collection and entry into the database was 
undertaken in collaboration with two doctoral researchers, whilst the database 
management, data screening and analyses were undertaken independently. A secondary 
round of data collection was undertaken one year subsequently, in order to obtain updated 
weight outcome data for all individuals attending the CWMS, and expand upon the weight 
outcome data which was initially collected, which included weight and BMI measures at 
baseline and last point of contact only. The secondary round of data collection was 
conducted independently and involved obtaining weight and BMI outcome data at 3-month 
intervals throughout individuals’ duration of attendance, from electronic patient records. 
 
1.1.4.2 Data from the Specialist Lifestyle Management (SLiM) programme 
Data was obtained for individuals attending the SLiM programme from the electronic 
database used by the healthcare professionals responsible for the delivery of the 
programme. Data processing was undertaken independently. This included screening the 
data, which involved the removal of duplicate cases, scoring the self-report questionnaire 
items, and transferring the data to an anonymised database to be analysed in conjunction 
with the CWMS data. 
 
1.1.5 Outline of the thesis 
The next section of this introductory chapter, Chapter 1.2 will provide contextual 
information on current understanding of the measurement, outcomes and prevalence of 
obesity, with a specific focus on extreme obesity. Subsequently the next section, Chapter 
1.3 will give a detailed description of weight management strategies to address the 
increasing prevalence of obesity, including an introduction to the HEFT Specialist Weight 
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Management Service and its two constituent treatment pathways; the Community Weight 
Management Service (CWMS) and the Specialist Lifestyle Management (SLiM) 
Programme. 
 Chapter two provides a detailed characterisation of individuals entering the CWMS 
pathway of the service, however detailed baseline demographic and clinical information 
for the SLiM sample were unfortunately not routinely collected and thus were not available 
for analyses. The chapter examines the baseline quality of life, mental health, perceived 
sleep quality and physical activity levels, offering a thorough account of the baseline 
features of individuals entering this specific treatment pathway. The implications of the 
findings will be considered, with recommendations generated from the findings offered for 
the potential improvement of weight management services. 
Chapter three presents a more detailed account of the quality of life and mental 
health characteristics of the individuals entering both the CWMS and SLiM treatment 
pathways. In addition, the cross-sectional association between baseline quality of life, 
mental health and adiposity will be explored in the lesser-researched extreme obese 
population, in order to determine the burden of psychological factors in this population. 
Based on the findings of the analyses, further recommendations for weight management 
services will be made.   
Chapter four is a literature review which provides a comprehensive overview of the 
body of research literature examining the efficacy of weight management interventions 
currently offered to obese individuals in the UK. The literature review will encompass a 
range of intervention approaches including primary care-led, commercially provided, 
sporting club-based and specialist weight management services, in order to place the 
outcomes of the two treatment pathways demonstrated in the present evaluation in context. 
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Chapter five evaluates the longitudinal weight outcomes of individuals attending 
the CWMS and SLiM pathways, offering comparison between the effectiveness of the two 
services. Additionally, factors associated with weight loss and weight gain will be 
identified and discussed, considering the potential implications for the service, with 
recommendations offered to maximise the opportunity for weight loss to be achieved 
during attendance. There will also be an in depth analysis of the impact of the SLiM 
pathway on quality of life. This work will follow on from the cross-sectional investigation 
of quality of life and adiposity, investigating the longitudinal changes in quality of life pre- 
and post- attendance at the SLiM programme. The longitudinal quality of life analyses is 
restricted to the SLiM sample due to the fact that baseline and follow-up quality of life 
measures were routinely collected for individuals attending the SLiM but not the CWMS 
treatment pathway. The factors associated with improvement in quality of life outcomes 
following attendance will be explored and the longitudinal association between change in 
quality of life and change in BMI will also be examined.  
Chapter six is a systematic review which describes the search for systematic 
reviews examining the effectiveness of medical and behavioural weight management 
interventions within exclusively extreme obese (BMI ≥40kg/m2) samples. The findings of 
the systematic review will inform whether there is a need for a systematic review of 
primary research examining the efficacy of medical and behavioural weight management 
interventions within extreme obese samples. 
Following on from the systematic review of systematic reviews, Chapter seven 
reports the findings of a systematic review of primary studies examining the effectiveness 
of medical and behavioural weight management interventions within extremely obese 
samples. The review will primarily examine weight and BMI outcomes, and in addition the 
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potential impacts of the interventions on the secondary outcomes of cardiovascular and 
psychological factors will also be evaluated. 
Finally, Chapter eight is the thesis summary which will draw together findings 
from the data chapters examining the characterisation and outcomes of individuals 
attending the HEFT Specialist Weight Management Service and the two systematic 
reviews of weight management interventions for extreme obesity, discussing them in the 
context of the research aims and current understanding. The contribution of this 
programme of research and implications for weight management services will be 
considered, in addition to the strengths and limitations of the research study and directions 
for future research. 
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1.2 INTRODUCTION TO EXTREME OBESITY 
 
1.2.1 Measuring and defining overweight and obesity 
The most widely used measure of adiposity is Body Mass Index (BMI) which provides a 
measure of an individual’s weight in kilograms divided by the square of their height in 
metres (9). BMI is used to estimate whether individuals are overweight or obese, and are 
subsequently more likely to experience increased risk of morbidity and mortality (10, 11). 
Figure 1.2 illustrates the international classification of adult underweight, overweight, and 
obesity as outlined by the World Health Organisation (WHO) consultation report ‘Obesity: 
preventing and managing the global epidemic’ published in 2000 (10). The figure shows 
that using this classification system, those individuals with BMI ≥40.00kg/m2 classed as 
extremely obese or ‘Obese class III’ experience the greatest increased risk of morbidity, 
relative to those of normal BMI. 
 
Figure 1.2: World Health Organisation (WHO) classification of BMI 
Classification BMI (kg/m
2
) Risk of co-morbidities 
Underweight <18.50 
Low (but risk of other clinical 
problems increased) 
Normal range 18.50-24.99 Average 
Overweight ≥25.00  
Pre-obese 25.00-29.99 Increased 
Obese class I 30.00-34.99 Moderate 
Obese class II 35.00-39.99 Severe 
Obese class III ≥40.00 Very severe 
Source: WHO (10). 
 
However, it is important to acknowledge that the cut-points shown in Figure 1.2 are 
arbitrary and should be interpreted with caution as the health risks associated with 
increasing adiposity are continuous and evidence suggests that the threshold at which 
increased health risks are experienced varies across different populations, with Asian 
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populations experiencing increased risk of morbidity at lower BMI levels (12). As such, 
cut-points at the lower BMI levels of ≥23.0kg/m2 and ≥25.0kg/m2 have been used to 
identify overweight and obesity, respectively, among Asian populations (12). 
Although BMI is the most commonly used measure to indicate risk of morbidity 
associated with obesity, it is not a direct measure of adiposity, rather it is a proxy measure 
of total excess body fat distributed around the body. Alternative measures of excess body 
fat including waist circumference, waist to hip ratio, and skin fold thickness have been 
used to measure the distribution of excess weight specifically around the abdomen, 
providing an indication of central adiposity (13). As such, the  National Institute for Health 
and Care Excellence (NICE) has recommended that additional measures of obesity such as 
waist circumference should be used in the assessment of the health risks of obesity for 
those with a BMI <35.0kg/m
2
, as illustrated in Figure 1.3. However this suggests that 
individuals with BMI  ≥35.0kg/m2 experience very high risk of morbidity regardless of 
waist circumference (14).  
 
Figure 1.3: Assessment of the health risks associated with overweight and obesity as 
recommended by the National Institute for Health and Care Excellence (NICE) 
BMI classification Waist circumference 
 Low High Very high 
Overweight No increased risk Increased risk High risk 
Obese class I Increased risk High risk Very high risk 
Obese class II Very high risk Very high risk Very high risk 
Obese class III Very high risk Very high risk Very high risk 
For men, waist circumference <94cm = low, 94-102cm = high and >102 cm = very high 
For women, waist circumference <80cm = low, 80-88cm = high and >88cm = very high 
Source: NICE (14). 
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1.2.2 Health outcomes of obesity and extreme obesity 
Obesity is a major public health concern due to its association with co-morbid health 
conditions. Figure 1.4 illustrates the increased risk of experiencing a range of health 
conditions faced by those who are obese, relative to those who are non-obese. The data 
which were obtained in a review conducted by the National Audit Office to provide 
estimates of risk for the population in England, indicate that the risk of developing type 2 
diabetes is especially high for obese individuals, with males over five times as likely and 
females over 12 times as likely to develop the condition relative to those with a BMI 
<30.0kg/m
2
. 
 
Figure 1.4: Increased risk of co-morbid health conditions experienced by obese 
(≥30.0kg/m2) relative to non-obese (<30.0kg/m2) individuals in England 
Condition Males Females 
Type 2 diabetes 5.2 12.7 
Hypertension 2.6 4.2 
Myocardial infarction 1.5 3.2 
Cancer of the colon 3.0 2.7 
Angina 1.8 1.8 
Gall bladder diseases 1.8 1.8 
Ovarian cancer - 1.7 
Osteoarthritis 1.9 1.4 
Stroke 1.3 1.3 
Source: Health and Social Care Information Centre (15). 
 
In addition to experiencing increased risk of co-morbid health conditions, obesity has also 
been demonstrated to be associated with mortality. Findings from the Prospective Studies 
Collaboration (PSC) which analysed data from 57 international prospective studies, 
suggest that moderate levels of obesity (BMI 30.0-35.0kg/m
2
) are associated with a 
reduction in life expectancy of between 2 and 4 years, whilst extreme obesity (BMI 
≥40.0kg/m2) is associated with an 8 to 10 year reduction in life expectancy, similar to that 
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observed with life-long smoking (11). The health outcomes and clinical characteristics of 
extreme obesity are explored in greater detail in Chapter two.  
 
1.2.3 The prevalence of obesity and extreme obesity 
Globally, the prevalence of obesity defined as BMI ≥30.0kg/m2, has nearly doubled since 
1980, and in 2008 over 200 million men and nearly 300 million women were classed as 
obese, equating to over 10% of the global adult population (16). The trend of increasing 
prevalence of obesity among adults in England has been demonstrated using data obtained 
from the Health Survey for England (HSE) (15, 17). Figure 1.5 shows the three-year 
average prevalence of obesity defined as BMI ≥30.0kg/m2, over a 19-year period from 
1993 to 2012, for those aged 16 years or older living in England. The graph illustrates that 
the prevalence of obesity gradually increased from 13.2% for males and 16.4% for females 
in 1993 to 24.4% for males and 25.1% for females in 2012.  
When considering the specific population of Birmingham, data on the prevalence of 
obesity are conflicting. The Birmingham unitary authority health profile published by 
Public Health England in 2014 indicated an obesity prevalence rate obtained using data 
from the Active People Survey, 2012, of 23.0% which was the same as the average rate for 
England of 23.0% (18). However, previous health profile reports published by Public 
Health England in 2011 (19), 2012 (20) and 2013 (21) used modelled estimates based on 
the 2006-2008 HSE data, which gave obesity prevalence rates of 26.2% for Birmingham 
and 24.2% for England. This suggests that previously released data modelled on estimates 
may have overestimated the discrepancy between the prevalence of obesity in Birmingham 
relative to the average prevalence for England, or alternatively may suggest that the gap 
between the obesity prevalence for Birmingham and England has decreased. 
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Figure 1.5: The prevalence of obesity (BMI ≥30.0kg/m2) in England from 1993 - 2012 
 
Source: Public Health England (22). 
 
In addition to the trend of increasing prevalence of obesity among adults in England, HSE 
data (15, 17) also demonstrate that the prevalence of extreme obesity defined as BMI 
≥40.0kg/m2, increased over the same period from 1993 to 2012. Figure 1.6 demonstrates 
the increase in extreme obesity from 0.2% for males and 1.4% for females in 1993 to 1.7% 
of males and 3.1% of females in 2012 (15, 17).  
 
 
 
 
 
 
  
30%
25%
20%
15%
10%
5%
0%
Women
Men
P
re
v
a
le
n
ce
 o
f 
o
b
es
it
y
  
15 
 
Figure 1.6: The prevalence of extreme obesity (BMI ≥40.0kg/m2) in England from 
1993 - 2012 
 
Source:  Public Health England (23). 
 
The increase in levels of extreme obesity have also been observed in the US, with a 70% 
increase over the last decade between 2000 and 2010 and a current prevalence rate of 6.6% 
(24). Furthermore, recent estimates predict that the proportion of individuals of 
BMI ≥40kg/m2 will continue to increase, reaching 9% in the US by 2030 and 5% in the 
UK by 2033 (25). Given the current levels of extreme obesity and the fact that these levels 
are expected to rise, weight management strategies will play a crucial role in slowing the 
increasing prevalence and providing care to those individuals affected by extreme obesity. 
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1.3 INTRODUCTION TO WEIGHT MANAGEMENT 
 
1.3.1 Strategies to address obesity 
Chapter 1.2 has identified the challenging demand for strategies to address the increasing 
obesity epidemic. In 2006 NICE published Clinical guideline 43 which outlined 
recommendations for healthcare professionals on ‘the prevention, identification, 
assessment and management of overweight and obesity in adults and children’ (14). The 
clinical guideline which was last modified in May 2014, was used to create treatment 
pathways as illustrated in Figures 1.7 and 1.8. 
 
Figure 1.7: NICE treatment pathway for preventing and managing obesity 
 
Source: NICE (26). 
 
Figure 1.7 illustrates the care pathway developed by NICE and covers the prevention of 
obesity, the identification of individuals who are overweight or obese, and the management 
of obesity. The pathway and associated NICE guideline outline a whole-system approach, 
acknowledging that strategies to prevent and manage obesity require collaboration and 
Preventing and managing 
obesity
Identifying people who are 
overweight or obese
Preventing obesity
Interventions to 
prevent obesity
NICE pathway on 
local strategy in 
obesity: working with 
local communities
Managing obesity
Overweight and obese 
adults
Overweight and obese 
children and young 
people
Advice for everyone to 
prevent obesity
  
17 
 
prioritisation of the issue from local authorities, schools, early years settings, workplaces, 
community and voluntary organisations, as well as the NHS (14). Prevention, identification 
and management are all crucial aspects in stemming the rising prevalence of obesity and its 
associated co-morbid health conditions. Figure 1.8 illustrates the management of obesity 
pathway in greater detail and is designed to improve the care provided to obese adults, 
particularly in primary care settings. The guideline recommends that a person-centred 
approach should be taken, with the choice of intervention for weight management whether 
pharmaceutical through the provision of weight loss medication, the initiation of a lifestyle 
change weight management programme or referral to a specialist weight management 
service, discussed and made in negotiation between the individual and healthcare 
professional (14). The pathway in Figure 1.8 illustrates the cyclical nature of weight 
management whereby individuals receive continued support as long as it is required, with 
the level provided depending on individuals’ specific care needs.  
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Figure 1.8: NICE Pathway for the care of overweight and obese adults 
 
Source: NICE (27). 
 
1.3.2 Weight management 
1.3.2.1 Hierarchy of UK weight management services 
Weight management care available through the NHS is organised in a hierarchical 
structure with the provision of increasing support for more complex and extreme levels of 
obesity. Figure 1.9 illustrates the hierarchy as outlined in the British Obesity and Metabolic 
Surgery Society (BOMSS) Commissioning guide for weight assessment and management 
clinics published in 2014 (28). The hierarchical model of weight management services 
facilitates the transition of individuals between the levels of care, with the aim that 
individuals receive the most appropriate service according to their needs.   
General principles of care
Advice for women with a BMI 
of more than 30 before, during 
or after pregnancy
Advice for all other adults
Assess lifestyle, co-morbidities 
and willingness to change
Managing weight through 
lifestyle change in adults
Consider drug treatment
Consider referral to a specialist
Surgery
Overweight and obese adults
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Figure 1.9: Weight management levels of care 
 
Source: BOMMS (28).  
 
The first level of care, tier 1 incorporates health promotion at a population-level and is 
suitable for individuals of all weight levels. The next level of care, tier 2 incorporates 
lifestyle interventions such as those provided by primary care services or the commercial 
sector. Tier 3 and 4 services are available for individuals with higher BMI and associated 
complex medical needs who require more specialist services from multi-disciplinary 
teams, which may involve bariatric procedures and surgery.  
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1.3.2.2 Tier 2: Commercial and primary care-led weight management services 
A detailed examination of the efficacy of primary care-led and commercial services is 
provided in Chapter four, however a brief introduction is provided here. The primary care-
led weight management programme that has been most widely adopted is the 
Counterweight programme which delivers a nurse-led lifestyle intervention in group or 
individual sessions to obese individuals over a 3-month period,  with individuals 
encouraged to achieve 5-10% loss of their baseline weight (29). As an alternative to 
Counterweight, several primary care teams have delivered their own ‘in-house’ services 
(30-32). Whilst the majority of primary care-led interventions focus on the provision of 
lifestyle and behaviour change advice, a Low Energy Liquid Diet (LELD) approach may 
also facilitate greater weight loss (33). Primary care services may also refer individuals 
who are overweight or obese to commercial weight management providers such as Weight 
Watchers, Rosemary Conley, and Slimming World through ‘Slimming on referral’ 
schemes or through participation in RCTs such as the Lighten Up study (34, 35). 
Alternatively individuals may also self-refer to commercial services. A substantial number 
of commercial interventions have demonstrated clinically significant weight losses of ≥5% 
of individuals’ baseline body weight (36, 37).  
 
1.3.2.3 Tier 3: Specialist weight management services  
Specialist weight management services operate at the tertiary level of care, as 
demonstrated in Figure 1.9. Tier 3 services are usually available for individuals with BMI 
≥40.0kg/m2 or BMI ≥35.0kg/m2 with co-morbid health conditions. It is likely that those 
presenting for treatment at tertiary services, may have made multiple previous attempts to 
lose weight through primary care or commercial programmes, potentially achieving limited 
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weight loss success (28). The aim of specialist weight management services is to offer 
these individuals more intensive support through a multidisciplinary team approach which 
may include input from specialist physicians, dietitians, psychologists and exercise 
specialists. Tier 3 services may operate in community settings or be hospital-based, 
delivering medically-led pharmaceutical and or behavioural interventions encompassing 
education, dietary and activity advice and support for lifestyle change, and the provision of 
anti-obesity medication. Through continued support, tier 3 services aim to facilitate not 
only weight loss but also the long-term maintenance of weight loss. In addition, tier 3 
services evaluate co-morbid health conditions and relevant psychological factors, exclude 
underlying contributory diseases, whilst also evaluating attendance and engagement with 
the service (38). Individuals may then be referred from tier 3 services to be considered for 
assessment to receive bariatric surgery within a specialist tier 4 bariatric surgery service. 
Following bariatric surgery procedures individuals may then access tier 3 services to 
receive post-surgery support. 
 
1.3.2.4 Tier 4: Multidisciplinary specialist bariatric surgical services 
Surgical weight management may be considered as a treatment option for those individuals 
with BMI ≥40.0kg/m2 or BMI ≥35.0kg/m2 with co-morbid health conditions, who have 
received and engaged with medical weight management for a minimum period of 6 months 
(38). Tier 4 services are available to individuals who meet eligibility criteria which is 
assessed on an individual basis, with procedures carried out subject to the additional 
criteria of meeting funding requirements. Data released from the UK National Bariatric 
Surgery Registry (NBSR) indicated that in the financial year 2013/14, the 106 surgeons 
who contributed to the registry completed 4,389 NHS bariatric procedures across England 
  
22 
 
(39). Data provided by those who consented to the release of patient outcome data (95%), 
indicated that the mean baseline BMI was 50.6kg/m
2 
and 72.8% were female, with a 
survival rate of 99.9% and an average hospital stay of 2.5 days. Furthermore, estimates 
obtained using hospital episode statistics suggest that a total of 5,656 operations were 
conducted by 138 NHS surgeons during the same period, indicating that the majority of 
surgeons (77%) entered data to the registry and that these estimates are representative of 
the provision of bariatric surgery delivered through the NHS in England. 
 A systematic review assessing the effectiveness of bariatric surgery published in 
2009 revealed that of the 26 included studies only 3 RCTs and 3 prospective cohort studies 
compared surgical and non-surgical management of obesity, with findings suggesting that 
surgery resulted in greater weight loss, with results maintained for a minimum of ten years 
(40). However, the authors also concluded that surgical procedures can also be associated 
with adverse effects and additionally carry the risk of post-operative mortality. Whilst the 
estimates of weight loss and survival rates for bariatric surgery are encouraging, there is a 
discrepancy between the number of procedures conducted and the number of eligible 
individuals, thus bariatric surgery procedures are not available or suitable for all 
individuals affected by extreme obesity.  
 
1.3.3 Heart of England NHS Foundation Trust Specialist Weight Management 
Service 
The Specialist Weight Management Service is operated by the Heart of England NHS 
Foundation Trust (HEFT), which is one of the largest hospital trusts within England (41). 
The Specialist Weight Management Service was established in 2000 and provides both tier 
3 and 4 medical and surgical weight assessment and management services. The provision 
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of bariatric surgical services incorporates comprehensive pre- and post-surgery assessment 
and care from specialist multi-disciplinary teams, whilst the medical services incorporate 
pharmaceutical, educational and behavioural interventions delivered on an individual or 
group basis. 
Individuals are referred to the care of the service from primary care settings across 
the West Midlands and as such, it serves an ethnically and socioeconomically diverse 
population. The criteria for referral to the service is a BMI of ≥40.0kg/m2 or BMI of 
≥35.0kg/m2 for individuals with a co-morbid health condition such as type 2 diabetes or 
hypertension. On referral to the service individuals are invited to attend an appointment 
with a physician from the specialist weight management team, during which any potential 
undiagnosed underlying conditions such as hypothyroidism and Cushing’s syndrome or 
potential undiagnosed co-morbid health conditions such as type 2 diabetes are investigated. 
Individuals decide in collaboration with the physician which of the two treatment pathways 
offered by the service that the individual will proceed on; the Community Weight 
Management Service (CWMS) or the Specialist Lifestyle Management (SLiM) 
programme. 
 
1.3.3.1 Community Weight Management Service (CWMS) 
The CWMS provides support to individuals from a multi-disciplinary team (MDT) 
incorporating one-to-one appointments with physicians, dieticians and a psychologist. The 
aim of the CWMS is to support and facilitate individuals in making lifestyle changes and 
achieving a weight loss of at least 5% of their baseline weight. The CWMS clinic sessions 
operate from community settings such as General Practitioner (GP) practices in 
collaboration with local primary care providers. This approach allows individuals to 
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receive specialist care from the clinical team at local primary care centres without having 
to go to hospital, thus increasing access to the service. Those individuals who do not speak 
English can request to attend clinic sessions with a language interpreter provided by the 
service where available. 
 Individuals attend an initial CWMS appointment, which lasts for between two and 
three hours, and is designed to be an intensive introductory session. During the initial 
appointment, individuals will receive one-to-one consultations with each member of the 
MDT, addressing a range of topics as outlined in Table 1.1. After the initial appointment 
individuals are invited to contact the service to arrange a suitable time for their subsequent 
appointments, which can be made with each member of the MDT, or alternatively with one 
or two team members only. The frequency of contact varies as a result of individual 
requirements and session availability, with individuals attending subsequent appointments 
every two to three months or more frequently if needed. Individuals receive support 
through appointments within the service for a period of 12 months, after which individuals 
are discharged back to the care of their GP. However, some individuals choose to continue 
attending regular appointments within the service for longer durations depending on 
specific requirements. 
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Table 1.1: Outline of the Community Weight Management Service (CWMS) sessions 
Member of multi-disciplinary 
team 
Topics covered during appointment 
Physician During the initial appointment weight and BMI are recorded and 
discussed with the individual. Individuals’ weight history and previous 
weight loss efforts are discussed including age of current obesity onset. 
The completed self-report questionnaires are reviewed, during which 
quality of life and mental well-being are discussed and if appropriate 
individuals may be recommended to attend regular appointments with the 
psychologist. The self-reported sleep quality of individuals is also 
discussed, with investigation of potential undiagnosed co-morbid 
conditions such as obstructive sleep apnoea, through referral to a sleep 
specialist for an overnight sleep study if appropriate. Previous use of anti-
obesity medication is also reviewed, with medication prescribed if 
appropriate. 
Subsequent appointments incorporate a ‘weigh-in’ and discussion of 
weight loss progress, identifying barriers to changing behaviours where 
appropriate. Management of co-morbid health conditions such as type 2 
diabetes is also discussed, with alterations made to treatment and 
medication as appropriate. 
Dietitian 
During the initial appointment, the dietitian will review the 3-day food 
diary which individuals receive by post and are asked to complete before 
attending their first appointment, identifying areas for improvement 
including consumption of specific foods and drinks, portion sizes, missing 
meals and night-eating. Recommendations will be discussed with 
individuals for making dietary changes. 
Subsequent appointments discuss progress and individuals’ experiences of 
adopting new dietary behaviours. 
Psychologist 
During the initial appointment, individuals discuss factors influencing 
their weight and dietary and activity behaviour. Topics may include 
individuals’ support structure including current and previous relationships 
with spouses or partners and family and friends, whether there is a history 
of abuse, diagnosis of depression or other mental health condition, or 
alcohol or drug addiction. 
Subsequent appointments will incorporate discussion of topics in greater 
detail if desired by the individual, or alternatively no further appointments 
are attended. 
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1.3.3.2 Specialist Lifestyle Management (SLiM) Programme 
The SLiM programme is a medically-supported weight management patient education 
programme. The SLiM programme provides patients with a structured group-based 
educational curriculum encompassing advice and techniques for changing health behaviour 
and self-management. Table 1.2 details the content of each of the sessions and the specific 
behaviour change techniques which are employed. The sessions are facilitated by a dietetic 
assistant who received training in the delivery of the programme from the team of 
specialist weight management dietitians at Heartlands Hospital who developed the 
programme curriculum.  
 The key aims of the SLiM programme are to provide advice and guidance through 
structured education, to provide techniques and skills for long-term self-management of 
weight, and to facilitate individuals in achieving a weight loss of at least 5% of their 
baseline weight over the course of the programme. Individuals attend six sessions, 
attending one session per month over a total period of six months. The SLiM programme 
operates from the Heartlands Hospital site, on a rolling basis, with several concurrent 
groups, thus enabling individuals to attend an alternate group session if they are unable to 
attend their regular group session.  
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Table 1.2: Outline of the SLiM programme sessions 
 
Content of session Behaviour change techniques 
1 Getting to know each other, 
discussing weight loss 
expectations and introducing 
topics including: 
Healthy eating,  
Ideas for including activity in 
daily life. 
Goal setting: Individuals are encouraged to make SMART goals 
(Specific, measurable, achievable, relevant, time-bound) for diet and 
activity changes. In addition to personalised goals, a weight loss goal 
of 5% over the programme is set.  
Self-monitoring: Individuals receive a ‘food and mood diary’ to record 
foods eaten, time, place, who they were with and current mood, to 
promote awareness of eating behaviour.   
Homework: Individuals asked to complete the food and mood diary, to 
work towards their personal dietary SMART goal and to increase their 
intake of water. 
2 Discussion of progress from 
previous session and 
application of techniques 
during the month. 
Topics include: 
Eating regular meals, 
Achieving a balanced diet,  
Healthy cooking methods. 
Education: Individuals given information on healthy eating using 
principles of the ‘Eatwell plate’ which was devised by the Department 
of Health in association with the Welsh Assembly Government, the 
Scottish Government and the Food Standards Agency in Northern 
Ireland. In addition, individuals discuss the importance of eating 
regular meals to achieve stabilisation of eating, controlling portion 
sizes, menu planning and healthy cooking methods. 
Homework: Individuals asked to work towards their personal activity 
SMART goal, make their meals balanced and reduce portion sizes by 
25%. 
3 Discussion of progress from 
previous session and 
application of techniques 
during the month. 
Topics include: 
Conscious eating, 
Changing negative thoughts, 
Trying new foods. 
Stimulus control: Individuals play a game designed to increase 
awareness of external and internal triggers for eating, in order to 
promote conscious eating. 
Cognitive restructuring: Individuals discuss how negative thoughts can 
affect efforts to change behaviour, and how they can change negative 
unhelpful thoughts for positive ones to help them to achieve their 
goals. Individuals asked to challenge their ‘all or nothing’ beliefs, such 
as avoiding use of unhelpful words like ‘always, never, I have to’ 
when thinking about food and activity.  Individuals are introduced to 
the idea of practicing ‘positive self-talk’ and are given a diary to 
encourage putting this into practice. 
Homework: Individuals complete a ‘positive self-talk diary’ 
substituting negative for positive thoughts, to identify their eating 
triggers and use techniques to avoid them, and to work towards 
increasing variety of fruit and vegetable intake. 
4 Discussion of progress. 
Topics include: 
Interpreting food labels, 
Portion size control. 
Education: Individuals taught to read and interpret food labels, 
recommended serving sizes, and put this into practice using resources 
and playing a labelling game. 
Homework: Individuals asked to use these techniques for reading 
labels when selecting foods whilst shopping. 
5 Discussion of progress, 
including a virtual shopping 
trip employing label-reading 
skills. Topics include: 
Shopping for food,  
Support and reward. 
Support and Reward: Individuals are encouraged to use non-food 
rewards to aid motivation and to avoid thinking of food as a reward. 
Individuals are encouraged to ask for support from family and friends. 
Homework: Individuals asked to reflect on last 6 months and the skills 
they have learnt that have helped them to achieve their goals. 
6 Reflection on progress from 
the start of the programme, 
and giving thanks to each 
other.  
Topics include: 
Problem-solving,  
Maintenance, 
Self-esteem. 
Problem-solving: Individuals are given skills and techniques to help 
with recognising high risk situations that may lead to ‘slip-ups’ in 
behaviour and put plans in place to avoid this. 
Maintenance: Individuals discuss ‘slip-ups’ in behaviour and learn 
techniques such as avoiding negative self-talk to help prevent a ‘slip-
up’ leading to a relapse in previous behaviours. 
Boosting self-esteem: Brief discussion about how to improve self-
esteem and feel good themselves.  
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The format of the sessions follows a model whereby each session begins with a discussion 
of individuals’ experiences of adopting and employing the skills and techniques they have 
learned, which is primarily a peer-group discussion facilitated by the programme leader. 
The core material is then delivered incorporating interactive games and activities, and the 
session finishes with the setting of ‘homework’ activities to promote the adoption of new 
techniques and a ‘weigh-in’ to monitor weight loss progress. The ‘weigh-in’ is conducted 
without sharing individuals’ weight and progress with other group members unless 
individuals choose to do so. The timing of the ‘weigh-in’ at the end rather than the start of 
the session was selected as a pilot session had revealed that some individuals experienced 
negative emotions following the ‘weigh-in’ which influenced engagement with the 
remainder of the session. 
The curriculum of the programme is designed to equip individuals with the 
knowledge and skills to be able to achieve long-term self-management of their weight, and 
after completion of the programme individuals are discharged back to the care of their GP. 
Alternatively, some individuals may choose to repeat the programme in order to continue 
receiving guidance and support. 
 
1.3.3.3 Comparison of the CWMS and SLiM treatment pathways 
The nature of the two treatment pathways greatly differ in terms of both the duration and 
intensity of support provided, as well as differences in the numbers and types of staff 
involved in delivering the CWMS and SLiM pathways. Table 1.3 displays a comparison of 
the scale and costs associated with the provision of both treatment pathways. 
The comparison illustrates that the estimated annual staff-related costs associated 
with the CWMS are over five times greater than those associated with the SLiM pathway, 
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due to the greater number and expertise of staff providing support through the CWMS 
pathway. However it should also be noted that a greater number of individuals attend the 
CWMS pathway during each clinic session and during each week, relative to the SLiM 
pathway. Nevertheless the estimated weekly cost per individual suggests that the 
multidisciplinary team (MDT) approach employed by the CWMS pathway is likely to be 
more expensive, with an estimated cost of £75 - £90 per individual per week, whilst the 
SLiM pathway provides support at a lower estimated cost of between £31 per individual 
per week when sessions are fully attended and up to £155 per individual when attendance 
is at the minimum level of 2 individuals per session. Thus the SLiM pathway is likely to be 
the more cost-effective pathway, except in instances where attendance at the SLiM 
sessions is low and the pathway operates at minimum capacity. Regardless of attendance, 
when examining the fixed weekly staff costs alone, the estimated cost associated with the 
CWMS is much greater at £1,789 than that of the SLiM pathway at £310, which represents 
expenditure which would be incurred irrespective of attendance. 
The estimates are provided as a guide to facilitate comparisons of the scale and the 
costs associated with each pathway, however there are additional costs associated with the 
operation of both pathways including venue costs, provision of printed materials and 
resources, as well as the costs associated with the initial setting-up of each treatment 
pathway. A formal cost-effectiveness evaluation taking into consideration all of these 
factors would need to be performed in order to enable more accurate comparisons of the 
total costs associated with each pathway. Given that the actual number of individuals 
attending at each pathway greatly impacts upon the cost-effectiveness, this detailed level of 
data should also be incorporated. Thus a more robust health economic evaluation would be 
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necessary in order to generate firm conclusions as to the cost-effectiveness of the CWMS 
and SLiM treatment pathways. 
 
Table 1.3: Comparison of the scale and costs associated with the CWMS and SLiM 
treatment pathways 
 CWMS SLiM 
Duration of attendance 12 months 6 months 
Frequency of contact Every 3 months Every month 
Total number of contact points Range 5 - 13 6 
Time at each contact point First contact 2 - 3 hours, 
subsequent 0.5 hours 
1.5 hours 
Total contact time Range 4 - 9 hours 9 hours 
Weekly service provision 2 x 6.5-hour clinic sessions 1 x 1.5-hour session 
Number attending each session Range 10 - 12 Range 2 - 10 
Number attending each week Range 20 - 24 Range 2 - 10 
Number of staff 3 1 
Type of staff Consultant Physician, 
Psychologist, 
Dietitian 
Dietetic assistant 
Annual staff salary:   
Consultant Physician £77,850 - 
Psychologist £35,536 - 
Dietitian £29,759 - 
Dietetic assistant - £20,638 
Staff cost subtotal £143,145 £20,638 
WTE for staff 0.5 0.6 
Annual staff cost estimate £71,573 £12,383 
Weekly staff cost estimate* £1,789 £310 
Weekly cost per individual†  Range £75 - 90 Range £31 - £155 
Note: Annual staff salary values obtained from NHS terms and conditions of service handbook (42) based on 
the following pay bands and pay points: Consultant Physician Band 9 Point 49, Dietitian Band 6 Point 25, 
Psychologist Band 7 Point 30, Dietetic assistant Band 4 Point 14 
WTE= Whole Time Equivalent (dedicated to service provision including workload outside of contact hours) 
* Weekly staff cost estimate based on a 40-week year 
† Weekly cost per individual based on range of minimum-maximum attendances of 20-24 and 2-10 per week 
at the CWMS and SLiM pathways, respectively. 
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1.4 SUMMARY 
 
This chapter has discussed the increasing prevalence of obesity and specifically extreme 
obesity and the major challenge for healthcare services that this represents. The current 
structure of provision of weight management services that have been employed in the NHS 
to address the obesity epidemic have also been reviewed, with a detailed focus on 
specialist weight management services. In addition to outlining the rationale for the 
investigation of specialist weight management services for extreme obesity, this chapter 
has also introduced the aims and setting of the research project, placing it in the context of 
the healthcare setting and broader research design framework within which it is based. 
Chapter two discusses the clinical, demographic and mental well-being characteristics of 
extreme obesity, specifically of those individuals entering the CWMS pathway of the 
HEFT Specialist Weight Management Service in greater detail, giving insight to the 
individual experience of extreme obesity. 
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CHAPTER TWO 
 
2.0 CHARACTERISTICS OF EXTREME OBESITY: A STUDY OF INDIVIDUALS 
ENTERING THE COMMUNITY WEIGHT MANAGEMENT SERVICE (CWMS) 
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2.1 INTRODUCTION 
2.1.1 Clinical characteristics associated with extreme obesity 
It has been established that obesity and particularly extreme obesity is associated with 
increased risk of developing co-morbid health conditions including type 2 diabetes mellitus 
and insulin resistance, hypertension, cardiovascular disease, osteoarthritis, gallbladder 
disease, hyperuricaemia and gout, with additional increased risk of developing certain 
cancers, including colorectal and prostate cancer amongst men and breast and endometrial, 
cancer in women (43, 44). Furthermore, improvement in co-morbid health conditions 
including hypertension, dyslipidaemia, type 2 diabetes and impaired glucose tolerance, as 
well as improvements in fertility have been observed within extreme obese individuals 
when weight loss is achieved (45, 46). As well as being associated with increased 
prevalence of chronic health conditions, extreme obesity is also associated with increased 
mortality (11). 
The association between baseline BMI and mortality was examined by the 
Prospective Studies Collaboration (PSC), analysing data from 57 prospective studies 
including 900,000 individuals (11). The sample was recruited mostly from Europe and 
North America and was 61% male, with a mean age of 46 years and mean BMI of 
25.0kg/m
2
. The analyses which adjusted for age, sex, study and smoking status, revealed 
that after a mean follow-up period of 8 years, 66,552 deaths of known cause were 
recorded, and mortality was lowest in the upper-normal (22.5 - 25.0kg/m
2
) BMI range. 
BMI >25.0 kg/m
2
 was strongly positively associated with several speciﬁc causes of death 
including ischemic heart disease (Hazard Ratio: HR= 1.39, 1.34 - 1.44), stroke (HR= 1.39, 
1.31 - 1.48), diabetes (HR= 2.16, 1.89 - 2.46), non-neoplastic kidney disease (HR= 1.59, 
1.27 - 1.99), and non-neoplastic liver disease (HR= 1.82, 1.59 - 2.09). Furthermore, each 
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5kg/m
2
 increase in BMI was associated with an average increase of 29% overall mortality 
(HR= 1.29, 1.27 - 1.32), and specific increases in vascular mortality (HR= 1.41, 1.37 - 
1.45); diabetic mortality (HR= 2.16, 1.89 - 2.46), renal mortality (HR= 1.59, 1.27 - 1.99), 
hepatic mortality (HR= 1.82, 1.59 - 2.09), respiratory mortality (HR= 1.20, 1.07 - 1.34) 
and all other cause mortality (HR= 1.20, 1.16 - 1.25). Obesity and particularly extreme 
levels of obesity were also demonstrated to be associated with a reduction in median 
survival, with a BMI between 30.0 and 35.0kg/m
2
 associated with a reduction of between 2 
and 4 years, and an 8 to 10 year reduction in survival within the extremely obese 40.0 to 
45.0kg/m
2
 BMI range. It is important to note that the PSC study excluded those individuals 
with BMI >50.0kg/m
2
 meaning that the detrimental health impacts of extreme obesity may 
have been underestimated in the analyses, and thus may be even more damaging than those 
reported. 
 
2.1.2 Demographic characteristics associated with extreme obesity 
The capacity for social relationships to have an impact on individuals’ state of health has 
been demonstrated (47). Specifically marital status has been demonstrated to be associated 
with morbidity and mortality, with those individuals in relationships experiencing lower 
risk of poor health and death. Findings from the National Longitudinal Mortality Study 
demonstrated that those who were non-married experienced increased risk of mortality 
across ethnicity and gender groups (48). However, a different pattern of association has 
been observed in the relationship between marital status and obesity (49). The findings of a 
cross-sectional telephone survey of 3,025 US adults which adjusted for demographic, 
social, and physical factors, indicated that married men were significantly more likely to be 
obese than men who were previously married or never married. Interestingly, this 
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association was not observed in females, whereby marital status was not significantly 
associated with obesity. This pattern of observation has been shown in another study which 
assessed the association between relationship status and a range of health behaviours in 
young adults conducted in the US (50). The findings indicated that married men were more 
likely to be overweight or obese relative to males who were single, in casually-dating 
relationships or in committed-dating relationships, whereas no association between 
relationship status and weight was observed amongst females. Taken together these 
findings suggest that marital status may exert a negative impact on weight and obesity in 
males but not females. Gender thus plays a key role in the association, and further research 
required in order to identify the complex mechanisms underlying the relationship. In 
addition to marital status, the association between obesity and socioeconomic status (SES) 
has also been demonstrated. 
A seminal review of the literature examining the association between SES and 
obesity including 144 studies was published in 1989 (51). The review identified that within 
developed societies there was a strong inverse relationship among females, with a higher 
likelihood of obesity among females of lower SES, whereas a consistent relationship for 
males and children was not observed. In contrast, within developing societies a strong 
direct relationship was observed for females, males, and children, with a higher likelihood 
of obesity among those of higher SES. A subsequent systematic review of the literature 
examining the association between SES and obesity was published in 2007 to update the 
review, incorporating data from 333 studies (52). The systematic review classified the level 
of development for each of the study samples as either high, medium, or low using the 
United Nations Development Program 2003 Human Development Index. As with the prior 
literature review, findings indicated that within the more highly developed samples of 
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females it was commonly observed (63% of all associations) that lower SES was 
associated with greater weight and body size. The effect was not quite as marked in male 
samples, with 50% of observed associations indicating a relationship between lower SES 
levels and greater weight. The findings of the systematic review suggest that there are 
complex socio-economic and cultural factors that influence weight and body size, and that 
within highly developed countries such as the UK, this relationship is influenced by 
gender. 
The mechanism behind the SES and obesity association within developed societies 
may be attributable to diet, whereby individuals in higher SES groups are more likely to 
have a healthier diet incorporating increased consumption of fruit and vegetables and 
decreased consumption of fats (53). This may be due to the fact that economic income 
impacts upon food purchasing choices, with healthier foods demonstrated to be more 
expensive than less nutritious foods (54). Furthermore, those living in more affluent areas 
may experience increased access and opportunity to undertake physical activity and make 
healthier food choices (55). The SES and obesity association may be less consistent among 
males due to the conflict between the proposed societal phenomenon of thinness as an ideal 
to be pursued and valued (56), which although may be more salient among females 
remains omnipresent within society, and the perceived ideal of larger muscular body sizes 
indicating dominance and power among males (57). 
An additional potential contributing factor to the association between lower levels 
of SES and increasing BMI levels may be the presence of weight-related discrimination. 
The relationship between weight and experience of discrimination has been examined in 
the Midlife Development in the United States (MIDUS) survey which included a randomly 
selected sample of over 3,000 US adults aged between 25 and 74 (58). Findings indicated 
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that those with BMI ≥35.0kg/m2 were significantly more likely to report experiencing 
major lifetime discrimination (OR= 1.51, p <0.01), major job-related discrimination (OR= 
1.84, p <0.001), day to day discrimination (OR= 1.66, p <0.001), and experience of being 
denied medical care (OR= 2.98, p <0.001), than normal weight individuals. However, the 
cross-sectional association does not establish causality of whether obesity leads to 
discrimination affecting SES or vice versa. 
 
2.1.3 Psychological characteristics of extreme obesity 
The quality of life and mental health characteristics associated with extreme obesity are 
discussed in detail in Chapter three, however a brief introduction is provided here. 
Evidence has supported an association between increasing adiposity and depression (59), 
anxiety (60) and reduced quality of life (61). Furthermore, a link has been demonstrated 
between obesity and broader psychopathology with obese individuals more likely to 
attempt suicide and demonstrate suicidal behaviour, with an even greater risk observed in 
extreme obesity (62). However, there is a lack of consensus and inconsistencies in the 
literature, with some studies providing support for an association between obesity and 
physical, but not mental quality of life domains (63-65). Whilst the cross-sectional 
association between obesity and psychological characteristics has been debated, several 
studies have demonstrated a marked improvement in quality of life and mental health with 
weight loss achieved through both surgical (46, 66-71) and behavioural (32, 72-74) weight 
management interventions. 
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2.1.4 Sleep in extreme obesity 
The sleep characteristics of a sample of 1,550 US adults have been examined in the 
Wisconsin Sleep Cohort Study (WSCS), a population-based longitudinal study of sleep 
habits, sleep disorders and health, utilising data from self-report questionnaires, 6-day 
sleep diaries and overnight laboratory polysomnography studies (75). The association 
between sleep duration and BMI has been demonstrated in a study of 1,024 participants 
from the WSCS for whom polysomnography data was available. The findings indicated a 
U-shaped curvilinear association between BMI and sleep duration, whereby a minimum 
BMI was predicted when an average of 7.7 hours of sleep per night was achieved (76). 
Furthermore, a considerable proportion of the sample (74.4%) achieved less than eight 
hours sleep, with increased BMI shown to be proportional to decreased sleep within these 
individuals. 
Longitudinal data from the WSCS has also demonstrated that overweight and 
obesity are strong causal factors of certain sleep disorders, specifically sleep disordered 
breathing (SDB) (77). In a study which combined data from the US National Health and 
Nutrition Examination Survey (NHANES) with data from the WSCS, models of the 
prevalence of SDB were computed, giving estimates for two time periods, from 1988 - 
1994 and 2007 - 2010. Data was available for 1,520 participants of the WSCS, 47.0% of 
whom were obese (BMI ≥30.0kg/m2) including 10.8% of the sample who were classed as 
extremely obese (BMI ≥40.0kg/m2). The estimated prevalence rates of SDB increased 
across all age and sex subgroups between the two time points. The largest prevalence 
increases were observed among the younger age category of individuals aged 30 - 49 
years, with the proportion of individuals with the most severe SDB symptoms defined as 
Apnoea Hypopnea Index (AHI) score ≥15 with Epworth Sleepiness Scale (ESS) score >10 
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increasing from 3.1% to 4.8% in males and from 0.6% to 0.8% in females, while mild SDB 
(AHI score ≥5) also increased from 20.0% to 26.6% in males and from 6.6% to 8.7% in 
females. The ﬁndings of the study suggest that the prevalence rates of SDB have increased 
substantially over the recent decades. The authors suggest that the current obesity epidemic 
will result in so-called “offspring epidemics”, with the increased prevalence of obesity-
related conditions such as obstructive sleep apnoea (OSA) associated with the rise in the 
prevalence of obesity. 
 In addition to US population-based studies, the sleep characteristics of extremely 
obese individuals have also been studied in a sample of individuals entering the University 
Hospital Aintree Specialist Weight Management Service in the UK (78). The sample of 
144 individuals completed the following self-report questionnaires in order to assess the 
association between night eating, sleep quality, and excessive daytime sleepiness; the 
Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Score (ESS), and Night Eating 
Questionnaire (NEQ). The sample were predominantly female (68%), with a mean BMI of 
46.9kg/m
2 
and a mean age of 44.6 years, with findings indicating that 73.0% of the sample 
had poor sleep quality (PSQI >5), 30.8% had suspected OSA (ESS ≥10), and 2.8% showed 
symptoms of night-eating behaviour (NEQ ≥30). The findings indicated that poor sleep 
quality was significantly associated with night-eating, with a strong correlation observed 
between PSQI and NEQ scores (r= 0.54, p <0.001), which remained after controlling for 
excessive daytime sleepiness.  The study suggests that among the sample of extremely 
obese individuals seeking weight management, the prevalence of night-eating was low 
whilst the prevalence of poor sleep quality was widespread across the sample. 
Whilst the evidence suggests that obesity and particularly extreme levels of obesity 
are associated with sleep dysfunction, weight loss has been shown to reduce the harmful 
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impact of excess weight on sleep. The findings of a systematic review and meta-analysis 
have demonstrated that lifestyle interventions are able to reduce the severity of OSA (79). 
The review highlighted that whilst the levels of SDB were not normalised after 
intervention, modest interventions were able to yield a reduction in the severity of OSA 
and that further exploration of the impact of weight loss on OSA after more intensive 
interventions is required. Indeed, it has been suggested that whilst lifestyle interventions 
offer the safest approach to reducing the severity of OSA, bariatric surgery may provide 
more immediate and long-lasting alleviation of conditions such as OSA as well as 
improving individuals’ overall sleep function and quality (46, 80, 81). 
 
2.1.5 Rationale for the characterisation of extreme obesity 
The prevalence of extreme obesity is increasing (82), and as such the co-morbid health 
conditions associated with excess body weight are also increasing (77), placing increased 
burden on healthcare services and reducing the quality of life of those affected. Given the 
rising prevalence of obesity and in particular the rising prevalence of extreme obesity, 
there is an essential need to ensure greater understanding of this population. Whilst several 
studies have documented the sleep characteristics associated with obesity within 
population-based studies across the BMI range, the impact of extreme obesity on sleep 
within clinical extreme obese samples is less understood. Furthermore, the impacts on 
quality of life and mental health also require further investigation due to inconsistencies in 
the body of literature. The construction of a detailed picture of the demographic and 
clinical characteristics including the sleep and psychological features, of the extremely 
obese population will enhance our understanding of this at-risk group. The knowledge 
gained can then be fed back into service design and delivery, thus improving service 
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provision and ensuring that extreme obese individuals receive the most effective weight 
management services and thus are given the greatest opportunity to achieve weight loss. 
 
2.1.6 Aims 
This chapter aims to explore the characteristics of individuals attending the Community 
Weight Management Service (CWMS) which runs within the HEFT Specialist Weight 
Management Service. The baseline demographic and clinical characteristics of participants 
will be examined in this exploratory analysis in order to construct a detailed profile of the 
individuals attending the service, with no pre-defined hypotheses investigated. The factors 
which will be examined include the demographic characteristics, incorporating age, sex, 
ethnicity, marital status and occupation, and a range of clinical characteristics including 
waist circumference, systolic and diastolic blood pressure, smoking status, and alcohol 
consumption, as well as presence of obesity-related co-morbid health conditions including 
type 2 diabetes, cardiovascular disease (CVD), hypertension, OSA, and arthritis. Further 
analyses will also examine the self-reported measures of sleep quality, sleepiness, quality 
of life and mental health within the sample. The chapter concludes with a detailed 
summary of the characteristics of the extreme obese population attending the service, and 
in light of these findings recommendations to further enhance the design and delivery of 
the service will be presented. 
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2.2 METHODS 
 
2.2.1 Research design  
The characteristics of a sample of extreme obese individuals entering the CWMS pathway 
were explored as part of an evaluation of the efficacy of the Specialist Weight 
Management Service. The baseline demographic and clinical information for individuals 
entering the alternate treatment pathway, the SLiM programme are not included, as this 
information was not routinely collected and thus was not available for analyses. 
Individuals attending the CMWS pathway were referred from primary care by their GP if 
they had a BMI ≥40.0kg/m2 or alternatively BMI ≥35.0kg/m2 with a weight-related health 
condition, such as type 2 diabetes or hypertension. The study included a sample of 262 
individuals aged 19 to 76 years, who entered the CWMS between February 2008 and 
August 2012. 
 
2.2.2 Community Weight Management Service (CWMS) 
The CWMS has been described in detail in Chapter one, however a brief description of the 
service is provided for reference. The CWMS is a medically supported specialist weight 
management service providing comprehensive multidisciplinary care for a 12 month period 
from a team of specialist physicians, dietitians, and psychologist, delivered through 
individual appointments at GP practices in the community.  
 
2.2.3 Demographic and clinical information 
Demographic details including participants’ age, gender, and ethnicity were routinely 
collected at baseline, along with additional details including marital status, employment 
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status and whether participants had children. Participants’ initial weight and height data 
were recorded at baseline and BMI was calculated by dividing participants’ weight in kg 
by height in meters squared. Details of obesity-related co-morbid health conditions 
focussing specifically on type 2 diabetes, CVD, hypertension, OSA, and arthritis were also 
recorded from health records. Participants’ waist circumference, systolic and diastolic 
blood pressure, smoking status, alcohol consumption, and use of weight medication were 
routinely recorded prior to treatment commencement. Additionally, subsequent referral to 
bariatric surgery after attendance at the service was recorded. It is important to note 
however, that referral of an individual to the bariatric surgery team indicated that the case 
was reviewed but may not have resulted in the performance of a surgical procedure. 
 
Questionnaire booklet 
Upon referral to the CWMS, participants were sent a questionnaire booklet by post which 
they were asked to complete before attending their first appointment. The questionnaire 
booklet comprised the following previously validated self-report questionnaires:  
 
Table 2.2.1: Self-report questionnaire administered to individuals entering the 
CWMS 
Domain assessed Questionnaire 
Quality of life- weight specific Impact of Weight on Quality of Life (IWQOL-Lite) 
Quality of life- general EQ5D-3L 
Mental health Hospital Anxiety and Depression Scale (HADS) 
Sleep Pittsburgh Sleep Quality Index (PSQI short-form) 
Sleep Epworth sleepiness scale (ESS) 
Activity International Physical Activity Questionnaire (IPAQ long-
form) 
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2.2.4 Quality of life and mental health measures 
Quality of life and mental health were assessed using three measures, the obesity-specific 
Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire, the EQ5D-3L, which is 
a general quality of life measure, and the Hospital Anxiety and Depression Scale (HADS) 
which is a screening tool widely used in both clinical and research settings.  
The IWQOL-Lite consists of 31-items which measure the impact of obesity on an 
individual’s physical function, self-esteem, sexual life, public distress and work (83). 
Respondents are asked to rate the extent to which a series of statements is applicable to 
them using a Likert scale ranging from 5 ‘Always true’ to 1 ‘Never true’. Responses to the 
questionnaire items yield a total score as well as individual subscale scores for each of the 
five domains. 
The EQ5D-3L consists of five-items relating to five dimensions of health; mobility, 
self-care, usual activities, pain and discomfort and anxiety and depression (84). 
Respondents are asked to indicate which of three statements best describe their current 
health state. A ‘level 1’ response indicates that the respondent has no problem in the 
specific dimension, a ‘level 2’ response indicates some problems, and a ‘level 3’ response 
indicates extreme problems. Respondents are asked to repeat this process for the five 
dimensions. Perceived current health state is measured by asking respondents to indicate 
their current health state on a Visual Analogue Scale (VAS) with endpoints labelled 0 
‘Worst imaginable health state’ and 100 ‘Best imaginable health state’.  
The Hospital Anxiety and Depression Scale (HADS) comprises 14-items, 7 relating 
to anxiety, and 7 to depression (85).  Respondents are asked to rate the extent to which a 
series of statements represents how they currently feel using a Likert scale ranging from 0-
3.  The scale yields individual anxiety and depression scores as well as an overall HADS 
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score. Individual subscale scores range from 0-21, with a score of ≥8 established as a cut-
point for identifying presence of symptoms of anxiety and depression (86) and ≥11 
identifying severe symptoms (87). 
 
2.2.5 Sleep and physical activity measures 
Two sleep measurements were used to assess feelings of sleepiness and perceived sleep 
quality, the Epworth Sleepiness Scale (ESS) (88) and the Pittsburgh Sleep Quality Index 
(PSQI) short-form version (89). The ESS is an 8-item self-report tool which measures 
individuals’ general levels of daytime sleepiness, by asking respondents to rate their usual 
chance of falling asleep during a range of situations, using a 4-point scale ranging from 0 
‘Would never doze’ to 3 ‘High chance of dozing’. The eight different situations and daily 
life activities are those that most people would engage in, including sitting and reading, 
watching television, sitting inactive in a public place such as a theatre, as a passenger in a 
car for an hour without a break, lying down to rest in the afternoon when circumstances 
permit, sitting and talking to someone, sitting quietly after a lunch without alcohol, and in a 
car while stopped for a few minutes in traffic. The tool yields a total ESS score ranging 
between 0-24, with higher scores indicating higher levels of daytime sleepiness, and scores 
≥11 indicating symptoms of excessive daytime sleepiness (90). 
 The PSQI is a self-reported measure of perceived sleep quality, comprising 19-
items which generate scores for the following seven components; subjective sleep quality, 
sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping 
medications, and daytime dysfunction. Respondents are asked to rate their sleep habits and 
difficulties over the past month on a 4-point scale ranging from 0 ‘Not during the past 
month’ to 3 ‘Three or more times a week’. Responses to the items yield seven mean 
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component scores ranging between 0-3 and a global PSQI score ranging between 0-21, 
with higher scores indicating worse levels of sleep quality, and PSQI global scores ≥6 
indicating poor sleep quality (89). 
To measure sedentary time, the International Physical Activity Questionnaire 
(IPAQ long-form) (91) was used. The IPAQ long-form version comprises 31-items relating 
to the following five domains; job-related activity, transportation, housework, house 
maintenance and caring for family, recreation, sport and leisure-time, and time spent 
sitting. Responses to the items are summed to yield estimates of weekly activity within 
each activity domain, and yield an estimate of total weekly physical activity, in hours and 
minutes. An error in the reproduction of the questionnaire administered to individuals 
entering the service, whereby sections of the items were missing or were duplicated, led to 
invalidation of the tool and a low completion rate. However data from the last domain of 
the questionnaire, time spent sitting, had been completed by a larger number of 
participants, with 64.9% and 62.6% of the sample completing estimates of sedentary time 
during weekdays and weekend days, respectively. As such, data from the sedentary activity 
domain was used in isolation as a reliable and valid estimate of sedentary activity. 
 
2.2.6 Statistical analysis 
Anonymised data were analysed using IBM SPSS Statistics (version 21.0). Independent t-
test calculations were conducted to compare the mean demographic and clinical 
characteristics of males and females at baseline, with mean and standard deviation values 
also provided for the combined sample. Cross-tabulation and Chi
2
 analyses were conducted 
to compare the prevalence of the co-morbid health conditions between gender groups. The 
following categories of baseline BMI were created; 30.0-39.9kg/m
2
, 40.0-49.9kg/m
2
, 
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50.0-59.9kg/m
2, and ≥60.0kg/m2. The proportions of individuals in each BMI category 
were compared for the gender groups using cross-tabulation, and Chi
2
 calculations. The 
proportions of individuals within different occupation, marital status, smoking status, and 
ethnicity groups were also compared using the same method. Additionally, analyses were 
repeated to compare the baseline demographic and clinical characteristics across the 
following BMI groups; BMI <40.0kg/m
2
, 40.0 <50.0kg/m
2, and ≥50.0kg/m2 and the 
following age groups; <40 years, 40 <50 years, and ≥50 years. The self-report measures 
were scored following the standardised protocols outlined for each tool. Means and 
standard deviations were presented for subscales and total scores, along with proportions 
of individuals scoring above established cut-points, in order to aid interpretation of the 
measures.  
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2.3 RESULTS 
 
2.3.1 Characteristics of the general relative to the study populations 
Table 2.3.1 shows the demographic, lifestyle and clinical characteristics of the general 
population. The prevalence of married individuals within the general population (49% 
females and 52% males) is similar to that observed in the sample attending the CWMS 
(52.5% females and 46.5% males). However the proportion of White British individuals in 
England (79.8%) is lower than the proportion within the CWMS (90.8%), suggesting that 
this ethnicity group may be over-represented. Furthermore, examination of the general 
population ethnicity data highlights the fact that Birmingham is a super-diverse city with 
residents from a wide range of national, ethnic and religious backgrounds and thus has a 
lower prevalence of individuals of White British ethnicity (53.1%). Additionally, the 
unemployment rate of the West Midlands (9.8%) is higher than that of the UK (5.3% in 
2008 and 7.9% in 2012), reflecting the trend of higher unemployment and lower gross 
weekly earnings experienced by individuals in the region compared to the rest of the UK. 
In addition to the demographic characteristics, differences in the lifestyle 
characteristics of the general population and those reported by the CWMS sample are also 
observed. Whilst the proportion of males within the CWMS sample that consumed alcohol 
(62.7%) was consistent with the proportion of males within the general population who 
reported consuming alcohol in the past week (64%), the proportion of females consuming 
alcohol was higher within the CWMS (65.5%) than the general population (52%). Both 
gender groups were also more likely to spend more time engaged in sedentary activity than 
the general population, during both weekdays (females 6.5 vs 4.7 hours; males 7.6 vs 4.9 
hours) and during weekend days (females 6.2 vs 5.1 hours; males 7.6 vs 5.4 hours).  
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Table 2.3.1: Characteristics of the UK general population by gender and combined 
 
Genders 
combined 
Females Males 
1 
Single marital status (%) - 21 27 
Married marital status (%) - 49 52 
2
 White British ethnicity (within England, %) 79.8 - - 
2 
Ethnicity (within Birmingham, %)    
White British 53.1 - - 
Pakistani 13.5 - - 
Indian 6.0 - - 
Black Caribbean 4.4 - - 
3
 Current smoking (%) - 19 22 
4
 Alcohol consumption (%) - 52 64 
5
 Weekday sedentary activity (hours) - 4.7 4.9 
5 
Weekend sedentary activity (hours) - 5.1 5.4 
6
 Mean sleep duration per night (hours) 7.0 - - 
7
 Anxiety (%) 33.0 - - 
7 
Depression (%) 11.4 - - 
8
 Type 2 diabetes (%) 6.0 - - 
9
 OSA (%) - 2.0 4.0 
10
 Hypertension (%) - 28.0 31.0 
11
 Cardiovascular disease (%) - 13.4 13.9 
12
 Arthritis of the hip (%) 11 - - 
12
 Arthritis of the knee (%) 24.0 - - 
13 
UK employment: Feb-April 2008 (%) 74.9 - - 
14
 UK employment: June-August 2012 (%) 71.3 - - 
13 
UK unemployment: Feb-April 2008 (%) 5.3 - - 
14
 UK unemployment: June-August 2012 (%) 7.9 - - 
15 
Regional employment and earning 2010:    
West Midlands unemployment 9.8 - - 
West Midlands median gross weekly earnings (£) 456 - - 
UK median gross weekly earnings (£) 489 - - 
Data are percentages and means unless otherwise stated 
1
Office for National Statistics(ONS):
 
General Lifestyle Survey 2011 (92). 
2
ONS:
 
2011 UK census (93). 
3
ONS: 
Opinions and lifestyle survey 2012 (94). 
4
ONS: Opinions and lifestyle survey 2012 (95). 
5
Health and Social 
Care Information Centre (HSIC): Health Survey for England (HSE) 2012 (96). 
6
Survey of 1997 adults 2003 
(97). 
7
Survey of 1792 adults 2001 (98). 
8
Diabetes UK 2014 (99). 
9
Sleep Apnoea Trust Association 2013 
(100). 
10
HSIC: HSE 2011 (101). 
11
HSIC: HSE 2011 (102). 
12
Systematic review of osteoarthritis in the general 
population (103). 
13
ONS:
 
Labour market statistical bulletin 2008 (104). 
14
ONS:
 
Labour market statistical 
bulletin 2012 (105). 
15
ONS: Regional Trends: Portrait of the West Midlands 2011 (106).  
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2.3.2 Demographic characteristics 
Table 2.3.2 shows the demographic characteristics of the sample. Males were significantly 
older than females at baseline (48.0 vs 41.5 years). However there were no other 
significant differences in demographic characteristics between males and females. The 
sample was predominantly female (74.8%), White European (90.8%), with a substantial 
proportion reporting that they have at least one child (88.1%). A large proportion of the 
sample (62.0%) were employed, whilst 22.3% were unemployed. 
 
Table 2.3.2: Demographic characteristics of the CWMS sample by gender and 
combined 
 Whole sample Females Males P 
N (%) 262 196  (74.8) 66 (25.2)  
Age (years) 43.1±11.8 41.5±11.0 48.0±12.9 <0.001 
Ethnicity (%)    0.068 
White European 90.8 89.0 97.0  
Asian 5.6 7.3 0.0  
Black African/Caribbean 2.8 3.7 0.0  
Other 0.8 0.0 3.0  
Marital status (%)    0.613 
Single 24.2 23.0 27.9  
Married 50.9 52.5 46.5  
Living with partner 14.5 15.6 11.6  
Divorced 6.7 6.6 7.0  
Widowed 3.6 2.5 7.0  
Occupation (%)    0.117 
Employed 62.0 61.7 63.0  
Unemployed 22.3 23.3 19.6  
Retired 8.4 6.0 15.2  
Studying 7.3 9.0 2.2  
Children (%) 88.1 88.0 88.2 0.975 
Data are percentages and means ± standard deviations.  
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2.3.3 Clinical and lifestyle characteristics 
Table 2.3.3 shows the clinical and lifestyle characteristics of the CWMS sample. Males 
were significantly heavier (146.4 vs 127.2kg), with greater waist circumference (143.0 vs 
127.7cm), however there was no significant difference in BMI between the gender groups. 
The majority of the sample (53.4%) were in the 40.0-49.9kg/m
2
 BMI range, however 
23.3% of the sample had a baseline BMI of 50.0-59.9kg/m
2
, with a further 6.1% of the 
sample with baseline BMI ≥60.0kg/m2. The prevalence of several co-morbidities were 
significantly greater in males than females, including type 2 diabetes (43.9 vs 20.4%), 
hypertension (60.6 vs 25.5%), OSA (39.4 vs 20.9%), and CVD (27.3 vs 5.6%). The 
majority of the sample reported experiencing at least one of the above co-morbidities, with 
42.7% of the sample reporting either one or two and 17.6% reporting the presence of at 
least three co-morbidities. Hypertension was the most commonly reported co-morbidity by 
34.4% of the sample. There was a high prevalence of type 2 diabetes (26.3%), OSA 
(25.6%), arthritis (24.0%) and cardiovascular disease (11.1%). Thus the individuals 
attending the service have multiple health concerns contributing to poor overall health 
status and as a result have complex medical needs. 
 The lifestyle characteristics indicate that the sample were predominantly non-
smokers (60.7%), whilst 64.7% of the sample reported regular consumption of alcohol. 
There was a high level of sedentary activity among the sample at baseline, with a mean of 
6.7 hours spent sedentary during weekdays and 6.5 hours during weekend days, with males 
spending significantly more sedentary time at the weekend than females (7.6 vs 6.2 hours). 
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Table 2.3.3: Clinical and lifestyle characteristics of the CWMS sample by gender and 
combined 
 Whole sample Females Males P 
N (%) 262 196  (74.8) 66 (25.2)  
Weight (kg) 132.1±24.7 127.2±23.6 146.4±22.6 <0.001 
Body mass index (BMI, kg/m
2
) 47.0±7.9 47.4±8.4 46.0±6.3 0.211 
Proportion in BMI group (%)    0.113 
BMI 30.0-39.9kg/m
2
 17.2 16.3 19.7  
BMI 40.0-49.9kg/m
2
 53.4 53.1 54.5  
BMI 50.0-59.9kg/m
2
 23.3 22.4 25.8  
BMI ≥60.0kg/m2 6.1 8.2 0.0  
Waist circumference (cm) 131.6±14.5 127.7±12.4 143.0±14.7 <0.001 
Systolic blood pressure (mmHg) 140.9±17.7 140.7±18.4 141.3±15.5 0.849 
Diastolic blood pressure (mmHg) 85.2±11.7 85.3±11.8 84.7±11.5 0.773 
Type 2 diabetes (%) 26.3 20.4 43.9 <0.001 
Hypertension (%) 34.4 25.5 60.6 <0.001 
Arthritis (%) 24.0 24.5 22.7 0.772 
Obstructive sleep apnoea (OSA, %) 25.6 20.9 39.4 0.003 
Cardiovascular disease (CVD, %) 11.1 5.6 27.3 <0.001 
Number of (above) co-morbidities (%)    <0.001 
0 39.7 48.0 15.2  
1-2 42.7 40.3 50.0  
≥3 17.6 11.7 34.8  
Alcohol consumption (%) 64.7 65.5 62.7 0.728 
Weight medication (%) 80.4 79.7 82.6 0.667 
Referral to surgery (%) 14.5 13.3 18.2 0.327 
Smoking status (%)    0.352 
Non-smoker 60.7 62.8 54.9  
Current smoker 25.5 25.5 25.5  
Former smoker 13.8 11.7 19.6  
Weekday sedentary time (hours)     
Mean 6.7±3.9 6.5±3.8 7.6±4.1 0.118 
IQR 6.0 5.3 7.5  
Range 20.0 (0 - 20) 20.0 (0  - 20) 15.0 (2 - 17)  
Weekend sedentary time (hours)     
Mean 6.5±3.6 6.2±3.5 7.6±3.5 0.027 
IQR 4.0 4.0 5.0  
Range 17.0 (1 - 18) 15.0 (1 - 16) 16.0 (2 -18)  
Data are percentages and means ± standard deviations 
IQR= Interquartile range. 
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2.3.4 Quality of life and mental health characteristics 
Table 2.3.4 shows the quality of life and mental health characteristics of the sample at 
baseline. Quality of life was markedly impaired across all IWQOL-Lite domains, with 
scores ranging from 26.2 (self-esteem) to 51.2 (work), whereby 100 represents optimum 
quality of life. Males had significantly higher IWQOL-Lite scores on several of the 
subscales including self-esteem (36.5 vs 22.5), sexual life (50.3 vs 38.8) and IWQOL-Lite 
total score (44.2 vs 37.8), indicating that perceived quality of life was better for males than 
females. The prevalence of symptoms of anxiety (70.3%) and depression (66.2%) was 
high, with a significantly greater proportion of females than males reporting symptoms of 
anxiety (75.4 vs 55.7%). Scores on the EQ5D-3L general quality of life measure show 
anxiety and depression, pain and discomfort, and performing usual activities were areas 
that were more widely perceived as extremely problematic by 18.7%, 28.0% and 8.8% of 
the sample, respectively. The mean EQ5D-3L Perceived health status score of 44.0 
indicates that the perceived health of the sample was poor, with 100 representing best and 
0 representing worst possible health state. The psychological characteristics of the sample 
are examined in greater detail in Chapter three. 
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Table 2.3.4: Quality of life and mental health characteristics of the CWMS sample by 
gender and combined 
 Whole sample Females Males P 
N (%) 262 196  (74.8) 66 (25.2)  
Baseline IWQOL-Lite  
Physical function 42.4±25.3 41.7±24.2 44.6±28.3 0.433 
Self-esteem 26.2±27.5 22.5±24.5 36.5±32.6 <0.001 
Sexual life 41.9±35.9 38.8±35.7 50.3±35.6 0.039 
Public distress 40.5±28.9 39.9±28.6 42.3±30.0 0.570 
Work 51.2±30.3 49.9±30.0 55.4±31.4 0.244 
IWQOL-Lite total 39.5±22.1 37.8±21.2 44.2±24.0 0.047 
HADS  
HADS anxiety 10.4±4.5 10.9±4.3 9.2±5.0 0.012 
HADS depression 9.1±4.0 9.2±4.0 8.7±4.0 0.388 
HADS Total 19.6±7.7 20.1±7.5 17.9±8.2 0.064 
Anxiety present % (≥8) 70.3 75.4 55.7 0.004 
Depression present % (≥8) 66.2 66.3 66.1 0.978 
Severe Anxiety present % (≥11) 48.3 50.9 41.0 0.184 
Severe Depression present % (≥11) 40.4 42.0 35.7 0.405 
EQ5D-3L Mobility    0.219 
No problems % 33.3 34.3 30.5  
Some problems % 66.3 65.7 67.8  
Extreme problems % 0.4 0.0 1.7  
EQ5D-3L Self-care    0.181 
No problems % 64.3 66.1 59.3  
Some problems % 35.3 33.9 39.0  
Extreme problems % 0.4 0.0 1.7  
EQ5D-3L Anxiety/depression    0.196 
No problems % 24.7 21.7 32.8  
Some problems % 56.6 57.8 53.4  
Extreme problems % 18.7 20.5 13.8  
EQ5D-3L Pain/discomfort    0.510 
No problems % 14.7 13.8 17.3  
Some problems % 57.3 56.3 60.3  
Extreme problems % 28.0 29.9 22.4  
EQ5D-3L Usual activities    0.970 
No problems % 31.0 30.5 32.2  
Some problems % 60.2 60.5 59.3  
Extreme problems % 8.8 9.0 8.5  
EQ5D-3L Perceived health status 44.0±20.1 43.1±20.2 46.8±20.0 0.250 
Data are percentages and means ± standard deviations.   
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2.3.5 Sleep characteristics 
Table 2.3.5 shows the sleep characteristics of the sample. The mean Global PSQI score of 
8.3 indicates poor sleep quality, with 65.1% of the sample achieving scores ≥6 which 
indicate poor quality. The sample estimated a mean of 8.6 hours spent in bed and 6.4 hours 
of sleep per night, suggesting that individuals in the sample may have perceived difficulty 
in maintaining sleep, with only 34.0% of the sample achieving a habitual sleep efficiency 
score ≥85%. Indeed, slightly less than half of the sample (49.8%) reported sleeping for ≥7 
hours per night, whilst 12.0% reported achieving <5 hours of sleep per night, and 38.2% of 
the sample reported sleeping 5-7 hours per night, indicating that a substantial proportion 
may not be meeting their sleep needs. Furthermore this was reflected in participants’ 
subjective ratings of sleep quality, with 60.7% of the sample rating their sleep as either 
fairly or very bad and 13.6% of the sample reporting the regular use of sleep medication ≥3 
times per week.  
The mean ESS score of 8.8, which is within normal limits indicates that the 
experience of symptoms of sleepiness was not widespread across the sample. Indeed, 
males achieved significantly greater mean ESS scores (10.2 vs 8.3), indicating higher 
levels of sleepiness than reported by females. Furthermore 39.7% of the sample achieved 
ESS scores ≥11, which indicate presence of excessive daytime sleepiness symptoms. 
Together the findings of the PSQI and ESS measures indicate that perceived sleep quality 
is low, however this is not reflected in the experience and reporting of symptoms of 
sleepiness. 
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Table 2.3.5: Sleep characteristics of the CWMS sample by gender and combined 
 Whole sample Females Males P 
N (%) 262 196  (74.8) 66 (25.2)  
PSQI-1 Subjective sleep quality     
Mean score (0-3) 1.7±0.9 1.8±0.9 1.6±1.1 0.326 
Proportion (%)    0.014 
Very/fairly good 39.3 35.5 51.8  
Very/fairly bad 60.7 64.5 48.2  
PSQI-2 Sleep latency     
Mean score (0-3) 1.4±1.0 1.4±1.0 1.1±1.0 0.022 
PSQI-3 Sleep duration     
Mean score (0-3) 1.3±1.1 1.3±1.1 1.3±1.1 0.636 
Proportion (%)    0.787 
≥7 hours 49.8 50.6 47.5  
6-6.9 hours 21.9 20.7 25.4  
5-5.9 hours 16.3 17.2 13.6  
≤4.9 hours 12.0 11.5 13.6  
PSQI-4 Habitual sleep efficiency     
Mean score (0-3) 1.4±1.2 1.4±1.2 1.3±1.2 0.655 
Proportion (%)    0.939 
>85% 34.0 33.8 34.7  
75-84% 21.8 21.0 24.5  
65-74% 17.0 17.2 16.3  
<65% 27.2 28.0 24.5  
Estimated time in bed (hours) 8.6±1.5 8.6±1.5 8.5±1.4 0.487 
Estimated time asleep (hours) 6.4±1.6 6.4±1.6 6.5±1.6 0.853 
PSQI-5 Sleep disturbances     
Mean score (0-3) 1.6±0.8 1.7±0.8 1.5±0.9 0.219 
PSQI-6 Use of sleep medication     
Mean score (0-3) 0.6±1.1 0.6±1.1 0.4±1.0 0.152 
Proportion (%)    0.302 
Not during past month 77.9 75.2 86.5  
Less than once a week 2.3 3.1 0.0  
Once or twice a week 6.1 6.8 3.8  
Three or more times a week 13.6 14.9 9.6  
PSQI-7 Daytime dysfunction     
Mean score (0-3) 1.2±0.9 1.3±0.9 1.1±1.0 0.276 
Global PSQI score 8.3±5.3 8.7±5.5 7.0±4.6 0.024 
Proportion PSQI ≥6 (%) 65.1 66.3 61.5 0.483 
ESS Mean score 8.8±5.7 8.3±5.6 10.2±6.0 0.025 
Proportion ESS ≥11 (%) 39.7 36.8 48.3 0.121 
Data are percentages and means ± standard deviations. 
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2.3.6 Characteristics of the CWMS sample by BMI group 
Table 2.3.6 shows the characteristics of the sample by BMI group. There were no 
significant differences in demographic characteristics between the groups. Those in the 
BMI ≥50.0kg/m2 group were more likely to have hypertension (44.2%) and report the 
presence of ≥3 co-morbidities (26.0%), whilst a considerable proportion of those in the 
≤40.0kg/m2 group (22.3%) also reported the presence of ≥3 co-morbidities, due to the 
service referral criteria. 
 
Table 2.3.6: Characteristics of the CWMS sample by BMI group 
 
Whole 
sample 
BMI <40.0 
BMI 40.0 
<50.0 
BMI ≥50.0 P 
N (%) 262 45 (17.2) 140 (53.4) 77 (29.4)  
Age (years) 43.1±11.8 44.4±13.7 42.2±11.3 44.0±11.6 0.427 
Sex (% female) 74.8 71.1 74.3 77.9 0.690 
Systolic blood pressure (mmHg) 140.9±17.7 137.1±17.5 138.7±15.7 147.8±20.0 0.007 
Diastolic blood pressure (mmHg) 85.2±11.7 82.7±8.8 84.8±11.2 87.6±13.8 0.192 
Type 2 diabetes (%) 26.3 22.2 22.1 36.4 0.059 
Hypertension (%) 34.4 37.8 27.9 44.2 0.047 
Arthritis (%) 24.0 24.4 20.0 31.2 0.183 
Obstructive sleep apnoea (OSA, %) 25.6 17.8 24.3 32.5 0.175 
Cardiovascular disease (CVD, %) 11.1 8.9 8.6 16.9 0.153 
Number of co-morbidities ≥3 (%) 17.6 22.3 11.4 26.0 0.033 
Weekday sedentary time (hours) 6.7±3.9 6.1±4.4 6.5±3.6 7.6±3.9 0.142 
Weekend sedentary time (hours) 6.5±3.6 5.2±3.2 6.4±3.3 7.6±4.0 0.011 
Baseline IWQOL-Lite      
Physical function 42.4±25.3 56.1±25.0 42.7±24.7 35.1±24.0 <0.001 
Self-esteem 26.2±27.5 34.7±31.8 24.1±25.9 25.6±27.6 0.116 
Sexual life 41.9±35.9 50.4±35.9 41.5±36.5 38.4±34.6 0.310 
Public distress 40.5±28.9 66.4±30.0 40.5±27.0 27.4±22.3 <0.001 
Work 51.2±30.3 64.6±26.5 49.3±30.3 48.2±30.8 0.022 
IWQOL-Lite total 39.5±22.1 53.4±21.6 39.1±21.8 33.3±20.2 <0.001 
Mean ESS score 8.8±5.7 5.9±4.9 9.7±5.9 8.7±5.3 0.001 
Proportion ESS ≥11 (%) 39.7 23.1 45.5 38.6 0.043 
Mean global PSQI score 8.3±5.3 7.4±4.5 8.5±5.0 8.6±6.2 0.408 
Proportion PSQI ≥6 (%) 65.1 62.2 67.9 61.8 0.610 
Data are percentages and means ± standard deviations. 
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 Those in the BMI ≥50.0kg/m2 group reported experiencing significantly worse 
physical function, public distress, and work, as well as total quality of life as measured by 
IWQOL-Lite. Those in the BMI ≥50.0kg/m2 group also spent significantly more time 
engaged in sedentary activity at the weekend (7.6 hours) compared to the other BMI 
groups. Interestingly, those in the BMI 40.0 ≥50.0kg/m2 group reported the greatest 
amount of sleepiness, with 45.5% of the group reporting ESS scores indicative of 
excessive daytime sleepiness, however there was no significant difference in the self-
reported sleep quality across by the BMI groups. 
 
2.3.7 Characteristics of the CWMS sample by age group 
Table 2.3.7 shows the characteristics of the sample by age group. The ≥50 year age group 
comprised a significantly smaller proportion of females (57.5%) compared to the younger 
age groups. Those in the ≥50 year age group also had a significantly greater waist 
circumference and were more likely to experience co-morbid health conditions than those 
of younger age. Interestingly, those in the youngest <40 year age group reported 
significantly worse anxiety, self-esteem and public distress, but better physical function 
and fewer problems relating to mobility and self-care than the older age groups.  
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Table 2.3.7: Characteristics of the CWMS sample by age group 
 
Whole 
sample 
Age <40 
years 
Age 40 
<50 years 
Age ≥50 
years 
P 
N (%) 259 96 (37.1) 90 (34.7) 73 (28.2)  
Sex (% female) 74.9 81.3 82.2 57.5 <0.001 
Weight (kg) 132.0±24.8 134.9±28.9 126.8±21.5 134.5±22.0 0.051 
Body mass index (BMI, kg/m
2
) 47.1±8.0 47.6±8.9 46.2±6.9 47.4±7.9 0.477 
Waist circumference (cm) 131.6±14.5 129.5±14.8 129.0±13.0 137.5±14.5 0.022 
Systolic blood pressure (mmHg) 140.9±17.7 137.8±14.4 141.5±18.1 143.9±20.4 0.194 
Diastolic blood pressure (mmHg) 85.3±11.8 85.3±10.7 87.9±11.5 82.2±12.7 0.043 
Type 2 diabetes (%) 26.3 8.3 23.3 53.4 <0.001 
Hypertension (%) 34.4 11.5 34.4 64.4 <0.001 
Arthritis (%) 23.9 6.3 25.6 45.2 <0.001 
Obstructive sleep apnoea (OSA, %) 25.9 16.7 28.9 34.2 0.025 
Cardiovascular disease (CVD, %) 11.2 2.1 6.7 28.8 <0.001 
Number of co-morbidities ≥3 (%) 17.8 2.1 14.4 42.5 <0.001 
Baseline IWQOL-Lite      
Physical function 42.0±25.2 48.4±23.1 42.1±24.5 33.3±26.5 0.001 
Self-esteem 26.1±27.5 15.9±19.6 26.6±26.6 39.1±32.2 <0.001 
Sexual life 41.9±36.0 44.5±35.9 40.3±36.0 40.1±36.5 0.704 
Public distress 40.2±28.8 31.6±25.4 44.9±29.8 45.9±29.6 0.001 
Work 51.1±30.3 47.0±28.6 54.4±32.1 52.7±30.2 0.272 
IWQOL-Lite total 39.2±22.1 37.4±19.8 40.2±22.8 40.3±24.5 0.631 
EQ5D-3L      
Mobility (% problems) 67.1 53.5 70.3 82.3 0.001 
Self-care (% problems) 35.7 23.0 31.5 59.0 <0.001 
Anxiety/depression (% problems) 75.1 78.6 70.8 75.4 0.536 
Pain/discomfort (% problems) 85.6 79.3 90.4 88.7 0.098 
Usual activities (% problems) 69.5 64.8 67.6 78.7 0.175 
HADS      
HADS anxiety 10.4±4.6 11.2±4.1 10.5±4.4 9.3±5.1 0.046 
HADS depression 9.1±4.0 9.6±4.2 9.1±3.6 8.5±4.3 0.264 
Anxiety present % (≥8) 70.4 75.6 72.5 60.3 0.111 
Depression present % (≥8) 66.2 69.4 67.1 60.3 0.520 
Severe Anxiety present % (≥11) 48.5 57.8 46.3 38.1 0.050 
Severe Depression present % (≥11) 40.5 47.1 39.2 32.8 0.222 
Data are percentages and means ± standard deviations. 
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2.4 DISCUSSION 
 
Examination of the demographic characteristics revealed that there were no significant 
gender differences in marital status, and that the findings are consistent with the general 
population rates for adults living in England and Wales obtained by the General Lifestyle 
Survey (GLS) in 2011 (92). Indeed within the current sample 52.5% of females and 46.5% 
of males reported to be married compared to 49% of females and 52% of males in the 
GLS, whilst 23.0% of females and 27.9% of males were classed as single within the 
current sample compared to 21% of females and 27% of males in the GLS. It is surprising 
that married marital status was not more highly prevalent amongst males within this 
extremely obese sample relative to the general population, as two studies have 
demonstrated an association between obesity and marital status in males whereby 
overweight and obese men were more likely to be married (49, 50). However, the two 
previous studies did not specifically address extreme levels of obesity, with findings from 
the current sample suggesting a different pattern of association between marital status and 
obesity at the extreme end of the BMI spectrum, which more closely resembles the marital 
status of the general population. 
A large proportion of the sample attending the CWMS were White European 
(90.8%), with the remaining sample classed as Asian (5.6%), Black African or Caribbean 
(2.8%) and other ethnic background (0.7%). The ethnicity data highlights that individuals 
of White European ethnicity were over-represented in the sample, with the sample 
prevalence rate of 90.8% higher than the rate of 79.8% of individuals in England reporting 
to be of White British ethnicity as detailed in the UK 2011 census, and considerably higher 
than the rate of 53.1% of Birmingham residents reporting to be of White British ethnicity 
(93). Indeed, Birmingham is a super-diverse city with residents from a wide range of 
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national, ethnic and religious backgrounds, with large proportions of individuals reporting 
their ethnicity as Pakistani (13.5%), Indian (6.0%), and Black Caribbean (4.4%) (93). The 
ethnicity data reported in the present sample, suggests that individuals from minority 
ethnic groups may not be accessing the specialist weight management service. This would 
indicate a need to take action in order to identify potential shortcomings in the referral 
process and in the delivery of the service, which may be limiting inclusivity. However, it is 
important to note that the over-representation of White European individuals may also be 
due to errors in the collection of ethnicity data, with a high proportion of missing ethnicity 
data (45.8%), and due to the fact that White British could not be differentiated from White 
European status. 
There were no gender differences in the occupational status reported by the sample. 
However the level of employment reported by the sample (62.0%) was below the UK 
national averages, of 74.9% for the period February-April 2008 (104), and 71.3% for the 
period June-August 2012 (105), which correspond to the first and last 3-month periods of 
individuals commencing attendance at the service. In addition, the levels of unemployment 
(22.3%) reported by the sample exceeded the national averages of 5.3% (104) and 7.9% 
(105), suggesting that unemployment was significantly greater amongst the sample 
attending the CWMS than in the general UK adult population. Furthermore when the 
unemployment rate of the sample is compared to the regional unemployment figures for 
the West Midlands, a large discrepancy remains. Since 2005 there has been a persistent 
trend of higher unemployment rates in the region compared to the UK, with the West 
Midlands having the second highest unemployment rate (9.8%) of all the UK regions and 
countries compared with the UK average of 7.9% in the fourth quarter of 2010 (106). The 
impact of the lower employment level is reflected in the fact that median gross weekly 
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earnings were also lower in the region (£456) than for the UK (£489) (106). Despite the 
higher regional rate of unemployment, the rate observed in the current sample of 
individuals attending the CWMS (22.3%), can still be considered to be markedly higher 
than the West Midlands average. 
The higher levels of unemployment within the sample attending the service could 
be due to a number of factors including reduced physical and psychological capacity thus 
reducing ability to work, and limited employment opportunities due to weight-related 
discrimination from existing or potential employers. This is supported by a study of over 
3,000 adults which found that those with BMI ≥35.0kg/m2 were significantly more likely 
to report experiencing major job-related discrimination (58). The higher level of 
unemployment in the sample may also be a reflection of the fact that the service operates 
clinic sessions during normal working hours on weekdays, thus making the service less 
accessible to those in full-time employment who are not able to attend during the time the 
service runs clinics.  
It is also conceivable that the higher level of unemployment observed in the sample 
is a reflection of the social gradient phenomenon whereby the poorest individuals with the 
lowest SES have the worst health status (107). The phenomenon is observed in low, middle 
and high income countries, with the gradient running across the entire SES spectrum, with 
health inequities affecting everyone. The conditions in which individuals live and work are 
determinants of health, directly impacting upon well-being, and thus SES and health status 
are inextricably linked (108). Further investigation of these issues would be facilitated by 
the routine collection of more robust SES measures for individuals commencing 
attendance at the CWMS, including current income, educational attainment and specific 
occupation details, rather than employment status alone (109). Additionally, Indices of 
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Multiple Deprivation (IMD) data for participants’ area of residence could also be 
examined, in order to determine if there are certain specific highly deprived local areas 
from which participants are more commonly referred to the service. 
SES has also been demonstrated to be related to lifestyle characteristics such as 
smoking status (110) and alcohol consumption (111) with lower SES groups more likely to 
engage in these behaviours. A slightly greater proportion of the sample (25.5% for both 
males and females) reported to be current smokers, compared to 19% of females and 22% 
of males in the UK general population over age 16 (94). The proportion of males within 
the sample that consumed alcohol (62.7%) is in line with data from the Opinions and 
Lifestyle Survey in which 64% of males in the UK general population reported drinking 
alcohol in the previous week. However  the proportion of females consuming alcohol 
within the sample exceeded the UK general population prevalence  (65.5% vs 52%) (95). 
In addition to females within the sample consuming more alcohol than those in the 
general population, females spent more time engaged in sedentary behaviour than those in 
the general UK adult population, during weekdays (6.5 vs 4.7 hours) and during weekend 
days (6.2 vs 5.1 hours), as did males during both weekdays (7.6 vs 4.9 hours) and weekend 
days (7.6 vs 5.4 hours) (96). The sample reported that their level of activity was markedly 
sedentary, with males spending significantly more sedentary time at the weekend 
compared to females. These findings are consistent with a study of ten extremely obese 
individuals in the US seeking weight management. Activity was measured using an arm-
based activity sensor over a 72-hour period, which showed that the sample engaged in an 
average of 8.4 minutes of moderate activity per day, defined as 3-6 metabolic equivalents 
(METs), with the remainder spent engaged in sedentary activity, defined as (<3 METs) 
(112). Furthermore, the study indicated that participants took an average number of 3,763 
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daily steps, which is considerably less than the target of 10,000 steps per day which has 
been widely utilised as a goal in health promotion interventions (113). These findings 
indicate that physical activity is limited within populations of extremely obese individuals. 
However further investigation of the physical and sedentary activity levels of individuals 
entering the service is required. The collection and utilisation of the complete IPAQ 
measure rather than a single domain (sedentary time) and the additional inclusion of an 
objective measure of physical activity using pedometers or sensors to record data in 
addition to self-reported measures, would facilitate more detailed examination of the 
baseline physical activity levels of the sample and identify areas for improvement. Given 
the contribution of physical inactivity to cardiovascular disease (114), type 2 diabetes 
(114), cancers (114) and impairment in mental health (115, 116) it is important to 
understand the full extent of sedentary activity within this at-risk patient population.  
In addition to low levels of physical activity, the sample also demonstrated low 
levels of perceived sleep quality, with a substantial proportion (65.1%) achieving PSQI 
scores indicative of poor sleep quality and providing subjective ratings that their sleep was 
fairly or very bad (60.7%). The observation of poor sleep quality within the sample is 
consistent with a study which has also demonstrated widespread poor sleep quality in a 
sample attending the University Hospital Aintree weight management service, whereby 
73.0% of the sample achieved global PSQI scores >5. However it is important to note that 
the larger proportion of 73.0% may be due to the fact that a lower threshold (>5) was 
utilised than the cut-point utilised in the present study (≥6), with the developers of the 
PSQI instrument recommending a threshold of scores ≥6 to indicate poor sleep quality 
(89). Despite the methodological differences, these findings provide further support that 
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poor sleep quality is experienced in extremely obese individuals attending weight 
management services. 
The present sample reported a mean of 6.4 hours of sleep per night, which is lower 
than the mean of 7.0 hours per night reported in a study of 1,997 adults recruited from the 
UK general population (97). Indeed, findings from the Hordaland Health Study, a large 
scale cross-sectional study of 8,860 individuals living in Norway have also demonstrated 
longer mean self-reported sleep durations of 7 hours 11 minutes for females and 6 hours 
and 52 minutes for males, than those observed in the present sample (117). Furthermore, 
slightly less than half of the present sample (49.8%) reported sleeping ≥7 hours per night, 
indicating that a considerable proportion of the sample may not be meeting their sleep 
requirements. It has been demonstrated that there are individual differences in habitual 
sleep duration (118) and in subjective sleep need (119), suggesting that individuals require 
and take varying amounts of sleep per night.  However, the fact that a considerable 
proportion of the sample (28.3%) report a mean <6 hours per night gives cause for 
concern. A systematic review and meta-analysis has established that individuals who report 
short sleep duration and indeed also those who are long-sleepers are at increased risk of 
all-cause mortality (120). 
It is of interest that the reporting of poor sleep quality was not reflected in the 
experience of symptoms of sleepiness. Indeed, whilst 65.1% of the present sample 
obtained poor sleep quality scores, only 39.7% of the sample achieved scores indicative of 
excessive daytime sleepiness. A similar pattern of results was observed in the study of 
individuals attending the University Hospital Aintree weight management service, whereby 
30.8% of the sample reported scores indicative of excessive daytime sleepiness, whilst a 
much higher proportion (73.0%) of the sample reported poor sleep quality. These findings 
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suggest that some of the participants either were not experiencing negative impacts of their 
poor sleep or alternatively that these symptoms were instead attributed to generalised low 
mood and quality of life rather than to sleepiness. 
Quality of life has been demonstrated to be markedly low within the sample, with 
mean total IWQOL-Lite scores of 37.8 for females and 44.2 for males, with females 
experiencing significantly poorer quality of life than males. In addition, widespread high 
prevalence of symptoms of anxiety (70.3%) and depression (66.2%) were observed across 
the sample, which greatly exceeds the prevalence in the UK general population of 33.0% 
for anxiety and 11.4% for depression, also measured using the HADS tool (98). The 
findings indicate that the mental well-being of females was more severely impacted, with a 
significantly greater proportion experiencing anxiety (75.4 vs 55.7%) and greater 
impairment across several quality of life domains, relative to males. The level of 
impairment observed in the present sample is consistent with a study of extremely obese 
individuals in the US seeking bariatric surgery which also demonstrated widespread 
reduction in quality of life, with IWQOL-Lite scores ranging from 40.4-46.2 across 
domains (61). However, it is important to note that obese individuals who are not seeking 
treatment have been demonstrated to report lower levels of psychological distress (121) 
and impairment in quality of life (61) than those who are treatment-seeking. As such, the 
findings of the present sample reflect the mental well-being of a treatment-seeking 
population and may not be representative of extremely obese non-treatment-seeking 
individuals. Furthermore, obese individuals, incorporating both treatment-seeking and non-
treatment-seeking individuals, have been demonstrated to report greater use of maladaptive 
coping strategies which avoid thinking about and actively facing stressful events, relative 
to normal weight individuals who are more likely to employ coping styles which actively 
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address stressors  (121). This may be a potential mechanism behind the impairment in 
mental well-being among the extremely obese patient population.  
In addition to psychological co-morbidity, the findings have highlighted the 
pervasiveness of co-morbid physical health conditions. These findings are consistent with 
the literature which has previously documented the co-morbid health conditions commonly 
associated with obesity (43, 44). Indeed, studies have also demonstrated that the negative 
health impacts of obesity are alleviated with weight loss (45, 46), with findings of the Look 
AHEAD study demonstrating that those overweight and obese individuals with type 2 
diabetes achieving modest losses of 2-5% baseline body weight were more likely to 
experience clinically significant improvement in systolic blood pressure (OR= 1.24, 1.02 - 
1.50), HbA1c (OR= 1.80, 1.44 - 2.24), and triglycerides (OR= 1.46, 1.14 - 1.87), relative to 
those who did not lose weight (122).  
A greater prevalence of several conditions was observed within the sample 
compared to the general population, including type 2 diabetes (26.3 vs 6.0%) (99), OSA 
(39.4 vs 4.0% males, and 20.9 vs 2.0% females) (100), hypertension amongst males (60.6 
vs 31.0%) (101), cardiovascular disease amongst males (27.3 vs 13.9%) (102), and arthritis 
24.0% within the present sample vs 11% (arthritis of the hip) observed in the general 
population (103). Interestingly, the prevalence of arthritis within the sample was the same 
as the general population prevalence of arthritis of the knee 24.0% (103), thus an increased 
prevalence within this clinical sample was not observed. This may be due to the fact that 
the general population prevalence rates are elevated due to an increased prevalence of 
arthritis observed in older age groups. It is also of interest that the prevalence of 
hypertension among females of the sample was similar to the UK female prevalence (25.5 
vs 28.0%) (101), and the prevalence of cardiovascular disease among females of the 
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sample was considerably lower than that of the general female population (5.6 vs 13.4%) 
(102). Interestingly, further gender differences were observed in the present sample 
whereby all of the co-morbid conditions except arthritis were demonstrated to be more 
widespread amongst males than females, with a significantly greater proportion of males 
(slightly more than a third of all male participants) reporting the presence of ≥3 co-morbid 
conditions. These findings demonstrate that the physical health of the individuals attending 
the service was considerably poorer amongst the male participants. This may reflect gender 
differences in individuals’ motivation for attending the service, with males being prompted 
to seek help as a result of physical symptoms and difficulties, whilst females may have 
been motivated as a result of the experience of psychological symptoms. 
Further potential motivation for attendance was identified in the analyses 
demonstrating the characteristics of the sample stratified by BMI and age group. The 
findings indicate that those in the BMI ≤40.0kg/m2 and ≥50.0kg/m2 groups were more 
likely to report the presence of ≥3 co-morbidities, which is likely due to the service referral 
criteria which specify that those with BMI ≤40.0kg/m2 must also have a co-morbid health 
condition in order to be eligible to attend the service. Furthermore, those in the older (≥50 
year) age group were more likely to experience physical co-morbidities and as a result 
report problems in mobility and self-care than those of younger age. The findings suggest 
that those in the younger (≤40 year) age group were potentially motivated to attend the 
service due to the greater reported experience of psychological co-morbidities including 
experience of anxiety, public distress and low self-esteem, rather than physical co-
morbidities which appear to be less pertinent. 
This chapter has constructed a detailed profile of individuals attending the CWMS, 
however it is important to highlight the limitations of this work. Firstly, caution must be 
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taken when generalising the findings of this study to the broader extreme obese population, 
as the sample described are those who were seeking weight management support. This 
study does not shed light on the health and well-being of non-treatment-seeking extreme 
obese individuals, with the possibility that these individuals experience better mental well-
being than the present sample and thus have not been compelled to seek help. Conversely, 
it is conceivable that the well-being of those not seeking treatment could be considerably 
worse than the present sample, with these individuals not seeking support as a consequence 
of their extremely poor mental and physical health and potentially due to a greater number 
of unsuccessful prior weight loss experiences. In addition, the study is also limited by the 
relatively small sample size and due to the fact that detailed demographic, clinical and self-
report questionnaire data were only available for those individuals attending the CWMS 
and not those attending the SLiM pathway which also operates within the Specialist 
Weight Management Service. Whilst there was not the same level of detailed information 
collected for the SLiM sample, additional longitudinal quality of life data for those 
attending the SLiM programme were obtained and are examined in Chapter three. Despite 
the discussed limitations, there are several notable strengths of the work including the 
measurement of a wide range of factors affecting individuals’ lives, the use of validated 
and reliable self-report measures, the investigation of an under-researched group, the 
clinical utility of examining a service currently in operation, and the potential to impact 
service development. 
 
2.4.1 Summary of findings 
This chapter has provided a detailed profile of the characteristics of the individuals 
attending the CWMS pathway of the specialist weight management service. The 
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characterisation of individuals in the patient population has enhanced current 
understanding of individuals attending the service and more broadly of individuals with 
extreme obesity. Key findings include the over-representation of individuals of White 
European ethnicity as well as those who were unemployed, in addition the presence of co-
morbid health conditions were also demonstrated to be highly prevalent. Furthermore, the 
study has highlighted the poor sleep quality and impaired quality of life experienced by the 
individuals in the sample, as well as the widespread prevalence of anxiety and depression. 
These findings have highlighted that the individuals entering the CWMS are a sample with 
very complex medical and psychological needs, whereby quality of life is substantially 
reduced. 
 
2.4.2 Recommendations 
The findings outlined in this chapter have enhanced current understanding of this patient 
population and the following recommendations are supplied in order to improve weight 
management services which currently provide vital care and support to individuals with 
extreme obesity, to aid them in making changes and commencing weight loss. The high 
proportion of females, White European individuals and those who are unemployed, 
indicates that consideration may need to be taken in the referral and commencement 
procedures of the service. Action may be required in order to reach those individuals who 
are not accessing the service, such as events to raise awareness held in local communities 
in order to promote the service and engage with individuals from minority ethnicity 
communities. Further contact such as follow-up telephone calls may also be required with 
individuals who do not respond to initial communications regarding appointments and 
commencement at the service. Alternative commencement approaches could also be 
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considered including informal information sessions whereby individuals who have been 
referred can receive information about the service and have their queries answered before 
committing to attend. Additional consideration may also be needed for those individuals 
who cannot attend due to employment commitments, such as the provision of ‘out of 
hours’ clinic sessions. Through the modification of existing service referral and delivery 
processes or the trial of new approaches, it is anticipated that the service could be 
accessible to a greater number of individuals of all backgrounds, thus increasing the 
inclusivity of the service and maximising the opportunity for weight loss for all of those 
individuals who would benefit from attendance. 
The findings highlight additional areas to potentially be addressed in the 
multidisciplinary management of these individuals, including the psychological and 
physical co-morbidities faced by a large proportion of those attending the service. 
Consideration should be given to individuals with co-morbid psychological and physical 
conditions, which may potentially affect ability to achieve weight loss. These individuals 
may potentially require additional support, which could be provided through one-to-one 
clinic sessions. Additionally, targeted support groups could be operated which are tailored 
to specific areas of concern such as improving mental health and well-being, or support in 
managing the demands of chronic conditions such as type 2 diabetes and OSA. Those 
individuals with multiple co-morbidities may also potentially benefit from receiving 
further tailored support and specific advice in managing and coping with the burden of 
facing multiple threats to health. Whilst the prevalence levels of co-morbidities observed in 
this chapter have highlighted areas of concern, further investigation of the physical and 
psychological impact of extreme obesity will be required in order to advise more detailed 
recommendations. Furthermore, the introduction of any new additional support 
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interventions would need to be trialled in a small-scale pilot intervention study and 
thoroughly evaluated to ensure clinical efficacy and acceptability with participants. It is 
anticipated that in light of the findings demonstrated in this chapter and through the 
consideration of recommendations, that the design and delivery of specialist weight 
management services will be enhanced. 
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CHAPTER THREE 
 
3.0 QUALITY OF LIFE AND EXTREME OBESITY: A STUDY OF INDIVIDUALS 
ENTERING THE COMMUNITY WEIGHT MANAGEMENT SERVICE (CWMS) 
AND SPECIALIST LIFESTYLE MANAGEMENT (SLIM) PROGRAMME 
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3.1 INTRODUCTION 
 
3.1.1 Extreme obesity and quality of life: Literature search procedure 
The physical co-morbidities of extreme obesity are well documented and research suggests 
that there are also substantial negative impacts on quality of life and mental health, as such 
a systematic literature search was conducted focusing on quality of life and mental health 
in extreme obesity in adult populations. A search of the literature was conducted using free 
text terms, of the PubMed database for articles published in English up to and including 
September 2013.  The search strategy is displayed in Table 3.1.1. 
 
Table 3.1.1: Search strategy 
1 Extreme obes* 
2 Quality of life 
3 Mental health 
4 Mental well-being 
5 Depression 
6 Anxiety 
7 2 or 3 or 4 or 5 or 6 
8 1 and 7 
 
A total of 37 articles were identified, through the database, hand-searching reference lists 
and relevant journals. Of the identified studies, 20 were cross-sectional, 7 intervention 
studies and 10 review articles. 
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3.1.2 Cross-sectional studies 
The 20 cross-sectional studies included in this review are described in Table 3.1.2. The 
cross-sectional data included 200,778 individuals, conducted between 1998 and 2013, 
within Western population samples, namely the UK, US, Canada, Germany, Spain, and 
Australia. Whilst the majority of studies identified in the present literature search have 
exclusively studied extreme obese samples, several studies have focussed on the cross-
sectional relationship between quality of life and obesity in the non-clinical general 
population. These studies have facilitated comparisons between those individuals that are 
normal weight, overweight and within the various classes of obesity, including extreme 
obese (BMI ≥40kg/m2) samples.  
The first population-based study conducted in the UK was a postal-survey whereby 
questionnaires were received from 8,889 randomly-selected adults living in four English 
counties in 1997 (63). Data collected included self-reported height and weight, chronic 
illness status and the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36). 
Of the sample, 11% were categorised as obese (BMI 30.0-39.9kg/m
2
), with a further 1% 
categorised as extreme obese (BMI ≥40.0kg/m2). Findings showed that there were 
significant differences in all dimensions of the SF-36 between the BMI categories, with 
those with extreme obesity scoring the lowest across both the physical and mental 
dimensions. Extreme obese individuals also had the lowest physical component score, 
which was significantly lower than the normal weight score (40.6 vs 51.2, p <0.001), 
whilst for the mental component score, the underweight group had the lowest score, with 
the extreme obese score being second lowest and significantly lower than that of normal 
weight individuals (48.1 vs 50.1, p <0.001). Furthermore, those with obesity and additional 
co-morbid chronic health conditions, which accounted for 56% of those with obesity, 
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reported further impairment in both physical and mental health. However, the authors note 
that the deterioration in health status seen with increasing adiposity was more marked in 
the physical than in the mental components, whereby in the mental and social dimensions 
those individuals in the overweight and obese categories reported a similar level of 
impairment to those in the underweight category. The authors concluded that in this 
population-based sample, obesity was associated with greater impairment in physical than 
mental quality of life, suggesting that the presence of co-morbid health conditions may 
mediate the relationship between obesity and impairment in mental quality of life. Results 
of the study should be interpreted with caution as the study was limited by the use of self-
reported weight and height measures, rather than a more accurate physical measurement, 
which may have resulted in erroneous data as it has been widely reported that individuals 
underestimate their weight. Thus the potential measurement and reporting bias may result 
in misinterpretation of the relationship between adiposity and the psychosocial variables. 
 The second and most recent cross-sectional study conducted in a UK 
population-based sample utilised data from the 2003 Health Survey for England (HSE) 
(123). The sample comprised 14,416 randomly selected adults, with whom questionnaire-
based face-to-face interviews were conducted, which included the EQ-5D quality of life 
measure, and height and weight measurements were obtained. Prevalence of extreme 
obesity was slightly higher in females (2.9%) than males (1%), and after adjusting for 
confounding factors, analyses showed a clear association between being underweight or 
obese and impairment in quality of life as measured by EQ5D in both males and females. 
Those in the overweight, obese or extreme obese categories reported increased problems in 
all dimensions of the EQ-5D (mobility, self-care, anxiety and depression, pain and 
discomfort, and performing usual activities), with the exception of anxiety and depression 
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for which the prevalence was the same for overweight and normal weight individuals. The 
study utilised a large sample size and reliable physical measurements, which enables 
confidence in the observed strong association between above and below normal BMI and 
decreased quality of life.  
The final cross-sectional study conducted in the UK was a small sample (N=179) 
questionnaire survey completed by BMI ≥30.0kg/m2 female magazine subscribers (64). 
Findings indicated that those in the extreme obese category reported significantly poorer 
self-esteem as measured by the Rosenberg Self-Esteem scale, compared to those with BMI 
30.0-39.0kg/m
2
, however there were no significant differences between the groups 
regarding mental health as measured by the Mental Health Inventory. The authors 
conclude that in this sample of obese females the relationship between obesity and 
psychological well-being is complex, with those extreme obese individuals reporting the 
greatest dissatisfaction with their body weight, shape and appearance. However, the sample 
did not differ significantly in terms of mental health, a finding which is in contrast to some 
previous population-based studies. The study benefits from the inclusion of a sample 
recruited from a non-clinical setting, thus capturing the experiences of non-treatment-
seeking individuals. However, the fact that individuals were recruited from a population of 
subscribers to a magazine focusing on ladies fashion for clothes sizes ≥16 means that the 
sample is not representative of all individuals. In addition, the small sample size is likely 
underpowered and the use of self-reported weight and height measures introduces the 
potential for measurement error as previously described. 
Several cross-sectional population-based studies have been conducted in the US 
(124-126), the largest of which utilised data from the 1999 Behavioural Risk Factor 
Surveillance Survey (124). The study sample comprised 155,989 adults who completed 
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self-reported height and weight data along with four questions designed to assess 
individuals’ perceived health-related physical and mental quality of life over the past 30 
days. A J-shaped association between BMI and quality of life was observed, whereby 
compared to those in the BMI 18.0-24.9kg/m
2
 group, those who were underweight, 
overweight, and in obesity classes I, II, and III were significantly more likely to report 
fair/poor general health status, with respective odds ratios of 1.57 (1.39 - 1.76), 1.19 (1.14 - 
1.24), 1.95 (1.85 - 2.05), 2.72 (2.53 - 2.93) and 4.36 (3.97 - 4.80), p <0.001. The findings 
of this large scale population-based study indicate that the health-related quality of life was 
poorest for those in the extreme obese category. However the use of self-reported height 
and weight measures is a limitation despite the overall high methodological rigour of the 
study. 
Another large sample, US population-based study utilised data from the third 
National Health and Nutrition Examination Survey (NHANES) collected between 1988 
and 1994 (125). The sample comprised 8,410 individuals aged 15-39 years who completed 
weight and height measures as well as a structured diagnostic interview which was used to 
assess the presence of major depression according to DSM-IV (Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition) criteria. Analyses assessing risk of 
experiencing depression over the past month were conducted adjusting for age, gender and 
socioeconomic status. These findings indicated a dose-response relationship between 
depression and adiposity, with extreme obese individuals having greater odds of 
experiencing depression in the past month (OR= 4.63, 2.06 - 10.42) than those with BMI 
35.0-39.9kg/m
2
 (OR= 1.90, 0.79 - 4.60) and BMI 30.0-34.9kg/m
2
 (OR= 1.33, 0.57 - 3.13), 
relative to those of BMI 24.9-29.9kg/m
2
. Furthermore, the authors identified that across the 
sample the prevalence of past-month major depression was approximately 2.5-fold higher 
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in females than males, a finding which is consistent with other population-based studies. 
Within extreme obese individuals specifically, the prevalence of past-month major 
depression was higher in females (13.03%) than males (11.54%). The authors conclude 
that the association between obesity and depression varies with the severity of obesity, 
with the prevalence of depression being highest in the extreme obese category.  
Only one population-based study was conducted outside of the UK and US, which 
was conducted in Germany. The study examined the association between obesity and 
suicidal behaviour which was assessed using the revised Suicidal Behaviours 
Questionnaire in a sample of 2,436 individuals (62). Findings indicate that those with BMI 
30.0-34.9kg/m
2
 were significantly more likely to attempt suicide (OR= 3.49, 1.76 - 6.90, p 
<0.001) relative to overweight (BMI 24.9-29.9kg/m
2
) individuals, with extreme obese 
individuals at even greater risk (OR= 12.43, 3.87 - 39.86, p <0.001). Furthermore, extreme 
obese individuals are also at greater risk of suicidal behaviour (OR= 21.22, 6.51 - 69.20) 
than those with BMI 30.0-34.9kg/m
2
 (OR= 3.02, 1.50 - 6.08), relative to overweight (BMI 
24.9-29.9kg/m
2
) individuals. This novel study benefits from the use of a tool which goes 
beyond the measurement of emotion and examines the consequences of mood disturbance 
on individuals’ actions in terms of both suicidal ideation and actions. The study also 
highlights the obese and specifically extreme obese population as an at-risk group and 
indicates that there is potentially a need for the introduction of screening to identify and 
provide support for vulnerable individuals. 
The following studies have been conducted in treatment-seeking extreme obese 
samples. Only one treatment-seeking cross-sectional study has examined the relationship 
between quality of life and extreme obesity in a UK sample (127). The study examined 
baseline data from 253 individuals entering one of two specialist weight management 
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centres, Luton and Dunstable Hospital NHS Trust, Luton and Addenbrooke’s Hospital 
NHS Trust, Cambridge. The authors did not detail the nature of the service delivered at the 
centres. Self-report questionnaire data were collected at baseline including the Hospital 
Anxiety and Depression Scale (HADS), the Eating Disorder Inventory (EDI-2), and the 
Impact of Weight on Quality of Life scale (IWQOL-Lite). Analysis of the baseline data 
revealed that within the sample entering the specialist weight management centres, 56% 
achieved a HADS score indicative of anxiety and 48% for depression. Furthermore, gender 
differences were observed, whereby the prevalence of anxiety was higher in females 
(60.5%) than males (42%, p <0.01). Interestingly, the authors reported no significant 
gender difference in prevalence rates of depression, which were 47.8% for females and 
47.5% for males. Analysis of the EDI-2 data revealed that 11.5% of the sample 
demonstrated a score indicative of presence of bulimia nervosa. The IWQOL-Lite data 
revealed widespread reduction of quality of life in the sample, with substantial proportions 
scoring within 10% of the lowest possible score, indicating the poorest quality of life. In 
males, sexual life was the most affected area with 32.8% of the sample scoring within the 
lowest 10%, whilst in females self-esteem was the most affected domain, with 20.5% of 
the sample achieving a score within 10% of the lowest possible score. The authors 
concluded that their findings demonstrate a high prevalence of psychological co-
morbidities, including anxiety, depression, and eating disorders, as well as marked 
impairment in quality of life within the sample, proposing that psychological diagnoses 
should be considered prior to commencement on weight management programmes in order 
to increase the effectiveness of treatment. However, it is important to note that the high 
prevalence of psychological co-morbidity was observed in a treatment-seeking sample and 
may not be representative of non-treatment-seeking individuals. 
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One study comprising a treatment-seeking sample has been conducted in Germany. 
The study assessed health-related quality of life utilising the SF-36, in a sample of 640 
adults attending one of four obesity treatment centres (65). BMI was shown to be 
significantly associated with the physical but not the mental component of the SF-36. 
Those with extreme obesity scored significantly lower than the other obese groups on the 
physical component subscale and correspondingly a significant negative association was 
observed between BMI and the physical component score (r= -0.56, p <0.001). However, 
there were no significant differences between the BMI groups in terms of mental 
component score, likewise, there was no association between BMI and the mental 
component score. The absence of an observed relationship between BMI and mental health 
is in contrast to the previously discussed studies, and could be due to limitations in the 
capabilities of the SF-36 tool in detecting the mental health issues of this population, rather 
than due to the fundamental absence of an association with BMI. The inclusion of 
additional mental health measures is necessary in order to further assess the relationship 
between adiposity and adverse mental health within this population. 
Additional cross-sectional design studies are those that have examined the use of 
assessment tools such as validation of the IWQOL-Lite in non-English languages (128), 
development of new tools such as the Obesity Adjustment Survey (129), and the 
comparison of a selection of assessment tools such as the EQ5D and SF-36 (130). 
One study did not use quantitative assessment tools, instead opting for a qualitative 
approach conducting in-depth semi-structured interviews with 76 obese Australian adult 
participants (131). Although the study included participants across the spectrum of obesity, 
the mean BMI of the sample (42.5kg/m
2
)
 
was within the extreme obese category. 
Capturing the social experiences of obesity and the effects on daily life was a key topic of 
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enquiry in this study and findings indicated that nearly all of the participants reported that 
they had experienced stigma and discrimination because of their weight. Interestingly, a 
small proportion of the sample also reported feelings of social isolation, rarely interacting 
with others. The authors conclude that whilst there was variation in the lived experiences 
of obesity reported by the study participants, several recurring themes were identified, 
including experience of discrimination, stigma and social isolation, repeated unsuccessful 
attempts at weight loss, and the perception of being misunderstood by healthcare 
professionals. The authors propose that weight management interventions should recognise 
the common enduring themes as well as the variation in the experience of obesity and its 
impact on daily life. Interestingly, this was the only study within the present literature 
review to adopt a qualitative approach to examine the relationship between adiposity, 
quality of life and mental well-being. The lack of qualitative studies highlighted by the 
present literature review, is surprising given that this methodology facilitates the 
exploration of lived experiences and has the potential to add to our understanding of the 
relationship.  
Several quantitative studies have been published examining the impact of social 
stigma in obesity (132-134). The most recently published study comprised a sample of 574 
individuals seeking treatment at two bariatric surgery centres in the US (132). A telephone 
survey was conducted with participants whereby self-reported weight and height data were 
collected along with data from two questionnaires, the SF-36 and the IWQOL-Lite. A 
preference-based quality of life measure was also used to assess individuals’ health utility 
through a series of gambling scenarios which assessed willingness to risk death in order to 
lose various amounts of weight or achieve their most valued health and weight state. The 
health utility score indicated that the sample were willing to accept a 13% risk of death in 
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order to achieve their most desired health and weight state. The most prominent predictors 
of health utility were public distress as measured by IWQOL-Lite, which accounted for 
5.4% of the variance in health utility and role limitations due to physical health as 
measured by SF-36, which accounted for 6.0% of the variance. The study highlights that as 
well as having a detrimental effect on individuals’ mental well-being, the experience of 
stigma and public distress may have further implications as these experiences could deter 
individuals from seeking contact with healthcare professionals. 
Indeed, another study has focussed on the experience of weight-related stigma and 
its association with quality of life and depressive symptoms in a sample of extreme obese 
individuals seeking bariatric surgery (133). The sample comprised 117 extreme obese 
individuals (mean BMI 48.2kg/m
2
) who completed baseline self-report questionnaires 
including the Stigma Situations Questionnaire, IWQOL-Lite, and the Beck Depression 
Inventory, second edition (BDI-II). The findings indicate that participants reported 
relatively minimal weight-related stigma experienced ‘several times’ in participants’ lives. 
Several specific forms of stigmatisation were related to BMI including ‘Being stared at’ 
(r= 0.43, p <0.001), ‘Comments from children’ (r= 0.36, p <0.001), ‘Physical barriers’ (r= 
0.45, p <0.001), and ‘Loved ones embarrassed by your size’ (r= 0.26, p <0.01). BMI was 
not significantly associated with total experiences of stigmatisation or experience of 
depressive symptoms, however, BMI was significantly associated with lower quality of life 
as measured by IWQOL-Lite total scores (r= 0.41, p <0.01). Interestingly, those 
participants who reported more frequent experience of stigma also reported poorer quality 
of life across all IWQOL-Lite domains; physical function (r= 0.26, p <0.01), self-esteem 
(r= 0.48, P <0.001), sexual life (r= 0.28, p <0.01), public distress (r= 0.52, p <0.001), and 
work (r= 0.42, p <0.001). The findings of the study demonstrate that the sample reported 
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experiencing a surprisingly low level of stigmatisation. However, where stigmatisation was 
present, this was linked to more widespread negative emotional state including depressive 
symptoms and impairment in quality of life.  
The link between depression and quality of life in extreme obesity was also studied 
by the same group in a separate sample of 306 individuals seeking bariatric surgery at the 
same institution (134). This study measured quality of life using the SF-36 and BDI-II. 
Significant negative associations between BMI and the physical functioning, physical role 
limitations, and bodily pain domains of the SF-36 were observed, with higher BMI being 
associated with lower physical quality of life. BMI was also demonstrated to be 
significantly associated with symptoms of depression however, the correlation was weak 
(r= 0.11, p ≤0.05). Regression analyses between these variables revealed that physical role 
limitations and bodily pain each contributed significantly to the experience of symptoms of 
depression with these predictors accounting for 15.9% and 4.3% of the variance in 
depression, respectively. Interestingly, the physical function variable and BMI each 
explained less than 1% of the remaining variance in depression scores indicating that these 
factors play less of an important role in the relationship between depression and quality of 
life in extreme obesity. 
Several studies conducted in the US have examined the relationship between 
extreme obesity and quality of life among various subgroups of treatment-seeking 
individuals such as ethnic group and gender (135), ethnic group and treatment status (61), 
gender and treatment status (136), and across BMI categories and treatment status (137). 
Findings of the treatment-seeking extreme obese sample sub-group analysis revealed that 
African-American males reported significantly less impairment in quality of life than the 
other ethnicity groups, despite having the highest BMI levels. Additionally, White females 
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reported the greatest impairment in quality of life (p <0.05), despite having the lowest BMI 
levels when compared to the other ethnicity groups (p <0.05) (135), suggesting that 
ethnicity and gender factors impact upon the self-reported experience of obesity among 
extreme obese samples. Whilst a significant negative association was observed between 
BMI and quality of life, both within the overall sample and ethnicity and gender 
subgroups, analyses was limited to correlation and a regression analyses would be required 
in order to account for potential confounding variables. These studies support the use of 
the IWQOL-Lite tool in assessing the quality of life of extreme obese samples and have 
highlighted its efficacy (135). 
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Table 3.1.2: Cross-sectional studies examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Country Sample 
size 
Sample  Psychosocial 
measures 
Other 
measures 
Findings 
Doll, 2000 UK 8,889 General population: 
Residents of four 
counties in southern and 
central England (mean 
BMI= 24.9kg/m
2
) 
SF-36 Self-reported height 
and weight, chronic 
illness status 
Extreme obese had significantly lower SF-36 
physical component scores compared to normal 
BMI group (40.6 vs 51.2, p <0.001), as well as 
significantly lower mean mental score than normal 
weight group (48.1vs 50.1, p <0.001). 
Soltoft, 
2009 
UK 14,416 General population:  
The  Health Survey for 
England (2003) (mean 
BMI= 27.2kg/m
2
 for 
males, 27.0kg/m
2
 for 
females) 
EQ-5D Nurse-measured 
weight and height  
Significant negative association between BMI and 
quality of life. Extreme obese reported increased 
problems in all EQ-5D dimensions relative to 
24.9-29.9kg/m
2
 BMI group (mobility problems in 
35.4% of extreme obese women vs 10.1% of 
normal BMI women, self-care 9.8% vs 2.6%, usual 
activities 22.6% vs 11.2%, pain 48.0% vs 25.4%, 
and anxiety problems in 30.6% vs 21.3%). 
Hill, 1998 UK 179 General population:  
Survey of female 
magazine subscribers 
clothes size 16 (mean 
sample BMI not given, 
39% BMI 40.0kg/m2) 
RSE, MHI Body shape 
assessment, Body 
shape satisfaction, 
DEBQ 
Extreme obese had significantly lower self-esteem 
scores compared to Class II and I obese groups, 
26.6 vs 29.0 and 30.2, p <0.01, respectively.  No 
significant difference in mental health between 
class I-III groups. 
Heo, 2003 US 155,989 General population:  
The  Behavioural Risk 
Factor Surveillance 
Survey, 1999 (mean 
BMI= 26.3kg/m
2
) 
Four questions 
assessing perceived 
health-related 
physical and mental 
quality of life over 
past 30 days 
Self-reported height 
and weight 
J-shaped association between BMI and quality of 
life. Underweight, overweight, and class I to III 
obese groups significantly more likely to report 
fair/poor general health, relative to normal weight. 
Extreme obese most likely to report fair/poor 
health (OR= 4.36, 3.97 - 4.80) 
SF-36= Medical Outcomes Study Short Form Health Survey, RSE= Rosenberg self-esteem scale, MHI= Mental Health Inventory, DEBQ= Dutch Eating Behaviour 
Questionnaire . 
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Table 3.1.2 Continued: Cross-sectional studies examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Country Sample 
size 
Sample  Psychosocial 
measures 
Other 
measures 
Findings 
Onyike, 
2003 
US 8,410 General population:  
The third National 
Health and Nutrition 
Examination Survey 
(NHANES). Aged 15-39 
years (mean BMI not 
given, 16.3% BMI 
30.0kg/m2) 
Structured diagnostic 
interview assessing 
presence of major 
depression using 
DSM-IV criteria 
Researcher-
measured weight 
and height 
Dose-response relationship between depression 
and adiposity with extreme obese at greater risk of 
depression in the past month (OR= 4.63, 2.06 - 
10.42) than class I obese (OR= 1.33, 0.57 - 3.13) 
and class II obese (OR= 1.90, 0.79 - 4.60), relative 
to normal weight. 
Yancy, 2002 US 1,168  General population: 
males attending one 
Veterans’ primary care 
medical centre (mean 
BMI not given, 3.0%  
BMI 40.0kg/m2) 
SF-36, CES-D, FPAI Researcher-
measured weight 
and height 
Extreme obese had significantly lower scores on 
the physical functioning (35.0 vs 56.7, p <0.001), 
role-physical (27.5 vs 50.8, p <0.05), bodily pain 
(38.8 vs 53.1, p <0.01) and vitality (33.0 vs 50.0, 
p <0.05) SF-36 subscales, relative to normal 
weight individuals. However there were no 
significant differences in the SF-36 mental 
component scores. 
Wagner, 
2013 
Germany 2,436 General population: 
randomly generated 
sample (mean sample 
BMI not given, 8.1% 
BMI 30.0kg/m2, 0.6% 
BMI 40.0kg/m2) 
SBQ-R Self-reported 
weight and height 
Extreme obese at greater risk of attempting suicide 
(OR= 12.43, 3.87 - 39.86) than Class I obese 
(OR= 3.49, 1.76 - 6.90), relative to normal weight. 
Extreme obese at greater risk of suicidal behaviour 
(OR= 21.22, 6.51 - 69.20) than Class I obese 
(OR= 3.02, 1.50 - 6.08), relative to normal weight. 
Tuthill, 
2006 
UK 253 Extreme obese seeking 
treatment at two 
specialist weight 
management centres  
(mean BMI= 45.8kg/m
2
 
for males, 46.4kg/m
2
 for 
females) 
HADS, EDI-2, 
IWQOL-Lite 
Nurse-led medical 
assessment 
including weight 
and height 
Anxiety prevalence= 56%, depression= 48% 
bulimia nervosa= 11.5%. For females, self-esteem 
was the most impaired aspect, 20.5% scoring 
within 10% of the lowest possible IWQOL-Lite 
score. In males, sexual life was most affected, with 
32.8% scoring within 10% of lowest score. 
DSM-IV= Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, SF-36= Medical Outcomes Study Short Form Health Survey, CES-D= Center for 
Epidemiological Studies Depression Scale, FPAI= Framingham Physical Activity Index, SBQ-R= Suicidal Behaviours Questionnaire-Revised, HADS= Hospital 
Anxiety and Depression Scale, EDI-2= Eating Disorder Inventory, IWQOL-Lite= Impact of Weight on Quality of Life scale.  
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Table 3.1.2 Continued: Cross-sectional studies examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Country Sample 
size 
Sample  Psychosocial 
measures 
Other 
measures 
Findings 
de Zwann, 
2009 
Germany 640 Adults attending 1 of 4 
obesity centres, 1 of 6 
surgery units, or 
randomly selected 
general population (mean 
BMI= 37.3kg/m
2
, 39.1% 
BMI 40.0kg/m2) 
SF-36 Researcher or 
clinician-measured 
weight and height 
Significant negative association between BMI and 
SF-36 physical component score (r= -0.56, 
p <0.001). Extreme obese scored significantly 
lower (p <0.05) than class I and II obese groups in 
physical component score.  No significant 
association between BMI and mental component 
scores. 
Andres, 
2012 
Spain 109 Obese adults seeking  
bariatric surgery at an 
obesity outpatient unit 
(mean BMI= 47.2 kg/m
2
) 
 
IWQOL-Lite, 
DASS-21, BSI,  
items from the self-
perception scale of 
the WALI 
Weight and height, 
unknown whether 
self-reported or 
measured 
Significant negative association between BMI and 
IWQOL-Lite total scores (r= −2.98, p <0.01), with 
BMI also accounting for 8.9% of variance in 
IWQOL-Lite total score. Construct validity of 
Spanish version supported. 
Butler, 1999 Canada 89 Obese adults accepted 
for bariatric surgery at a 
health service centre 
(mean BMI= 48.1 kg/m
2
) 
OAS, MHI, SIP, EI Pre-surgical weight 
and height, 
unknown whether 
self-reported or 
measured 
OAS significantly associated with MHI (r= -0.49, 
p <0.001) and SIP (r= 0.43, p <0.001) but not any 
of the EI measures (r= -0.14, r= 0.17, r= 0.11, 
p >0.05). 
Sach, 2007 UK 1,865 Adults aged ≥45 years 
recruited onto a study 
assessing lifestyle 
interventions for knee 
pain (mean BMI= 26.0 
kg/m
2
) 
EQ5D and SF-6D 
(derived from SF-36) 
Self-reported 
weight and height 
collected via 
questionnaire 
Obese Classes I-III had significantly lower scores 
on EQ5D and SF-6D, relative to normal weight 
group. Extreme obese mean EQ5D score 
significantly lower (0.62 vs 0.80, p <0.001) than 
the normal weight group, as well as SF-6D score 
(0.67 vs 0.78, p <0.001). 
SF-36= Medical Outcomes Study Short Form Health Survey, IWQOL-Lite= Impact of Weight on Quality of Life scale, DASS-21= Depression Anxiety Stress Scales, 
BSI= Brief Symptom Inventory, WALI= Weight and Lifestyle Inventory, OAS= Obesity Adjustment Survey, MHI= Mental Health Inventory, SIP= Sickness Impact 
Profile, EI= Eating Inventory. 
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Table 3.1.2 Continued: Cross-sectional studies examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Country Sample 
size 
Sample  Psychosocial 
measures 
Other 
measures 
Findings 
Thomas, 
2008 
Australia 76 General population:  
Obese aged ≥16 years 
(mean BMI= 42.5kg/m
2
) 
In-depth semi-
structured interviews 
Self-reported 
weight and height 
Majority of sample reported weight-related stigma 
and discrimination. Small proportion reported 
social isolation and lack of interaction. 
Wee, 2013 US 574 Extreme obese seeking 
treatment at two bariatric 
surgery centres (mean 
BMI= 46.5kg/m
2
) 
Collected via 
telephone survey: 
IWQOL-Lite, SF-36 
and willingness to 
risk death in order to 
lose weight items 
Self-reported 
weight and height 
collected via 
telephone survey 
Sample willing to accept a 13% risk of death in 
order to achieve most desired health and weight 
state. Public distress and physical limitations 
predicted willingness to risk death, each 
accounting for 5.4% and 6.0% of the variance in 
health utility, respectively.  
Sarwer, 
2008 
US 117 Extreme obese seeking 
bariatric surgery at 
Pennsylvania University 
Hospital (mean BMI= 
48.2 kg/m
2
) 
IWQOL-Lite, SSQ 
and BDI-II 
Weight measured at 
pre-surgery 
evaluation, height 
self-reported 
BMI significantly negatively associated with 
IWQOL-Lite (r= 0.41, p <0.01). BMI significantly 
associated with several stigmatisation subscales 
(r= 0.43, 0.36, 0.45, 0.26, p <0.001). BMI not 
significantly associated with depressive symptoms. 
Low levels of weight-related stigma experienced 
by sample. Stigma significantly negatively 
associated with quality of life. 
Fabricatore, 
2005 
US 306 Extreme obese seeking 
bariatric surgery at 
Pennsylvania University 
Hospital (mean BMI= 
52.8 kg/m
2
)  
SF-36 and BDI-II Weight measured at 
pre-surgery 
evaluation, height 
self-reported 
BMI significantly negatively associated with 
physical functioning (r= -0.36, p <0.001), physical 
role limitations (r= -0.21, p <0.001), and bodily 
pain (r= -0.23, p <0.001) of the SF-36. BMI 
significantly positively associated with symptoms 
of depression (r= 0.11, p ≤0.05). 
IWQOL-Lite= Impact of Weight on Quality of Life scale, SF-36= Medical Outcomes Study Short Form Health Survey, SSQ= Stigma Situations Questionnaire, 
BDI-II= Beck Depression Inventory, Second Edition. 
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Table 3.1.2 Continued: Cross-sectional studies examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Country Sample 
size 
Sample  Psychosocial 
measures 
Other measures Findings 
White, 2004 US 512 Extreme obese seeking 
bariatric surgery (mean 
BMI= 53.3 kg/m
2
) at a 
medical unit 
IWQOL-Lite and 
BDI 
Pre-surgical weight 
and height, 
unknown whether 
self-reported or 
measured 
BMI significantly negatively associated with total 
IWQOL-Lite (r= -0.22, p <0.01) and subscales 
physical function (r= -0.21, p <0.01), public 
distress (r= -0.39, p <0.01) and work (r= -0.18, 
p <0.01), but not sexual life and self-esteem. BMI 
not significantly associated with depression score. 
African-American males had highest BMI and 
reported significantly less impairment in quality of 
life than other ethnicity groups. White females had 
lowest BMI and reported greater impairment in 
quality of life than other ethnicity groups. 
Kolotkin, 
2002 
US 3,353 Individuals not enrolled 
in weight-loss treatment 
BMI ≥25kg/m2, 
participants of obesity 
medication clinical trials, 
individuals attending a 
weekly weight-loss 
programme, individuals 
attending a daily 
intensive programme, 
individuals seeking 
bariatric surgery, (mean 
BMI= 36.1kg/m
2
 for 
males, 36.8kg/m
2
 for 
females) 
IWQOL-Lite Weight and height, 
unknown whether 
self-reported or 
measured. 
BMI significantly negatively associated with 
quality of life, IWQOL-Lite total (r= -0.53, 
p <0.001), with BMI accounting for almost 28% of 
the variance in IWQOL-Lite total score. White 
females scored significantly lower than African 
American females on all IWQOL-Lite subscales. 
White males scored significantly lower than 
African American males on all IWQOL-Lite 
subscales except ‘work’. Significant effect of 
treatment modality, with those seeking bariatric 
surgery and intensive daily obesity treatment 
programme reporting the lowest quality of life 
scores across all domains (p <0.001). 
 
IWQOL-Lite= Impact of Weight on Quality of Life scale, BDI= Beck Depression Inventory. 
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Table 3.1.2 Continued: Cross-sectional studies examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Country Sample 
size 
Sample  Psychosocial 
measures 
Other 
measures 
Findings 
Kolotkin, 
2006 
US 1,158 Individuals not enrolled 
in weight-loss treatment 
BMI ≥30kg/m2, 
individuals seeking 
bariatric surgery, 
individuals attending an 
intensive programme 
(mean BMI of all 
samples ≥40kg/m2) 
IWQOL-Lite, with 
specific focus on the 
‘sexual life’ 
component 
Researcher or 
clinician-measured 
weight and height 
Participants in the Class III obesity group reported 
less sexual enjoyment (p <0.01), more difficulty 
with sexual performance (p <0.01), and greater 
avoidance of sexual encounters (p <0.05), relative 
to class I and II obese individuals. Gender effects 
were also observed whereby in the class III obese 
group, women reported significantly less sexual 
enjoyment (p <0.01), less sexual desire (p <0.01), 
and greater avoidance of sexual encounters 
(p <0.01), relative to males. 
Wadden, 
2006 
US 239 Females seeking bariatric 
surgery (mean BMI= 
52.6kg/m
2
) or 
behavioural weight-loss 
programme (mean BMI= 
33.8kg/m
2
) 
BDI-II, WALI, RSE Weight and height, 
unknown whether 
self-reported or 
measured. 
Women with class III obesity, reported 
significantly more symptoms of low self-esteem 
(19.9 vs 16.6, p <0.01) and more symptoms of 
depression (13.2 vs 8.1, p <0.01), relative to class 
I-II obese individuals. 25% of class III group had 
BDI-II scores which indicated that they would 
benefit from treatment. Class III obese also 
significantly more likely to report a history of 
physical abuse (24.3 vs 6.6%, p <0.01) and sexual 
abuse (19.9 vs 8.9%, p <0.05), relative to class I-II 
individuals. 
IWQOL-Lite= Impact of Weight on Quality of Life scale, BDI-II= Beck Depression Inventory-Second edition, WALI= Weight and Lifestyle Inventory, 
RSE= Rosenberg self-esteem scale.  
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3.1.3 Intervention studies 
The seven intervention studies included in this review are described in Table 3.1.3. The 
intervention data were from 2,859 individuals, conducted between 2005 and 2013, within 
predominantly European population samples, namely the UK, Germany, France, Sweden 
and Norway, with only one study outside of Europe, which was conducted in the US. 
Whilst the majority of the intervention studies focus on the impact of surgical 
interventions on quality of life outcomes, one UK study has detailed the quality of life 
outcomes of a medical weight management intervention (74). The sample comprised 199 
adult individuals of BMI ≥30.0kg/m2 with co-morbidities or BMI ≥35.0kg/m2. The 
intervention consisted of a group-programme led by a dietician with input from a clinical 
psychologist, comprising nine fortnightly-sessions (lasting 1.5 hours) focussing on diet and 
activity lifestyle advice and behavioural change strategies. Quality of life and mental 
health were assessed by the IWQOL-Lite and HADS, pre- and post- intervention. Findings 
indicated that both weight loss (OR= 0.85, 0.75 - 0.95) and changes in depression (OR= 
0.78, 0.65 - 0.93) were significant predictors of improvement in post-intervention quality 
of life scores. For those individuals losing ≥5kg, improvement in quality of life was 
predicted by weight loss. However, for those losing smaller amounts of weight <5kg, 
improvement in quality of life was predicted by positive changes in depression scores. The 
findings demonstrate that a clinically meaningful improvement in quality of life was 
achieved through this group-based medical weight management intervention. The authors 
suggest that the improvement in depression scores seen in those losing smaller amounts of 
weight could be due to the social interaction within the group having a positive effect on 
well-being and quality of life. However, for those individuals losing greater amounts of 
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weight, the improvement in quality of life was attributable to weight loss rather than the 
group-based nature of the intervention. 
 The remaining intervention studies focused on surgical intervention. A review of 
the impact of bariatric surgery on psychosocial functioning was conducted in 2003 (138). 
The review included 40 studies involving 3,739 patients which detailed psychosocial and 
mental health outcomes following bariatric surgery. The review concluded that for the 
majority of individuals undergoing bariatric surgery, mental health and psychosocial status 
are improved post-intervention. Specifically, psychiatric co-morbidity, affective disorders 
including anxiety and depression and psychopathologic symptoms were shown to decrease 
following surgical intervention, with post-surgery Axis I DSM-III psychiatric disorder 
prevalence rates ranging from no diagnosis, to half and a third of the pre-surgical rates 
which ranged between 27.4-41.8%. Other subsequent studies detailing the impact of 
bariatric surgical interventions on quality of life outcomes among extreme obese 
individuals have shown similar results (66-71). In a small sample study of 50 extreme 
obese females undergoing gastric banding, 3 year post-surgery BMI reduction was shown 
to be associated with reduced depression (r= -0.61, p <0.05) and improvement in quality of 
life as measured by the SF-36 subscales: physical functioning (r= -0.71, p <0.01), role 
physical (r= 0.59, p <0.05), mental health (r= 0.62, p <0.05) and vitality (r= 0.57, p <0.05). 
A subsequent follow-up of the same sample after a further three years, revealed that 6-
years post-baseline, the reduction in BMI and improvement in depression and quality of 
life remained (67). The Swedish Obese Subjects study also examined the long-term effects 
of bariatric surgery on quality of life outcomes (68). The study included a large sample size 
of 1,276 individuals and incorporated a control group comparator receiving medical weight 
management, with significant improvements in all quality of life measures from baseline to 
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10-years for the surgical group, whereas most initial significant improvements in quality of 
life for the medical group were lost by 2-years, with the exception of anxiety, which 
remained significantly reduced from baseline to 10-years. The final large sample size 
intervention study included 1,156 extreme obese individuals, receiving Roux-en-Y gastric 
banding or non-surgical care (71). Six-year post-baseline mean weight change was -27.7% 
for the group receiving surgery, +0.2% for those seeking but not receiving surgery and 0% 
change in those not-seeking surgery. There were significant improvements in SF-36 and 
IWQOL-Lite scores from baseline to 6-years for all groups. The improvement in quality of 
life as measured by IWQOL-Lite was significantly greater for the surgery group than the 
control group, with a mean difference of 34.2 (28.7 - 39.7), p <0.001, as well as the SF-36 
physical function score, with a mean difference of 11.2 (8.2 - 14.3), p <0.001. However, 
the improvement in mental component score was not significantly different between the 
surgical and control group, with a mean difference of 0.6 (-2.6 - 3.9), p >0.05, indicating 
that the psychological co-morbidities had remained independent of weight loss. 
 This review has highlighted the limited number of studies which report the impact 
of medical weight management interventions on the quality of life and mental health of 
individuals with extreme obesity, with the majority of the evidence base originating from 
surgical interventions. Future studies examining the efficacy of medical weight 
management interventions should incorporate psychological outcome measures, in order to 
improve understanding of the role of psychological factors in extreme obesity. 
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Table 3.1.3: Intervention studies examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Country Sample 
size 
Sample  Psychosocial 
measures 
Other 
measures 
Findings 
Wright, 
2013 
UK 199 Extreme obese receiving 
a non-surgical medical 
weight management 
intervention (mean BMI 
≥30kg/m2, mean weight= 
114.5kg) 
IWQOL-Lite, HADS Dietitian-measured 
weight and height 
Baseline BMI significantly positively correlated 
with depression (r= 0.16, p <0.05) but not anxiety 
(r= 0.10, p >0.05). Baseline BMI significantly 
negatively correlated with all subscales and total 
IWQOL-Lite (r= -0.43, p <0.001), physical 
function (r= -0.43, p <0.001), self-esteem 
(r= -0.19, p <0.01), sexual life (r= -0.18, p <0.05), 
public distress (r= -0.58, p <0.001), and work (r= 
-0.30, p <0.001). Post-intervention weight loss 
(OR= 0.85, 0.75 - 0.95) and improvement in 
depression (OR= 0.78, 0.65 - 0.93) were 
significant predictors of quality of life 
improvement. 
Nickel, 
2005 
Germany 50 Females seeking gastric 
banding procedure. 21 
had procedure (mean 
BMI= 47.4kg/m
2
), 29 
opted out of procedure 
(mean BMI= 45.1kg/m
2
) 
TFEQ, HADS, SF-36 Researcher or 
clinician-measured 
weight and height 
Three-year post-surgery reduction in BMI was 
significantly associated with reduction in 
depression (r= -0.61, p <0.05) and the SF-36 
subscales: physical functioning (r= -0.71, p <0.01), 
role physical (r= 0.59, p <0.05), mental health (r= 
0.62, p <0.05) and vitality (r= 0.57, p <0.05). 
Nickel, 
2007 
Germany 50 Females seeking gastric 
banding procedure. 
Sample same as reported 
2005. 21 had procedure 
(mean BMI= 47.4kg/m
2
), 
29 opted out of 
procedure (mean BMI= 
45.1kg/m
2
) 
TFEQ, HADS, SF-36 Researcher or 
clinician-measured 
weight and height 
Six-year post-surgery reduction in BMI was 
significantly associated with improvements on all 
TFEQ scales (p <0.01), on HADS anxiety 
(p <0.05), depression (p <0.05), and on all SF-36 
scales (p <0.01). 
IWQOL-Lite= Impact of Weight on Quality of Life scale, HADS= Hospital Anxiety and Depression Scale, TFEQ= Three-Factor Eating Questionnaire, 
SF-36= Medical Outcomes Study Short Form Health Survey. 
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Table 3.1.3 Continued: Intervention studies examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Country Sample 
size 
Sample  Psychosocial 
measures 
Other 
measures 
Findings 
Karlsson, 
2007 
Sweden 1,276 Individuals taking part in 
the Swedish obese 
subjects (SOS) 
intervention. 655 
receiving banding or 
bypass bariatric surgery 
(mean BMI= 41.9kg/m
2
), 
621 receiving medical 
weight-management 
(mean BMI= 39.9kg/m
2
) 
SOS Quality of Life 
Survey, items of the 
CH selected from the 
GHRI, MACL, 
HADS, SI category 
from the SIP, OP 
scale 
Researcher or 
clinician-measured 
weight and height 
Ten-year post-intervention mean BMI change was 
-6.7kg/m
2 
for the surgical group and +0.7kg/m
2
 for 
the medical group. In the surgical group, there 
were significant improvements in all quality of life 
measures from baseline to 10 years. In the medical 
group, there were significant improvements in 
quality of life measures, with most lost by two 
years, however anxiety remained significantly 
reduced from baseline to 10 years. 
Andersen, 
2010 
Norway 50 Individuals receiving 
duodenal switch bariatric 
surgery (mean BMI= 
51.7kg/m
2
) 
HADS, SF-36 Researcher or 
clinician-measured 
weight and height 
At baseline 50% of sample showed presence of 
anxiety (≥8) and 36% presence of depression. 
Two-year post-surgery mean BMI change was 
-20.0kg/m
2. 
Anxiety prevalence reduced to 22.7% 
at 2 years, and depression reduced to 4.5%. BMI 
change was not significantly associated with 
change in HADS scores, but was significantly 
associated with improvement in PCS scores. MCS 
change scores were not presented. 
Fezzi, 
2011 
France 78 Individuals receiving 
laparoscopic sleeve 
gastrectomy bariatric 
surgery (mean BMI= 
47.0kg/m
2
) 
SF-36, IWQOL-Lite Researcher or 
clinician-measured 
weight and height 
One-year post-surgery mean BMI change was 
-14.0kg/m
2. 
There were
 
significant improvements 
in all SF-36 and IWQOL-Lite domains from 
baseline. One-year change in quality of life was 
not significantly associated with change in weight. 
CH= Current Health scale, GHRI= General Health Rating Index, MACL= Mood Adjective Check List, SI= Social Interaction, SIP= Sickness Impact Profile, 
OP= Obesity-related Problems Scale, HADS= Hospital Anxiety and Depression Scale, SF-36= Medical Outcomes Study Short Form Health Survey, 
IWQOL-Lite= Impact of Weight on Quality of Life scale. 
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Table 3.1.3 Continued: Intervention studies examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Country Sample 
size 
Sample  Psychosocial 
measures 
Other 
measures 
Findings 
Adams, 
2012 
US 1,156 418 individuals receiving 
Roux-en-Y gastric 
bypass (RYGB), 417 
individuals seeking but 
not receiving surgery, 
321 extreme obese 
individuals not-seeking 
surgery (mean BMI= 
45.9kg/m
2
) 
SF-36, IWQOL-Lite Researcher or 
clinician-measured 
weight and height 
Six-year post-baseline mean weight change was 
-27.7% for the group receiving surgery, +0.2% for 
those seeking but not receiving surgery and 0% in 
those not-seeking surgery. The improvement in 
IWQOL-Lite was significantly greater for the 
surgery group than the control group, mean 
difference= 34.2, 28.7 - 39.7, p <0.001, as well as 
the SF-36 physical function score mean 
difference= 11.2, 8.2 - 14.3, p <0.001. The 
improvement in mental component score was not 
significantly different between the surgical and 
control group, mean difference= 0.6, -2.6 - 3.9, 
p >0.05. 
SF-36= Medical Outcomes Study Short Form Health Survey Questionnaire, IWQOL-Lite= Impact of Weight on Quality of Life scale. 
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3.1.4 Reviews 
The ten review articles included in this review are identified in Table 3.1.4. The reviews 
which were published between 1985 and 2012 encompassed data from 699 papers. Whilst 
the number of included participants could only be ascertained for four of the review 
articles, this gives rise to the following minimum number of included participants 
N=517,456. However, it is anticipated that the actual number of included individuals is 
considerably larger. 
The first review to encompass the association between quality of life and obesity 
published in 1985, focused on the associated health complications of extreme obesity 
(139). The authors commented that whilst “functional impairment of activities of daily 
living” was an area that had been greatly ignored when considering health complications, 
several studies had however, reported an association between increasing weight and 
impairments in physical ability, ability to participate in recreation, work and social 
interaction. This narrative review provides a useful insight into the developing field of the 
study of extreme obesity including the terms and definitions utilised. Indeed, extreme 
obesity was termed by the authors as “morbid obesity” and defined as “an absolute (45.4kg 
i.e. 100lb) or relative (60%) excess in weight above desirable weight associated with 
maximum life expectancy”. This is in contrast to the subsequent World Health 
Organisation (WHO) classification based on BMI which proposed the cut-points of 25.0-
29.9kg/m
2
 for overweight, 30.0-34.9kg/m
2
 for obese class I, 35.0-39.9kg/m
2
 for class II 
obese, and a cut-point of ≥40.0 kg/m2 for class III obesity (10, 140, 141). 
The first literature review which focussed specifically on the psychological 
characteristics of extreme obese individuals seeking bariatric surgery published in 1992, 
concluded that the patient population did not report greater levels of psychopathology than 
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average-weight individuals (142).  However, this narrative non-systematic review included 
only eight papers studying extreme obese individuals (N=366 included individuals), with 
the remaining papers comprising samples of unknown weight. A more recent review 
published in 2004 (143) which also detailed the baseline psychological characteristics of 
extreme obese bariatric surgery-seeking individuals utilised a systematic literature review 
approach. This review contrasted with the previous review, concluding that most studies 
within the body of literature indicate that those surgery-seeking extreme obese individuals 
report significantly poorer quality of life. The stronger methodological rigour provides 
greater support for the findings of the later review. Two additional reviews published by 
the same author in 2005 (144) and 2008 (145) have focused on the pre- and post-operative 
psychosocial status of bariatric surgery-seeking extreme obese individuals. Indeed, the 
impact of bariatric surgery on psychosocial outcomes was also reviewed in 2002 by a 
different research group (146), concluding that bariatric surgery has been shown to 
improve psychosocial outcomes through improvement in mood and reduction in depression 
and anxiety. However the reviews also conclude that the extent of the impact of obesity on 
psychosocial functioning and the impact of psychosocial factors on post-intervention 
success remain unclear. 
The most recent systematic review published in 2012 focussed on the relationship 
between extreme obesity, quality of life and specifically sexual quality of life, with the 
authors proposing  that sexual function is an important yet under-researched aspect 
contributing to quality of life (147). The review details the small body of literature which 
suggests that extreme obese individuals report experiencing greater difficulties in sexual 
functioning than their normal weight counterparts. It was suggested that these difficulties 
may be a consequence of the changes in reproductive hormones associated with excess 
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body weight, the presence of obesity-related co-morbidities including hypertension and 
type 2 diabetes and additionally due to psychosocial factors including poor body image and 
depression. Other reviews which have focused on specific aspects of mental well-being are 
the 2008 systematic review which examined the literature investigating the association 
between obesity and depression (59) and the 2010 systematic review and meta-analysis 
which examined the association between obesity and anxiety (60), both in non-clinical 
general population samples. The authors conclude that evidence supporting the association 
between obesity and depression is inconclusive with cross-sectional studies reporting 
varied effects of no significant increased likelihood of depression (OR= 0.60, -1.55 - 1.70), 
and increased likelihood of depression (OR= 1.50, 1.1 - 2.1) in obesity. Unfortunately a 
meta-analysis was not conducted, with analyses restricted to a narrative synthesis (59). The 
systematic review and meta-analysis examining the association between obesity and 
anxiety concluded that there is a moderate level of evidence supporting the association 
between obesity and anxiety disorders, with pooled cross-sectional data indicating that 
obese individuals are more likely to experience anxiety (OR= 1.4, 1.2 - 1.6) than non-obese 
individuals, however, the role of obesity severity has not yet been established (60). We can 
accept the conclusions of the two reviews with confidence, incorporating data from 24 
studies and 167,062 individuals within the obesity and depression review (59) and data 
from 16 studies and 346,289 individuals for the review focussing on obesity and anxiety 
(60). 
The systematic literature search conducted and reported within this chapter has 
highlighted that within the body of literature examining the relationship between 
psychological factors and adiposity, there is a need for greater methodological rigour 
within review articles. Of the ten reviews discussed, only two reported the number of 
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studies included in the reviews (59, 60), with the remaining reviews not providing this 
information. Additionally, many of the identified reviews utilised a non-systematic 
approach which means that any reported results should be interpreted with caution. 
Furthermore, a narrative rather than statistically-based approach was widely used, with 
only one of the reviews including a meta-analysis providing an estimate of the effect of 
obesity on mental health, indicating a gap in the body of literature.  
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Table 3.1.4: Reviews examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Sample size Focus of review Conclusions 
Kral, 1985 32 papers 
referenced, number 
of individuals 
unknown 
Narrative, non-systematic review, 
focussing on defining and characterising 
the health risks of “morbid obesity”, 
defined as “an absolute (45.4kg or 100lb) 
or relative (60%) excess in weight above 
desirable weight associated with maximum 
life expectancy”. 
Extreme obesity is associated with dramatic increases in mortality relative to the 
normal-weight population. The health risk of extreme obesity is well recognized. 
Decreased quality of life, specifically functional limitations and impairment of 
daily activities are evident and should be quantified in the same way as morbidity 
and mortality. 
Stunkard, 
1992 
82 papers 
referenced, total 
number of 
individuals 
unknown 
Narrative, non-systematic review, 
focussing on the psychological aspects of 
severe obesity. Specifically, baseline 
associations and changes following weight 
loss after bariatric surgery are examined. 
Severe obesity is not associated with any single personality type or trait and is not 
associated with greater levels of psychopathology than average-weight individuals. 
Complications which are associated with severe obesity include body image 
disturbance and binge eating. Post-surgery studies have shown improvements in 
self-esteem, body image, eating behaviour, positive emotion and marital 
satisfaction. Greater improvements are seen for those receiving surgery relative to 
dietary treatment alone. 
Herpertz, 
2003 
40 papers 
referenced, number 
of individuals 
N=3,739 
Narrative, non-systematic review, 
focussing on the psychosocial and mental 
health outcomes following bariatric 
surgery 
Mental health and psychosocial status are improved post bariatric surgery 
intervention for the majority of individuals, with psychiatric co-morbidity, affective 
disorders including anxiety and depression and psychopathologic symptoms shown 
to decrease following surgery. 
van Hout, 
2004 
75 papers 
referenced, number 
of individuals 
unknown 
Systematic literature search, focussing on 
defining the psychological profile of the 
morbidly obese. 
“Morbid obesity” is associated with impaired quality of life, depression, anxiety, 
low self-esteem, poor impulse control and eating behaviour which includes rigid 
control, dieting and disinhibition. These characteristics are more pronounced in 
surgery-seeking individuals. The literature is not conclusive and assessment 
methods require improvement. 
Sarwer, 
2005 
128 papers 
referenced, number 
of individuals 
unknown 
Non-systematic literature review, 
focussing on the psychosocial and 
behavioural aspects of individuals seeking 
bariatric surgery. Specifically, baseline 
associations and changes following weight 
loss after bariatric surgery are examined. 
Surgery-seeking individuals are at increased risk of psychosocial complications, 
suggesting an increased prevalence of psychiatric symptoms and psychopathology, 
including mood and anxiety disorders and binge-eating disorders, as well as 
impairments in quality of life encompassing physical health, body image, and 
relationship functioning. Whilst numerous studies have shown post-surgery 
psychosocial improvements, conclusions are limited by lacking standardised 
measurements and control groups. Some studies have shown improvements 
decrease with time and post-surgery deterioration in psychosocial status. 
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Table 3.1.4 Continued: Reviews examining the relationship between psychosocial variables and adiposity  
First 
author, 
year 
Sample size Focus of review Conclusions 
Sarwer, 
2008 
123 papers 
referenced, number 
of individuals 
unknown 
Non-systematic literature review, 
focussing on the psychosocial and 
behavioural changes following weight loss 
after bariatric surgery and after body-
contouring post-weight loss.  
Post-surgery weight loss is associated with psychosocial improvements including 
quality of life, depression, self-esteem and body image, however this may be 
limited to the first few years. It is unclear whether baseline characteristics impact 
on post-surgery outcomes. There is limited research examining associations 
between psychosocial characteristics and body-contouring surgery. 
Bocchieri, 
2002 
79 papers 
referenced, number 
of individuals 
unknown 
Systematic literature review of the 
psychosocial outcomes of bariatric surgery 
for morbid obesity, with an assessment of 
the theoretical and methodological issues. 
Post-surgery weight loss appears to be associated with improvements in mood, 
depression and anxiety, however more research is needed to understand surgery 
outcomes, specifically relating to the impacts on psychological distress and 
discrimination, general quality of life, obesity-related pain and gender differences. 
More consistency in research methodology is required. 
Sarwer, 
2012 
100 papers 
referenced, number 
of individuals 
unknown 
Non-systematic literature review, 
focussing on the relationships between 
extreme obesity and quality of life, with 
specific emphasis on sexual function, 
examining baseline characteristics and 
post-surgery changes. 
Extreme obesity appears to be associated with difficulties in sexual functioning and 
impairment in sexual quality of life. The relationship between sexual quality of life, 
obesity and other related psychosocial constructs including body image 
dissatisfaction and depression is complex. The association between sexual quality 
of life and extreme obesity is under-researched and requires further investigation. 
Atlantis, 
2008 
24 studies included, 
4 prospective 
cohort, 20 cross-
sectional studies. 
Number of 
individuals 
N=167,062 
Systematic literature review of 
epidemiological studies, focussing on the 
effects of obesity on depression.  
Obesity appears to increase the odds of future depression outcomes, with consistent 
effect sizes reported in prospective cohort studies however, those reported in some 
cross-sectional studies showed the association in females but not males, and some 
studies showed no association in combined samples. Obesity appears to be related 
to depression, however evidence is weak as good-quality prospective studies are 
limited and cross-sectional studies cannot confirm causality. 
Gariepy, 
2010 
16 studies included, 
2 prospective 
cohort, 14 cross-
sectional studies. 
Number of 
individuals 
N=346,289 
Systematic review and meta-analysis 
focussing on the association between 
obesity and anxiety disorders in the 
general population. 
There appears to be a positive association between obesity and anxiety amongst 
males and females, with pooled cross-sectional studies suggesting obesity is 
associated with increased risk of anxiety (OR= 1.4, 1.2 - 1.6). Effect sizes from 
prospective data were varied and a causal relationship cannot be inferred. However, 
there is a moderate level of evidence for a positive association between obesity and 
anxiety. Further research is needed to determine causality through prospective 
studies and determine the role of obesity severity which is as yet not established. 
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3.1.5 Rationale for the assessment of quality of life in extreme obesity 
Evidence suggests an association between increasing adiposity and depression (59), 
anxiety (60) and reduced quality of life (61). Indeed, obesity has been linked to widespread 
psychopathology with obese individuals more likely to attempt suicide and demonstrate 
suicidal behaviour, and an even greater risk is observed in extreme obesity (62). However, 
there are inconsistencies in the research literature, with some studies supporting an 
association between obesity and physical but not mental quality of life (63-65). 
Furthermore, current understanding is limited as studies have focused on those extreme 
obese individuals who are specifically seeking bariatric surgery (68) and with the 
exception of one study (74), have not encompassed those individuals attending medical 
weight-management services. 
 
3.1.6 Aims 
This chapter aims to explore the quality of life and mental health characteristics of a 
sample of extreme obese individuals attending two different treatment pathways offered by 
the HEFT Specialist Weight Management Service; the Community Weight Management 
Service (CWMS) and the Specialist Lifestyle Management (SLiM) programme. The cross-
sectional association between adiposity and quality of life will be examined using baseline 
clinical examination and self-report data collected from individuals seeking treatment at 
the service prior to treatment commencement. Additional subsample analysis will examine 
the quality of life and mental well-being characteristics of the CWMS subsample in greater 
detail. The chapter concludes with a summary of the observed relationship between 
adiposity, mental health and quality of life, and finally recommendations to enhance 
specialist weight management services are presented.  
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3.2 METHODS 
 
3.2.1 Research design  
The study explored the mental health and quality of life characteristics of a sample of 
extreme obese individuals entering the Specialist Weight Management Service, conducted 
as part of an evaluation of the efficacy of the service. All patients were referred to the 
service by their GP as a result of fulfilling the criteria of having BMI ≥40.0kg/m2 or 
alternatively BMI ≥35.0kg/m2 with a weight-related health condition, such as type 2 
diabetes or hypertension. The study included a sample of 414 individuals aged 19 to 76 
years, 262 of whom entered the Specialist Community Weight Management Service 
(CWMS) between February 2008 and August 2012 and 152 of whom entered the Specialist 
Lifestyle Management (SLiM) programme between August 2009 and February 2013. 
 
3.2.2 Specialist Weight Management Service  
The two medically supported treatment pathways delivered within the Specialist Weight 
Management Service operated by HEFT have been described in Chapter one; however the 
following brief description is for reference. The CWMS provides comprehensive 
multidisciplinary care for a 12-month period from a team of specialist physicians, 
dietitians, and psychologist, delivered through one-to-one appointments in the community. 
The SLiM programme provides patient education, peer-support and self-management 
through a structured programme of six consecutive monthly weight management group-
sessions.  
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3.2.3 Demographic and clinical information 
Participants’ initial weight and height data were recorded at baseline and BMI was 
calculated by dividing participants’ weight in kg by height in meters squared. 
Demographic details including participants’ age, gender, and ethnicity as well as clinical 
details including whether participants had co-morbid type 2 diabetes were routinely 
recorded prior to treatment commencement for individuals attending both the CWMS and 
SLiM pathways. The use of insulin was routinely collected for those entering the SLiM 
pathway only. Additional data were routinely collected for those entering the CWMS 
pathway including waist circumference, blood pressure, smoking status and alcohol 
consumption. Details of obesity-related co-morbid health conditions were also recorded 
focussing specifically on type 2 diabetes, CVD, hypertension, OSA, and arthritis. 
Additional demographic details were also routinely collected for those attending the 
CWMS, including marital status, employment status and whether participants had children. 
 
3.2.4 Quality of life and mental health measures 
The quality of life and mental health measures have been described in detail in Chapter 
two, however the following brief description is provided for reference. Upon entering both 
treatment pathways, participants were asked to complete validated self-report 
questionnaires before attending their first service appointment. Quality of life and mental 
health were assessed using three measures, an obesity-specific quality of life measure, the 
IWQOL-Lite (83), a general quality of life measure, the EQ5D-3L (84), and the HADS 
anxiety and depression screening tool (85). The IWQOL-Lite was administered to 
individuals entering the CWMS and SLiM pathways, whilst the EQ5D-3L and HADS were 
administered to individuals entering the CWMS only.  
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3.2.5 Statistical analysis 
Data were analysed using IBM SPSS Statistics (version 21.0). T-tests, cross-tabulation, 
Chi
2
 and analysis of variance (ANOVA) were conducted to examine the associations 
between variables. BMI tertile groups were created for the CWMS and the SLiM samples 
separately. This gave rise to the following groups for the CWMS sample: first, BMI tertile 
≤42.99kg/m2; second, BMI tertile 43.00≤48.61kg/m2; third, BMI tertile 48.62kg/m2. The 
following groups were created for the SLiM sample: first, BMI tertile ≤46.85kg/m2; 
second, BMI tertile 46.86≤53.82kg/m2; third, BMI tertile 53.83kg/m2. Linear regression 
coefficients were calculated to assess the relationship between BMI and quality of life as 
measured by IWQOL-Lite scores and overall perceived health status as measured by 
EQ5D-3L VAS. Analyses were conducted for the whole sample and repeated in gender-
stratified sub-groups. Three hierarchical models are presented: crude; adjusting for age and 
sex and interaction between sex and BMI; and additionally adjusting for the presence of 
co-morbid type 2 diabetes, hypertension, arthritis, OSA and CVD. 
 Within the CWMS subsample, logistic regression models were constructed to 
assess the association between BMI and presence of anxiety and depression as measured 
by HADS, and presence of problems in mobility, self-care and performing usual activities 
as measured by EQ5D-3L, with the first BMI tertile group as the reference. The odds ratios 
(ORs) and 95% confidence intervals (CIs) for three hierarchical models are presented: 
crude; adjusting for age and sex; and additionally adjusting for the co-morbidities; 
diabetes, hypertension, arthritis, OSA and CVD. 
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3.3 RESULTS 
 
3.3.1 Demographic, clinical and quality of life characteristics 
Table 3.3.1 shows the comparison between the samples entering the CWMS and the SLiM 
pathways. Those attending the CWMS were significantly younger with a mean age of 43.1 
vs 48.5 years (p <0.001), of lower BMI with a mean of 47.0 vs 51.3 kg/m
2
 (p <0.001), less 
likely to have type 2 diabetes: 26.3 vs 35.5% (p <0.05) and less likely to be referred for 
bariatric surgery: 14.5 vs 30.9% (p <0.001), than those attending the SLiM programme. 
Those attending the CWMS also reported significantly better physical function, with mean 
IWQOL-Lite physical function scores of 42.4 vs 32.3 (p <0.001), than those attending the 
SLiM programme, whilst there were no significant differences in other IWQOL-Lite scores 
between the two samples. Data indicate that within both samples quality of life was low, 
with sample mean IWQOL-Lite scores ranging from 26.2 (self-esteem) to 51.2 (work) for 
the CWMS sample, and 28.5 (self-esteem) to 50.3 (work) for the SLiM sample, whereby 
100 represents optimum quality of life.  
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Table 3.3.1: Comparison of the demographic and clinical characteristics of the 
CWMS and SLiM samples 
 CWMS SLiM P 
N 262 152  
Age (years) 43.1±11.8 48.5±11.1 <0.001 
Sex (% female) 74.8 73.0 0.690 
Ethnicity (%)   0.069     
White European 90.8 80.3  
Asian 5.6 9.9  
Black African/Caribbean 2.8 8.6  
Other 0.7 1.3  
Weight (kg) 132.1±24.7 140.0±28.3 0.003 
Body mass index (BMI, kg/m
2
) 47.0±7.9 51.3±9.9 <0.001 
Type 2 diabetes (%) 26.3 35.5 0.049 
Referral to surgery (%) 14.5 30.9 <0.001 
Baseline IWQOL-Lite    
Physical function 42.4±25.3 32.3±22.1 <0.001 
Self-esteem 26.2±27.5 28.5±27.8 0.424 
Sexual life 41.9±35.9 46.5±31.1 0.219 
Public distress 40.5±28.9 36.3±26.7 0.154 
Work 51.2±30.3 50.3±28.3 0.760 
IWQOL-Lite total 39.5±22.1 36.1±19.9 0.130 
Data are percentages and means ± standard deviations. 
 
Table 3.3.2 illustrates that within the CWMS sample those with increasing levels of 
adiposity were more likely to have type 2 diabetes mellitus, hypertension, CVD and OSA 
and were also more likely to be referred to receive bariatric surgery. Table 3.3.3 shows that 
in the CWMS sample those with increasing levels of adiposity also experienced 
significantly more problems in mobility, self-care and performing usual activities. 
Increasing levels of adiposity were also associated with poorer scores on the IWQOL-Lite 
subscales, physical function, public distress, work and IWQOL-Lite total score. Perceived 
health status as measured by EQ5D-3L was also poor with a sample mean of 44.0, 
whereby 100 represents best possible health state; which is considerably worse than the 
UK general population mean score of 82.8 (148). There were no significant differences in 
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anxiety and depression scores, with prevalence of anxiety and depression consistently high 
across the BMI groups. Data for the whole CWMS sample indicate that the prevalence 
rates of symptoms of anxiety (70.3%) and depression (66.2%) are very high. Indeed, levels 
of severe anxiety and depression symptoms defined by the higher cut-point of scores ≥11 
are also substantial, with severe anxiety symptoms experienced by 48.3% of the sample 
and 40.4% of the sample experiencing symptoms of severe depression.  
 
Table 3.3.2: Demographic and clinical characteristics of the CWMS sample across 
BMI tertiles 
 
Whole 
sample 
1
st
 BMI 
tertile 
≤42.99 
2
nd
 BMI 
tertile 
43.00 ≤ 48.61 
3
rd
 BMI 
tertile 
48.62 
P 
N 262 87 87 88  
Age (years) 43.1±11.8 43.0±13.2 41.7±10.2 44.7±11.8 0.234 
Sex (% female) 74.8 72.4 77.0 75.0 0.783 
Ethnicity (%)     0.585 
White European 90.8 90.0 95.5 87.9  
Asian 5.6 5.0 2.3 8.6  
Black African/Caribbean 2.8 2.5 2.3 3.4  
Other 0.7 2.5 0.0 00  
Weight (kg) 132.1±24.7 112.6±14.7 129.1±15.6 154.2±22.3 <0.001 
Body mass index (BMI, kg/m
2
) 47.0±7.9 39.4±2.6 45.8±1.6 55.8±6.6 <0.001 
Waist circumference (cm) 131.6±14.5 123.8±11.8 128.6±12.7 142.4±12.5 <0.001 
Systolic blood pressure 
(mmHg) 
140.9±17.7 136.0±14.5 140.4±17.0 146.4±20.0 0.009 
Diastolic blood pressure 
(mmHg) 
85.2±11.7 83.3±9.7 85.5±11.4 86.9±13.6 0.263 
Type 2 diabetes (%) 26.3 24.1 18.4 36.4 0.022 
Hypertension (%) 34.4 31.0 26.4 45.5 0.022 
Arthritis (%) 24.0 21.8 19.5 30.7 0.190 
OSA (%) 25.6 16.1 26.4 34.1 0.024 
CVD (%) 11.1 9.2 5.7 18.2 0.026 
Smoking (%) 25.5 31.7 23.0 22.2 0.655 
Alcohol consumption (%) 64.7 62.9 81.0 52.9 0.004 
Referral to surgery (%) 14.5 10.3 10.3 22.7 0.027 
Data are percentages and means ± standard deviations 
OSA= Obstructive Sleep Apnoea, CVD= Cardiovascular disease. 
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Table 3.3.3: Quality of life and mental health characteristics of the CWMS sample 
across BMI tertiles 
 
Whole 
sample 
1
st
 BMI 
tertile  
≤42.99 
2
nd
 BMI 
tertile  
43.00 ≤ 48.61 
3
rd
 BMI 
tertile  
48.62 
P 
N 262 87 87 88  
Baseline IWQOL-Lite  
Physical function 42.4±25.3 54.1±24.9 40.4±23.6 34.1±23.7 <0.001 
Self-esteem 26.2±27.5 30.4±30.5 24.1±24.4 24.5±27.5 0.286 
Sexual life 41.9±35.9 47.3±36.9 43.5±35.6 35.2±34.7 0.128 
Public distress 40.5±28.9 56.6±31.5 38.9±25.2 27.7±22.7 <0.001 
Work 51.2±30.3 61.6±30.4 46.1±27.4 47.1±31.3 0.003 
IWQOL-Lite total 39.5±22.1 49.0±23.3 38.5±19.9 32.1±20.2 <0.001 
EQ5D  
Mobility problems % 66.7 55.9 63.0 80.3 0.006 
Self-care problems % 35.7 29.9 27.2 50.0 0.006 
Anxiety/depression problems % 75.3 73.1 75.6 77.0 0.864 
Pain/discomfort problems % 85.3 80.0 86.3 89.3 0.272 
Usual activities problems % 69.0 58.0 70.4 77.6 0.036 
Perceived health status 44.0±20.1 47.4±19.4 42.4±19.0 42.9±21.8 0.303 
HADS  
HADS anxiety 10.4±4.5 10.5±4.3 10.7±4.8 10.2±4.5 0.780 
HADS depression 9.1±4.0 8.6±4.0 9.3±3.9 9.3±4.1 0.436 
HADS Total 19.6±7.7 19.0±7.6 20.2±7.8 19.6±7.9 0.654 
Anxiety symptoms  
% (≥8) 
70.3 74.0 68.7 68.8 0.716 
Depression symptoms  
% (≥8) 
66.2 62.3 72.5 63.2 0.333 
Severe Anxiety symptoms  
% (≥11) 
48.3 50.7 48.2 46.3 0.860 
Severe Depression symptoms  
% (≥11) 
40.4 33.3 42.5 44.7 0.338 
Data are percentages and means ± standard deviations 
HADS= Hospital anxiety and depression scale. 
 
Table 3.3.4 shows that within the SLiM sample those with increasing levels of 
adiposity were more likely to be referred to receive bariatric surgery, with 54.0% of the 
third BMI tertile being referred (p <0.001). Those participants with increasing levels of 
adiposity attending the SLiM programme also reported significantly poorer baseline 
physical function, public distress, work and IWQOL-Lite scores.  
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Table 3.3.4: Demographic, clinical and quality of life characteristics of the SLiM 
sample across BMI tertiles 
 
Whole 
sample 
1
st
 BMI 
tertile 
≤46.85 
2
nd
 BMI 
tertile 
46.86 ≤ 
53.82 
3
rd
 BMI 
tertile 
53.83 
P 
N 152 51 51 50  
Age (years) 48.5±11.1 46.8±11.6 51.4±10.3 47.3±11.1 0.071 
Sex (% female) 73.0 62.7 76.5 80.0 0.118 
Ethnicity (%)     0.678     
White European 80.3 80.4 82.4 78.0  
Asian 9.9 11.8 9.8 8.0  
Black African/Caribbean 8.6 5.9 5.9 14.0  
Other 1.3 2.0 2.0 0.0  
Weight (kg) 140.0±28.3 118.4±16.3 137.1±18.0 164.9±27.1 <0.001 
Body mass index (BMI, kg/m
2
) 51.3±9.9 41.8±3.7 50.2±2.0 62.2±8.2 <0.001 
Type 2 diabetes (%) 35.5 39.2 31.4 36.0 0.707 
Insulin use (%) 9.2 13.7 5.9 8.0 0.367 
Referral to surgery (%) 30.9 5.9 33.3 54.0 <0.001 
Baseline IWQOL-Lite  
Physical function 32.3±22.1 41.2±23.3 32.6±22.3 22.8±16.5 <0.001 
Self-esteem 28.5±27.8 28.6±28.1 28.4±28.3 28.4±27.3 0.999 
Sexual life 46.5±31.1 48.4±29.1 50.3±32.1 40.7±31.9 0.292 
Public distress 36.3±26.7 47.5±27.1 35.5±27.6 25.5±20.6 <0.001 
Work 50.3±28.3 58.4±29.0 48.4±30.2 43.0±23.3 0.026 
IWQOL-Lite total 36.1±19.9 41.9±19.8 36.5±19.9 29.6±18.2 0.008 
Follow-up IWQOL-Lite      
Physical function 39.5†±24.0 51.4±24.2 40.4±23.9 28.9±19.2 <0.001 
Self-esteem 34.7*±29.5 36.6±32.1 33.8±30.3 33.9±26.9 0.894 
Sexual life 55.9*±34.4 56.6±34.4 62.9±34.2 49.3±34.0 0.221 
Public distress 37.7*±29.5 49.3±28.1 39.2±33.4 27.9±24.1 0.020 
Work 55.2†±30.6 65.8±31.1 57.8±30.9 43.6±26.2 0.003 
IWQOL-Lite total 42.9†±22.3 51.2±23.6 43.3±22.1 35.4±18.9 0.005 
Data are percentages and means ± standard deviations 
*Indicates value is significantly different from baseline value, p <0.05, † p <0.001. 
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3.3.2 Gender differences in quality of life 
Table 3.3.5 shows the mean baseline IWQOL-Lite data for both samples split by gender. 
Within the CWMS there were significant gender differences in the self-esteem (p <0.001), 
sexual life (p= 0.039) and total IWQOL-Lite scores (p= 0.047), whereby scores indicated 
significantly poorer quality of life in females. There were more widespread gender 
differences within the SLiM sample, with significant differences observed in all subscales; 
physical function (p= 0.001), self-esteem (p= 0.001), sexual life (p= 0.035), public distress 
(p= 0.001), work (p= 0.020) and total IWQOL-Lite scores (p <0.001). As with the CWMS 
sample, scores within the SLiM sample indicated significantly poorer quality of life for 
females. 
 
Table 3.3.5: Mean IWQOL-Lite quality of life scores in CWMS and SLiM samples 
split by gender 
 Gender 
P 
 Males Females 
CWMS:     
N 66 196  
Physical function  44.6±28.3 41.7±24.2 0.433 
Self-esteem  36.5±32.6 22.5±24.5 <0.001 
Sexual life  50.3±35.6 38.8±35.7 0.039 
Public distress  42.3±30.0 39.9±28.6 0.570 
Work  55.4±31.4 49.9±30.0 0.244 
Total 44.2±24.0 37.8±21.2 0.047 
SLiM:     
N 41 111  
Physical function  42.4±22.1 28.6±21.0 0.001 
Self-esteem  40.9±29.9 23.9±25.6 0.001 
Sexual life  55.3±25.5 43.0±32.4 0.035 
Public distress  48.1±25.6 32.1±26.0 0.001 
Work  59.3±26.5 46.9±28.4 0.020 
Total 46.8±18.8 32.2±18.9 <0.001 
Data are means ± standard deviations.  
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Table 3.3.6 shows the EQ5D-3L scores for the CWMS sample split by gender, with 
the proportion of individuals reporting the experience of ‘some problems’ or ‘extreme 
problems’ for each quality of life domain. There were no significant gender differences 
observed in EQ5D-3L scores. Table 3.3.7 shows the mean HADS scores for the CWMS 
sample split by gender. There were significant gender differences in HADS anxiety scores 
with a greater mean score for females (p= 0.012) and presence of anxiety in a greater 
proportion of the female sample (p= 0.004). Interestingly, there were no significant gender 
differences observed in mean total HADS scores (p= 0.064) and in HADS depression 
scores (p= 0.388). There were also no significant gender differences in presence of severe 
anxiety (p= 0.184) and severe depression (p= 0.405). 
 
Table 3.3.6: Proportion of individuals reporting problems in EQ5D-3L quality of life 
in CWMS sample split by gender 
 Gender 
P 
 Males Females 
CWMS: 
  
 
N 66 196  
Mobility problems (%) 69.5 65.7 0.592 
Self-care problems (%) 40.7 33.9 0.354 
Anxiety/depression problems (%) 67.2 78.3 0.095 
Pain/discomfort problems (%) 82.8 86.2 0.520 
Usual activities problems (%) 67.8 69.5 0.812 
Data are percentages 
Presence of problems defined as level 2 (some problems) and level 3 (extreme problems) scores on EQ5D-3L 
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Table 3.3.7: Mean HADS anxiety and depression scores in CWMS sample split by 
gender 
 Gender 
P 
 
Males Females 
CWMS:    
N 66 196  
HADS anxiety  9.2±5.0 10.9±4.3 0.012 
HADS depression  8.7±4.0 9.2±4.0 0.388 
HADS Total 17.9±8.2 20.1±7.5 0.064 
Anxiety symptoms % (≥8) 55.7 75.4 0.004 
Depression symptoms % (≥8) 66.1 66.3 0.978 
Severe Anxiety symptoms % (≥11) 41.0 50.9 0.184 
Severe Depression symptoms % (≥11) 35.7 42.0 0.405 
Data are percentages and means ± standard deviations 
Presence of anxiety and depression symptoms defined as HADS subscales Anxiety 8, Depression 8 
Presence of severe anxiety and depression symptoms defined as HADS subscales Anxiety 11, 
Depression 11. 
 
3.3.3 Linear regression: BMI, IWQOL-Lite and perceived health status 
The IWQOL-Lite total measure and the subscales physical function, self-esteem, public 
distress and work were significantly negatively associated with increasing BMI in the 
CWMS sample, as illustrated in Table 3.3.8. An increase in one BMI unit was associated 
with a decrease of 1.93 in physical function, 1.62 in self-esteem, 2.69 in public distress, 
1.33 in work, and 1.79 in total scores for the CWMS sample. Stratification by gender 
revealed that the observed effect sizes were greater in males for the physical function, 
public distress and total scores, indicating that within the male sample, BMI was more 
strongly negatively associated with these measures. Interestingly, BMI was not 
significantly associated with the sexual life subscale. The perceived health status measure 
(EQ5D-3L VAS) was also not significantly associated with BMI in the linear regression 
analysis. 
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Table 3.3.8: Linear regression of BMI predicting IWQOL-Lite subscale and total 
scores and perceived health status (EQ5D-3L VAS) in the CWMS sample stratified 
by gender 
 
Univariate Model 1 Model 2 
U.B. S.E. U.B. S.E. U.B. S.E. 
Physical function (N=238) -0.83† 0.20 -1.95† 0.48 -1.93† 0.47 
Male § (N=62) -1.66* 0.54 -1.92* 0.53 -2.00† 0.50 
Female § (N=176) -0.66* 0.21 -0.56* 0.20 -0.51* 0.21 
Self esteem (N=239) -0.34 0.22 -1.53* 0.53 -1.62* 0.53 
Male § (N=62) -1.80* 0.63 -1.39* 0.60 -1.19 0.63 
Female § (N=177) 0.01 0.22 -0.06 0.22 -0.11 0.22 
Sexual life (N=213) -0.56 0.32 -1.55* 0.77 -1.45 0.79 
Male § (N=57) -1.47 0.75 -1.55* 0.76 -1.21 0.81 
Female § (N=156) -0.33 0.35 -0.27 0.35 -0.29 0.36 
Public distress (N=240) -1.44† 0.22 -2.82† 0.53 -2.69† 0.54 
Male § (N=62) -3.00† 0.49 -2.76† 0.48 -2.48† 0.51 
Female § (N=178) -1.14† 0.24 -1.19† 0.24 -1.18† 0.25 
Work (N=219) -0.83* 0.25 -1.34* 0.65 -1.33* 0.66 
Male § (N=53) -1.39* 0.67 -1.23 0.68 -1.22 0.73 
Female § (N=166) -0.70* 0.27 -0.70* 0.28 -0.68* 0.28 
IWQOL-Lite total (N=235) -0.79† 0.17 -1.84† 0.43 -1.79† 0.44 
Male § (N=62) -1.82† 0.44 -1.78† 0.45 -1.60* 0.46 
Female § (N=173) -0.56* 0.19 -0.54* 0.19 -0.52* 0.19 
Perceived health status (N=205) -0.17 0.18 -0.12 0.49 -0.07 0.49 
Male § (N=51) -0.12 0.48 -0.11 0.50 -0.08 0.50 
Female § (N=154) -0.18 0.19 -0.18 0.20 -0.12 0.20 
U.B.= Unstandardised Beta, S.E.= Standard error, * p <0.05, † p <0.001 
Model 1 adjusting for age, gender and interaction between BMI and gender. Model 2 additionally adjusting 
for diabetes, hypertension, arthritis, obstructive sleep apnoea, cardiovascular disease 
§ Model 1 and 2 adjusting for age only. 
 
Table 3.3.9 shows the association between IWQOL-Lite scores and increasing 
adiposity in the SLiM sample. Interestingly, there was a different pattern of association 
between BMI and IWQOL-Lite compared to that observed in the CWMS sample. Physical 
function and public distress were significantly negatively associated with increasing BMI 
in the female subgroup, with an increase in one BMI unit associated with a decrease of 
0.67 in physical function and 0.91 in public distress for females in the SLiM sample.  
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Table 3.3.9: Linear regression of baseline BMI predicting baseline IWQOL-Lite 
subscale and total scores in the SLiM sample stratified by gender 
 
Univariate Model 1 Model 2 
U.B. S.E. U.B. S.E. U.B. S.E. 
Physical function (N=152) -0.61* 0.18 -0.42 0.27 -0.42 0.27 
Male § (N=41) -0.42 0.29 -0.42 0.29 -0.41 0.29 
Female § (N=111) -0.67* 0.21 -0.66* 0.21 -0.67* 0.21 
Self esteem (N=149) 0.28 0.23 0.45 0.35 0.45 0.35 
Male § (N=40) 0.45 0.40 0.44 0.36 0.44 0.36 
Female § (N=109) 0.23 0.27 0.22 0.27 0.19 0.27 
Sexual life (N=139) 0.06 0.26 -0.27 0.42 -0.27 0.41 
Male § (N=39) -0.27 0.35 -0.27 0.35 -0.28 0.32 
Female § (N=100) 0.31 0.35 0.32 0.35 0.28 0.35 
Public distress (N=148) -0.68* 0.22 -0.26 0.33 -0.25 0.33 
Male § (N=39) -0.25 0.35 -0.27 0.34 -0.26 0.34 
Female § (N=109) -0.90* 0.26 -0.90* 0.26 -0.91* 0.26 
Work (N=141) -0.39 0.24 -0.15 0.37 -0.15 0.37 
Male § (N=38) -0.15 0.36 -0.14 0.31 -0.13 0.31 
Female § (N=103) -0.52 0.31 -0.52 0.31 -0.49 0.31 
IWQOL-Lite total (N=146) -0.28 0.16 -0.11 0.25 -0.10 0.25 
Male § (N=39) -0.11 0.25 -0.12 0.25 -0.11 0.24 
Female § (N=107) -0.35 0.20 -0.35 0.20 -0.37 0.20 
U.B.= Unstandardised Beta, S.E.= Standard error, * p <0.05, † p <0.001 
Model 1 adjusting for age, gender and interaction between BMI and gender 
Model 2 additionally adjusting for diabetes 
§ Model 1 and 2 adjusting for age only. 
 
3.3.4 Logistic regression: BMI, EQ5D-3L and HADS anxiety and depression 
Table 3.3.10 shows the logistic regression analyses of the EQ5D-3L subscales mobility, 
self-care and usual activities which were significantly associated with BMI. The fully 
adjusted model revealed an increased risk of mobility problems with increased BMI, with 
the odds ratios of 1.64 (0.78 - 3.44) and 3.44 (1.47 - 8.05) for second and third BMI tertile 
groups (P for trend <0.05) respectively, compared to those in the first BMI tertile group. 
There was a non-significant increased risk of self-care problems in the upper BMI tertile 
group, with an odds ratio of 1.87 (0.86 - 4.09) (P for trend= 0.104). The fully adjusted 
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model also revealed an increased risk of problems performing usual activities, with the 
odds ratios of 2.04 (0.98 - 4.26) and 2.45 (1.10 - 5.46) for second and third BMI tertile 
groups (P for trend <0.05) respectively, compared to those in the first BMI tertile group. 
Interestingly, the logistic regression analyses of presence of anxiety and depression 
symptoms as defined as HADS subscale score 8 revealed that anxiety and depression 
were not significantly associated with BMI across the range encountered in the sample of 
individuals attending the CWMS. 
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Table 3.3.10: Logistic regression of presence of problems in mobility, self-care and usual activities (EQ5D) and presence of anxiety 
and depression (HADS) in the CWMS sample by BMI tertiles  
 
1
st
 tertile 
( ≤42.99) 
2
nd
 tertile 
(43.00 ≤ 48.61) 
3
rd
 tertile 
( 48.62) 
P for linear trend 
 Odds ratio (95% CI)  
Mobility problems 
(N=222) 
Univariate 1.00 1.25 (0.64 – 2.44) 2.95 (1.40 – 6.22)* 0.004 
Model 1 1.00 1.32 (0.66 – 2.63) 2.83 (1.31 – 6.15)* 0.008 
Model 2 1.00 1.64 (0.78 – 3.44) 3.44 (1.47 – 8.05)* 0.009 
Self-care  problems 
(N=221) 
Univariate 1.00 0.84 (0.41 – 1.72) 2.19 (1.09 – 4.39)* 0.018 
Model 1 1.00 0.88 (0.42 – 1.88) 2.05 (0.98 – 4.27) 0.044 
Model 2 1.00 0.89 (0.41 – 1.96) 1.87 (0.86 – 4.09) 0.104 
Problems performing 
usual activities 
(N=223) 
Univariate 1.00 1.71 (0.86 – 3.37) 2.65 (1.27 – 5.52)* 0.008 
Model 1 1.00 1.73 (0.86 – 3.44) 2.48 (1.17 – 5.23)* 0.016 
Model 2 1.00 2.04 (0.98 – 4.26) 2.45 (1.10 – 5.46)* 0.040 
Anxiety  
(N=233) 
Univariate 1.00 0.75 (0.37 – 1.51) 0.73 (0.36 – 1.45) 0.409 
Model 1 1.00 0.68 (0.33 – 1.42) 0.74 (0.35 – 1.54) 0.460 
Model 2 1.00 0.71 (0.34 – 1.50) 0.81 (0.37 – 1.74) 0.633 
Depression  
(N=222) 
Univariate 1.00 1.57 (0.78 – 3.15) 1.00 (0.51 – 1.98) 0.958 
Model 1 1.00 1.59 (0.79 – 3.20) 1.06 (0.53 – 2.11) 0.910 
Model 2 1.00 1.65 (0.80 – 3.40) 1.26 (0.61 – 2.62) 0.550 
Presence of problems defined as level 2 (some problems) and level 3 (extreme problems) scores on EQ5D-3L; Presence of anxiety and depression symptoms defined as 
HADS anxiety and depression subscale scores 8. * p <0.05, † p <0.001 
Model 1: adjusting for age and sex 
Model 2 additionally adjusting for diabetes, hypertension, arthritis, obstructive sleep apnoea, cardiovascular disease. 
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3.4 DISCUSSION 
 
The findings demonstrated that quality of life was markedly impaired in this sample of 
extreme obese individuals entering the CWMS and SLiM pathways of the service. 
Furthermore, gender differences were observed whereby quality of life was significantly 
poorer and prevalence of anxiety was greater for females. Whilst much of the research 
investigating the association between adiposity, quality of life and mental well-being has 
incorporated individuals across the spectrum of obesity, the present study is of particular 
importance as it focuses on the lesser-researched extreme obese population. Indeed, a 
significant negative association between increasing BMI and reduced quality of life was 
also observed, however this association was not observed for anxiety and depression, 
whereby the prevalence was consistently high across the sample. 
The extreme obese individuals attending the service are those who have chosen to 
seek weight management support. It appears that those attending the SLiM programme are 
an even more complex group than those attending the CWMS, with a higher BMI and a 
greater proportion facing threats to health through type 2 diabetes. Indeed the SLiM group 
are also older than those individuals attending the CWMS, suggesting that they may have 
been facing the challenges of weight management for a longer period of time and may not 
have succeeded with previous weight loss and weight loss maintenance efforts.  
A significant negative association was observed between increasing adiposity at 
these extreme BMI levels and quality of life, specifically in the areas of physical function, 
self-esteem, public distress, work and overall quality of life as measured by IWQOL-Lite 
scores, with increased adiposity associated with reduced quality of life in the CWMS 
sample. However, a different pattern of association was observed in the SLiM sample, 
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whereby a significant negative association between adiposity and quality of life was 
observed in the physical function and public distress areas of life for females only. Despite 
the fact that the association with adiposity was not significant in all subscales, the quality 
of life scores were markedly low, indicating substantial impairment. The association 
between adiposity and weight-specific quality of life as measured by IWQOL-Lite has 
been established, with the findings of one study indicating that BMI accounts for 
approximately 28% of the variance in total IWQOL-Lite scores (61). Previous research has 
shown that scores vary with degree of adiposity and treatment status, with those of higher 
BMI and those seeking treatment reporting significantly worse quality of life (61). In 
addition, changes in IWQOL-Lite score from baseline to follow-up post weight 
management intervention have been shown to correlate significantly with percentage of 
weight loss (149). The results obtained in the present study show a similar level of 
impairment in quality of life to those obtained in a study of bariatric surgery-seeking 
individuals, which reported scores ranging from 40.4 (work) to 46.2 (self-esteem) across 
IWQOL-Lite subscales (61). Interestingly, the present study reported one subscale, sexual 
life which was not shown to be significantly associated with adiposity. A similar pattern of 
results whereby significant association was not observed between BMI and sexual life has 
also been reported in a sample of over 400 bariatric surgery-seeking extreme obese 
individuals (135). The authors conclude that the lack of observed association is due to the 
high level of co-morbidities which may diminish the association between quality of life 
and BMI at the level of extreme obesity. However, the results of the present study show 
that the association between BMI and quality of life remains when controlling for co-
morbid health conditions, suggesting that obesity negatively impacts on quality of life 
independently of the co-morbidities associated with extreme obesity. The fact that the 
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expected association between adiposity and sexual life was not observed in the present 
study and previous studies (135) indicates that there are additional factors outside of those 
measured which contribute to the reduced level of quality of life in the specific domains 
such as sexual life. Indeed, the substantial impairments in sexual quality of life in this 
population have been suggested to be greatly under-researched (136) and are thought to be 
associated with the broader aspects of stigmatisation and discrimination (150) as well as 
negative perceived body image (136, 151) experienced by this population.  
Scores on the self-esteem subscale were notably lower than the other subscales, 
indicating specific impairment in this quality of life domain. The observed low level of 
self-esteem is consistent with findings from a comparison of White and African American 
US women, whereby White women scored significantly lower on self-esteem and sexual 
life compared to their African American counterparts in both class II and III obesity groups 
(152). These findings suggest that ethnic and cultural factors play a large role in the 
relationship between adiposity and quality of life and that self-esteem is an area which is 
particularly impaired in extreme obese individuals.  
A similar pattern of association was observed for the EQ5D-3L, whereby 
significant associations were observed between adiposity and some, but not all of the 
EQ5D-3L subscales. Adiposity was associated with experience of problems in mobility, 
self-care and performing usual activities, with those in the upper BMI tertile more likely to 
experience problems in these areas. Whilst the fully adjusted models remained significant 
for the mobility and performing usual activities analyses, the self-care model was no longer 
significant. These findings are consistent with the limited previous studies that have shown 
general quality of life as measured by EQ5D-3L being poorest for individuals with extreme 
obesity, compared to those of BMI 30.0-34.9kg/m
2
 and 35.0-39.9kg/m
2
, as well as 
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overweight and underweight groups, relative to those of normal weight where quality of 
life scores are optimum (130, 153). Interestingly, the present study reported no significant 
association with adiposity for the other two EQ5D-3L subscale scores, pain and discomfort 
and anxiety and depression, despite individuals reporting the greatest amount of problems 
in these domains. The observed lack of association between anxiety and depression and 
adiposity is in contrast to previous research which has identified that individuals who are 
obese are at greater risk of experiencing depression (59), anxiety (60), and pain (130), 
relative to normal weight individuals. Likewise, no significant association between 
adiposity and perceived health status as measured by EQ5D-3L VAS was observed which 
is again in contrast to the findings of previous studies (130). There was however, a non-
significant trend whereby perceived health status was highest for the first BMI tertile group 
(47.4) and lowest for the third BMI tertile group (42.9). Together, these findings suggest a 
possible ceiling effect for the EQ5D-3L tool being unable to detect differences within such 
a homogeneous group as the present sample in which the quality of life is consistently low. 
An additional aspect is the absence of normal weight individuals which truncates the BMI 
range, reducing the opportunity to identify an association, with those studies identifying an 
association usually including non-obese comparator groups.  
The expected significant associations between adiposity and presence of anxiety 
and depression as measured by HADS were also not observed in the present study. 
However, it was evident that the prevalence rates of these psychological symptoms, 
indicated by scores ≥8, were consistently high across the sample (anxiety, 70.3% and 
depression, 66.2%) and are far greater than the UK general population rates of 33.0% for 
anxiety and 11.4% for depression (98). Indeed, the adjustment of cut-points to indicate 
severe levels of anxiety and depression (scores ≥11), revealed that these levels remained 
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high with 48.3% experiencing severe symptoms of anxiety and 40.4% severe symptoms of 
depression. The relationship between depression and obesity has been widely documented 
in the literature, with results from prospective studies indicating that obesity is associated 
with future incidence of depression and cross-sectional studies revealing significant 
positive associations between adiposity and depression, particularly in females (59). Data 
from the NHANES study demonstrated a dose-response relationship between depression 
and adiposity, with extreme obese individuals facing greater odds of experiencing lifetime 
major depression (OR= 2.60, 1.38 - 4.91), recurrent major depression (OR= 2.28, 0.93 - 
5.60), depression in the past month (OR= 4.63, 2.06 - 10.42) and past year (OR= 2.92, 1.28 
- 6.67) than those of BMI 30.0-34.9kg/m
2
 and 35.0-39.9kg/m
2
,
 
relative to those of normal 
BMI (125). However, no significant variation in prevalence of anxiety and depression was 
observed across the levels of adiposity in the current sample, probably due to the truncated 
BMI range and homogeneity of the sample caused by the overall high prevalence of these 
conditions. Whilst much research has demonstrated evidence for an association between 
adiposity and both depression and anxiety (59, 60, 125) it is important to note that some 
studies have reported no significant association (154) or have reported non-significant 
trends (155-158). A systematic review and meta-analysis of the association between 
obesity and anxiety concluded that there is evidence in support of a positive association 
between obesity and anxiety, with pooled cross-sectional data indicating that obese 
individuals are more likely to experience anxiety (OR= 1.4, 1.2 - 1.6) (60). The results of 
the present study did not concur as no relationship was observed within this extreme obese 
sample, however the consistently high levels of anxiety and depression highlight that these 
conditions are widespread in this population. Furthermore, the truncation of the adiposity 
range is likely to contribute to the lack of observed association despite the high prevalence 
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of anxiety and depression symptoms within the sample. It is also of interest that the 
findings of the present study indicate that anxiety was more prevalent in the sample than 
depression, which reflects the UK general population prevalence rates which are also 
greater for anxiety than depression. 
The mechanism of the association between adiposity, impairment in quality of life 
and presence of anxiety and depression is not yet established, with several proposed 
pathways through which obesity may lead to psychological co-morbidity and vice versa. 
Firstly, through the multiple health threats associated with obesity acting as stressors, and 
secondly through the negative effects of stigma and weight-related discrimination. Indeed 
frequency of stigmatisation and inability to adopt effective coping strategies have been 
shown to result in depressed mood (158). The relationship between obesity and depression 
specifically, appears to be bi-directional with obesity associated with increased experience 
of depression, and depressive episodes associated with further weight gain. Indeed, obese 
individuals are more likely to over-eat and gain weight relative to non-obese individuals 
during an episode of depression (159). A systematic review of the literature on the 
relationship between depression and adiposity reported however, that the majority of the 
evidence base was cross-sectional and thus causality could not be established (59). 
Previous research has been criticised for the inclusion of only one measure of 
quality of life (130), and as such the inclusion of several quality of life measures is a novel 
aspect of the present study. Previous studies have utilised either general measures such as 
the EQ5D-3L (130, 153), and the SF-36 (134, 160), or condition-specific measures such as 
the Obesity Adjustment Survey (OAS) (129) and the Obesity Related Well-being 
(ORWELL 97) questionnaire (161); however, the IWQOL-Lite measure is the most widely 
used weight-specific measure (162). Findings of the present study suggest that in the 
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assessment of quality of life in the extreme obese patient population, both weight-specific 
and general quality of life measures can be utilised. Interestingly, the IWQOL-Lite and 
EQ5D-3L measures and the HADS mental health screening tool all contained subscales 
that were not associated with adiposity. Indeed, the specific domains which were not 
associated with adiposity; pain and discomfort, anxiety and depression, and sexual life 
were in fact the more severely affected aspects of life, likewise, none of the components of 
the HADS mental health screening tool were associated with adiposity, despite the fact that 
the tool determined the high prevalence of anxiety and depression in this extreme obese 
sample. Thus, the overall low quality of life and high prevalence of anxiety and depression 
symptoms and the BMI truncation are more likely to be responsible for masking the 
association with adiposity, rather than there being no association. This suggests that each 
of the tools may have limitations in capability of identifying differences between levels of 
extreme adiposity. Future studies likewise should utilise several quality of life measures, 
including those that are weight-specific and general in order to establish the responsiveness 
and validity of the measures in this minority patient group (163), as well as enabling 
deeper understanding of the additional factors which may influence the complex 
relationship between adiposity, quality of life and mental well-being. 
A key strength of the present study is that it demonstrates that the negative impact 
on quality of life associated with increasing BMI remains even when controlling for the 
presence of co-morbid health conditions commonly experienced by the extreme obese 
population. Previous studies have concluded that the association between adiposity and 
quality of life is mediated by co-morbid health conditions such as chronic pain, 
cardiovascular disease and type 2 diabetes (63, 124, 164). However, the present study 
supports that the association is independent of co-morbid health conditions and suggests 
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that the role of co-morbidities in the relationship may have previously been over-estimated, 
while the impact of adiposity itself may have been underestimated in extreme obesity.  
An additional strength of the present study is that it facilitates greater understanding 
of the quality of life and mental health characteristics of this lesser-researched extreme 
obese population. However, the present study has several limitations. The individuals 
characterised in the sample are those that had sought assistance in managing their weight 
and as a consequence it may not be appropriate to extrapolate these findings to the general 
extreme obese population. There are many extreme obese individuals who do not seek 
treatment and evidence suggests that non-treatment-seeking obese individuals experience 
lower levels of psychological distress (121) and impairment in quality of life (61) than 
those treatment-seeking individuals. The cross-sectional design of the present study means 
that it has not been possible to confirm a causal relationship between adiposity and the 
quality of life measures, however, the following longitudinal analyses chapter examines 
the association between change in BMI and change between pre- and post-intervention 
quality of life scores. The present study was also conducted as part of a pragmatic 
evaluation which meant that it was not possible to compare the characteristics of the 
extreme obese treatment-seeking group with a non-obese control group or an extreme 
obese non-treatment-seeking group for comparison. As such the findings of the present 
study should be interpreted with consideration of these factors, and future studies adopting 
a controlled design should be utilised in further investigation of the psychological co-
morbidities of extreme obesity. 
 
  
  
128 
 
3.4.1 Summary of findings 
The present chapter has highlighted the substantial psychological co-morbidity associated 
with extreme obesity. Among this sample of extreme obese individuals seeking treatment 
at the service there is a high prevalence of psychological co-morbidity, including presence 
of anxiety and depression symptoms and markedly impaired quality of life. Increasing 
adiposity was associated with a reduction in several areas of quality of life, but was not 
significantly associated with prevalence of anxiety and depression, although the lack of an 
observed association may be the result of limitations in study design. 
 
3.4.2 Recommendations 
Individuals attending weight management services have complex psychological needs and 
as such should receive support in managing the physical as well as mental co-morbidities 
of extreme obesity. If obesity is driven by underlying psychological issues, it is essential 
that support is given to address these factors if long-term weight loss is to be achieved. 
Support should be provided through tailored weight management interventions which 
focus on enhancing mental health and well-being, with a specific emphasis on self-esteem 
as an area for improvement, as this was the domain within which individuals showed the 
greatest impairment in quality of life. These strategies should be incorporated into the 
multi-disciplinary care of extreme obese individuals in order to minimise the harmful 
impact of the impairment in quality of life and mental well-being faced by these 
individuals.  
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CHAPTER FOUR: 
 
4.0 LITERATURE REVIEW OF UK WEIGHT MANAGEMENT 
INTERVENTIONS FOR OBESITY 
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4.1.1 Literature review of UK weight management interventions for obesity: 
Literature search procedure 
In order to place the outcomes of the Specialist Weight Management Service demonstrated 
in the present evaluation in context, the body of research literature examining the efficacy 
of other weight management approaches offered to obese individuals in the UK is 
reviewed. A literature search was conducted using the PubMed database, hand-searching 
reference lists of relevant articles and searching research project websites. The search 
included articles that detailed interventions aimed at achieving weight loss with or without 
weight maintenance components, delivered by individuals from healthcare or non-
healthcare background, to an obese sample, defined as mean BMI 30.0kg/m2. The review 
excluded studies describing surgical interventions and those which described baseline 
characteristics without outcome data. Articles were included if they were published up to 
and including March 2014, written in English and included an adult study population. A 
total of 25 studies were identified, 11 of which were primary care-led (Table 4.1.1), 5 
specialist weight management services (Table 4.1.2), 8 commercial weight management 
programmes (Table 4.1.3) and the remaining study related to a sporting club-based 
programme (Table 4.1.4).  
 
4.1.2 Primary care programmes 
The most widely adopted primary care-led weight management programme is the 
Counterweight programme which was developed and launched in 2000 and provides 
training for primary care staff to implement and deliver a structured and evidence-based 
programme to obese individuals. The aims of the Counterweight programme were to 1) 
conduct a needs assessment and evaluate current service provision in primary care practice, 
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2) provide support and training to practice staff, 3) implement structured, theoretically- and 
evidence-based weight management interventions in the primary care setting, and 4) to 
evaluate the programme through a UK-wide trial (29). A total of 70 primary care practices 
took part, of which 58 were randomised to implement the Counterweight programme and 
12 were randomised to act as a control comparator group, who would deliver the 
programme after a deferred period of two years once the second audit of practice activity 
had been completed.  Practices of varying sizes were recruited from seven centres; 
Hammersmith, Luton, Bath, Birmingham, Leeds, Glasgow and Aberdeen, enabling 
variation in geographical location and levels of deprivation across the UK.  
The initial audit collected information on the baseline approaches to weight 
management in the primary care practices, which was analysed in order to identify 
potential gaps in the provision of weight management care (165). This large-scale survey 
comprised anonymously-completed questionnaires and structured interviews conducted 
with 141 General Practitioners (GPs) and 66 practice nurses from 40 primary care practices 
in order to examine healthcare professionals’ accounts of the service delivered under their 
care. Additionally the proportion of patients who had a weight or BMI ever recorded was 
obtained for the total patient population for each practice. A randomly selected sample of 
100 medical records of obese patients were also reviewed from each practice to establish 
the use of anti-obesity medication and rates of referral to specialist weight management 
services.  
The 40 practices recruited to the baseline audit were selected from within the seven 
Counterweight sites across the UK. Findings from the survey revealed that BMI was 
recorded for 64.2% of patients, suggesting that obesity may have been under-reported and 
under-diagnosed in primary care. The results of the self-reported questionnaires indicated 
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that the majority of GPs (83%) and nearly all nurses (97%) reported that they would raise 
the issue of weight with obese patients, with significantly more nurses discussing the issue 
(p <0.05). Furthermore, the findings indicated that nurses spent more time discussing 
weight issues with patients, with 15% of GPs and 76% of nurses spending up to 10 minutes 
in consultations discussing weight-related issues (p <0.001). Practice-based dietary 
counselling was the most common referral for obese patients (20%), with relatively few 
referrals to dietetic centres (4%) and obesity centres (1%), with prescription of anti-obesity 
medication also low (2%). The investigators concluded that the findings of the baseline 
audit indicated that there was a need for better recording and diagnosis of obesity. Where 
obese patients received an intervention this was most likely to take the form of brief 
opportunistic consultations with practice nurses. Furthermore, healthcare professionals 
tended to favour practice-based weight management interventions, with relatively few 
patients referred to external weight management services. As such the authors highlighted 
that these findings demonstrate the importance of establishing effective weight 
management interventions to be delivered in the primary care setting. Data collected from 
the baseline audit demonstrated that the annual healthcare expenditure of the patient 
sample increased by £16 for each obese individual with every increase in BMI unit, 
providing further evidence of the need for effective weight management interventions 
(166).  
The findings of the baseline audit were primarily used to inform the development 
of a training programme to equip the practice nurses with the skills required to deliver the 
individual and group-based interventions. The aim of the programme was to introduce a 
new model of weight management in primary care incorporating complex patient 
interventions, modification of healthcare professionals’ behaviour and practice screening 
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and referral systems. The outcomes of the first 12-month period of the Counterweight 
programme indicated that the majority of the recruited practices had received the training 
programme (93.5%), and a considerable proportion of practices were actively 
implementing the new weight management model (75.8%) (167). At 12 months a total of 
1,549 patients had been recruited, with a mean BMI of 36.9kg/m
2
, with 26% of those 
recruited classed as extremely obese with a BMI ≥40.0kg/m2. Of those who had completed 
the minimum number of appointments (49% of those recruited), receiving the lifestyle 
intervention either in the group or individual consultation format, a substantial proportion 
(40%) had achieved weight losses of ≥5% of their baseline body weight at 12 months. The 
preliminary results indicated that the Counterweight programme was effective at 
facilitating weight loss in a primary care setting. However, it is important to note that when 
including all individuals who commenced the programme, thus including those who did 
not complete, a more modest proportion (16.2%) achieved weight losses of ≥5% body 
weight. Furthermore, during the initial 12-month evaluation period four practices withdrew 
prior to healthcare professional staff training and 11 practices stopped recruiting additional 
patients, with the authors suggesting that this was due to difficulties incorporating the 
programme into routine practice without additional funding resources.  
A subsequent evaluation has also reported final outcomes of the five-year 
evaluation phase of the Counterweight programme (168). At the end of the evaluation 
period 2,095 patients were identified for inclusion, of which 1,906 were eligible across the 
56 participating practices. Weight data was obtained for 642 individuals who completed a 
minimum of 12 months attendance, and 357 individuals who completed 24 months 
attendance. The characteristics of the total sample entering the programme (N=1,906) 
indicated that the sample were predominantly female (77%) with a mean age of 49.4 years 
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and mean BMI of 37.1kg/m
2
, with 25.4% of the sample classed as extremely obese. The 
mean weight loss for those attending a minimum of 12 months was -3.0±6.6kg with a 
mean BMI reduction of -1.1±2.4kg/m
2, with weight losses of ≥5% baseline body weight 
achieved by 30.7% of the sample attending at 12 months. For those attending a minimum 
of 24 months, a mean weight loss of -2.3kg was achieved, with weight losses of ≥5% 
baseline body weight achieved by 31.9% of the sample. It is important to note that the 
reported outcomes were achieved via a variety of treatments which comprise the complex 
multi-component programme. For instance, of those completing 12 months attendance, 
70% received the lifestyle intervention through individual consultations, 34% through 
group interventions, and 19% were prescribed anti-obesity medication, with some 
individuals receiving these treatments in combination and others in isolation. With such a 
complex intervention it is imperative to establish which components are the ‘active 
ingredients’ that contribute to the observed intervention effects. However these analyses 
were not conducted, meaning that such conclusions cannot be drawn. The initial 
publication (29) outlining the programme design stated that 18 practices were randomised 
to act as control comparators in the evaluation. However, the subsequent evaluations (167, 
168) make no reference to the control practices, which is a major flaw in the 
implementation of the study design and reporting of outcomes.  
A cost-effectiveness analysis of the Counterweight programme has been conducted 
(169), which suggested that the weight losses of -3.0kg and -2.3kg achieved by those 
attending the programme, at 12 and 24 months respectively, is a significant improvement 
relative to  the estimated population rate of weight gain of +1kg per year. The estimated 
cost of delivery of the Counterweight programme was £59.83 per individual entered onto 
the programme, and was cost-saving, assuming that the 12-month weight loss of -3.0kg 
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achieved by 45% of the sample was completely regained over the following two-year 
period and assuming that non-attenders (55% of the sample) gained weight at the rate of 
+1kg per year. Evaluation of the Counterweight programme has demonstrated the efficacy 
of a novel weight management model implemented in primary care settings on a large 
scale across the UK. However, the observed weight losses were relatively small. 
 In order to increase individuals’ access to the programme, a pilot service operating 
the programme from pharmacies was introduced to areas where the programme was not 
available at GP practices (170). Sixteen community pharmacies took part in the pilot study 
in Fife, Scotland, recruiting a total of 458 individuals. The sample was predominantly 
female (74.7%), with a mean age of 54 years and mean BMI of 36.1kg/m
2
, with 21.2% of 
the sample classed as extreme obese at baseline. The Counterweight lifestyle intervention 
was delivered by pharmacy staff through one-to-one appointments, with initial 
appointments lasting between 10-30 minutes in duration and taking place monthly for the 
first six months, with follow-up appointments at 6, 9 and 12 months. Total patient contact 
time was estimated to be approximately 130 minutes for the entire duration of the 
programme. Follow-up data was available for 314 individuals at 12 months post-baseline, 
with these individuals achieving a mean weight loss of -4.1kg (-2.8 - -5.4), with 41.6% of 
individuals attending at 12 months achieving losses of ≥5% of their baseline body weight. 
In addition to analysing available case data the authors also reported 12-month weight 
outcomes calculated through analysis of Last Observation Carried Forward (LOCF) data. 
This demonstrated a more conservative mean weight loss of -1.7kg (-1.3 - -2.1), with a 
reduced proportion of the sample, 15.9% achieving ≥5% loss of baseline body weight. 
Furthermore, subgroup analyses of 64 extreme obese individuals with baseline BMI 
≥40.0kg/m2 were conducted, with those completing 12 months of attendance achieving a 
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mean weight loss of -7.4kg (-3.1 - -11.6), with 46.7% achieving ≥5% loss of baseline body 
weight. Similarly, analyses of the LOCF data indicated more conservative weight losses 
for the BMI ≥40.0kg/m2 subgroup, with a mean loss of -2.4kg (-1.1 - -3.7), with 15.6% 
achieving ≥5% weight loss. Interestingly, there were no significant differences in the 
weight loss achieved by individuals across the baseline BMI range, supporting that the 
Counterweight programme as delivered in a community pharmacy setting was able to 
facilitate weight loss across the spectrum of overweight and obesity. However, when 
considering all of those enrolled on the programme, analysis of Baseline Observation 
Carried Forward (BOCF) data demonstrated much more conservative losses at 12 months, 
with a mean weight loss of -1.0kg (-0.6 - -1.4), with 10.2% achieving ≥5% baseline body 
weight loss. A key strength of the study is that it effectively demonstrated the 
implementation of an established weight management model in a new setting, delivered by 
a different group of healthcare professionals, namely pharmacists and predominantly 
pharmacy-assistants, rather than by trained nurses. The study also included a detailed level 
of reporting of outcome measures, enabling comparison between those completing the 
programme for whom data were available and those with missing data whereby imputation 
of last and baseline observations was used. Whilst the study included 12-month outcome 
data for individuals, longer-term data would be necessary in order to demonstrate whether 
the initial weight loss achieved could be maintained beyond the initial one year period.   
 A different weight management approach combining lifestyle education with a Low 
Energy Liquid Diet (LELD) approach has also been implemented in 25 practices delivering 
the original Counterweight programme in Scotland (33). A total of 91 patients with a BMI 
≥40.0kg/m2 were recruited to the feasibility study assessing the effectiveness of a LELD 
intervention in extreme obese individuals in a primary care setting. The sample was 
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predominantly female (81.3%), with a mean BMI of 48.0kg/m
2
, and a mean age of 
45.7years. The intervention was delivered by primary care nurses and dietitians who had 
received specialist training in the use of LELD, and the aim of the intervention was to 
facilitate ≥15kg weight loss over the 12-month programme duration. The intervention 
comprised three stages, the provision and supervision of the LELD which was maintained 
for a period 12-weeks or until individuals had obtained ≥20kg weight loss, during which 
time individuals also received structured lifestyle education during fortnightly 
appointments. This was followed by a phase of food reintroduction lasting approximately 
6-8 weeks in duration, during which time the fortnightly lifestyle education appointments 
continued. The final phase of the intervention was aimed at achieving weight maintenance, 
whereby individualised meal plans were followed in conjunction with lifestyle education at 
monthly appointments. The LELD phase of the intervention was completed by 64% of the 
sample, with a sample mean weight loss at 14-weeks of -16.9±6.0kg, which equated to a 
loss of -12.6±4.5% baseline body weight, with 69% of those completing the LELD phase 
achieving the targeted weight loss of ≥15kg. The food reintroduction phase was completed 
by 41% of the sample, with a mean further weight change of -2.1±3.7kg after the 9-week 
period. On completion of the LELD and food reintroduction phases, a mean weight loss 
from baseline of -19.1±7.5kg, equating to -14.6±5.1%, was achieved, with 77% of those 
completing both phases achieving ≥15kg weight loss. The final phase of the intervention, 
weight maintenance was completed by 75% of the sample, with a mean weight change 
from baseline of -12.4±11.4kg, equating to -9.1±8.2%, with weight loss ≥15.0kg achieved 
by 44% of those completing the final phase and 33% of those recruited to the feasibility 
study. The feasibility study demonstrated that the LELD in combination with lifestyle 
education was effective at facilitating larger weight losses, as necessary for those 
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individuals with extreme obesity. The estimated cost of delivery of the LELD intervention 
was £861.05 per patient entered, a cost which is considerably larger than that of the 
original Counterweight programme which was delivered at a cost of £59.83 per individual. 
The larger cost is expected given the greater intensity of the LELD intervention and the 
greater amount of weight loss achieved. The LELD intervention can be implemented to 
large numbers of individuals in primary care settings and was demonstrated to be a cost-
effective alternative to surgical intervention. For instance, for the cost of £1million a total 
of 1161 patients receiving LELD treatment would result in 12-month maintained ≥15kg 
weight losses for 383 patients, compared to 133 patients receiving laparoscopic banding, 
resulting in ≥15kg weight loss for 110 patients also for a cost of £1 million (171). 
 The outcomes of 6,715 individuals attending the Counterweight programme have 
been published providing an overview of the overall effectiveness of the programme (172). 
The evaluation comprised outcome data from the implementation of the programme in 184 
general practices, 16 community pharmacies and a community-based service. Attendance 
for the combined implementation at 12 months was 28%, which was markedly lower than 
the 45% attendance rate reported in the original evaluation detailing the five-year outcomes 
(168). Those attending at 12 months achieved a mean weight loss of  -3.7kg (-3.3 - -4.4), 
with 35.2% achieving ≥5% weight loss, which is a greater proportion than the 30.7% of the 
sample reported to achieve ≥5% weight loss in the original evaluation (168). Interestingly, 
the evaluation additionally reported intention to treat data detailing the outcomes for the 
whole sample, incorporating data from those individuals who did not attend enough 
sessions to classify as completers of the programme, with data indicating that of the whole 
sample, a more modest proportion of 10.0% achieved ≥5% weight loss at 12 months. This 
evaluation provides support for the efficacy of the Counterweight programme delivered in 
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primary care settings, with consistent weight loss achieved, and demonstrates that the 
greatest weight losses achieved are among those who fully attend the programme. The 
study highlights the importance of understanding reasons for non-attendance and strategies 
to overcome barriers to attendance, in order to maximise the efficacy and weight losses 
achieved through the implementation of the programme. 
As an alternative to delivering the Counterweight programme, other primary care 
teams have devised and delivered their own ‘in-house’ services facilitated by healthcare 
professionals, an example of this is a programme delivered by community nurses in 
Camelon,  a region of high socio-economic deprivation in Scotland (30). The Camelon 
model which was delivered by community nurses and a dietitian, focussed on weight 
management specifically for obese adult men. The model comprised an initial 40-minute 
screening appointment conducted in community settings, in which individuals were invited 
to join the Camelon programme, followed by a 20-minute pre-programme individual 
assessment appointment in which individuals were given further information about the 
programme, and baseline measures were obtained. The subsequent 12-week weight 
management programme was conducted in male-only groups, with each session lasting 60-
minutes and taking place in the evening. The programme used behaviour change 
techniques to achieve a balanced healthy diet and increased physical activity, with an aim 
of facilitating between -0.5 and -1.0kg weight loss per week. The evaluation provides an 
extremely useful detailed description of the intervention programme, providing explicit 
detail of the content of each of the sessions and specifically describing the techniques used 
in order to tailor the lifestyle information and delivery of the information to be most 
appropriate for the male patient population. This detail of reporting is a major strength of 
the evaluation as transparency enables replication of the principles of the programme in the 
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design and implementation of future weight management programmes. Of the 1,855 males 
attending the initial health clinic visit, 105 eligible individuals took part in the programme, 
with analyses comparing the outcomes of those participants who attended the programme 
with those who chose not to join the programme. At the end of the 12-week programme, of 
the 105 males that took part, 80 (76.2%) completed the programme, achieving a mean 
weight loss of -5.0kg, with 44.3% of those completing the programme achieving a weight 
loss of ≥5% of their baseline weight, of whom 8.9% achieved losses of ≥10% of their 
baseline body weight. Post-programme follow-up was available for a very limited number 
of 20 individuals, obtained between 1-49 months after finishing the programme, who 
achieved a mean weight loss of -3.7% of their baseline weight after the longer-term follow-
up. Long-term outcome data would be needed for a larger sample size in order to establish 
the efficacy of the programme. Furthermore, the quantitative analysis would have been 
improved by including comparison of the baseline characteristics and outcomes obtained 
between those completing the programme and those who did not, and additionally 
including intention to treat data detailing the outcomes for all individuals entering the 
programme. It is a limitation of the study that such a small proportion (13.6%) of the 770 
obese individuals identified as eligible potential participants went on to attend the 
programme, with a total of only 110 joining the programme over the four-year period 
between 2003-2007. The majority of those identified as eligible (69.4%) chose not to join 
the programme waiting list, with this suggesting that a greater understanding of the barriers 
to participation are required in order to improve attendance rates and thus strengthen the 
intervention. 
A major strength of the evaluation is the inclusion of a qualitative component, 
which examined individuals’ experiences of attending the programme through two focus 
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groups conducted with separate samples of eight participants and one focus group 
conducted with eight partners of the participants. The qualitative work explored the 
participants’ reasons for joining the programme, which were identified as personal health 
concerns, pressure from family members and the use of humour and male-only aspects of 
the programme. The participants also highlighted which information delivered during the 
programme that they had personally found to be the most helpful. These included advice 
about reducing portion sizes, changing cooking methods and learning about nutritional 
labelling. Participants’ reasons for continued attendance in the programme were also 
shown to be enjoyment and the rapport built with facilitators of the programme. Finally, 
family member involvement with the programme was also discussed by both participants 
and partners, suggesting that the lifestyle changes had extended beyond the individual 
participants and were adopted by the wider family. 
 The effectiveness of other primary care-led interventions have been evaluated using 
the more rigorous Randomised Controlled Trial (RCT) design (31, 32, 173). The first of 
which, evaluated the impact of a brief training intervention delivered to nurses and GPs 
from 22 primary care practices in the north of England, in the provision of a new weight 
management model (173). The training consisted of three 90-minute sessions delivered to 
nurses. These were completed within a two-week period, detailing information on the 
clinical benefits associated with weight loss and a range of treatment options to be offered 
to patients including the prescription of an individualised 500 calorie deficit low-energy 
diet, guidance on increasing physical activity and pharmaceutical treatment. On completion 
of the training, the new model of weight management was delivered to 415 obese 
individuals, recruited as a result of meeting the inclusion criteria of having a BMI ≥30.0 
kg/m
2
 and being aged 16-64 years. Participants received individual fortnightly 
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appointments until ≥10% body weight loss was achieved, after which there was a period of 
weight maintenance which comprised monthly or bi-monthly appointments.  
The primary care-based RCT evaluated the effectiveness of the new weight 
management model versus a control arm comprising 22 of the 44 recruited practices who 
were instructed to provide usual care to obese individuals for the duration of the 18-month 
study period. Weight outcomes were obtained at 3, 12 and 18 months post-intervention and 
whilst there were no significant differences in weight between the intervention and control 
arms at each time point, there was a non-significant trend for the intervention arm to be 
heavier than the control group by +0.6kg (-2.1 - 3.2), +1kg (-1.9 - 3.9), and +1.3kg (-1.8 - 
4.4), respectively across the study duration (p >0.05). There was also little change from the 
baseline values, with the intervention arm achieving losses of -0.4kg and -0.5kg at 3 and 12 
months from baseline. However this slight weight loss was regained and at 18 months 
there was no change from the baseline weight of 100.8±18.1kg. The control arm of the 
study achieved greater weight loss than the intervention arm, with losses of -0.4kg, -0.9kg 
and -0.7kg at 3, 12 and 18 months post-baseline, respectively. The analyses were 
conducted using available case data, with 3-month data obtained for 78.8%, 12-month data 
obtained for 67.0%, and 18-month data obtained for 63.0% of the sample. This RCT 
demonstrated that the intervention did not facilitate weight loss in the sample of high BMI 
individuals, with mean baseline BMI values of 37.0kg/m
2
 in the intervention arm and 
36.9kg/m
2
 in the control arm. The investigators suggested that greater weight change was 
not observed in individuals receiving the intervention due to low levels of implementation, 
with intervention practices reporting that individuals were receiving an average of eight 
consultations over the 12-month period, which is far less contact than the fortnightly 
appointments which were recommended as per study protocol, which would equate to a 
  
143 
 
minimum of 20 consultations. Indeed, individuals in the control arm of the study received a 
similar number of appointments, 6 over the 12-month duration, which may account for the 
similar weight outcomes achieved by the study arms. Whilst the RCT was not able to 
determine the effectiveness of the intervention, as the new weight management model was 
not implemented as per protocol, the trial has highlighted the difficulties of implementing 
new models of practice in primary care settings where training time is limited and there are 
competing priorities.  
In a separate pilot RCT conducted in the primary care setting, the effectiveness of a 
structured lifestyle support intervention with and without the use of pedometers was 
evaluated (32). In this pilot trial 103 individuals with BMI ≥27 kg/m2 were randomised to 
one of four arms; structured lifestyle support with pedometer, structured lifestyle support 
without pedometer, usual care with pedometer, and usual care without pedometer. Eight 
primary care practices took part, with nurses receiving training via a CD-ROM, in the 
delivery of the 12-week structured support intervention which comprised fortnightly group 
sessions. A detailed description of the material delivered during the sessions was provided 
by the authors, which is a major strength of the reporting of the study. In addition, the 
intervention was developed following the complex interventions guidance issued by the 
Medical Research Council (MRC). The intervention utilised behaviour change techniques 
including goal setting, and monitoring to improve diet and activity levels. Individuals 
randomised to receive usual care received a single individual 30-minute appointment 
during the 12-week period. Those individuals who were randomised to receive a 
pedometer alongside either the structured group support intervention or usual care, were 
provided with the device and given instructions on its use as well as a leaflet highlighting 
the benefits of achieving a target of 10,000 steps per day and individuals were also 
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instructed to record the number of steps taken per day. The authors reported 12-week 
intervention-end weight outcomes, with losses of -4.0±3.5kg (-4.0±3.4%) achieved by 
those receiving the structured support (either with or without pedometer), with 34% 
achieving ≥5% loss of baseline body weight. Those not receiving structured support 
achieved smaller losses of -1.2±3.8kg (-1.2±4.1%), with 18.9% achieving ≥5% baseline 
body weight loss. Analyses comparing those receiving the structured group support 
intervention with those who did not receive support was conducted, with findings 
indicating that those receiving support lost significantly more weight than those not 
receiving support, with adjusted mean differences of -2.6kg (-4.1 - -1.2) and -2.8% (-4.3 - -
1.3) body weight. Analyses showed that there were no significant differences in weight 
loss between those receiving a pedometer and those who did not receive a pedometer, with 
mean weight losses of -2.5±4.0kg and -2.5±3.9kg, respectively. However, the findings of 
these analyses should be interpreted with caution due to the fact that this was a pilot RCT 
and was thus not sufficiently powered to detect between group differences.  
 Following the pilot RCT, a larger scale RCT was conducted, with a revised 
intervention design (31). The trial inclusion criteria was also widened to include those with 
BMI ≥25.0 kg/m2, although the mean baseline BMI of 33.5kg/m2 indicates that the sample 
were predominantly obese rather than overweight. The new primary care-based 
intervention was termed the Camwel programme and delivered in 23 practices in the 
Camden area of London, and was delivered on a one-to-one rather than group basis, to a 
much larger sample size of 381 individuals. The RCT evaluated the Camwel structured 
lifestyle support programme versus usual care. The intervention comprised fortnightly one-
to-one appointments, each lasting 30 minutes for the first 12 weeks, after which there was 
a further 12 weeks of appointments which took place every 3 weeks, followed by monthly 
  
145 
 
appointments for the final 12 weeks, giving a total of 14 sessions over a 9-month period. 
The intervention covered diet and physical activity behaviour change and as with the pilot 
RCT the reporting of the intervention was a key strength of the study, describing in great 
detail the specific behaviour change techniques utilised in the programme and the 
theoretical frameworks underpinning each of the techniques. The intervention was 
delivered by a team of six Camwel advisors who were non-healthcare professionals who 
received two days of training including the CD-ROM tool utilised in the pilot study, 
supplemented with further quarterly meetings with the research team. The 6-month weight 
outcomes revealed that there was no significant difference in weight loss between the 
intervention and control arms. The intervention arm achieved mean losses of -1.7kg (-2.5 - 
-1.0) and  -1.8% (-2.5 - -1.1), with 23.9% achieving ≥5% baseline body weight loss, whilst 
the control arm achieved mean weight losses of -1.0kg (-1.7 - -0.2) and -1.0% (-1.9 - -0.2), 
with 13.2% achieving ≥5% baseline body weight loss. The adjusted mean difference 
between intervention and control arms was 0.8kg (-1.9 - 0.3). A similar pattern of results 
were observed in the 12-month data, with the intervention arm achieving mean losses of -
2.4kg (-3.5 - -1.3) and -2.6% (-3.7 - -1.5), with 34.0% achieving ≥5% baseline body weight 
loss. The control arm achieved mean weight losses of -1.3kg (-2.2 - -0.4) and -1.4% (-2.4 - 
-0.4), with 19.3% achieving ≥5% baseline body weight loss, with an adjusted mean 
difference between intervention and control arms of 1.1kg (95% CI: -2.5 - 0.3). However, 
the intervention arm had a significantly greater proportion of individuals losing ≥5% 
baseline body weight at both 6 and 12 months, with adjusted mean differences of 10.7% 
(1.4 - 20.0), and 14.7% (3.0 - 26.4), respectively. 
In conclusion, the weight management interventions delivered in primary care 
settings have all focussed on the provision of lifestyle and behaviour change advice, with 
  
146 
 
the exception of one study which provided participants with an alternative Low Energy 
Liquid Diet (LELD) approach (33). Despite the homogeneity in intervention type, there has 
been great variation in the effectiveness of the interventions, with two RCTs reporting no 
significant differences in weight loss between intervention and control arms (31, 173). 
However, the studies utilising poorer quality designs have reported weight losses ranging 
from -5.0kg (30) and -3.0±6.6kg (168) achieved after lifestyle intervention, and a loss of 
-12.4±11kg obtained after completion of the LELD intervention (33). It appears that whilst 
the majority of the lifestyle focussed primary care-led weight management programmes 
have demonstrated weight loss, the weight losses achieved have been modest and may not 
be sufficient to produce the clinically significant improvement to health that is required.  
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Table 4.1.1: Studies examining the effectiveness of weight management interventions in Primary care 
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Counter-
weight 
project 
team, 
2005 
UK, 7 
regions: 
Aberdeen, 
Bath, 
Birming-
ham & 
Solihull, 
Glasgow, 
Hammer-
smith 
(London), 
Leeds, 
Luton 
1,549  Mean 
BMI=36.9kg/m
2 
Age=49years 
26% classed as 
extreme obese 
BMI≥40.0kg/m2 
74% had ≥1 
obesity co-
morbidity 
Counterweight weight management model 
comprising changes to clinician behaviour, 
practice systems, and nurse training to 
deliver Counterweight lifestyle 
intervention.  
Nurse-led lifestyle intervention, 3 month 
duration aimed at achieving ≥5-10% body 
weight loss delivered either in: 
 Group sessions, lasting 1 hour, 6 
total 
 Individual consultation, comprising 
6 appointments (10-30min duration) 
All patients received follow-up 
appointments every 3 months 
Interim findings: at 12 months after initiation 93.5% of 
practices had received the training programme, with 75.8% of 
practices implementing the Counterweight weight 
management model and 91% of patients recruited receiving 
lifestyle intervention. 
Of those completing the programme (attending ≥6 
appointments in 12 months, N=445)  mean weight loss -4.5kg, 
with 40% achieving ≥5% weight loss,   
Analysis of LOCF data: 16.2% achieved ≥5% weight loss 
(N=893) at 12 months 
Counter-
weight 
project 
team, 
2008 
As 
Counterwe
ight project 
team, 2005 
1,906 Mean 
BMI=37.1kg/m
2 
Age=49.4years 
77% female 
25.4% classed as 
extreme obese 
BMI≥40.0kg/m2 
As Counterweight project team, 2005 Five-year outcomes: 
At 12 months (N=1,419, data available for N=642, 45%) mean 
weight loss of -3.0±6.6kg (-3.5 - -2.4), mean BMI loss of 
-1.1±2.4kg/m
2, with 30.7% achieving ≥5% weight loss 
Sub-group analysis of baseline BMI≥40.0kg/m2 individuals 
(N=160), at 12 months: mean weight loss of -4.6±8.9kg (-6.0 - 
-3.2) 
At 24 months (N=357) mean weight loss of -2.3kg (-3.2 - 1.4), 
with 31.9% achieving ≥5% weight losses 
Counter-
weight 
project 
team, 
2010 
As 
Counterwe
ight project 
team, 2005 
1,906 As Counterweight 
project team, 
2008 
 
 As Counterweight project team, 2005 Cost-effectiveness evaluation: 
Estimated Counterweight delivery cost of £59.83 per 
individual entered onto programme 
Weight loss of -3.0kg at 12 months and -2.3kg at 24 months, 
is a significant improvement relative to the expected +1kg per 
year weight gain. 
Counterweight was cost-saving, assuming 12 month loss of 
-3.0kg was regained over 2 years and non-attenders (55%) lost 
no weight and gained +1kg/year. 
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Table 4.1.1 Continued: Studies examining the effectiveness of weight management interventions in Primary care  
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Counter-
weight 
project 
team, 
2012 
UK 6,715 Mean 
BMI=37.0kg/m
2 
Age=53years 
74.3% female 
25.8% classed as 
extreme obese 
BMI≥40.0kg/m2 
Counterweight programme implemented in 
184 general practices, 16 community 
pharmacies and 1 community service 
At 12 months attendance was 28% (lower than the 45% in 
original 2008 evaluation) mean weight loss of -3.7kg (-3.3 - 
-4.4), with 35.2% achieving ≥5% weight loss. 
Analysis of all eligible participants at 12 months (including 
those not completing full attendance, N= unknown) 10.0% 
achieved ≥5% weight loss. 
Morrison, 
2013 
Fife, 
Scotland 
458 Mean 
BMI=36.1kg/m
2 
Age=54years 
74.7% female 
21.2% classed as 
extreme obese 
BMI≥40.0kg/m2 
Counterweight programme implemented in 
16 community pharmacies where 
Counterweight not available via GP.  
Lifestyle intervention delivered one to one 
by pharmacy staff through 6 monthly 
appointments lasting 10-30mins, with 
follow-up appointments at 6, 9, 12 months. 
Estimated total patient contact time of 130 
minutes. 
At 12 months (N=314) mean weight loss of -4.1kg (-2.8 - 
-5.4), with 41.6% attenders achieving 5% weight loss 
Sub-group analysis of baseline BMI≥40.0kg/m2 individuals 
(N=64, 23%), at 12 months: mean weight loss of -7.4kg (-3.1 - 
-11.6), with 46.7% achieving 5% weight loss. No significant 
difference in weight loss between baseline BMI subgroups. 
LOCF analyses indicated mean weight loss of -1.7kg (-1.3 - 
-2.1), with 15.9% achieving 5% weight loss. 
BOCF analyses indicated mean weight loss of -1.0kg (-0.6 - 
-1.4), with 10.2% achieving ≥5% weight loss. 
Lean, 
2013 
UK 91 
 
Mean 
BMI=48.0kg/m
2 
Age=45.7years 
81.3% female 
Only those with 
BMI≥40.0kg/m2 
recruited 
 
Intervention aiming to achieve ≥15kg 
weight loss after 12 months total duration, 
delivered by primary care nurses and 
dietitians to patients recruited from 
primary care practices delivering 
Counterweight, comprising: 
 Low Energy Liquid Diet (LELD) for 
12 weeks or ≥20kg weight loss, with 
fortnightly structured appointments 
 Food re-introduction for 6-8 weeks 
with fortnightly appointments,  
 Weight maintenance until 12 months 
with individualised meal plan and 
monthly appointments  
LELD stage completed by 64% of the sample, mean weight 
change  at 14 weeks -16.9 ±6.0kg, -12.6±4.5%, with 69% of 
those completers achieving ≥15kg weight loss  
Food re-introduction completed by 41% of the sample, mean 
further weight change -2.1±3.7kg after 9 week period. Mean 
difference from baseline of -19.1±7.5kg, -14.6±5.1%, with 
77% of those completing achieving ≥15kg weight loss at end 
of food re-introduction stage. 
Weight maintenance completed by 75% of the sample. At end 
of intervention (12 month): mean weight change -12.4 
±11.4kg, -9.1 ±8.2%, with 33% of total sample achieving 
15.0kg weight loss. 
Estimated cost per patient entered =£861.05 
48% received Orlistat at some point during duration. 
  
  
149 
 
Table 4.1.1 Continued: Studies examining the effectiveness of weight management interventions in Primary care 
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Gray, 
2009 
Camelon, 
Scotland 
105 Males only 
Mean BMI=not 
known
 
Age=50.9years 
9.3% classed as 
extreme obese 
BMI≥40.0kg/m2  
The Camelon model delivered by 
community nurses and a dietitian 
comprised  
 One 40-minute appointment at a 
men’s health clinic held in the 
community at a GP practice, 
discussing health and lifestyle 
where obese individuals were 
invited to join the Camelon 
programme 
 One 20-minute pre-programme 
individual assessment, describing 
the 12-week programme, answering 
questions and obtaining baseline 
measures 
 Weight loss intervention comprising 
a 12-week male only group 
programme, with each session 
lasting 60-minutes and taking place 
in the evening. The programme used 
behaviour change techniques to 
achieve balanced healthy diet and 
increased physical activity, with an 
aim of achieving -0.5 - -1.0kg 
weight loss per week 
 Post-programme meetings held 
every 3 months for those who 
completed the programme, in order 
to help maintain weight loss 
Of the 1,855 males attending the initial men’s health clinic 
visit, 105 eligible individuals took part in the programme. 
Analyses compared participants (those who began attending 
the programme regardless of whether they completed it) and 
non-participants (those who chose not to join the waiting list 
or subsequently decided not to join the programme). 
At 12-weeks, of the 105 males who took part, 80 (76.2%) 
completed the programme, achieving -5.0kg weight loss, with 
44.3% achieving ≥5% weight loss, of whom 8.9% achieved 
≥10% weight loss. 
At post-programme follow-up (between 1-49 months after 
programme-end), data was available for 20 individuals who 
achieved mean weight loss of -3.7% of their baseline weight. 
 
Qualitative study examining the experiences of attending the 
programme comprising 2 focus groups conducted with 
separate groups of 8 participants and 1 focus group conducted 
with 8 partners of the participants. 
Reasons for joining the programme were identified as health 
concerns, pressure from family and the use of humour and all-
male aspects of the programme. 
Advice identified as most useful was reducing portion sizes, 
changing cooking methods and learning about nutritional 
labelling. 
Reasons for continued attendance were identified as 
enjoyment of the programme and rapport with facilitators. 
Family member involvement with the programme was also 
discussed by participants and partners, suggesting that the 
lifestyle changes had been extended to the wider family as 
well as the individual participants. 
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Table 4.1.1 Continued: Studies examining the effectiveness of weight management interventions in Primary care 
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Moore, 
2003 
UK: 
Durham, 
Leeds, 
Newcastle, 
Scarborough 
843 Intervention 
arm:  
Mean 
BMI=37.0kg/m
2 
Weight 
=100.8kg  
Age= 48.4years 
75.0% female 
 
Control arm: 
Mean 
BMI=36.9kg/m
2 
Weight 
=100.2kg 
Age= 48.8years 
73.0% female 
Primary care RCT of new weight 
management model for obese individuals 
versus usual care.  
 
Training delivered to GPs and nurses at 22 
practices, comprising three 90-minute 
sessions within 2 weeks, including 
information on benefits of weight loss, and 
treatment options of low energy diet 
(500cal deficit), increased physical activity 
and pharmaceutical options. The 
intervention comprised individual 
fortnightly appointments until ≥10% body 
weight lost, then weight maintenance 
appointments every 1-2 months.  
 
The 22 practices in the control arm 
provided usual care to patients for the 18 
month study period. 
There were no significant differences between intervention 
and control groups, however at 3, 12 and 18 months post 
intervention non-significant trend of the intervention arm 
being heavier than the control group by +0.6kg, +1kg, and 
+1.3kg, respectively (p>0.05). 
 
The following changes were obtained from baseline: 
At 3 months: Intervention arm -0.4kg, control -0.4kg 
At 12 months: Intervention arm -0.5kg, control -0.9kg 
At 18 months: Intervention arm 0kg, control -0.7kg 
 
Analyses conducted using available case data, with 3 month 
data obtained for 78.8%, 12 month data obtained for 67.0%, 
and 18 month data obtained for 63.0% of the sample. 
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Table 4.1.1 Continued: Studies examining the effectiveness of weight management interventions in Primary care 
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Nanchahal
2009 
UK 103 Mean 
BMI=35.9kg/m
2 
Weight= 98.5kg 
Age= 47.2years 
80.3% female 
 
Primary care Pilot RCT with 4 arms: 
 Structured lifestyle support 
 Structured support with pedometer 
 Usual care 
 Usual care with pedometer 
Nurses from 8 practices were given a 
CD-ROM training tool, then structured 
lifestyle support delivered to individuals 
BMI ≥27 kg/m2. The 12-week support 
intervention comprised fortnightly group 
sessions covering diet and activity 
behaviour change. Usual care comprised 
a single individual 30-minute 
appointment during the 12-week period. 
Those receiving pedometer were given 
leaflet of benefit of 10,000 steps per day 
and asked to record steps taken. 
At 12 weeks, the following losses were obtained (available data): 
Structured support group achieved -4.0kg, -4.0%, with 34% 
achieving ≥5% baseline body weight loss. Not receiving support 
achieved -1.2kg, -1.2%, with 18.9% achieving ≥5% baseline body 
weight loss. 
Pedometer group achieved -2.5kg, -2.7%, with 29.2% achieving 
≥5% baseline body weight loss. Not receiving pedometer 
achieved -2.5kg, -2.4%, with 23.6% achieving ≥5% baseline body 
weight loss. 
Those receiving structured support lost significantly more weight 
than those not receiving support, adjusted mean differences of 
-2.6kg (-4.1 - -1.2) and -2.8% (-4.3 - -1.3). No significant 
difference in weight lost between those receiving pedometer and 
those not, adjusted mean differences of -0.1kg (-1.5 - 1.3) and 
-0.4% (-1.8 - 1.1). Losses ≥5% baseline weight associated with 
improved scores on the Rosenberg self-esteem +14.1 (9.82 - 
18.4), HADS anxiety -1.50 (-2.79 - -0.21) and depression -1.76 
(-2.92 - -0.60), and EQ5D-VAS +12.2 (7.5 - 17.0). 
Nanchahal
2012 
UK, 
Camden, 
London 
381 Mean 
BMI=33.5kg/m
2 
Weight= 92.3kg 
Age= 48.8years 
72.2% female 
 
Primary care RCT evaluating structured 
lifestyle support (Camwel) versus usual 
care. Structured support comprised 
fortnightly 30-minute one to one 
appointments for the first 12 weeks, 
followed by a further 12 weeks of 
appointments every 3 weeks, followed 
by monthly appointments for 12 weeks, 
giving a total of 14 sessions over 9 
months. Intervention covered diet and 
activity behaviour change and was 
delivered by trained Camwel advisors 
(non-healthcare professionals) after 2 
days training including CDROM tool. 
At 6 months intervention arm achieved losses of -1.7kg, -1.8% 
with 23.9% achieving ≥5% baseline weight loss, whilst control 
arm achieved -1.0kg, -1.0%, with 13.2% achieving ≥5% baseline 
weight loss. At 12 months intervention arm achieved losses of 
-2.4kg, -2.6% with 34.0% achieving ≥5% baseline weight loss, 
whilst control arm achieved -1.3kg, -1.4%, with 19.3% achieving 
≥5% baseline weight loss. There were no significant differences 
between weight losses achieved by intervention and control at 6 
and 12 months, adjusted mean differences -0.8kg (-1.9 - 0.3) and 
-1.1kg (-2.5 - 0.3). There were significant differences in 
proportions achieving ≥5% baseline weight loss at 6 and 12 
months, with adjusted mean differences 10.7% (1.4 - 20.0), and 
14.7% (3.0 - 26.4), respectively. Quality of life measures obtained 
at follow-up but not reported. 
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4.1.3 Specialist weight management programmes 
The Glasgow and Clyde Weight Management Service is a specialist multidisciplinary 
service, similar to that described in the present evaluation, delivered by a team comprising 
dietitians, psychologists and physiotherapists. The weight outcomes of the service have 
been evaluated, incorporating data from 2,976 individuals who were referred to the service 
as a result of fulfilling the criteria of having a BMI ≥35.0kg/m2 without obesity-related co-
morbidities or a BMI ≥30.0kg/m2 with co-morbidities (174). The mean BMI of the sample 
at baseline was not reported, however 52.3% of the sample were classed as extreme obese 
(BMI ≥40.0kg/m2). The sample was also predominantly from regions of high socio-
economic deprivation, with
 
62.1% of the sample living in areas classed within the fifth 
quintile of the Scottish Index of Multiple Deprivation (SIMD) index. The evaluation 
reported outcomes of the first phase of the intervention delivered to participants, which 
comprised nine fortnightly group sessions delivered over a 16-week period. The group 
programme sessions were delivered in community and outpatient hospital settings and 
focussed on facilitating lifestyle and behaviour change through the use of a cognitive 
behavioural approach, with input from psychologists. Participants were also provided with 
individually calculated 600 calorie deficit diet plans, with an overall aim of the first phase 
of the intervention to facilitate ≥5kg weight loss for individuals. A total of 2,976 
individuals were referred to the service, of which 2,156 (72.4%) attended the service, with 
809 individuals going on to complete phase one of the intervention (27.2% of those 
referred). 
A major limitation of the study is that the mean weight and BMI outcomes 
achieved on completion of the programme were not reported, however the proportion of 
individuals achieving the target weight loss of ≥5kg was reported, with 35.5% of the 809 
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completers achieving this. When analysing BOCF data, thus considering all participants 
who entered the service, including those who did not complete phase one, 13.6% achieved 
the target weight loss of ≥5kg. The fact that the evaluation did not report mean weight 
change is a substantial flaw, however the emphasis was placed on analyses identifying the 
predictors of the target ≥5kg weight loss. Findings demonstrated that among all individuals 
referred to the service, the factors associated with successful target weight loss were age 
≥40 years, male sex (OR= 1.39, 1.05 - 1.82), BMI ≥50 kg/m2 (OR= 1.70, 1.14 - 2.54) and 
experiencing symptoms of depression, with depression defined as HADS score ≥12 (OR= 
1.81, 1.35 - 2.44). Conversely, presence of diabetes (OR= 0.55, 0.38 - 0.81) was associated 
with a decreased risk of achieving ≥5kg weight loss. Separate analyses of the sub-group of 
intervention-completers only, indicated that males were more likely to achieve the target 
weight loss (OR= 1.85, 1.33 - 2.58), whilst those with diabetes were less likely to achieve 
≥5kg weight loss (OR= 0.45, 0.29 - 0.68). The evaluation of the Glasgow service 
highlights the need for greater consistency in the reporting of outcomes within the body of 
weight management literature, so that there is greater transparency of intervention 
effectiveness and so that comparisons between services can be made. 
 A subsequent evaluation of the Glasgow service, has been published, describing the 
outcomes of a separate sample of 1,838 individuals in a much greater level of detail of 
reporting than in the prior publication (175). The second publication reported the mean 
BMI of the sample as 43.3kg/m
2
, with a mean weight of 118.1kg. Whilst it is not possible 
to compare baseline values between the two evaluations, as this was not reported for the 
first evaluation, it is possible to compare the proportion of extreme obese individuals, with 
the second publication comprising a greater proportion, 63.1% compared to 52.3% of the 
first sample, classified as extreme obese.  Whilst the first publication reported outcomes of 
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the first phase of the intervention comprising the 16-week group programme only, the 
second publication described outcomes obtained in the second and third phases of the 
intervention. The second phase of the intervention comprised three 60-minute sessions 
delivered monthly consisting of further lifestyle advice, a prescribed low calorie diet, and 
weight loss medication, whilst the third phase of the intervention comprised twelve 60-
minute sessions delivered monthly, aimed at achieving weight maintenance. 
 Of the 6,505 individuals referred to the service, 5,637 were eligible to attend the 
service and 3,460 chose to opt into the service (61.4% of those who were eligible), with 
1,838 attending the phase one intervention (32.3% of those who were eligible). The 
majority of individuals attending phase one (71.9%), completed the 16-week programme, 
achieving a mean weight loss of -4.0kg (-4.3 - -3.8), with 36% achieving ≥5kg weight loss 
and 29% achieving ≥5% weight loss. LOCF data was analysed, with this data indicating a 
more conservative mean weight loss of -2.9kg (-3.1 - -2.7), with 26% achieving ≥5kg 
weight loss and 21% achieving ≥5% weight loss. Of those completing phases one and two, 
mean weight loss was -6.4kg (-6.9 - -5.8), with 55% achieving ≥5kg weight loss and 49% 
achieving ≥5% weight loss. LOCF data again indicated more conservative weight losses of 
-3.6kg (-3.9 - -3.4), with 30% achieving ≥5kg weight loss and 25% achieving ≥5% weight 
loss. Of those completing all three phases of the intervention (N=208), mean weight loss of 
-8.5kg (-9.7 - -7.2) was achieved, with 58% achieving ≥5kg weight loss and 56% achieving 
≥5% weight loss, with LOCF data (N=1,838) indicating mean weight losses of -3.6kg 
(-3.8 - -3.3), with 28% achieving ≥5kg weight loss and 24% achieving ≥5% weight loss. 
This evaluation is greatly strengthened by the large sample size and the detailed reporting 
of weight outcomes, including the reporting of weight change at each phase of the 
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intervention, the separate analyses of the outcomes of those individuals completing each of 
the phases, and the imputation of LOCF data.  
In addition to the evaluation of large weight management services, smaller scale 
programmes have been developed and evaluated in several UK dietetic departments, with 
findings published as pragmatic service evaluations. One evaluation conducted at a London 
hospital compared the effectiveness of one-to-one appointments at a dietetic outpatient 
clinic with a 10-week hospital group-based dietetic weight loss programme (176). The 
small study included 44 individuals receiving individual consultations and 105 receiving 
the group programme. Analyses demonstrated that there was no significant difference 
(p >0.05) in mean weight loss between the interventions, with mean weekly losses of -
0.4kg, -0.2kg, -0.1kg and 0.0kg  from sessions one to four, for the one-to-one clinic and 
mean weekly losses of -0.4kg, -0.2kg, -0.3kg and -0.1kg for the group-based programme. 
However, there was a significant difference in the proportion of individuals achieving 
weight loss, with 52% of those attending the one-to-one clinic achieving weight loss, and 
60% of those attending the group programme achieving weight loss (p =0.001). The 
evaluation demonstrated that the two interventions achieved a similar level of weight loss. 
These losses were considerably below the level of -0.5 - -1.0kg per week weight loss 
which is recommended by the National Institute of Health and Care Excellence (NICE) 
(14) in order to achieve long-term weight loss for adult individuals. This was a small 
pragmatic service evaluation and continued evaluation of the services incorporating a 
greater number of individuals would be required, in order to detect any potential 
differences between the weight outcomes of the two services. 
In an evaluation of another London-based dietetic centre, the weight outcomes of a 
structured lifestyle weight management clinic were examined at 6, 9 and 12 month follow-
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up (177). The clinic offered patients six monthly appointments which targeted ≥5% weight 
loss, which were followed by review sessions at 9 and 12 months in which weight loss 
maintenance was targeted. Of the 24 individuals for which 6-month data was available, 20 
(83%) achieved weight loss, and at 6 months the mean weight loss for the sample was -
6.2kg which equates to -5.5% baseline body weight loss. Of the patients attending the 9-
month follow-up (80% of the sample), 11 individuals (92%) achieved maintenance of their 
weight loss, with a mean loss of -7.2kg and -5.7% of baseline body weight loss. At the 12-
month follow-up 86% maintained some level of weight loss, with a mean loss of -5.1kg (-
4.1%). However, the data from this service evaluation demonstrated that weight loss 
decreased between the 9- and 12-month follow-up sessions, indicating that some of the 
sample did not maintain their weight loss and indeed re-gained weight. The authors 
concluded that attending the structured lifestyle weight management clinic aided 
individuals in achieving the desired ≥5% body weight loss, which was maintained at the 9-
month follow-up. However, findings indicate that further support may be required for 
individuals between the 9- and 12-month period in order to prevent weight re-gain and 
facilitate longer-term maintenance of the initial weight loss. The findings of the service 
evaluation must also be interpreted with caution due the small sample size and could 
ideally be utilised to inform the development of a larger scale evaluation of the service. 
In another small-sample evaluation, the long-term effectiveness of two 6-week 
programmes ‘Size Down’ and ‘Post-Natal Size Down’ were examined in a multicultural, 
deprived inner city area of Birmingham (178). The aim of the evaluation was to establish 
whether the initial weight loss achieved was maintained longer-term after the community-
based group programmes had finished. A total of 74 individuals completed a telephone 
survey after finishing the programme between 6-24 months previously in order to obtain 
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self-reported current weight data. On completion of the programmes, individuals who 
attended the Size Down programme achieved a mean weight loss of -1.7%, with the Post-
Natal Size Down programme achieving a mean body weight loss of -2.2% at intervention 
end. At follow-up, those attending Size Down reported a mean further weight loss of -
4.3%, whilst those attending the post-natal programme reported mean further losses of -
9.0% baseline body weight. However, not all individuals achieved further weight losses, 
with 28% achieving maintenance of their original loss without further loss and 18% 
achieving weight gain. When data from only those individuals who had completed the 
programmes more than 12 months ago was analysed, the mean overall weight loss for both 
programmes combined was -4.1kg (-3.9%). However, the validity of reporting combined 
outcome data for the two programmes is questionable, as weight loss would likely occur 
regardless of intervention in a post-natal sample. The findings of this evaluation indicate 
that the majority of participants were able to maintain their initial weight loss or indeed to 
achieve further weight loss in the longer-term. However, the amount of weight loss 
maintained at 12 months was below the recommended target of ≥5% baseline weight. A 
major limitation of the evaluation was the use of self-reported weight outcome data at 
follow-up, with additional weight measures obtained through home visits in only a subset 
of 23% of the sample, which introduces the risk of bias and inaccurate reporting of the 
main outcome measure for the majority of the sample. In addition, a relatively low 
response rate (44%) was achieved for the follow-up telephone survey, which introduces the 
potential for responder bias, whereby only those with better weight outcomes may have 
chosen to report their weight. As a result the findings of the evaluation should be 
interpreted with caution and further evaluations of the service would be improved by the 
use of measured weight outcomes rather than self-report at follow-up. 
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In conclusion, the body of literature evaluating specialist weight management 
services highlights the poor methodology utilised in the conduct of the studies and poor 
reporting of baseline and outcome data (174, 176-178). The first publication to evaluate 
outcomes of the Glasgow and Clyde Weight Management Service (174) was flawed by not 
reporting baseline weight and BMI and indeed post-intervention mean changes in weight 
and BMI. However, the second publication evaluating the Glasgow service (175) used 
excellent reporting methods and was the only study included in this review of specialist 
programmes that included sufficiently detailed reporting of baseline weight and BMI 
characteristics of the sample. Furthermore, this was the only study to explicitly outline the 
weight outcomes obtained on completion of each phase of the intervention, and include 
separate analyses to demonstrate the outcomes obtained using available case data from 
those completing the programme and using LOCF data, thus facilitating interpretation of 
the results. 
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Table 4.1.2: Studies examining the effectiveness of weight management interventions in Specialist services  
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Morrison, 
2012 
Glasgow 
and 
Clyde 
weight 
manage-
ment 
service, 
UK 
2,976 Mean BMI & 
weight 
=unknown 
72.6% female 
52.3% classed 
as extreme 
obese BMI 
≥40.0kg/m2 
62.1% highly 
deprived SES 
Multidisciplinary team comprising 
dietitians, psychologists, 
physiotherapists, delivered to patients 
referred to service with BMI ≥35 kg/m2 
or 30kg/m
2
 with co-morbidities, 
between 2004 and 2006. 
Phase 1 intervention comprised 9 
fortnightly 90-minute group sessions 
delivered over 16 weeks. Group 
programme of lifestyle and behaviour 
change using cognitive behavioural 
approach, and delivered in community 
and outpatient hospital setting, aiming 
to achieve ≥5kg weight loss. 600 
calorie deficit diet plan provided. 
Of the 2,976 referred, 2,156 opted into the service (72.4%), with 809 
completing the phase 1intervention (27.2% of those referred). 
Of the 809 completers: Mean weight and BMI change unknown, with 
35.5% achieving the target weight loss ≥5kg. Analysis of all those 
referred to service (N=2,976) established factors predicting ≥5kg 
weight loss success, with age ≥40 years, male sex (OR=1.39, 1.05 - 
1.82), BMI≥50 kg/m2 (OR=1.70, 1.14 - 2.54) and depression 
(OR=1.81, 1.35 - 2.44) associated with increased odds of achieving 
≥5kg weight loss. Those with diabetes mellitus (OR=0.55, 0.38 - 0.81) 
were less likely to achieve the target weight loss. Analysis of 
completers only (N=809), males were more likely to achieve weight 
loss (OR=1.85, 1.33 - 2.58), and those with diabetes were less likely to 
achieve ≥5kg weight loss (OR=0.45, 0.29 - 0.68). Follow-up HADS 
anxiety and depression scores were not reported. 
Logue, 
2014 
Glasgow 
and 
Clyde 
weight 
manage-
ment 
service, 
UK 
1,838 Mean BMI= 
43.3kg/m
2 
Weight= 
118.1kg  
Age= 
49.1years 
72.9% female 
43.3% highly 
deprived SES 
63.1% classed 
as extreme 
obese BMI 
≥40.0kg/m2 
 
Separate sample as Morrison, 2011, 
with sample attending between 2008 
and 2009. 
Phase 1 intervention: as Morrison, 
2011. 
Phase 2 intervention: Patients entered 
after completing phase 1, comprised 3 
sessions each of 60-minutes duration 
delivered monthly. Consisted of further 
lifestyle advice, prescribed low calorie 
diet, & Orlistat weight loss medication. 
Phase 3 intervention: Patients entered 
after completing phase 1 or 1&2, or 
repeating phase 2, comprised 12 
monthly 60-minute weight 
maintenance sessions. 
 
Of the 6,505 referred, 5,637 were eligible and 3,460 opted into the 
service (61.4% of eligible), 1,838 attended the phase 1intervention. 
Of the 1,322 phase 1 completers (71.9% of those attending) mean 
weight change was -4.0kg (-4.3 - -3.8), with 36% achieving ≥5kg 
weight loss and 29% achieving ≥5% weight loss. LOCF (N=1,838) 
data mean weight change of -2.9kg (-3.1 - -2.7), with 26% achieving 
≥5kg weight loss and 21% achieving ≥5% weight loss. 
Of the 639 phase 1&2 completers (34.8% of those attending) mean 
weight change was -6.4kg (-6.9 - -5.8), with 55% achieving ≥5kg 
weight loss and 49% achieving ≥5% weight loss. LOCF data 
(N=1,838) mean weight change -3.6 (-3.9 - -3.4), with 30% achieving 
≥5kg weight loss and 25% achieving ≥5% weight loss. 
Of the 208 phase 1, 2 & 3 completers (11.3% of those attending) mean 
weight change was -8.5kg (-9.7 - -7.2), with 58% achieving ≥5kg 
weight loss and 56% achieving  ≥5% weight loss. LOCF data 
(N=1,838) mean weight change -3.6 (-3.8 - -3.3), with 28% achieving 
≥5kg weight loss and 24% achieving ≥5% weight loss. 
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Table 4.1.2 Continued: Studies examining the effectiveness of weight management interventions in Specialist services  
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Mayre-
Chilton, 
2010 
Dietetic 
department 
London, UK 
149 Mean BMI & 
weight 
=unknown 
 
One-to-one 
clinic= 66% 
female 
 
Group 
programme= 
79% female 
Two interventions within a dietetic 
service: 
 One-to-one appointments at a general 
adult dietetic outpatient clinic. Initial 
30 min appointment with 15 min 
follow-up appointments. N= 44 
 Group-based dietetic weight loss 
programme ‘Healthy Choice Group 
Programme’ delivered over 10-week 
period at hospital setting with one 
90-min session per week. N= 105 
No significant difference (p>0.05) in mean weight loss 
between two interventions. 
One-to-one intervention: mean weekly losses of -0.4kg, 
-0.2kg, -0.1kg and 0.0kg from sessions one to four. 
 
Group intervention:  mean weekly losses of -0.4kg, -0.2kg, 
-0.3kg and -0.1kg.  
 
Significantly greater proportion of individuals achieving 
weight loss in group intervention (60%) compared to one-to-
one intervention (52%), p=0.001. 
Forrest, 
2011 
Dietetic 
service, 
London, UK 
24 Mean BMI & 
weight 
=unknown 
 
 
No baseline 
information 
Structured lifestyle weight management 
clinic incorporating 6 monthly 
appointments which targeted ≥5% weight 
loss 
Followed by review sessions at 9 and 12 
months, which targeted weight loss 
maintenance 
At 6 months: mean weight loss of -6.2kg, -5.5%, with 83% 
achieving weight loss. 
At 9 month follow-up: mean loss of -7.2kg, -5.7%, with 92% 
achieving maintenance of weight loss.  
At 12 month follow-up: mean loss of -5.1kg, -4.1%, with 86% 
maintaining some level of weight loss. 
Gordon, 
2011 
Dietetics 
department 
Birmingham 
UK 
74  Mean BMI & 
weight 
=unknown 
 
Combined 
intervention 
sample= 97.3% 
female  
 
 
Two interventions within a dietetic 
service: 
 
 Size Down programme 
 Post-Natal Size Down programme 
Both programmes community-based, 
group weight management programmes of 
6-week duration 
At 6 weeks, Size Down intervention achieved mean loss of 
-1.7% baseline body weight, and post-natal programme 
achieved mean loss of -2.2% baseline body weight. 
Individuals completed a telephone survey after finishing the 
programme 6 - 24 months prior (44% response rate). At 
telephone follow-up, Size Down achieved mean further 
weight loss of -4.3% baseline body weight, and post-natal 
programme achieved mean further loss of -9.0% baseline body 
weight. 
At a minimum follow-up period of 12 months, interventions 
combined: 28% reported achieving maintenance of their 
original loss without further loss, 18% achieved weight gain, 
with mean losses of -4.1kg, and -3.9% baseline body weight 
loss. 
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4.1.4 Commercial programmes 
Individuals may gain access to a range of commercial programmes currently operating in 
the UK such as Weight Watchers, Rosemary Conley, and Slimming World either through 
self-referral or by referral from a healthcare professional. The outcomes of a model 
operating referrals from primary care to the commercial Slimming World 12-week 
programme have been evaluated in a small pilot study conducted in Derbyshire, UK (72) 
and subsequently in a larger scale UK-wide service evaluation comprising data from 
34,271 individuals referred to the Slimming World programme (37). The pilot study which 
was designed to assess the feasibility of referral to the commercial programme from a 
primary care setting, employed a much smaller sample size of 91 obese individuals who 
were referred to the programme after attending a GP appointment for non-weight related 
reasons (72). The programme was completed by 68.1% of individuals, achieving a 
12-week intervention-end mean weight loss of -5.4±3.2kg (-6.4%), with 57% of these 
individuals achieving ≥5% loss of baseline body weight. A substantial proportion (51.6%) 
of the original sample who were referred to receive the 12-week programme free of charge, 
elected to self-fund a further 12-week duration of programme attendance. Of those who 
completed 24 weeks total programme attendance, a mean weight loss of -11.1±5.5kg 
(-11.3%) was achieved. Of those attending for 24 weeks, the majority of the sample (86%) 
achieved ≥5% loss of baseline body weight, whilst 59% achieved losses in excess of 10% 
of their baseline body weight. The service evaluation demonstrated that referral to the 
commercial Slimming World programme was feasible for healthcare professionals and that 
the programme produced substantial weight loss for individuals after the initial 12-week 
programme. Further weight loss was achieved when individuals chose to continue their 
attendance to 24 weeks. The authors concluded that the ‘slimming on referral’ service 
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could be considered as a cheaper, effective alternative to pharmaceutical treatment or in-
house primary care-led weight management interventions. 
A larger scale Slimming World evaluation (37) was conducted in order to examine 
the efficacy of the ‘slimming on referral’ service which was rolled out across much of the 
UK following the feasibility study (72). The mean age of the sample included in the 
evaluation was 47.3 years with mean a BMI of 36.8kg/m
2
. The sample was predominantly 
female (89.3%) and a large proportion were classed as extreme obese, with 25.4% of those 
referred having a BMI ≥40.0kg/m2 at baseline. The large proportion of extreme obese 
individuals within the sample is likely to be due to the fact that individuals were recruited 
to the service via referral from primary and secondary healthcare professionals. This 
approach would reach a wider BMI range than had individuals been recruited from primary 
care alone. Of those referred, 19,907 (58.1%) completed the programme by attending a 
minimum of 10 sessions, with the remaining 41.9% attending 9 or fewer sessions and 
consequently being classed as non-completers. The mean weight change of the sample at 
intervention-end (3-month follow-up), incorporating all individuals entering the 
programme, was -4.0±3.7kg (-4.0±3.6%) and mean BMI change was -1.5±1.3kg/m
2
. 
Analyses of the weight outcome data were limited to comparisons by gender and by 
programme completion status. Males achieved a significantly greater reduction in body 
weight and BMI from baseline than females (-5.8kg vs -3.8kg, p <0.001) and (-1.8kg/m
2
 vs 
-1.4kg/m
2
), and those completing the programme achieved a significantly greater reduction 
in body weight and BMI from baseline than non-completers (-5.5kg vs -1.8kg, p <0.001) 
and (-2.0kg/m
2
 vs -0.7kg/m
2
). In a subsequent publication, further analyses were conducted 
on data from the same evaluation sample (179), which enabled weight loss outcomes to be 
compared across baseline BMI subgroups.  Across the BMI subgroups, there were 
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statistically significant (p <0.001) differences between mean weight change values at 
intervention-end (3-month follow-up), of -2.9±2.8kg for the <30kg/m
2
 group, -3.6±3.2kg 
for the 30.0-34.9kg/m
2 
group, -4.1±3.7kg for the 35.0-39.9kg/m
2 
group, and -4.8±4.4kg for 
the ≥40.0kg/m2 group. There were also statistically significant differences (p <0.001) in 
BMI change across the BMI groups, respectively; -1.1±1.0kg/m
2
, -1.3±1.2kg/m
2
, 
-1.5±1.3kg/m
2
, -1.8±1.6kg/m
2
, as well as statistically significant differences (p <0.001) in 
percentage body weight change; -3.7±3.6%, -4.0±3.6%, -4.0±3.6%, -3.9±3.5%. Whilst the 
differences in outcomes between the baseline BMI groups were statistically significantly 
different, in real terms these were clinically small differences with a range of only 
0.7kg/m
2
 across all of the baseline BMI subgroups. 
The results of the Slimming World evaluation demonstrate that a substantial 
proportion of each baseline BMI group achieved ≥5% baseline body weight loss at 
intervention end; 33.4%, 36.6%, 36.4% and 35.8% across the BMI groups, respectively. 
This indicates that lifestyle interventions such as the Slimming World programme can be 
as effective in extremely obese individuals as for those with lower levels of obesity and 
overweight. However, in order to establish the efficacy of the Slimming World programme 
within the extreme obese patient population, the weight outcomes must be compared 
against other weight management programmes, specifically within this BMI subgroup. 
Additionally, a comparator group, ideally within an RCT, would be necessary and 
extended follow-up periods would be needed in order to determine the longer-term weight 
outcomes. Only then can well-founded conclusions be drawn about the efficacy of such 
programmes for this patient population. 
In addition to Slimming World, primary care providers have also made referrals to 
the Weight Watchers commercial programme, which has been evaluated in a large scale 
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UK-wide audit (180). Data were retrospectively analysed from 29,326 referrals made from 
primary care over a one-year period, whereby overweight and obese individuals received 
the Weight Watchers commercial 12-week programme free of charge. The sample were 
predominantly female (90.0%), with a median age of 49.0 years and median BMI of 
35.1kg/m
2
. The majority of the referrals (75%) were first referrals to the programme, 
however 19% represented individuals’ second and 5% represented a third referral to the 
programme. Data were analysed for all first referrals in which a minimum attendance of 
one session was reported (N=22,519), with a median weight loss of -3.6kg (-3.6%), with 
38% achieving ≥5% baseline weight loss at 12 weeks. Separate analyses including first 
referrals in which all programme sessions were attended (N=11,851) yielded a greater 
weight loss of -5.4kg (-5.6%), with 57% of the sample achieving ≥5% weight loss. Whilst 
these findings demonstrate that a substantial proportion of those completing the Weight 
Watchers programme were able to achieve a clinically significant weight loss, it highlights 
a low retention rate, with 46% of the commenced referral courses not being completed. A 
considerable proportion (24%) of those completing a first time referral were classed as 
extreme obese BMI ≥40kg/m2. Analysis revealed that the subgroup experienced 
significantly poorer weight loss with a median percentage weight change of +0.38%, 
relative to an overweight BMI <30kg/m
2
 subgroup (p <0.05), suggesting that the 
programme did not meet the weight loss needs of the extreme obese subgroup. 
The Slimming World and Weight Watchers interventions have also been evaluated 
in the Lighten Up trial which is the only RCT to compare the effectiveness of both 
commercial and primary care programmes within a single trial, whereas other RCT studies 
have compared the effects of either commercial interventions (36, 181), or primary care 
interventions (31, 32, 173) against control arms separately. The Lighten Up trial used 
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rigorous RCT methodology to evaluate the efficacy and cost-effectiveness of the 
commercially available and primary care-led weight management services (34, 35). The 
multi-arm trial compared the following six 12-week programmes; Weight Watchers, 
Slimming World, Rosemary Conley, Size Down group-based dietetic-led programme, 
general practice one-to-one counselling, pharmacy-led one-to-one counselling, or a choice 
of one of the six programmes, and a comparator group who were provided with exercise 
vouchers enabling free admission to local fitness facilities. A total of 740 individuals were 
randomly assigned to one of the eight arms, with follow-up data available for 658 
individuals (88.9%) at 3 months and 522 individuals (70.5%) at 12 months. The mean BMI 
of individuals joining each arm ranged from 33.1kg/m
2
 (general practice counselling arm) 
to 34.0kg/m
2
 (Weight Watchers arm), with mean age ranging from 47.5 years (choice of 
intervention arm) to 50.7 years (Weight Watchers arm). At intervention-end (3-month 
follow-up) each of the seven intervention arms and the minimal intervention comparator 
arm achieved the following statistically significant weight losses from baseline; -4.4kg, p 
≤0.001 (Weight Watchers), -4.2kg, p ≤0.001 (Rosemary Conley), -3.6kg, p ≤0.001 
(Slimming World), -3.3kg, p ≤0.001 (choice of intervention arm), -2.4kg, p ≤0.001 (Size 
Down dietetic group), -2.1kg, p ≤0.001 (Pharmacy counselling), -2.0kg, p ≤0.001 
(comparator receiving exercise vouchers), and -1.4kg, p <0.05 (General practice 
counselling). At the 12-month follow-up, the following significant weight losses from 
baseline were achieved; -3.5kg, p ≤0.001 (Weight Watchers), -2.5kg, p ≤0.001 (Size Down 
dietetic group), -2.2kg, p ≤0.001 (choice of intervention arm), -2.1kg, p ≤0.001 (Rosemary 
Conley), -1.9kg, p ≤0.001 (Slimming World) and -1.1kg, p <0.05 (comparator group 
receiving exercise vouchers). However, the two primary care-led intervention arms did not 
achieve significant weight losses from baseline at 12 months, with the General practice 
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counselling arm achieving a loss of -0.8kg (p >0.05) and the Pharmacy counselling arm 
achieving a loss of -0.7kg (p >0.05).  Indeed, further analyses adjusting for baseline 
weight, physical activity, age, gender and ethnicity, revealed that when comparing the 
individual arms against the exercise voucher comparator arm, at intervention-end, only the 
Weight Watchers and Rosemary Conley arms produced significantly greater weight loss 
than the comparator arm, with adjusted mean differences of -2.3kg, p ≤0.001 and -2.4 kg, 
p ≤0.001, respectively. At the 12-month follow-up, only the Weight Watchers arm 
produced significantly greater weight loss than the comparator arm, with an adjusted mean 
difference of -2.5kg, p <0.05. The findings of the Lighten Up trial demonstrate that the 
commercial weight management programmes produced better weight loss outcomes and 
were more cost-effective than the primary care-led weight management services. However, 
the weight loss achieved was modest and it is uncertain whether the mean loss of -2.5kg 
which was achieved by the Weight Watchers arm would be sufficient to produce the 
substantial health benefits required. Furthermore, the trial did not demonstrate the efficacy 
of the programmes for extreme obese individuals, indeed only 37 of the 740 individuals 
included in the trial (5%) were classed as extreme obese at baseline. In order to establish 
whether the weight loss outcomes achieved by the commercial programmes in the Lighten 
Up trial could potentially be achieved within the extreme obese patient population, a larger 
trial incorporating a subgroup of extreme obese individuals would be required. 
Additionally, whilst the Lighten Up trial included a follow-up period of one year, an 
extended follow-up period is necessary in order to determine whether the commercial and 
primary care-led programmes can produce lasting weight change and prevent the 
progression from mild to extreme levels of obesity.  
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Two additional RCTs have evaluated the effectiveness of commercial interventions, 
evaluating a single-intervention arm receiving the Weight Watchers programme (181), and 
a range of four commercial interventions (36). In a single-intervention arm RCT the 
effectiveness of a 12-month Weight Watchers programme versus usual care was evaluated 
internationally, with 772 individuals from the UK, Germany and Australia who were 
randomised to receive either the commercial programme or to a usual care comparator 
group (181). Those individuals who were randomised to the intervention arm received free 
access to weekly Weight Watchers group sessions for a period of 12 months. The aim of 
the Weight Watchers sessions which were held in the community, was to facilitate weight 
loss through promoting a low energy diet and increased physical activity through the 
provision of group support. Those individuals randomised to the control arm of the study 
received weight loss advice from a primary care professional in line with national clinical 
guidelines, during monthly appointments at their local GP practice over a 12-month period. 
Individuals who were aged ≥18 years with a BMI 27-35kg/m2 and at least one co-
morbidity risk factor such as dyslipidaemia, hypertension, osteoarthritis, impaired fasting 
glycaemia and family history of diabetes were recruited to the study from primary care 
practices. The primary outcome measure of the RCT was weight change post-intervention 
at 12 months. There was a remarkably high non-completion rate, with 12 month measures 
obtained for only 230 individuals (61%) of the intervention arm and 214 individuals (54%) 
of the control arm. Investigators reported that there were significant differences in the 
study completion rates between countries, with higher non-completion rates in the UK 
(42%) and Australia (41%) compared to Germany (25%) (p <0.0001). There were no 
significant differences in the observed effectiveness of the intervention between countries 
(p >0.10), with the intervention arm achieving significantly greater weight loss than the 
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control arm across all countries. A major strength of the study is the detailed reporting of 
results, with the findings reported for separate analyses using available case data for those 
who completed the study as well as LOCF and BOCF data. The greatest weight loss was 
seen in the available case data, with a mean loss of -6.7kg in the intervention arm and -
3.3kg in the control arm (p <0.0001), whilst the LOCF data showed more conservative 
losses of -5.1kg for the intervention arm and -2.3kg for the control arm (p <0.0001) and the 
BOCF data demonstrated losses of -4.1kg for the intervention arm and -1.8kg for the 
control arm (p <0.0001). Furthermore, those receiving the commercial programme were 
more likely to lose ≥5% baseline weight, OR= 3.0 (2.0 - 4.4), and ≥10% baseline weight, 
OR= 3.2 (2.0 - 5.3), compared to those receiving usual care. The likelihood of achieving 
weight loss was increased for those in the intervention arm who completed the study, for 
losing ≥5% baseline weight OR= 2.9 (2.1 - 3.9) and for losing ≥10% baseline weight OR= 
3.5 (2.3 - 5.4), compared to those receiving usual care. The findings of this RCT 
demonstrated that the Weight Watchers programme is effective at facilitating weight loss 
across a range of economically developed countries, with those completing the intervention 
achieving the greatest weight loss. The development and implementation of strategies to 
reduce attrition would further improve its effectiveness. 
The second of the two studies to utilise an RCT approach in evaluating commercial 
programmes was conducted as part of a UK television programme entitled ‘Diet Trials’ 
produced by the British Broadcasting Corporation (BBC) (36). The RCT compared the 
effectiveness of four commercial interventions widely available in the UK, for a period of 
six months, with a delayed treatment control group who were asked to maintain their 
current dietary patterns and physical activity levels for the duration of the study. The four 
intervention arms included Weight Watchers comprising weekly group support sessions, 
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Slim-Fast plan comprising the provision of two daily meal replacements and a support 
pack, Dr Atkins’ ‘New diet revolution’ comprising the provision of a self-help dietary 
guidance book, and Rosemary Conley’s ‘Eat yourself slim’ comprising weekly group 
exercise and dietary advice sessions. The trial which was conducted at five regional 
centres; Bristol University, Surrey University, Nottingham University, Queen Margaret 
University College Edinburgh and Ulster University, recruited 292 adult participants from 
community settings across the UK. The study included overweight and obese individuals 
who reported a BMI in the range of 27.0-40.0kg/m
2
, which is reflected in the relatively low 
mean baseline BMI of the sample, which ranged from 31.2-32.2kg/m
2
 across study arms. 
At six months post-baseline (intervention-end), there was no significant difference between 
the four intervention arms, with all interventions achieving significantly greater weight loss 
than the control arm (p <0.001). Using 6-month LOCF data the following losses were 
obtained for each intervention arm; Weight Watchers -6.6kg (-7.3%), Slim-Fast -4.8kg (-
4.9%), Dr Atkins’ ‘New diet revolution’ -6.0kg (-6.2%), and Rosemary Conley’s ‘Eat 
yourself slim’ -6.3kg (-7.0%). Additional analyses were conducted which demonstrated the 
6-month outcomes for those completing participation in the study, using available case 
data which was obtained for 71.9% of sample, facilitating the following losses; Weight 
Watchers -8.0kg (-9.0%), Slim-Fast -6.5kg (-6.8%), Dr Atkins’ ‘New diet revolution’ -
8.5kg (-8.9%), and Rosemary Conley’s ‘Eat yourself slim’-8.8kg (-9.9%). Follow-up data 
was obtained for 54% of the sample at 12 months. However, the majority of the sample 
had discontinued with their allocated diet, whilst only 19% reported that they had 
continued. In the following six months from the end of the study period up to 12 months, 
individuals attending the Weight Watchers arm reported a weight gain of +0.5kg, 
individuals attending Rosemary Conley also reported a gain of +1.2kg, whilst those 
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attending Slim-Fast reported further losses of -1.7kg, and those allocated to Dr Atkins’ 
‘New diet revolution’ achieved further losses of -1.5kg between the intervention-end 
period and 12 months. The study which used a novel approach, was conducted as part of a 
television programme and used rigorous methodology employing an RCT design, with 
findings demonstrating the effectiveness of four commercial weight loss programmes. The 
study highlights that referral to commercial programmes from community settings with no 
primary care input can facilitate clinically significant weight losses, with the majority of 
programmes achieving ≥5% baseline body weight loss for participants after six months. 
In conclusion, a large number of studies have evaluated the efficacy of commercial 
weight management programmes, with the body of literature encompassing a range of 
research methodologies, from a pilot trial, to a non-controlled yet large sample size 
evaluation of a slimming on referral scheme, to three studies which employed the gold-
standard research design of RCTs. The studies reported weight losses ranging from 
-11.1±5.5kg achieved after 6 months attendance at Slimming World (72) to -0.7kg 
achieved at 12 months by individuals in the Lighten Up trial receiving 3 months of 
pharmacy-led counselling (34), with a substantial number of commercial interventions 
facilitating clinically significant weight loss of ≥5% of individuals baseline body weight 
(36). 
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Table 4.1.3: Studies examining the effectiveness of weight management interventions in Commercial programmes 
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Lavin, 
2006 
Derbyshire 
UK 
91 Mean BMI= 
36.0kg/m
2 
Age= 49.5 years 
89% female 
23% classed as 
extreme obese 
BMI≥40.0kg/m2 
 
Individuals received the ‘Slimming 
World’ commercial 12-week programme 
free of charge, as part of a pilot of the 
‘Slimming on referral’ scheme whereby 
obese individuals are referred from 
primary care (GP practices). Individuals 
were given the option to continue the 
programme through self-funding beyond 
the 12-week period. 
At 12 weeks: mean weight loss of -5.4±3.2kg, -6.4%, with data 
obtained for 68.1%. Programme attendance continued by 51.6% 
to 24 weeks. At 24 weeks: mean weight loss of -11.1±5.5kg, 
-11.3%, with 86% achieving ≥5% loss of baseline weight, with 
59% achieving ≥10% loss. 
Self-rated well-being domains improved significantly from 
baseline, at 12 weeks: feeling calm p<0.001, energetic p<0.001, 
and down-hearted p<0.05, with these improvements maintained 
at 24 weeks p<0.05, p<0.001, p<0.001, respectively. 
Stubbs, 
2011 
UK, across 
77 PCTs 
34,271 Mean 
BMI=36.8kg/m
2 
Age=47.3 years 
89.3% female 
25.4% classed as 
extreme obese 
BMI≥40.0kg/m2 
Individuals received the ‘Slimming 
World’ commercial 12-week programme 
free of charge, in a large scale evaluation 
of the ‘Slimming on referral’ scheme 
whereby obese individuals are referred 
from primary care (GP practices). 
At 12 weeks: mean weight loss of -4.0±3.7kg, -4.0±3.6% and 
mean BMI change -1.5±1.3kg/m
2
. 
Those completing the programme by attending ≥10 sessions 
(58.1% of sample) achieved greater weight loss than non-
completers: -5.5kg vs -1.8kg, p<0.001 and greater BMI loss 
-2.0kg/m
2
 vs -0.7kg/m
2
 than non-completers. 
Stubbs, 
2013 
As Stubbs, 
2011 
As 
Stubbs, 
2011 
 
As Stubbs, 2011 As Stubbs, 2011 Analyses of 12-week outcomes by BMI sub-groups: 
<30kg/m
2
: -2.9±2.8kg, -3.7±3.6%, -1.1±1.0 kg/m
2
 
30.0-34.9kg/m
2
: -3.6±3.2kg, -4.0±3.6%, -1.3±1.2 kg/m
2
 
35.0-39.9kg/m
2
: -4.1±3.7kg, -4.0±3.6%, -1.5±1.3 kg/m
2
 
≥40.0kg/m2: -4.8±4.4kg, -3.9±3.5%, -1.8±1.6 kg/m2 
All change values were significantly different from baseline 
values p<0.001 for each BMI sub-group. 
At 12 weeks, 35.8% of the BMI ≥40.0kg/m2 group achieved 
≥5% loss of baseline weight.  
Ahern, 
2011 
UK 29,326 Median BMI= 
35.1kg/m
2 
Median 
Age=49years 
90.0% female 
 
Individuals received the ‘Weight 
Watchers’ commercial 12-week 
programme free of charge, as part of an 
NHS referral scheme whereby 
overweight and obese individuals are 
referred from primary care. Data were 
analysed as part of a retrospective audit. 
Median weight change for all first referrals attending minimum 
of 1 session (N=22,519) = -3.6kg (IQR -6.4 - -1.0kg), and -3.6% 
(IQR -6.7 - -1.1%), with 38% achieving ≥5% baseline weight 
loss. Median weight change for all first referrals completing 12 
sessions (N=11,851) = -5.4kg (IQR -7.8 - -3.1kg), and -5.6% 
(IQR -8.1 - -3.2%), with 57% achieving ≥5% baseline weight 
loss. 
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Table 4.1.3 Continued: Studies examining the effectiveness of weight management interventions in Commercial programmes 
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Jolly, 
2010, 
2011 
Birmingham
UK 
740 Mean values 
across arms: 
BMI=33.1-
34.0kg/m
2
 
 
Weight=91.7-
95.5kg  
Age=47.5-50.7 
years 
74-81% female 
2-8% classed as 
extreme obese 
BMI≥40.0kg/m2 
Individuals recruited through primary care 
practices to Lighten Up multi-arm RCT 
comparing 6 programmes: 
 Weight Watchers 
 Slimming World 
 Rosemary Conley 
 Size Down, dietetic-led 
 Counselling, general practice 
 Counselling, pharmacy-led 
 
Additional arms also comprised: 
 Choice of one of the 6 programmes  
 Comparator group given exercise 
vouchers enabling free access to 
local fitness facilities 
 
Individuals were provided with free of 
charge access after being randomised to 
one of the 8 arms for a period of 12 weeks. 
At 3 months follow-up data obtained for 88.9% with all arms 
achieving significant losses from baseline:  
Weight Watchers: -4.4kg, p≤0.001 
Slimming World: -3.6kg, p≤0.001  
Rosemary Conley: -4.2kg, p≤0.001 
Size Down: -2.4kg, p≤0.001 
Counselling, general practice: -1.4kg, p<0.05 
Counselling, pharmacy: -2.1kg, p≤0.001 
Choice: -3.3kg, p≤0.001  
Comparator: -2.0kg, p≤0.001  
 
At 12 months follow-up data obtained for 70.5% with 
following arms only, achieving significant losses from 
baseline: 
Weight Watchers: -3.5kg, p≤0.001 
Slimming World: -1.9kg, p≤0.001 
Rosemary Conley: -2.1kg, p≤0.001 
Size Down: -2.5kg, p≤0.001 
Choice: -2.2kg, p≤0.001 
Comparator: -1.1kg, p<0.05 
 
The two primary care arms did not achieve significant loss 
from baseline at 12 months: 
Counselling, general practice: -0.8kg, p>0.05 
Counselling, pharmacy: -0.7kg, p>0.05 
 
Adjusting for age, gender, baseline weight, ethnicity at 12 
month follow-up, only Weight Watchers produced 
significantly greater weight loss than the comparator arm, with 
an adjusted mean difference of -2.5kg, p<0.05. 
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Table 4.1.3 Continued: Studies examining the effectiveness of weight management interventions in Commercial programmes 
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Jebb, 2011 UK, 
Germany, 
Australia 
772 Intervention 
arm: Mean 
BMI= 
31.5kg/m
2 
Weight= 86.9kg 
Age= 46.5years 
88.0% female 
 
Control arm: 
Mean BMI= 
31.3kg/m
2 
Weight= 86.5kg 
Age= 48.2years 
86.0% female 
 
 
RCT comparing 12 months commercial 
Weight Watchers programme with primary 
care usual care comparator in overweight 
and obese adults.  
Intervention arm received 12 months of 
free access to weekly Weight Watchers 
meetings held in the community, which 
promote low energy diet and increased 
physical activity through group support. 
Control arm received 12 months of weight 
loss advice from a primary care 
professional in line with national clinical 
guidelines, at their local GP practice 
At 12 months, weight outcomes were obtained for 230 
individuals (61%) of the intervention arm while outcomes 
were obtained for 214 individuals (54%) of the control arm. 
Mean weight change was greater for intervention group using 
LOCF data: -5.1kg vs -2.3kg, p<0.0001 
BOCF: -4.1kg vs -1.8kg, p<0.0001 
Available case data: -6.7kg vs -3.3kg, p<0.0001 
Individuals receiving the commercial programme had 
increased odds of losing ≥5% baseline weight: OR= 3.0 (2.0 - 
4.4), and ≥10% weight: OR= 3.2 (2.0 - 5.3), compared to 
those receiving usual care. Odds of losing ≥5% baseline 
weight were increased for those completing the programme: 
OR= 2.9 (2.1 - 3.9), and ≥10% baseline weight: OR= 3.5 (2.3 
- 5.4), compared to those receiving usual care. No significant 
difference in intervention effectiveness between countries, 
p>0.10. Baseline and follow-up IWQOL-Lite not reported. 
Truby, 
2006 
UK, 5 
regions: 
Bristol, 
Surrey, 
Nottingham, 
Edinburgh 
and Ulster 
292 Mean values 
across arms: 
BMI=31.2-
32.2kg/m
2
 
 
Weight=87.9-
90.3kg 
Age=38.9-40.9 
years 
71-75% female 
 
RCT comparing the following 4 
commercial interventions for 6 months, 
with a control group who were asked to 
maintain current diet and exercise levels. 
 Weight Watchers comprising 
weekly group support sessions, 
 Slim-Fast plan comprising provision 
of two daily meal replacements and 
support pack, 
 Dr Atkins’ ‘New diet revolution’ 
comprising provision of a self-help 
dietary advice book, 
 Rosemary Conley’s ‘Eat yourself 
slim’ comprising weekly group 
exercise and diet advice sessions. 
At 6 months (intervention-end), no significant difference 
between intervention arms, with all interventions achieving 
significantly greater weight loss than control (p<0.001) with 
the following losses (LOCF data): 
Weight Watchers: -6.6kg, -7.3% body weight 
Slim-Fast: -4.8kg, -4.9% body weight 
Atkins: -6.0kg, -6.2% body weight 
Rosemary Conley: -6.3kg, -7.0% body weight. 
Available data at 6 months obtained for 71.9% of sample: 
Weight Watchers: -8.0kg, -9.0% body weight 
Slim-Fast: -6.5kg, -6.8% body weight 
Atkins: -8.5kg, -8.9% body weight 
Rosemary Conley: -8.8kg, -9.9% body weight. 
12 month data for 19.9% of sample who continued allocated 
diet, with changes from 6months: Weight Watchers +0.5kg, 
Slim-Fast -1.7kg, Atkins -1.5kg, Rosemary Conley +1.2kg. 
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4.1.5 Sporting club-based programmes 
A novel sporting club-based intervention, Football Fans in Training (FFIT) was evaluated 
in a large scale RCT (73) by the team who devised the male-only primary care-based 
Camelon programme (30). The FFIT intervention was delivered in partnership with 13 
Scottish professional football clubs from the Scottish Premier Football League to 747 male 
football fans aged 35 to 65 with a BMI ≥28 kg/m2. The mean BMI of individuals receiving 
the FFIT intervention at baseline was 35.5kg/m
2
, with a mean age of 47.0 years. The FFIT 
male-only adult group intervention comprised an initial programme of 12 weekly 90-
minute sessions delivered at individuals’ local football club stadiums by coaching staff 
who received training from the research team. The sessions were conducted in relatively 
large-sized groups, with up to 30 men per group, with a maximum of 15 individuals to 
every coach, with sessions comprising diet and activity advice using recognised 
behavioural change techniques, along with physical activity sessions which increased in 
intensity throughout the programme. On completion of the 12-week intervention, there was 
a weight maintenance phase comprising six email prompts delivered to participants over 
the following 9 month period and a final group session which was delivered 6 months after 
the completion of the initial 12-week programme of sessions, making the total duration of 
the FFIT intervention 12 months.  
An additional publication describing the development of the FFIT intervention 
provides detail of how data gathered during the implementation of a pilot study, the p-FFIT 
intervention which was delivered at 11 football clubs and a feasibility study conducted in 
two football clubs was used to inform the design of the FFIT intervention (182). 
Additionally, the FFIT intervention has been described in greater detail, providing 
excellent description of the specific behaviour change techniques which were utilised in 
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the delivery of the FFIT programme. The  techniques were been mapped onto the 
taxonomy of behaviour change techniques (version 1) which was developed in response to 
the need for more accurate reporting and description of complex behavioural interventions 
(183). This detailed reporting allows the reader to see which techniques have been used in 
each FFIT session and in each email communication with the participants, and additionally 
the theoretical constructs which underpin each of the specific techniques.  The process 
identified that the techniques of self-monitoring, development of implementation 
intentions, and goal setting, which are associated with control theory and social cognitive 
theory were prominent in the FFIT intervention. 
 The findings of the RCT of the FFIT programme were published in the Lancet (73). 
Data were obtained for 92% of the sample at 12 months, with analyses conducted using 
LOCF data. On completion of the initial 12 weekly sessions, the intervention arm receiving 
the FFIT programme achieved mean losses of -5.8kg (-5.2%) and -1.9kg/m
2
 BMI, with 
47% of those receiving the intervention achieving a loss of ≥5% of their baseline body 
weight. The adjusted mean differences between the intervention and control arms at 12 
weeks were -5.2kg (-4.7%) and -1.7kg/m
2
 BMI, p <0.0001, with greater losses achieved by 
the intervention arm. At 12 months, the intervention arm achieved mean losses of -5.6kg 
(-5.0%) and -1.8kg/m
2
 BMI, with 39% achieving a baseline body weight loss ≥5%. The 
adjusted mean differences between the intervention and control arms at 12 months were 
-4.9kg (-4.4%) and -1.6kg/m
2
 BMI, p <0.0001, with greater losses in the intervention arm. 
The evaluation also encompassed a cost-effectiveness assessment and the inclusion of 
quality of life outcomes, which indicated that psychological and mental health outcomes 
were significantly better for those receiving the FFIT intervention rather than the control 
group (p <0.01), with the exception of the 12 month longer-term mental health component 
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of the SF-12, where there were no significant differences between the intervention and 
control groups (p >0.05). 
 The RCT was strengthened by the rigorous trial methodology, the detailed 
reporting of the intervention and its development and by the inclusion of quality of life 
measures and a cost-effectiveness evaluation. However it would be beneficial to include 
outcome data and separate analyses for those individuals who completed the programme, 
in addition to the LOCF data which was presented. In conclusion, the study demonstrates 
the effectiveness of a weight management intervention delivered to an at-risk hard to reach 
group of males, as an alternative to more traditional weight management interventions 
implemented either in healthcare or commercial settings. These are often perceived to be a 
female-orientated domain, with predominantly female samples, which males may consider 
to be an uninviting prospect. There are plans for the research group to extend the 
intervention to additional target groups including a female-only group for individuals 
recruited through football clubs and a male-only group delivered at local rugby clubs, to 
offer other individuals the opportunity to attend weight management programmes in 
settings which may be deemed to be more engaging and acceptable. 
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Table 4.1.4: Studies examining the effectiveness of weight management interventions in Sporting clubs 
First 
author, 
year 
Setting Sample 
size 
Sample  Intervention  
(Weight loss or maintenance) 
Findings 
Hunt, 
2014 
Scotland, 
across 13 
football 
clubs 
747 Intervention 
arm: Mean 
BMI= 
35.5kg/m
2 
Weight= 
110.3kg 
Age= 47.0years 
0% female 
 
Control arm: 
Mean BMI= 
35.1kg/m
2 
Weight= 
108.7kg 
Age= 47.2years 
0% female 
 
 
Football Fans in Training (FFIT) 12-week 
male-only adult group intervention 
delivered at local football club stadiums. 
Coaching staff employed by the clubs 
received 2-days training from research 
team and delivered intervention to groups 
of up to 30 males, with a maximum of 15 
per coach. The weekly 90-minute sessions 
comprised diet and activity advice using 
techniques including self-monitoring and 
goal setting, along with physical activity 
sessions which increased in intensity 
throughout the programme.  
Initial 12-week intervention followed by 
weight maintenance phase comprising 6 
email prompts over the following 9 month 
period and a group session 6 months after 
12-week session end, making total FFIT 
intervention duration of 12 months. 
Data obtained for 688 individuals (92%) of sample at 12 
months, analyses of LOCF data: 
At 12 weeks, FFIT achieved mean losses of -5.8kg, -5.2%, 
-1.9kg/m
2, with 47% achieving ≥5% weight loss. 
Adjusted mean difference between intervention and control: 
-5.2kg, -4.7% and -1.7kg/m
2
, p<0.0001. 
At 12 months, FFIT achieved mean losses of -5.6kg, -5.0%, 
-1.8kg/m
2, with 39% achieving ≥5% weight loss. 
Adjusted mean difference between intervention and control: 
-4.9kg, -4.4% and -1.6kg/m
2
, p<0.0001. 
 
Estimated cost of £680 per participant to receive intervention 
and £475 per participant to receive no intervention. FFIT 
associated with a gain in QALYs of 0.015 (0.003-0.027), and 
cost-effectiveness of £13,847 per QALY gained. 
 
Psychological and mental health outcomes significantly better 
for intervention arm, with adjusted mean differences in: 
Rosenberg self-esteem score of +0.2 at 12 weeks, p<0.0001 
and +0.1 at 12 months, p<0.0001. 
Positive affect PANAS score of +0.4 at 12 weeks, p<0.0001 
and +0.3 at 12 months, p<0.0001. 
Negative affect PANAS score of -0.1 at 12 weeks, p<0.01 and 
-0.1 at 12 months, p<0.01. 
Physical component SF12 score of +2.6 at 12 weeks, 
p<0.0001 and +1.9 at 12 months, p<0.001. 
Mental component SF12 score of +2.0 at 12 weeks, p<0.001 
however there was no significant difference between 
intervention and control, with adjusted mean difference of 
+0.5 at 12 months, p>0.05. 
  
178 
 
CHAPTER FIVE 
 
5.0 LONGITUDINAL WEIGHT AND QUALITY OF LIFE OUTCOMES OF THE 
COMMUNITY WEIGHT MANAGEMENT SERVICE (CWMS) AND SPECIALIST 
LIFESTYLE MANAGEMENT (SLIM) PROGRAMME 
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5.1 INTRODUCTION 
 
5.1.1 Rationale 
The increasing prevalence of obesity and the associated detrimental impacts on 
individuals’ health and quality of life, have led to the development of a wide variety of 
weight management programmes implemented in the UK and delivered across primary 
care settings, specialist weight management centres, commercial group programmes and 
sporting club-based initiatives.  The literature review presented in Chapter four has 
highlighted the limited availability of good quality evaluations of weight management 
services in the body of the literature. The majority encompass evaluations of primary care-
led programmes, whilst the effectiveness of specialist weight management services has not 
been established. 
The lack of evidence base has meant that the variation in weight management 
service provision available for individuals in the UK has continued. However, the 
increasing prevalence of obesity and subsequent demand for services means that 
establishing the effectiveness of weight management services is essential in order to ensure 
that individuals are given the best opportunity at achieving weight loss. It is therefore 
important to establish whether the two treatment pathways operating within the Specialist 
Weight Management Service; the Community Weight Management Service (CWMS) and 
the Specialist Lifestyle (SLiM) programme, provide effective weight loss and quality of 
life outcomes.  
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5.1.2 Aims 
This chapter aims to examine the efficacy of two treatment pathways offered by the HEFT 
Specialist Weight Management Service; the CWMS and the SLiM programme. The 
baseline and longitudinal weight and quality of life outcomes of participants will be 
examined in order to compare the efficacy of the two medically-supported weight 
management pathways and establish if they can yield clinically significant weight loss 
outcomes. Further analyses will examine the factors associated with successful weight loss 
and improvement in quality of life. Additional subsample analyses will examine the 
association between change in BMI and change in quality of life from baseline to 
programme-end in further detail within the SLiM subsample. The chapter will conclude 
with a summary of the outcomes achieved by the services, the factors predicting changes in 
weight and quality of life outcomes and recommendations to further improve the service in 
light of these findings. 
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5.2 METHODS 
5.2.1 Research design  
The baseline determinants of longitudinal outcomes in a sample attending a Specialist 
Weight Management Service were analysed in order to examine the efficacy of two 
different treatment pathways which run within the service; CWMS and SLiM. Individuals 
fulfilling the eligibility criteria of having BMI ≥40.0kg/m2 or alternatively BMI 
≥35.0kg/m2 with a weight-related health condition were referred to the service by their GP. 
The sample of 700 extreme obese individuals attended either the CWMS (N=262), or the 
SLiM programme (N=438). The sample comprised individuals aged 19 to 76, who entered 
the CWMS between February 2008 and August 2012, and entered the SLiM programme 
between August 2009 and February 2013. 
 
5.2.2 Specialist Weight Management Service  
The two medically supported treatment pathways delivered within the Specialist Weight 
Management Service operated by HEFT have been described in Chapter one; however the 
following brief description is for reference. The CWMS provides comprehensive 
multidisciplinary care for a 12-month period from a team of specialist physicians, 
dietitians, and psychologist, delivered through one-to-one appointments in the community. 
The SLiM programme provides patient education, peer-support and self-management 
through a structured programme of six monthly weight management group-sessions. 
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5.2.3 Weight and BMI change 
Baseline weight and height were obtained from all individuals on entry to the service and 
BMI was calculated by dividing participants’ weight in kg by height in meters squared. In 
addition to recording participants’ initial weight and BMI data at baseline, weight and BMI 
data were collected at each point of contact for individuals in the CWMS for the duration 
of service attendance, which ranged across the sample from 3 months to 36 months. 
However, for individuals attending the SLiM programme, weight and BMI were collected 
at baseline, at 3 months post-baseline and at programme-end which was at 6 months. 
During the period of evaluation, the recording of weight data at each month of the SLiM 
programme was initiated. However as this was only available for a limited number of 
cases, these data were not included in the analyses in the present evaluation.  
 
5.2.4 Predictors of weight and quality of life change 
A wide range of baseline clinical and demographic data were obtained from individuals on 
entry to the service, including age, gender, ethnicity, self-reported quality of life as 
measured by IWQOL-Lite, HADS and EQ5D-3L, and co-morbid health conditions 
including diabetes, obstructive sleep apnoea (OSA), cardiovascular disease (CVD), 
arthritis and hypertension. These factors have been described in detail in Chapter two.  
 
5.2.5 Missing data 
As expected due to the pragmatic approach used to evaluate the efficacy of the service, 
there were instances of missing weight and BMI data, whereby for individual or practical 
reasons weight and BMI measures were not recorded. For the SLiM group, weight data 
was obtained for 86.1% of the sample at 3 months, and 100% of the sample at 6 months 
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post-baseline. However, for the CWMS sample, data was obtained for 62.6% of the sample 
at 3 months, 44.7% of the sample at 6 months, 32.1% at 12 months, 11.8% at 18 months, 
and 8.4% at 24 months. The observed attrition rate of 67.9% at 12 months is consistent 
with the rate demonstrated by the Glasgow and Clyde Specialist Weight Management 
Service, of 65.2% (175). Indeed, medical and behavioural weight management 
interventions have been demonstrated to be at risk of high attrition, with a systematic 
review of 13 studies demonstrating attrition rates ranging from 16-59% (184). 
A high attrition rate may demonstrate a significant source of withdrawal bias and 
has the potential to lead to misleading results (185). It is therefore imperative to assess 
whether there are clinically and statistically significant differences in the characteristics of 
those attending and withdrawing from weight management services as this will greatly 
impact on the interpretation of the outcomes achieved. Thus sensitivity analyses were 
conducted within the present study to assess for differences between those who attended at 
12 months (the minimum attendance period for the CWMS), and those who had 
withdrawn. There were no significant differences in the demographic characteristics of 
age, gender, ethnicity, marital status, occupation and children. Furthermore there were no 
significant differences in the baseline clinical characteristics of weight, BMI, waist 
circumference, systolic and diastolic blood pressure, presence of diabetes, hypertension 
and arthritis, use of weight medication, smoking and alcohol consumption, sedentary time 
as well as self-reported scores on the HADS, ESS and PSQI measures. The only significant 
differences identified between those attending and withdrawing were a smaller proportion 
of those with OSA (21.9% vs 33.3%, p= 0.048) and CVD (8.4% vs 16.7%, p= 0.047) in 
those withdrawing at 12 months, relative to those attending at 12 months, and a smaller 
proportion reporting the presence of 3 or more co-morbid health conditions (13.5% vs 
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26.2%, p= 0.034). Whilst there were no significant differences in continuous baseline BMI, 
there was a significantly smaller proportion of individuals in the BMI 50-59 category 
(17.4% vs 35.7%, p= 0.002) for those withdrawing at 12 months. There were also 
significant differences in self-reported physical function, self-care and pain and discomfort, 
whereby those withdrawing at 12 months reported better physical function (44.6 vs 37.7, 
p= 0.046), were more likely to report experiencing no problems in self-care (69.7% vs 
52.2%, p= 0.018) and less likely to report experiencing extreme problems pain and 
discomfort (23.1% vs 39.1%, p= 0.003). Furthermore, the initial weight loss outcomes 
achieved during the service did not appear to impact upon attrition, with no significant 
differences in the weight change achieved at 3 months and 6 months between those who 
had withdrawn or were attending at 12 months. In summary, despite the relatively high 
attrition rate, there did not appear to be substantial differences in the baseline 
characteristics of those attending and withdrawing from the service, and importantly initial 
weight loss outcomes were not demonstrated to impact on attrition. Thus the outcomes 
demonstrated by those attending can be considered to be representative of the outcomes 
which could have been achieved by those individuals withdrawing from the service, had 
they remained and completed their attendance. 
To deal with the missing data, a LOCF approach was utilised, whereby the last 
observed data points were imputed in cases where follow-up data for specific time points 
were not available, which increased the proportion of data for the CWMS sample to 100%. 
The analysis of LOCF data is an accepted approach that has been widely used to deal with 
the problem of missing outcome data in RCTs assessing treatment effects (186). In order to 
facilitate comparison, the findings of descriptive analyses are presented using data from 
available cases, which gives an indication of the outcome for individuals who attend the 
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service more fully, as well as data imputed using the LOCF approach which gives a more 
conservative outcome for all individuals attending the service for varied periods of time. 
All further analyses examining the predictors of weight loss and gain were conducted using 
LOCF data, in order to give a more conservative estimate of the outcome of all individuals 
entering the service, irrespective of attendance. 
 
5.2.6 Statistical analysis 
All data were analysed using IBM SPSS Statistics (version 21.0). The mean weight and 
BMI of the CWMS and SLiM groups at baseline were compared using independent t-test. 
The proportion of individuals in the following baseline BMI groups 30.0-39.9kg/m
2
, 40.0-
49.9kg/m
2
, 50.0-59.9kg/m
2, and ≥60.0kg/m2 were compared using cross-tabulation and 
Chi
2
 calculations (Table 5.3.1). The mean changes in weight, BMI and change in 
percentage of baseline body weight lost at 3 and 6 months from baseline were analysed by 
paired t-test (Tables 5.3.2a and b). Linear regression was used to establish if the mean 
changes in weight and BMI at 3 and 6 months from baseline differed between the CWMS 
and SLiM samples, adjusting for age, sex and baseline weight (Tables 5.3.2a and b). The 
mean changes in weight, BMI and change in percentage of baseline body weight lost at 3, 
6, 12, 18 and 24 months from baseline for the CWMS sample were analysed by paired 
t-test, indicating significant differences between baseline and follow-up values, and 
additionally indicating significant differences between 12 and 24 month values (Tables 
5.3.3a and b). The proportion of individuals losing any amount of weight (>0%) was 
calculated for the SLiM and CWMS samples separately and combined, throughout service 
attendance, as were the proportions of the sample losing >0-4.9%, 5-9.9%, ≥5%, and ≥10% 
of their baseline body weight and the proportion gaining or maintaining their baseline 
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weight. The proportion of individuals in each category was compared for the CWMS and 
SLiM groups using cross-tabulation and Chi
2
 calculations (Tables 5.3.4a and b). The mean 
weight loss and gain values for the CWMS and SLiM samples were compared using linear 
regression to establish if the mean weight gain and weight loss from baseline values 
differed between the CWMS and SLiM samples, adjusting for age, sex and baseline weight 
(Table 5.3.5). 
Logistic regression analyses were conducted to examine factors predicting 
clinically significant weight loss (≥5%), and weight gain (>0kg). Predictors of ≥5% weight 
loss and weight gain at 6 months were examined in the CWMS and SLiM samples 
separately using a hierarchical approach: Model 1 included age and gender; Model 2 
additionally included baseline weight, presence of diabetes, and ethnicity; Model 3 
additionally included the IWQOL-Lite subscales. The factors predicting ≥5% weight loss 
and weight gain at 12 months (minimum attendance) in the CWMS sample comprised: 
Model 1 which included age and gender; Model 2 additionally included baseline weight, 
presence of diabetes, OSA, CVD, arthritis and hypertension; Model 3 additionally included 
the IWQOL-Lite subscale scores, EQ5D-3L self-reported perceived health rating and 
HADS anxiety and depression score. Ethnicity was not included in the factors predicting 
≥5% weight loss and weight gain at 12 months as this greatly reduced the sample size and 
the numbers within each ethnicity group remained too small to meaningfully contribute to 
the analyses, despite collapsing the categories to create a binary White European and non-
White European variable.  
Linear regression analyses were also used to identify predictors of weight change 
using a continuous variable, whereby negative values indicated weight gain and positive 
values indicated weight loss, at 6 months in the CWMS and SLiM samples separately 
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using a hierarchical approach: Model 1 included age and gender; Model 2 additionally 
included baseline weight, presence of diabetes, and ethnicity; Model 3 additionally 
included the IWQOL-Lite subscales. The factors predicting weight change at 12 months 
(minimum attendance) in the CWMS sample comprised: Model 1 which included age and 
gender; Model 2 additionally included baseline weight, presence of diabetes, OSA, CVD, 
arthritis, hypertension and ethnicity; Model 3 additionally included the IWQOL-Lite 
subscale scores, EQ5D-3L self-reported perceived health rating and HADS anxiety and 
depression score. 
Follow-up IWQOL-Lite data were obtained for a subset of the SLiM sample and 
the mean IWQOL-Lite subscales and total scores were analysed by paired t-test, to 
establish whether the 6-month follow-up scores were significantly different from baseline 
scores (Table 5.3.15). Additionally, a binary quality of life improvement variable was 
created distinguishing between those who experienced gain in IWQOL-Lite total scores 
between baseline and programme-end. Logistic regression analysis was then conducted to 
examine factors predicting quality of life improvement at 6 months using a hierarchical 
approach: Model 1 included age and gender; Model 2 additionally included baseline 
weight, presence of diabetes, and ethnicity; Model 3 additionally included baseline 
IWQOL-Lite subscales and total scores (Table 5.3.16). Linear regression coefficients were 
calculated to assess the association between change in IWQOL-Lite total and subscale 
scores from baseline to programme-end (dependent variable) and change in BMI from 
baseline to programme-end, in order to establish if change in BMI predicted change in 
quality of life. Three hierarchical models are presented: crude; adjusting for age and sex; 
and additionally adjusting for the presence of co-morbid type 2 diabetes (Table 5.3.17). 
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Post-hoc power calculations were conducted in order to assess whether there was 
sufficient power to detect the target ≥5% weight loss within both the CWMS and SLiM 
treatment pathways. The design was specified as a two independent study sample design 
with the dichotomous outcome of ≥5% weight loss, and calculations were performed using 
both available case and LOCF data. The post-hoc analysis indicated that on the basis of the 
available case data whereby ≥5% weight loss was achieved by 30.3% of the SLiM sample 
(N= 438) at programme completion (6 months) and by 40.5% of the CWMS sample 
(N= 84) at minimum attendance (12 months), the design was underpowered with 45.3% 
power. Similarly, when using LOCF data the design was also underpowered with 47.0% 
power, whereby ≥5% weight loss was achieved by 30.3% of the SLiM sample (N= 438) at 
6 months and 23.7% of the CWMS sample (N= 262) at 12 months. A post-hoc power 
calculation was also conducted to assess whether there was sufficient power to detect 
differences between baseline and follow-up IWQOL-Lite quality of life scores within the 
SLiM sample. The design was specified as a one study group versus population design 
with a continuous end-point outcome of mean IWQOL-Lite total score. The post-hoc 
analysis indicated that on the basis of a known mean baseline score of 35.8±20.1 and an 
expected mean score of 42.7 (observed mean follow-up score) within the SLiM sample 
(N= 116), that the design was highly powered with 96% power to detect the observed 
difference between the baseline and intervention-end mean IWQOL-Lite total scores. 
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5.3 RESULTS 
 
5.3.1 Mean weight and BMI change during service attendance 
Table 5.3.1 shows the mean baseline weight and BMI of the SLiM and CWMS samples 
separately and combined. The SLiM sample had a significantly greater mean weight and 
BMI at baseline, with a greater proportion of individuals in the more extreme obese BMI 
≥50.0kg/m2 and ≥60.0kg/m2 groups. The baseline data of the CWMS sample are described 
in more detail in Chapter two. 
 
Table 5.3.1: Comparison of the baseline weight and BMI of the CWMS and SLiM 
samples separately and combined 
 Combined CWMS SLiM P 
N 700 262 438  
Weight (kg) 135.2±27.2 132.1±24.7 137.1±28.5 0.018 
Body mass index (BMI, kg/m
2
) 48.7±9.0 47.0±7.9 49.8±9.4 <0.001 
Proportion in BMI group (%)    <0.001 
BMI 30.0-39.9kg/m
2
  13.9 17.2 11.9  
BMI 40.0-49.9kg/m
2
 49.1 53.4 46.6  
BMI 50.0-59.9kg/m
2
 25.6 23.3 26.9  
BMI ≥60.0kg/m2 11.4 6.1 14.6  
Data are percentages and means ± standard deviations. 
 
Tables 5.3.2a and 2b show the mean change in weight (kg and %) and BMI across 
the first 6 months of service attendance for both samples separately and combined. The 
available case data (Table 5.3.2a) show that there were no significant differences between 
the SLiM and CWMS samples in the mean weight and BMI change values at both 3 and 6 
months post-baseline. The LOCF data (Table 5.3.2b) show that there were significantly 
smaller reductions in weight (kg and %) in the CWMS sample at 3 and 6 months post-
baseline relative to the SLiM sample. There was no significant difference in BMI at 3 
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months. However at 6 months there was a significantly smaller reduction in BMI for the 
CWMS sample. The significantly smaller reductions in weight and BMI observed for the 
CWMS sample are due to the fact that there was a greater proportion of missing data in the 
CWMS sample at 3 months (37.4% vs 13.9%) and at 6 months (55.3% vs 0%), with 
imputed LOCF values attributing to a decrease in the weight and BMI loss values for the 
CWMS sample. The LOCF sample combined values show mean weight reductions of 
-3.0kg (-2.1%) at 3 months with further reductions reaching -4.5kg (-3.2%) at 6 months 
post-baseline. The available case data demonstrate greater weight change, with mean 
losses of -3.9kg (-2.7%) and -1.4kg/m
2
 at 3 months with further reductions reaching -5.2kg 
(-3.8%) and -1.9kg/m
2
 at 6 months. The SLiM programme is a 6-month intervention, with 
the 6-month post-baseline outcomes demonstrating that at programme-end the SLiM 
programme achieved mean reductions of -5.2kg (-3.7%) body weight and -1.9kg/m
2
 BMI. 
 
Table 5.3.2a: Mean change in weight, body weight percentage and BMI throughout 6 
month attendance in combined sample and by service using available case data 
 Combined CWMS SLIM P 
N 700 262 438  
Weight change (kg)            
3 month (N=541) -3.9†±6.1 -3.4†±5.9 -4.1†±6.1 0.546 
6 month (N=555) -5.2†±7.1 -5.4†±7.6 -5.2†±7.0 0.205 
Weight change (%)     
3 month (N=541) -2.7†±4.1 -2.4†±4.1 -2.9†±4.1 0.423 
6 month (N=555) -3.8†±4.9 -4.0†±5.5 -3.7†±4.7 0.208 
BMI change (kg/m
2
)      
3 month (N=541) -1.4†±2.3 -1.2†±2.1 -1.5†±2.4 0.867 
6 month (N=555) -1.9†±2.6 -2.0†±2.7 -1.9†±2.6 0.114 
Data are means ± standard deviations 
Changes in body weight (kg and %) and BMI are changes from baseline values 
*Indicates change value is significantly different from baseline value, p<0.05, † p<0.001, analysed by paired 
t-test 
P values indicate whether mean changes in weight and BMI at 3 and 6 months from baseline differ between 
the CWMS and SLiM samples, adjusting for age, sex and baseline weight.  
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Table 5.3.2b: Mean change in weight, body weight percentage and BMI throughout 6 
month attendance in combined sample and by service using LOCF data 
 Combined CWMS SLIM P 
N 700 262 438  
Weight change (kg)     
3 month (N=700) -3.0†±5.6 -2.1†±4.9 -3.5†±5.9 0.022 
6 month (N=700) -4.5†±6.8 -3.2†±6.4 -5.2†±7.0 0.008 
Weight change (%)     
3 month (N=700) -2.1†±3.8 -1.5†±3.5 -2.5†±3.9 0.011 
6 month (N=700) -3.2†±4.7 -2.3†±4.6 -3.7†±4.7 0.004 
BMI change (kg/m
2
)     
3 month (N=700) -1.1*±2.1 -0.7†±1.7 -1.3†±2.2 0.055 
6 month (N=700) -1.6†±2.5 -1.2†±2.3 -1.9†±2.6 0.032 
Data are means ± standard deviations 
Changes in body weight (kg and %) and BMI are changes from baseline values 
*Indicates change value is significantly different from baseline value, p<0.05, † p<0.001, analysed by paired 
t-test 
P values indicate whether mean changes in weight and BMI at 3 and 6 months from baseline differ between 
the CWMS and SLiM samples, adjusting for age, sex and baseline weight. 
 
Tables 5.3.3a and 3b show the longer-term follow-up data obtained for the CWMS 
sample. Data from available cases (Table 5.3.3a) indicate that significant reductions from 
baseline weight and BMI were achieved at each data collection point, with weight and 
BMI reductions increasing with longer service attendance. As anticipated, analysis of 
available cases data showed greater reductions of -7.0kg (-5.0%) and -2.6kg/m
2
, whilst 
LOCF data (Table 5.3.3b) demonstrated more conservative reductions of -4.1kg (-2.9%) 
and -1.5kg/m
2
 at 12 months post-baseline (CWMS minimum attendance). Similarly the 24 
month data also showed greater reductions when analysing available cases than LOCF 
data, with reductions of -13.4kg (-10.2%) and -5.1kg (-3.6%), respectively. Indeed, the 
LOCF data demonstrated that a further significant loss of -1.0kg was obtained between 12 
months and 24 months, indicating that weight loss continued with service attendance.  
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Table 5.3.3a: Weight change up to 24 months in CWMS sample using available case 
data 
 Weight change (kg) Weight change (%) BMI change (%) 
3 months (N=164) -3.4†±5.9 -2.4†±4.1 -1.2†±2.1 
6 months (N=117) -5.4†±7.6 -4.0†±5.5 -2.0†±2.7 
12 months (N=84) -7.0†±10.8 -5.0†±8.0 -2.6†±4.0 
18 months (N=31) -10.5*±18.7 -7.2*±10.9 -3.5*±5.6 
24 months (N=22) -13.4†±15.2 -10.2†±11.8 -4.8†±5.6 
Data are means ± standard deviations 
Changes in body weight (kg and %) and BMI are changes from baseline values 
*Indicates change value is significantly different from baseline value, p<0.05, † p<0.001, analysed by paired 
t-test 
≠ Indicates 24 month change value is significantly different from 12 month value, p<0.05, analysed by paired 
t-test. 
 
Table 5.3.3b: Weight change up to 24 months in CWMS sample using LOCF data 
 Weight change (kg) Weight change (%) BMI change (%) 
3 months (N=262) -2.1†±4.9 -1.5†±3.5 -0.7†±1.7 
6 months (N=262) -3.2†±6.4 -2.3†±4.6 -1.2†±2.3 
12 months (N=262) -4.1†±8.2 -2.9†±5.9 -1.5†±3.0 
18 months (N=262) -4.8†±10.2 -3.4†±6.8 -1.7†±3.5 
24 months (N=262) -5.1†≠±10.7 -3.6†≠±7.1 -1.8†≠±3.6 
Data are means ± standard deviations 
Changes in body weight (kg and %) and BMI are changes from baseline values 
* Indicates change value is significantly different from baseline value, p<0.05, † p<0.001, analysed by 
paired t-test 
≠ Indicates 24 month change value is significantly different from 12 month value, p<0.05, analysed by paired 
t-test. 
 
Tables 5.3.4a and 4b show the proportion of individuals in the samples gaining or 
losing weight throughout service attendance. There was a significantly greater proportion 
of individuals losing weight in the SLiM sample (78.5%) than the CWMS sample (70.1%) 
at 3 months when analysing available case data. This significant difference remained at 6 
months, with 83.3% of the SLiM sample and 79.4% of the CWMS sample achieving 
weight loss. Indeed, at the point of programme-end for SLiM (6 months), 30.3% of the 
sample achieved a clinically meaningful weight loss of ≥5% of their baseline weight. The 
sample combined available case data demonstrated that attendance at the Specialist Weight 
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Management Service (through combined treatment pathways) resulted in weight loss for 
76.0% of individuals after 3 months and 82.5% of individuals after 6 months. As duration 
of CWMS service attendance increased, the proportions of individuals achieving greater 
amounts of weight loss increased, with the proportion of individuals losing ≥5% of their 
baseline body weight increasing from 18.9% at 3 months, to 59.1% at 24 months.  
 
Table 5.3.4a: Proportion of weight loss in CWMS and SLiM samples using available 
case data 
 
 
>0%     
loss 
>0-4.9% 
loss 
5.0-9.9% 
loss 
≥10% 
loss 
≥5%   
loss 
Weight 
gain or 
maintain  
S
L
iM
 3 months 
 (N=377) 
78.5 55.4 18.6 4.5 23.1 21.5 
6 months 
 (N=438) 
83.3 53.0 21.5 8.8 30.3 16.7 
C
W
M
S
 
3 months 
 (N=164) 
70.1 51.2 14.0 4.9 18.9 29.9 
6 months 
 (N=117) 
79.4 42.7 23.9 12.8 36.7 20.6 
12 months 
 (N=84) 
77.4 36.9 16.7 23.8 40.5 22.6 
18 months 
 (N=31) 
77.4 32.2 22.6 22.6 45.2 22.6 
24 months 
 (N=22) 
77.3 18.2 22.7 36.4 59.1 22.7 
C
o
m
b
in
ed
 
3 months 
 (N=541) 
76.0 54.2 17.2 4.6 21.8 24.0 
6 months 
 (N=555) 
82.5 50.8 22.0 9.7 31.7 17.5 
Data are percentages 
†Indicates value is significantly different between SLiM and CWMS samples, p<0.001. 
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As expected, analysis of LOCF data demonstrated more conservative losses than 
available cases data, with 23.7% of the sample achieving a loss of ≥5% of their baseline 
body weight at the end of CWMS minimum attendance, 12 months post-baseline. These 
proportions remained stable at 18 and 24 months, with 24.5% and 24.8% achieving ≥5% 
weight loss, respectively.  
 
Table 5.3.4b: Proportion of weight loss in CWMS and SLiM samples using LOCF 
data 
 
 
>0%     
loss 
>0-4.9% 
loss 
5.0-9.9% 
loss 
≥10% 
loss 
≥5%   
loss 
Weight 
gain or 
maintain  
S
L
iM
 3 months 
(N=438) 
67.6† 47.7† 16.0† 3.9† 19.9† 32.4† 
6 months 
(N=438) 
83.3† 53.0† 21.5† 8.8† 30.3† 16.7† 
C
W
M
S
 
3 months 
(N=262) 
43.9† 32.1† 8.7† 3.1† 11.8† 56.1† 
6 months 
(N=262) 
53.8† 33.1† 13.4† 7.3† 20.7† 46.2† 
12 months 
(N=262) 
58.0 34.3 10.7 13.0 23.7 42.0 
18 months 
(N=262) 
59.5 35.0 11.5 13.0 24.5 40.5 
24 months 
(N=262) 
58.4 33.6 10.7 14.1 24.8 41.6 
C
o
m
b
i-
n
ed
 
3 months 
(N=700) 
58.7 41.9 13.3 3.5 16.8 41.3 
6 months 
(N=700) 
72.3 45.6 18.4 8.3 26.7 27.7 
Data are percentages 
†Indicates value is significantly different between SLiM and CWMS samples, p<0.001. 
  
Table 5.3.5 shows the mean weight change values, distinguishing between those 
who lost and gained weight across service attendance. For those who gained weight, at 3 
months the combined sample mean weight gain was +0.9kg (+0.7%), and at 6 months 
mean weight gain was +1.8kg (+1.3%); whilst for those who lost weight, mean weight 
losses of -5.7kg (-4.1%) and -6.8kg (-4.9%) were achieved at 3 and 6 months, respectively. 
There were no significant differences in mean weight gain or loss values between the 
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SLiM and CWMS samples at 3 months, however at 6 months the mean weight gain values 
were significantly greater in the SLiM sample (+2.9kg, +2.1%) relative to the CWMS 
sample (+1.1kg, +0.8%). 
 
Table 5.3.5: Mean weight loss and gain at 3, 6, and 12 months for those losing and 
gaining weight in combined sample and by service using LOCF data 
 Combined CWMS SLiM P 
Baseline (N) 700 262 438  
Weight (kg) 135.2±27.2 132.1±24.7 137.1±28.5 0.018 
Mean weight loss (kg)     
3 months -5.7†±5.8 -5.7†±5.4 -5.7†±5.9 0.485 
6 months -6.8†±6.5 -6.9†±6.6 -6.8†±6.4 0.455 
12 months - -8.1†±8.5 - - 
Mean weight loss (%)     
3 months -4.1†±3.7 -4.2†±3.5 -4.0†±3.8 0.505 
6 months -4.9†±4.3 -5.1†±4.6 -4.9†±4.2 0.478 
12 months - -5.9†±6.0 - - 
Mean weight gain (kg)     
3 months 0.9†±1.6 0.7†±1.5 1.1†±1.6 0.114 
6 months 1.8†±2.3 1.1†±1.9 2.9†±2.4 <0.001 
12 months - 1.4†±2.6 - - 
Mean weight gain (%)     
3 months 0.7†±1.2 0.6†±1.3 0.8†±1.1 0.151 
6 months 1.3†±1.7 0.8†±1.5 2.1†±1.8 <0.001 
12 months - 1.1†±2.1 - - 
Data are means ± standard deviations 
* Indicates change value is significantly different from baseline value, p<0.05, † p<0.001, analysed by 
paired t-test. 
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5.3.2 Predictors of ≥5% weight loss at 6 months 
Table 5.3.6 displays the predictors of ≥5% weight loss at 6 months post-baseline for the 
SLiM sample, utilising LOCF data. A test of the fully adjusted model (Model 3) against a 
constant only model was not statistically signiﬁcant, indicating that the predictors as a set 
did not reliably distinguish between those losing ≥5% weight and those who did not 
(Chi
2
 =8.09, p =0.621). Nagelkerke’s R2 of 0.087 indicated that the model accounted for 
only 8.7% of the variance in weight loss status, with no signiﬁcant predictors of weight 
loss identified.  
 
Table 5.3.6: Predictors of ≥5% weight loss at 6 months in the SLiM sample  
 Predictor variables Odds Ratio (OR) 95% CI for OR 
Model 1 N=438 
 
Age 1.00 0.99 – 1.02 
Gender 0.61* 0.39 – 0.96 
Model 2 N=436 Age 1.00 0.99 – 1.02 
 Gender 0.72 0.45 – 1.16 
 Baseline weight 1.01 1.00 – 1.02 
 Diabetes 1.02 0.65 – 1.61 
 Ethnicity (non-white) 0.78 0.45 – 1.36 
Model 3 N=123 Age 1.01 0.97 – 1.05 
 Gender 0.81 0.30 – 2.21 
 Baseline weight 1.01 0.99 – 1.02 
 Diabetes 0.44 0.18 – 1.07 
 Ethnicity (non-white) 1.01 0.37 – 2.77 
 IWQOL-Lite physical function 1.01 0.98 – 1.03 
 IWQOL-Lite self-esteem 1.01 0.99 – 1.03 
 IWQOL-Lite sexual life 0.99 0.98 – 1.01 
 IWQOL-Lite public distress 1.00 0.98 – 1.03 
 IWQOL-Lite work 1.00 0.99 – 1.02 
* p<0.05 
† p<0.001. 
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Table 5.3.7 shows the predictors of ≥5% weight loss at 6 months post-baseline 
(utilising LOCF data) for the CWMS sample. The fully adjusted model (Model 3) was not 
statistically signiﬁcant (Chi2 =13.39, p =0.202), with Nagelkerke’s R2 of 0.195, indicating 
that the model accounted for 19.5% of the variance in weight loss status. Diabetes was a 
significant predictor of weight loss, with the odds ratio of 0.11 indicating that the 
likelihood of achieving ≥5% weight loss decreases by 89% for those with diabetes relative 
to those without the condition. Initial weight was also a significant predictor, with the odds 
ratio of 1.04 indicating that for every 1kg increase in baseline weight, the likelihood of an 
individual achieving ≥5% weight loss is increased by 4%, with those individuals who were 
heavier at baseline being more likely to lose ≥5% of their baseline weight.  
 
Table 5.3.7: Predictors of ≥5% weight loss at 6 months in the CWMS sample  
 Predictor variables Odds Ratio (OR) 95% CI for OR 
Model 1 N=259 
 
Age 1.02 0.99 – 1.04 
Gender 0.74 0.37 – 1.46 
Model 2 N=140 Age 1.03 0.99 – 1.07 
 Gender 0.72 0.26 – 1.97 
 Baseline weight 1.02* 1.01 – 1.04 
 Diabetes 0.75 0.27 – 2.12 
 Ethnicity (non-white) 2.53 0.66 – 9.75 
Model 3 N=106 Age 1.07 1.00 – 1.15 
 Gender 1.42 0.30 – 6.81 
 Baseline weight 1.04* 1.01 – 1.07 
 Diabetes 0.11* 0.02 – 0.75 
 Ethnicity (non-white) 1.22 0.18 – 8.15 
 IWQOL-Lite physical function 1.00 0.97 – 1.03 
 IWQOL-Lite self-esteem 0.98 0.94 – 1.01 
 IWQOL-Lite sexual life 1.01 0.99 – 1.03 
 IWQOL-Lite public distress 1.03 0.99 – 1.07 
 IWQOL-Lite work 0.99 0.96 – 1.03 
* p<0.05 
† p<0.001. 
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5.3.3 Predictors of ≥5% weight loss at 12 months in the CWMS sample 
Table 5.3.8 displays the predictors of ≥5% weight loss at 12 months post-baseline (utilising 
LOCF data) for the CWMS sample, as data for the SLiM sample were not collected at 12 
months post-baseline. The fully adjusted model (Model 3) was not statistically signiﬁcant 
(Chi
2
 = 16.67, p =0.339), with Nagelkerke’s R2 of 0.166 indicating that the model 
accounted for only 16.6% of the variance in weight loss status. Indeed there were no 
signiﬁcant predictors of ≥5% weight loss at 12 months, indicating that all factors: age, 
gender, initial weight, diabetes, OSA, CVD, arthritis, hypertension, quality of life, 
perceived health and anxiety and depression did not make a signiﬁcant contribution to the 
prediction of ≥5% weight loss in the CWMS sample at 12 months. 
 
Table 5.3.8: Predictors of ≥5% weight loss at 12 months in the CWMS sample  
 Predictor variables Odds Ratio (OR) 95% CI for OR 
Model 1 N=259 
 
Age 1.02 0.99 – 1.04 
Gender 0.51* 0.27 – 0.97 
Model 2 N=259 Age 1.01 0.98 – 1.05 
 Gender 0.69 0.33 – 1.43 
 Baseline weight 1.02* 1.01 – 1.03 
 Diabetes 0.76 0.36 – 1.61 
 OSA 0.67 0.33 – 1.38 
 CVD 0.84 0.31 – 2.27 
 Arthritis 1.30 0.62 – 2.72 
 Hypertension 1.86 0.90 – 3.86 
Model 3 N=156 Age 1.03 0.97 – 1.09 
 Gender 0.48 0.15 – 1.53 
 Baseline weight 1.02 1.00 – 1.04 
 Diabetes 0.57 0.17 – 1.84 
 OSA 0.66 0.22 – 1.94 
 CVD 1.12 0.23 – 5.49 
 Arthritis 1.28 0.39 – 4.21 
 Hypertension 1.46 0.46 – 4.65 
 IWQOL-Lite physical function 1.01 0.98 – 1.03 
 IWQOL-Lite self-esteem 1.00 0.98 – 1.03 
 IWQOL-Lite sexual life 1.01 1.00 – 1.03 
 IWQOL-Lite public distress 1.01 0.99 – 1.04 
 IWQOL-Lite work 0.99 0.97 – 1.02 
 EQ5D Perceived health 1.00 0.98 – 1.03 
 HADS Anxiety and depression 1.03 0.94 – 1.12 
* p<0.05 
† p<0.001. 
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5.3.4 Predictors of weight gain at 6 months 
Table 5.3.9 shows the predictors of weight gain at programme-end (6 months post-
baseline) for the SLiM sample, utilising LOCF data. The fully adjusted model (Model 3) 
was statistically signiﬁcant (Chi2 =21.76, p =0.016), with Nagelkerke’s R2 of 0.310 
indicating that the model accounted for 31.0% of the variance in weight gain status. Two 
significant predictors of weight gain were identified, age and public distress IWQOL-Lite 
score. The odds ratios of 0.91 and 0.95 indicate that for each increase in year of age the 
likelihood of gaining weight decreases by 9%, whilst for each one-point increase in public 
distress score the likelihood of weight gain decreased by 5%, suggesting that on 
completion of the 6-month SLiM programme individuals were more likely to have gained 
or maintained their baseline weight if they were younger and reported fewer experiences of 
public distress.  
 
Table 5.3.9: Predictors of weight gain at 6 months in the SLiM sample 
 Predictor variables Odds Ratio (OR) 95% CI for OR 
Model 1 
N=438 
Age 0.96* 0.94 – 0.98 
Gender 1.46 0.77 – 2.77 
Model 2 
N=436 
Age 0.96* 0.94 – 0.98 
Gender 1.43 0.73 – 2.81 
 Baseline weight 1.00 0.99 – 1.01 
 Diabetes 1.05 0.59 – 1.88 
 Ethnicity (non-white) 1.24 0.66 – 2.32 
Model 3 
N=123 
Age 0.91* 0.85 – 0.98 
Gender 0.30 0.05 – 1.74 
 Baseline weight 0.99 0.97 – 1.01 
 Diabetes 1.33 0.33 – 5.35 
 Ethnicity (non-white) 2.54 0.61 – 10.59 
 IWQOL-Lite physical function 0.99 0.94 – 1.03 
 IWQOL-Lite self-esteem 1.02 0.98 – 1.05 
 IWQOL-Lite sexual life 1.02 1.00 – 1.05 
 IWQOL-Lite public distress 0.95* 0.91 – 0.99 
 IWQOL-Lite work 1.01 0.97 – 1.04 
* p<0.05 
† p<0.001. 
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Table 5.3.10 shows the predictors of weight gain in the CWMS sample at 6 months 
post-baseline, utilising LOCF data. The fully adjusted model (Model 3) was not 
statistically signiﬁcant (Chi2 =15.04, p =0.131), with Nagelkerke’s R2 of 0.178 indicating 
that the model accounted for 17.8% of the variance in weight gain status. Two significant 
predictors of weight gain were identified, age and initial weight. The odds ratios of 0.95 
and 0.97 indicate that for each increase in year of age the likelihood of gaining weight 
decreases by 5%, whilst for each 1kg increase in baseline weight the likelihood of weight 
gain decreased by 3%, suggesting that after 6 months attendance at the CWMS service 
individuals were more likely to have gained or maintained their baseline weight if they 
were younger and of lower baseline weight.  
 
Table 5.3.10: Predictors of weight gain at 6 months in CWMS sample 
 Predictor variables Odds Ratio (OR) 95% CI for OR 
Model 1 
N=259 
Age 0.97* 0.95 – 0.99 
Gender 1.10 0.61 – 2.00 
Model 2 
N=140 
Age 0.95* 0.92 – 0.98 
Gender 1.25 0.47 – 3.28 
 Baseline weight 0.99 0.97 – 1.00 
 Diabetes 1.59 0.63 – 4.01 
 Ethnicity (non-white) 0.67 0.19 – 2.33 
Model 3 
N=106 
Age 0.95* 0.90 – 1.00 
Gender 0.86 0.24 – 3.07 
 Baseline weight 0.97* 0.95 – 0.99 
 Diabetes 2.49 0.76 – 8.17 
 Ethnicity (non-white) 1.22 0.26 – 5.76 
 IWQOL-Lite physical function 1.00 0.98 – 1.02 
 IWQOL-Lite self-esteem 1.03 1.00 – 1.06 
 IWQOL-Lite sexual life 1.00 0.98 – 1.01 
 IWQOL-Lite public distress 0.98 0.95 – 1.00 
 IWQOL-Lite work 1.00 0.97 – 1.02 
* p<0.05 
† p<0.001. 
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5.3.5 Predictors of weight gain at 12 months 
Table 5.3.11 shows the predictors of weight gain in the CWMS sample at 12 months post-
baseline (minimum attendance at the CWMS), utilising LOCF data. The fully adjusted 
model (Model 3) was not statistically signiﬁcant (Chi2 =10.48, p =0.789), indicating that 
the predictors as a set did not reliably distinguish between those gaining or maintaining 
their baseline weight and those who achieved weight loss. Nagelkerke’s R2 of 0.087 
indicates that the model accounted for only 8.7% of the variance in weight gain status and 
no significant predictors of weight gain were identified. 
 
Table 5.3.11: Predictors of weight gain at 12 months in CWMS sample 
 Predictor variables Odds Ratio (OR) 95% CI for OR 
Model 1 
N=259 
Age 0.98 0.96 – 1.00 
Gender 0.86 0.48 – 1.56 
Model 2 
N=259 
Age 0.98 0.96 – 1.01 
Gender 0.76 0.39 – 1.48 
 Baseline weight 0.99 0.98 – 1.01 
 Diabetes 0.67 0.35 – 1.30 
 OSA 0.99 0.54 – 1.81 
 CVD 1.48 0.59 – 3.67 
 Arthritis 1.06 0.55 – 2.05 
 Hypertension 0.93 0.48 – 1.79 
Model 3 
N=156 
Age 0.97 0.93 – 1.01 
Gender 1.03 0.40 – 2.68 
 Baseline weight 1.00 0.98 – 1.01 
 Diabetes 0.90 0.37 – 2.17 
 OSA 0.62 0.28 – 1.39 
 CVD 1.37 0.34 – 5.57 
 Arthritis 0.64 0.25 – 1.66 
 Hypertension 1.26 0.50 – 3.15 
 IWQOL-Lite physical function 0.99 0.97 – 1.01 
 IWQOL-Lite self-esteem 1.01 0.99 – 1.03 
 IWQOL-Lite sexual life 1.00 0.98 – 1.01 
 IWQOL-Lite public distress 1.00 0.98 – 1.01 
 IWQOL-Lite work 0.99 0.98 – 1.01 
 EQ5D Perceived health 1.01 0.99 – 1.03 
 HADS Anxiety and depression 0.96 0.90 – 1.03 
* p<0.05 
† p<0.001. 
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5.3.6 Predictors of linear weight change at 6 months 
Table 5.3.12 shows the predictors of weight change at programme-end (6 months post-
baseline) for the SLiM sample, using LOCF data. The fully adjusted model (Model 3) was 
statistically signiﬁcant (F (10, 122) =2.02, p =0.038), indicating that the predictors as a set 
reliably predicted weight change at 6 months. The Adjusted R
2
 value of 0.077 indicates 
that the final model (Model 3) accounted for 7.7% of the variance in weight change. 
Increasing age and initial weight were significantly positively associated with increasing 
weight loss. Each increase in one year of age was associated with a weight loss of 0.17kg, 
whilst every 1kg increase in baseline weight was associated with a weight loss of 0.07kg. 
 
Table 5.3.12: Predictors of linear weight change at 6 months in SLiM sample 
 Predictor variables B (SE) 95% CI for B 
Model 1 
 
Age 0.13* (0.07) 0.01 – 0.26 
Gender -2.21 (1.54) -5.26 – 0.84 
Model 2 Age 0.15* (0.07) 0.02 – 0.28 
 Gender -1.14 (1.60) -4.30 – 2.03 
 Baseline weight 0.05* (0.02) 0.00 – 0.10 
 Diabetes -0.61 (1.47) -3.51 – 2.30 
 Ethnicity (non-white) -2.29 (1.76) -5.78 – 1.19 
Model 3 Age 0.17* (0.07) 0.03 – 0.31 
 Gender 0.77 (1.81) -2.81 – 4.35 
 Baseline weight 0.07* (0.03) 0.02 – 0.13 
 Diabetes -1.02 (1.50) -4.00 – 1.96 
 Ethnicity (non-white) -2.55 (1.76) -6.04 – 0.94 
 IWQOL-Lite physical function 0.06 (0.04) -0.03 – 0.14 
 IWQOL-Lite self-esteem 0.03 (0.04) -0.04 – 0.09 
 IWQOL-Lite sexual life -0.03 (0.03) -0.08 – 0.03 
 IWQOL-Lite public distress 0.04 (0.04) -0.04 – 0.12 
 IWQOL-Lite work -0.03 (0.03) -0.09 – 0.04 
* p<0.05 
† p<0.001. 
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Table 5.3.13 shows the predictors of weight change at 6 months post-baseline for 
the CWMS sample, using LOCF data. The fully adjusted model (Model 3) was statistically 
signiﬁcant (F (10, 105) =2.13, p =0.029), indicating that the predictors as a set reliably 
predicted weight change at 6 months. The Adjusted R
2
 value of 0.097 indicates that the 
final model (Model 3) accounted for 9.7% of the variance in weight change. Similarly to 
the SLiM sample final model (Table 5.3.12), increasing baseline weight was significantly 
positively associated with increasing weight loss, with each 1kg increase in baseline 
weight was associated with a weight loss of 0.10kg. Scores on the IWQOL-Lite self-
esteem subscale were significantly negatively associated with weight change, whereby 
each one-point increase in self-esteem score was associated with a weight gain of 0.09kg. 
 
Table 5.3.13: Predictors of linear weight change at 6 months in CWMS sample 
 Predictor variables B (SE) 95% CI for B 
Model 1 
 
Age 0.05 (0.06) -0.07 – 0.16 
Gender -2.00 (1.57) -5.12 – 1.11 
Model 2 Age 0.07 (0.06) -0.05 – 0.20 
 Gender -0.22 (1.63) -3.46 – 3.02 
 Baseline weight 0.08* (0.03) 0.03 – 0.14 
 Diabetes -1.93 (1.66) -5.22 – 1.37 
 Ethnicity (non-white) 0.37 (2.21) -4.01 – 4.75 
Model 3 Age 0.13 (0.07) -0.01 – 0.27 
 Gender -0.57 (1.76) -4.06 – 2.93 
 Baseline weight 0.10* (0.03) 0.04 – 0.16 
 Diabetes -2.60 (1.70) -5.97 – 0.78 
 Ethnicity (non-white) -0.32 (2.30) -4.90 – 4.25 
 IWQOL-Lite physical function -0.01 (0.03) -0.08 – 0.06 
 IWQOL-Lite self-esteem -0.09* (0.04) -0.16 – -0.01 
 IWQOL-Lite sexual life 0.03 (0.02) -0.02 – 0.08 
 IWQOL-Lite public distress 0.04 (0.04) -0.03 – 0.12 
 IWQOL-Lite work -0.01 (0.04) -0.08 – 0.07 
* p<0.05 
† p<0.001. 
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5.3.7 Predictors of linear weight change at 12 months 
Table 5.3.14 displays the predictors of weight change at 12 months post-baseline for the 
CWMS sample, utilising LOCF data. The fully adjusted model (Model 3) was statistically 
signiﬁcant (F (16, 83) =2.13, p =0.011), indicating that the predictors as a set reliably 
predicted weight change at 12 months. The Adjusted R
2
 value of 0.194 indicates that the 
final model (Model 3) accounted for 19.4% of the variance in weight change. Increasing 
baseline weight and presence of arthritis were significantly positively associated with 
increasing weight loss, with each 1kg increase in baseline weight was associated with a 
weight loss of 0.11kg and presence of arthritis was associated with a weight loss of 4.09kg. 
Similarly to the CWMS 6-month final model (Table 5.3.13), scores on the IWQOL-Lite 
self-esteem subscale were significantly negatively associated with weight change, whereby 
each one-point increase in self-esteem score was associated with a weight gain of 0.10kg. 
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Table 5.3.14: Predictors of linear weight change at 12 months in CWMS sample 
 Predictor variables B (SE) 95% CI for B 
Model 1 
 
Age 0.03 (0.07) -0.11 – 0.16 
Gender -5.53* (1.84) -9.18 – -1.88 
Model 2 Age 0.04 (0.09) -0.13 – 0.21 
 Gender -3.75 (2.19) -8.10 – 0.61 
 Baseline weight 0.09* (0.03) 0.03 – 0.15 
 Diabetes -3.39 (2.01) -7.39 – 0.62 
 OSA -0.46 (1.71) -3.87 – 2.96 
 CVD -1.62 (2.78) -7.16 – 3.91 
 Arthritis 3.57 (1.86) -0.13 – 7.27 
 Hypertension 2.01 (1.94) -1.85 – 5.87 
 Ethnicity (non-white) 1.19 (2.59) -3.96 – 6.35 
Model 3 Age 0.10 (0.09) -0.09 – 0.28 
 Gender -3.45 (2.27) -7.98 – 1.07 
 Baseline weight 0.11* (0.04) 0.04 – 0.19 
 Diabetes -4.07 (2.03) -8.13 – -0.01 
 OSA -0.44 (1.79) -4.00 – 3.12 
 CVD 0.33 (3.04) -5.74 – 6.41 
 Arthritis 4.09* (1.92) 0.26 – 7.92 
 Hypertension 1.92 (2.04) -2.15 – 5.99 
 Ethnicity (non-white) 0.21 (2.75) -5.29 – 5.71 
 IWQOL-Lite physical function 0.03 (0.04) -0.06 – 0.12 
 IWQOL-Lite self-esteem -0.10* (0.05) -0.21 – 0.00 
 IWQOL-Lite sexual life 0.04 (0.03) -0.01 – 0.10 
 IWQOL-Lite public distress 0.07 (0.05) -0.02 – 0.17 
 IWQOL-Lite work -0.04 (0.04) -0.13 – 0.04 
 EQ5D Perceived health 0.02 (0.04) -0.07 – 0.11 
 HADS Anxiety and depression 0.06 (0.17) -0.27 – 0.39 
* p<0.05 
† p<0.001. 
 
5.3.8 Predictors of change in quality of life at 6 months 
Table 5.3.15 displays the mean quality of life scores at baseline and at programme-end, 6 
months post-baseline for the SLiM sample, along with the mean difference between the 
scores. Follow-up quality of life data were available for a subsample of the SLiM sample 
and were not collected for the CWMS sample. There was a significant improvement in all 
IWQOL-Lite subscales and total scores from baseline to programme-end. This effect was 
observed in both gender subgroups as well as in the overall SLiM sample, with the greatest 
improvement in quality of life observed in the physical function subscale. However, 
despite these significant improvements in quality of life, the programme-end self-reported 
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quality of life scores remained low, ranging from 35.0 for self-esteem and 57.4 for the 
work subscale, with 0 representing worst quality of life and 100 representing optimum 
quality of life. 
 
Table 5.3.15: Mean change in quality of life (IWQOL-Lite) from baseline to 
programme-end in the SLiM sample combined and split by gender  
 Baseline Programme-end Mean difference 
Physical function  31.7±22.7 39.5±24.0 +7.8† 
Male (N=34) 41.3±22.9 50.2±20.7 +8.9† 
Female (N=90) 28.1±21.7 35.5±24.1 +7.4† 
Self esteem 28.9±27.9 35.0±30.4 +6.1† 
Male (N=33) 37.8±29.3 46.1±31.6 +8.3* 
Female (N=87) 25.5±26.7 30.8±29.1 +5.3* 
Sexual life 48.1±30.6 55.1±34.4 +7.0* 
Male (N=31) 53.7±23.8 59.8±32.0 +6.1 
Female (N=80) 46.0±32.7 53.3±35.3 +7.3* 
Public distress 35.7±27.0 40.9±29.7 +5.2* 
Male (N=32) 45.9±26.0 51.6±22.8 +5.6 
Female (N=88) 32.0±26.6 37.1±31.1 +5.1 
Work 51.2±29.1 57.4±29.6 +6.2* 
Male (N=31) 57.3±27.8 63.1±28.8 +5.8* 
Female (N=80) 48.8±29.5 55.1±29.8 +6.3* 
IWQOL-Lite total  35.8±20.1 42.7±22.1 +6.9† 
Male (N=32) 44.7±18.7 51.9±22.4 +7.2† 
Female (N=84) 32.4±19.6 39.1±21.0 +6.8† 
Data are means and standard deviations calculated by paired samples t-test 
*P<0.05 
†P<0.001. 
 
Table 5.3.16 displays the predictors of change in quality of life from baseline to 
programme-end (6 months post-baseline) for the SLiM sample. The fully adjusted model 
(Model 3) was not statistically signiﬁcant (Chi2 =19.52, p =0.052), with Nagelkerke’s R2 of 
0.257 indicating that the model accounted for 25.7% of the variance in quality of life 
change. 
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Table 5.3.16: Predictors of change in quality of life (IWQOL-Lite total) from baseline 
to programme-end in SLiM sample 
 Predictor variables Odds Ratio (OR) 95% CI for OR 
Model 1 N=113 
 
Age 1.02 0.98 – 1.06 
Gender 1.18 0.47 – 2.98 
Model 2 N=113 Age 1.01 0.97 – 1.05 
 Gender 1.19 0.43 – 3.34 
 Baseline weight 1.00 0.98 – 1.01 
 Diabetes 2.12 0.78 – 5.75 
 Ethnicity (non-white) 0.32* 0.11 – 0.94 
Model 3 N=102 Age 0.97 0.91 – 1.02 
 Gender 0.34 0.08 – 1.44 
 Baseline weight 0.99 0.97 – 1.01 
 Diabetes 4.06* 1.09 – 15.07 
 Ethnicity (non-white) 0.27* 0.08 – 0.95 
Baseline IWQOL-Lite physical function 1.02 0.89 – 1.18 
 IWQOL-Lite self-esteem 1.05 0.96 – 1.15 
 IWQOL-Lite sexual life 1.04 0.98 – 1.10 
 IWQOL-Lite public distress 1.02 0.96 – 1.10 
 IWQOL-Lite work 1.05 1.00 – 1.11 
 IWQOL-Lite total 0.82 0.55 – 1.20 
*P <0.05 
†P <0.001. 
 
Two signiﬁcant predictors of change in quality of life were identified, diabetes and 
ethnicity. The odds ratio indicates that for those with diabetes the odds of experiencing 
improvement in their quality of life are 4.06 times as large as for those without the 
condition. For those of non-White European ethnicity, the odds of quality of life 
improvement decreased and were 0.27 times reduced, indicating that those of non-White 
European ethnicity were 73% less likely to experience improvement in quality of life 
compared to those of White European ethnicity. This indicates that those with diabetes are 
more likely to experience improvement in quality of life, whilst those of non-White 
European ethnicity are less likely to experience quality of life improvement following 
attendance at the SLiM programme. Interestingly, the baseline IWQOL-Lite subscales and 
total scores were not significant predictors of quality of life change, indicating that 
widespread change was observed for individuals across the spectrum of quality of life 
reported at baseline.   
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5.3.9 Association between change in BMI and change in quality of life 
Table 5.3.17 shows the association between change in BMI from baseline to 6-months 
(programme-end) utilising LOCF data and change in IWQOL-Lite total and subscale 
scores from baseline to programme-end, within the SLiM subsample. Change in BMI 
significantly predicted change in the IWQOL-Lite physical function subscale, with a 
decrease in one BMI unit from baseline to programme-end associated with an increase of 
1.06 in physical function score. A negative association was also observed between change 
in BMI and changes in the sexual life and public distress subscales as well as the IWQOL-
Lite total score, indicating that a reduction in BMI from baseline to programme-end was 
associated with improvement in these quality of life areas however, this was not 
significant.  
 
Table 5.3.17: Change in BMI from baseline to programme-end as a predictor of 
change in IWQOL-Lite scores from baseline to programme-end in the SLiM sample 
 
Univariate Model 1 Model 2 
U.B. S.E. U.B. S.E. U.B. S.E. 
Physical function  -0.91* 0.44 -0.85 0.45 -1.06* 0.48 
Self esteem 0.41 0.48 0.61 0.49 0.36 0.53 
Sexual life -1.08 0.62 -1.08 0.64 -1.14 0.70 
Public distress -0.96 0.73 -0.44 0.73 -0.47 0.75 
Work 0.45 0.52 0.36 0.54 0.12 0.57 
IWQOL-Lite total  -0.10 0.39 -0.03 0.40 -0.27 0.43 
U.B. =Unstandardised Beta, S.E. =Standard error 
*P<0.05 
†P<0.001 
Model 1 adjusting for age and gender 
Model 2 additionally adjusting for diabetes and baseline BMI. 
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5.4 DISCUSSION  
 
This study has highlighted the efficacy of the two treatment pathways operating within the 
Specialist Weight Management Service. Analysis of available case data, representing those 
who completed the programmes demonstrated mean losses of -5.2kg (-3.7%) for SLiM and 
-5.4kg (-4.0%) for CWMS after 6 months, with longer term CWMS mean losses of -7.0kg 
(-5.0%) and -13.4kg (-10.2%) at 12 and 24 months, indicating that 12 months of attendance 
at the CWMS yielded clinically meaningful weight losses of ≥5% baseline weight in the 
majority of participants. Indeed 40.5% of the CWMS sample had achieved ≥5% weight 
loss at 12 months, and 59.1% of the sample at 24 months. However as expected, analysis 
of LOCF data yielded more conservative weight outcomes with mean losses of -3.2kg 
(-2.3%) for the CWMS at 6 months, -4.1kg (-2.9%) at 12 months and -5.1kg (-3.6%) at 24 
months. Analysis of LOCF data demonstrated that on completion of the 6-month SLiM 
programme 30.3% achieved the clinically targeted weight loss of ≥5% baseline weight, 
whilst after 12 months (minimum duration) attendance at the CWMS 23.7% of the sample 
achieved ≥5% weight loss, with available case data suggesting a greater proportion 
(40.5%) of the sample who attended the CWMS more fully achieved ≥5% baseline weight 
loss.  
Analyses of available case data showed no significant differences in the weight and 
BMI outcomes between the CWMS and SLiM treatment pathways achieved after 3 and 6 
months, despite the patient populations significantly differing at baseline, with the SLiM 
sample having more complex health needs. However, analyses of LOCF data demonstrated 
significant differences in the weight and BMI of the samples at 6 months post-baseline. 
This is likely to be due to the greater proportion of missing data in the CWMS sample at 3 
months (37.4% vs 13.9%) and at 6 months (55.3% vs 0%), with the imputed LOCF values 
  
210 
 
potentially masking greater weight and BMI loss values for the CWMS sample, which 
were similar to the values attained in the SLiM sample. 
The 6 month outcomes of the combined programmes demonstrated using available 
case data (-5.2kg, -3.8%) and LOCF data (-4.5kg, -3.2%) are greater than the mean loss 
observed on completion of the first four-month phase of the Glasgow and Clyde Specialist 
Weight Management Service using available case data (-4.0kg) and LOCF data (-2.9kg) 
(175). Longer term outcomes of the Glasgow service were reported, with mean losses of 
-8.5kg (-9.7 - -7.2) using available case data and -3.6kg (-3.8 - -3.3) using LOCF data, after 
a minimum period of ≥19 months. In contrast the CWMS yielded greater mean losses of 
-13.4kg (-10.2%) when analysing available case data and -5.1kg (-3.6%) when analysing 
LOCF data at 24 months. Additionally, a substantial proportion of individuals in the 
CWMS achieved clinically meaningful weight loss, with ≥5% baseline body weight loss 
achieved by 24.8% of those attending the CWMS when analysing LOCF data and 59.1% 
when analysing available case data at 24 months, comparable to the 24% of those entering 
the Glasgow service and 56% of those classed as completing attendance at the Glasgow 
service. However, such comparisons should be interpreted with caution, as the exact 
duration of attendance and frequency of contact at the Glasgow service cannot be directly 
compared with the CWMS, as the intervention duration and frequency of contact varies for 
each individual, as with the CWMS. Furthermore, the baseline BMI of the CWMS was 
greater than that of the Glasgow service (48.7kg/m
2
 vs 43.3kg/m
2
) which may have 
additionally contributed to the greater weight losses observed in the CWMS, however the 
mean percentage of baseline weight lost by individuals attending the Glasgow service was 
not reported and so cannot be directly compared with the CWMS. In comparison to other 
specialist weight management services, analysis of available case data demonstrated 
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greater losses in the CWMS and SLiM programmes than three other specialist weight 
management dietetic-led programmes which have reported weight losses ranging from -1.0 
to -5.1kg using available case data (176-178). 
The demonstrated weight losses of ≥5% observed in the present sample, have been 
shown to be associated with clinically significant improvements in a range of 
cardiovascular risk factors, including HbA1c, triglycerides, diastolic and  systolic blood 
pressure, and HDL-cholesterol (122). Weight losses of ≥5% associated with these health 
benefits were achieved by 21.8% of the combined sample after just 3 months and 31.7% 
after 6 months using available case data, and 16.8% and 26.7% at 3 and 6 months using 
LOCF data, suggesting that the service was able to facilitate clinically meaningful weight 
losses for a substantial proportion of individuals after only a short period of attendance. 
This is a greater proportion than that achieved in primary care in an evaluation of 6,715 
individuals attending 12 months of the Counterweight weight management programme 
(analysed using LOCF data), in which 10% of participants achieved ≥5% weight loss 
(172). This suggests that the specialist service was better at facilitating larger weight losses 
than the primary care-led Counterweight programme.  
Another primary care-led weight management intervention incorporating a 12-week 
Low Energy Liquid Diet (LELD) approach with appointments up to 12 months was able to 
produce greater mean weight loss than the CWMS programme, with available case data 
demonstrating -12.4kg (-9.1%) loss after 12 months compared to -7.0kg (-5.0%) achieved 
by the CWMS (33). The Camelon primary care-led programme also yielded a greater mean 
loss than the CWMS and SLiM programmes after a 12-week intervention, with a mean loss 
of -5.0kg using available case data, compared to -3.4kg and -4.1kg achieved by the CWMS 
and SLiM samples after the same duration of attendance (30). Longer-term follow-up data 
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for the Camelon programme obtained in a smaller sample of 20 individuals obtained 
between 1-49 months post-programme indicated a mean loss of -3.7%, which is far less 
than the CWMS mean loss of -10.2% obtained at 24 months (30). A similar level of weight 
loss to that achieved by the CWMS and SLiM programmes after 3 months was achieved in 
a trial arm receiving a 12-week structured support programme as part of a primary care 
pilot RCT which yielded a mean loss of -4.0kg, compared to -4.1kg and -3.4kg in the 
SLiM and CWMS samples (32). In addition, a 12-month sporting club-based intervention 
yielded 12-month mean weight losses obtained using LOCF data, similar to that achieved 
by the CWMS (-5.6kg vs -4.1kg for the CWMS) (73).  
The CWMS and SLiM programmes yielded greater weight losses than two other 
primary care-led programmes evaluated in RCTs (31, 173) and indeed greater 12-month 
weight losses than all arms of the Lighten Up RCT evaluating primary care programmes 
and commercial programmes (34). Indeed the CWMS demonstrated greater 12-month 
weight loss, than Weight Watchers as demonstrated in a 12-month RCT (-7.0kg vs -5.1kg) 
(181). However, another RCT yielded conflicting findings, with all commercial trial arms 
including Weight Watchers, Slim-Fast, Atkins diet, and Rosemary Conley yielding greater 
weight losses than the CWMS and SLiM programmes after 6 months using available case 
data (36). These findings indicate that the CWMS and SLiM programmes were able to 
facilitate greater weight losses than achieved by other specialist weight management 
services and several primary care-led and commercial programmes. However some 
primary care and commercial programmes have demonstrated similar and indeed better 
weight loss outcomes, although in generally less severely obese populations than the 
CWMS and SLiM programmes. 
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Within the Specialist Weight Management Service significant weight loss was 
achieved by some but not all individuals attending the SLiM and CWMS programmes. 
Analyses indicated that age was identified as a significant predictor of weight gain in the 
SLiM and CWMS samples at 6 months, indicating that older individuals were less likely to 
gain weight. This was also supported by the findings of the predictors of linear weight 
change, whereby increasing age was significantly positively associated with increasing 
weight loss in the SLiM sample at 6 months. The finding that increasing age was 
associated with increased likelihood of weight loss is consistent with the evaluation of the 
Glasgow service which demonstrated that relative to those <40 years of age, there was 
increased likelihood of achieving ≥5kg weight loss in those aged 40-49 (OR= 1.52, 
1.09 - 2.12), aged 50-59 (OR= 1.47, 1.03 - 2.11) and those aged ≥60 (OR= 2.12, 
1.44 - 3.14) (174). These findings suggest that older individuals may be more motivated to 
lose weight, with younger individuals perhaps requiring additional support in achieving 
weight loss when attending specialist services.  
Baseline weight was also identified as a significant predictor of weight gain in the 
CWMS sample at 6 months, indicating that those with greater baseline weight were less 
likely to gain weight. Baseline weight was also a predictor of ≥5% weight loss at 6 months 
in the CWMS sample, with those of greater baseline weight more likely to achieve ≥5% 
weight loss. These findings are consistent with the Glasgow service which reported that 
those with baseline BMI ≥50kg/m2 were more likely to experience ≥5kg weight loss 
(OR= 1.70, 1.14 - 2.54) than those with a baseline BMI ranging from 35.0-39.0kg/m
2 
(174). 
The only quality of life and mental health factors which significantly predicted 
weight change were scores on the IWQOL-Lite self-esteem and public distress subscales, 
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whilst none of the remaining subscales or the HADS anxiety and depression scale were 
significant predictors. Self-esteem was significantly negatively associated with linear 
weight change at 6 and 12 months in the CWMS sample, whereby greater weight loss was 
associated with lower self-esteem scores, indicating that those with poorer levels of self-
esteem at baseline achieved greater weight loss. An opposite pattern of association was 
observed with the IWQOL-Lite public distress subscale, whereby public distress was a 
significant predictor of weight gain, with those reporting higher levels of baseline public 
distress being less likely to gain weight within the SLiM sample at 6 months. The fact that 
individuals with better self-esteem were less likely to lose weight gives cause for concern 
given that self-esteem was at a very low level, with mean IWQOL-Lite self-esteem scores 
of 26.2 and 28.9 for the CWMS and SLiM samples respectively, whereby 0 represents 
worst quality of life and 100 represents optimum level. One potential explanation for this 
observation is that low self-esteem and high levels of perceived public distress before 
treatment commencement may act as motivators for change during the service, thus 
resulting in greater weight loss among these individuals. Exploration of these complex 
issues through qualitative research would enhance understanding of the role of factors such 
as psychological and physical co-morbidities and the impact on individuals’ motivation to 
achieve weight loss throughout attendance at the service.  
Analyses indicated that the presence of co-morbid type 2 diabetes was a significant 
predictor of ≥5% weight loss within the CWMS sample at 6 months, whereby those with 
diabetes were less likely to achieve ≥5% weight loss (OR= 0.11, 0.02 - 0.75). This finding 
is consistent with the evaluation of the Glasgow service which demonstrated that those 
with diabetes were less likely to achieve the target ≥5kg weight loss (OR= 0.55, 
0.38 - 0.81) (174). The finding that those with diabetes were less likely to benefit from the 
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service also gives cause for concern and potentially indicates the need for the provision of 
further support of individuals with diabetes in order to achieve weight loss. Conversely, the 
presence of arthritis was shown to be significantly positively associated with increased 
weight loss in the analyses of linear weight change in the CWMS sample at 12 months. 
This finding potentially suggests that those with arthritis were more likely to achieve 
weight loss. However, due to the magnitude of the Beta value and the large confidence 
interval it is probable that the observed association is a type 1 error and thus may not 
actually provide support for an association between weight loss and arthritis. 
Analyses did not identify gender as a predictor of ≥5% weight loss, weight gain or 
linear weight change, which is in contrast  to the evaluation of the Glasgow service which 
demonstrated that males (OR= 1.39, 1.05 - 1.82) were more likely to achieve ≥5kg weight 
loss (174). Similarly, the mental health measure of anxiety and depression was not 
identified as a predictor of weight change, whilst the Glasgow service demonstrated that 
those with depression (OR= 1.81, 1.35 - 2.44) were more likely to achieve weight loss 
(174). These findings potentially suggest that the CWMS and SLiM programmes were 
effective regardless of gender and the experience of symptoms of anxiety and depression. 
Interestingly, analyses of the predictors of ≥5% weight loss at 6 months in the 
SLiM sample (programme-end) and at 12 months in the CWMS sample (minimum 
attendance) indicated that none of the demographic, clinical and self-report measures were 
significant predictors of weight loss. Similarly, no predictors of weight gain in the CWMS 
sample at 12 months were identified. The finding that none of the demographic, clinical 
and self-report measures were significant predictors of ≥5% weight loss at 6 months in the 
SLiM sample and ≥5% weight loss and weight gain at 12 months in the CWMS sample, 
potentially indicates that the service was successful in effectively facilitating weight loss 
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for participants regardless of demographic characteristics such as age, gender, and 
ethnicity. Furthermore the findings of some analyses indicate that participants’ weight, and 
presence of co-morbid health conditions such as diabetes, cardiovascular disease, 
hypertension, arthritis and OSA also did not have an impact on whether individuals 
successfully achieved weight loss, as well as perceived quality of life and mental health. 
This suggests a positive quality of the service, indicating that the service is suitable and 
effective for most individuals. However, the fact that no predictors of ≥5% weight loss 
were identified within the 6-month SLiM and 12-month CWMS samples could also be due 
to homogeneity within the samples, and is in contrast to the analyses of the remaining 
samples within which various predictors were identified and also to the findings of the 
evaluation of the Glasgow service (174). This is also in contrast to a review which has 
demonstrated that in the successful achievement of weight maintenance following initial 
weight loss, there are a number of factors including magnitude of initial weight loss, 
attainment of weight loss goals, control of eating and self-monitoring, which are associated 
with successful weight maintenance (187). 
Further research investigating potential factors associated with clinically significant 
weight loss and weight gain is required in order to definitively determine whether 
particular groups of individuals benefit more from attending the service than others who 
may require additional support, thus improving the efficacy of the programmes and 
increasing individuals’ opportunity to achieve weight loss. 
In addition to facilitating weight loss for individuals, the current evaluation has also 
demonstrated that attendance at the Specialist Weight Management Service facilitated 
improvement in individuals’ quality of life, with significant improvement on all mean 
baseline IWQOL-Lite subscales after attendance at the SLiM programme. However, 
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quality of life scores remained low at programme-end, indicating that individuals were still 
experiencing reduced quality of life, and that further support may be required. Analyses 
indicated that diabetes and ethnicity were significant predictors of 6 month quality of life 
change in the SLiM subsample. The finding that those with diabetes were more likely to 
experience improvement in quality of life suggests that the presence of the condition may 
have motivated individuals in their weight loss efforts. Indeed, findings from the Look 
AHEAD RCT which randomised 5,145 overweight and obese individuals with type 2 
diabetes to receive either an intensive lifestyle intervention or to receive education in the 
control arm, revealed that the intensive intervention facilitated weight losses of -8.6% after 
one year and -6.0% at study-end, as well as improvements in quality of life among 
individuals with the long-term condition (188). The finding that individuals of non-White 
European ethnicity were less likely to experience quality of life change relative to those of 
White European ethnicity gives cause for concern, suggesting a potential need to tailor the 
programmes to address and incorporate cultural and ethnic differences in food, physical 
activity and lifestyle practices. However, this finding should be interpreted with caution as 
the analyses were restricted to an over-simplistic White European and non-White European 
binary classification due to a large amount of missing ethnicity data. Further investigation 
of this issue is required in order to establish if indeed there are differences in the efficacy 
of the service between ethnic groups, which if present would need to be directly addressed.  
Furthermore, when examining change in BMI as a predictor of change in quality of 
life scores, a clear association between BMI and physical function was observed, with a 
reduction in BMI being associated with significant improvement in the physical function 
quality of life domain. A non-significant negative association was also observed between 
change in BMI and changes in the sexual life and public distress subscales as well as the 
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IWQOL-Lite total score. This suggests that there may be a more widespread association 
between reduction in BMI and improvement across the quality of life domains, however 
this did not achieve significance. This is consistent with the findings reported in a study 
evaluating the quality of life outcomes of extreme obese individuals attending the Glasgow 
service, which demonstrated that weight loss was a significant predictor of IWQOL-Lite 
improvement (74). It is important however, to note that in the evaluation of the Glasgow 
service the individual IWQOL-Lite subscales were not examined and the total quality of 
life scores were used to assess whether individuals’ quality of life had improved, 
deteriorated or remained unchanged with the use of an algorithm, thus utilising a different 
method from the present study. 
The collection of pre- and post-intervention quality of life data facilitates greater 
understanding of the impact of the Specialist Weight Management Service and provides 
another dimension on which efficacy can be assessed. Future service evaluations should 
also incorporate the collection and analysis of a range of demographic information and 
self-report measures, as conducted in the present evaluation. Despite the fact that this 
additional patient information was not able to identify a definitive range of factors 
associated with weight loss success, it does however facilitate greater understanding of the 
patient population, and indeed the detailed characterisation of patients attending the service 
is a major strength of this work. The evaluation is also strengthened by the inclusion of a 
relatively large sample size and due to the fact that it is a pragmatic evaluation providing 
evidence for the effectiveness of a currently operating service, of which the efficacy has 
not previously been formally evaluated. However, it is important to also acknowledge the 
limitations of the present evaluation, chief among which is the absence of a control group, 
which would enable comparison between the CWMS and SLiM services and treatment-
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seeking individuals not receiving intervention as well as non-treatment-seeking extreme 
obese individuals of the same BMI. In order to definitively compare the outcomes of the 
services, a different approach beyond the scope of this evaluation would be utilised, 
whereby an RCT with sufficient power to detect differences between the weight outcomes 
of the services would be conducted. A more robust study design such as an RCT would 
provide greater confidence in the generalisability of the findings and strengthen the 
capacity to draw conclusions about the efficacy of the programmes. Another limiting factor 
of the design of the present evaluation was the absence of an extended follow-up period, 
which would establish the longer-term outcomes and effectiveness of the pathways and 
whether weight loss outcomes are maintained. Additionally, there was a considerable 
proportion of missing weight outcome data in the CWMS sample, which meant that LOCF 
values were imputed which has the potential to attenuate the observed effects, with lower 
weight loss values produced when compared to available case data. This is due to the fact 
that the individuals providing data are those who have attended the programmes more fully 
and have achieved greater weight loss. However, the use of LOCF data in analyses is 
widely adopted in the reporting of weight management interventions (34, 36, 167, 170, 
175, 181), as a process of increasing sample size and power to detect statistical differences. 
The inclusion of detailed description of the outcome data and how it is obtained is vital in 
aiding accurate interpretation and facilitating comparisons of outcomes across studies.  
The present evaluation adds to the very limited body of literature examining the 
efficacy of specialist weight management services. Medically-supported services such as 
the present service are considered an essential intervention in the care of obese individuals, 
with NICE guidelines recommending a minimum of 6 months attendance at a specialist 
service before bariatric surgery is considered as a treatment option (14). The present 
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service delivers expert care from a multidisciplinary healthcare team available to those 
individuals who have been referred from primary care settings. Therefore the patient 
population accessing the more specialist level of care are those individuals with more 
complex healthcare needs who may not have succeeded with previous attempts to achieve 
and maintain the necessary level of weight loss through self-motivated, independent efforts 
or through primary care-led and commercial interventions. The sample attending the 
service have been demonstrated to experience substantial physical co-morbidity, with 
slightly less than a third (30.6%) living with type 2 diabetes, which is a long-term 
condition requiring careful self-management. There is also an extensive psychological co-
morbidity in this sample, with 70.3% and 66.2% experiencing symptoms of anxiety and 
depression, respectively. Given the competing demands and anticipated additional health 
concerns experienced by this at-risk patient population, it is essential to continue to 
improve and develop services that are offered to such patients to make sure that the limited 
resources and capacity for weight loss within these individuals are effectively capitalised 
upon. 
 
5.4.1 Summary of findings 
This chapter has demonstrated the value of this medically-supported service in the care of 
extreme obese individuals, who are an at-risk patient population with substantial physical 
and psychological co-morbidities. Despite the patient populations significantly differing at 
baseline, with the SLiM sample having more complex needs, both treatment pathways 
achieved clinically significant weight loss outcomes, with a substantial proportion 
achieving sufficient weight loss to reduce the risk of cardiovascular disease and overall 
mortality. In addition, the CWMS and SLiM pathways were able to facilitate greater 
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weight losses than other specialist weight management services and several commercial 
and primary care-led programmes. However some primary care and commercial 
programmes demonstrated better weight loss outcomes than those achieved by CWMS and 
SLiM. Post-hoc analyses indicated that the study was not sufficiently powered to detect 
significant differences in ≥5% weight loss achieved by CWMS and SLiM, however the 
study was highly powered (96% power) to detect differences between baseline and 
intervention-end quality of life scores within the SLiM sample. Several of the analyses 
exploring the predictors of weight change, specifically the models examining the predictors 
of ≥5% weight loss in the SLiM sample at 6 months and the CWMS sample at 12 months, 
and weight gain in the CWMS at 12 months, indicated that there were no significant 
predictors of weight change. The findings of these analyses may suggest that the service is 
effective for all individuals regardless of demographic and clinical characteristics, however 
this is in contrast to the remaining samples within which predictors were identified. The 
other models examining predictors of weight change identified that those individuals with 
type 2 diabetes, of younger age, lower baseline weight, and with better self-esteem were 
shown to be less likely to achieve weight loss success, indicating a need for the provision 
of tailored support for these individuals. Additionally, individuals with type 2 diabetes 
were shown to be more likely to experience improvement in quality of life following 
attendance at the SLiM programme, whilst those of non-White European ethnicity were 
shown to be less likely to experience quality of life improvement. Longitudinal analyses 
examined the association between change in BMI and change in pre- and post-intervention 
quality of life scores, which showed a clear association between BMI and physical function 
whereby weight loss was associated with improvement in quality of life.  
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5.4.2 Recommendations 
This evaluation demonstrates the value of medically-supported specialist weight 
management in the care of extremely obese patients, with both the CWMS and SLiM 
treatment pathways shown to facilitate clinically significant weight loss. Evaluations of 
weight management services should incorporate the collection of demographic information 
and the use of self-report measures to better understand the patient population, and identify 
those individuals who are benefitting most from the service, and those who may require 
additional support in order to fully benefit and achieve maximum potential weight change 
during attendance. Further support or tailoring of the programmes may be beneficial to 
those of younger age, those with higher levels of self-esteem, and lower baseline weight, in 
order to achieve their weight loss goals during attendance at the service. Further research is 
required in order to expand the currently limited evidence base for specialist weight 
management services. Future studies should utilise more methodologically rigorous 
designs such as RCTs in order to conclusively determine the efficacy of specialist weight 
management services. Such improvements to increase the efficacy and enhance 
understanding of the specialist weight management services and their patient populations 
will ensure that these individuals are given the greatest opportunity to achieve weight loss 
and diminish the negative health impacts of extreme obesity.  
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CHAPTER SIX 
 
6.0 MEDICAL AND BEHAVIOURAL WEIGHT MANAGEMENT 
INTERVENTIONS FOR EXTREME OBESITY:                                                                
A SYSTEMATIC REVIEW OF SYSTEMATIC REVIEWS 
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6.1 INTRODUCTION 
 
6.1.1 Rationale  
Several reviews have examined the impact of non-surgical medical and behavioural weight 
management interventions within obese populations, including a narrative review 
focussing specifically on weight management services in the UK (189), a review and meta-
analysis of interventions delivered solely to male samples (190) and a comprehensive  
Health Technology Assessment including a systematic review of 84 Randomised 
Controlled Trials (RCTs) of obesity treatments (191). The numerous reviews of weight 
management interventions reflect the extensive body of primary studies investigating the 
impact of weight management interventions in overweight (BMI ≥25.0kg/m2), and obese 
(BMI ≥30.0kg/m2) samples. However, the body of literature examining the efficacy of 
weight management interventions within extreme obese (BMI ≥40.0kg/m2) samples is 
relatively limited. As such it is anticipated that the synthesis of data from primary studies 
investigating the impact of interventions in extreme obese samples within reviews, will 
consequently also be limited. Given the increasing prevalence of extreme obesity and the 
associated detrimental impacts on the health and quality of life of individuals (82), it is 
important to examine the effectiveness of treatment pathways such as medical and 
behavioural interventions which have been widely adopted in the care of individuals with 
extreme obesity (14).  
This systematic review will search for systematic reviews examining the 
effectiveness of medical or behavioural weight management interventions within 
exclusively extreme obese (BMI ≥40kg/m2) samples. This systematic review will 
summarise data from included systematic reviews, and will additionally assess the quality 
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of the reviews and relevance by considering date of publication and the potential need for 
updating due to the accumulation of new primary research since publication.  
 
6.1.2 Objectives 
The specific objectives of the systematic review are: 
 To produce a systematic review of systematic reviews and health technology 
assessments which have examined the effectiveness of medical or behavioural 
weight management interventions for adults with extreme obesity (defined as 
baseline BMI ≥40.0kg/m2) on change in weight or BMI, change in presence or 
severity of co-morbid health conditions, change in cardiovascular profile, change in 
quality of life or change in mental health. 
 To produce a summary of the evidence of the effectiveness of medical and 
behavioural weight management interventions for extreme obesity.  
 To analyse the quality of the included reviews and provide a summary of the best 
evidence available. 
 
The systematic review question was formulated using the PICOS framework as illustrated 
in Table 6.1.1. The explicit question which will be answered by the systematic review is: 
‘What is the summarised evidence for the effectiveness of medical and behavioural weight 
management interventions for extreme obesity?’ 
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Table 6.1.1: Development of systematic review question using PICOS framework 
Population Adults with extreme obesity, defined as mean baseline BMI of 
all included primary studies 40.0kg/m2. 
Intervention Medical or behavioural weight management (any non-surgical 
intervention which encompasses behavioural modification, 
medical or pharmaceutical components) of any duration. 
Comparators The reviews may incorporate a range of comparator groups 
including but not limited to control not receiving intervention, 
control receiving usual care, or alternative non-surgical 
intervention. 
Outcomes The reviews may include any of the following outcomes: weight 
and BMI change, change in presence and severity of co-morbid 
health conditions, change in cardiovascular profile, change in 
quality of life and mental health. 
Study design Systematic reviews and health technology assessments. 
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6.2 METHODS 
 
6.2.1 Protocol and registration 
This systematic review was conducted according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (192). A systematic review 
protocol was produced for use as a reference to aid the two reviewers and ensure 
consistency in the conduct of the review (Appendix one). The systematic review was 
registered on the PROSPERO international database of prospectively registered systematic 
reviews in health and social care, with registration number CRD42014012988. 
 
6.2.2 Eligibility criteria 
The eligibility for inclusion in the systematic review was determined by the criteria 
outlined in Table 6.2.1. The criteria for inclusion in the systematic review incorporated 
reviews solely in adult extreme obese populations, excluding those reviews examining the 
efficacy of interventions in child and adolescent populations, which use a different 
approach and address different priorities to interventions for adult populations (193). The 
review also focused on the general extreme obese population, thus excluding those 
populations recruited solely on the basis of other health conditions. For instance this 
incorporated the exclusion of reviews examining the effectiveness of interventions among 
samples of individuals specifically who have survived cancer, who have gained weight 
following commencement of anti-psychotic medication, or those currently receiving 
treatment for heart disease. The inclusion of reviews of weight management interventions 
targeted at such specific patient populations would be beyond the scope of the present 
review, and would not facilitate understanding of intervention effectiveness within the 
general extreme obese population.  
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Table 6.2.1: Eligibility criteria 
Domain Criteria 
Population  Reviews reporting intervention effectiveness exclusively in BMI 
≥40.0kg/m2 populations were included. 
  Reviews reporting intervention effectiveness in broader 
overweight and obese BMI ≥30.0kg/m2 populations were 
excluded. 
  Reviews where included study populations are adult (≥18 years) 
were included. 
  Reviews including study populations based on health conditions 
other than obesity were excluded, for instance samples including 
solely individuals with heart disease, type 2 diabetes, cancer, or 
schizophrenia. 
Interventions  Reviews of non-surgical interventions providing medical and or 
behavioural support incorporating pharmaceutical therapies, 
counselling, education, and lifestyle modification incorporating 
diet and exercise were included. 
 Reviews including evaluations of bariatric procedures or surgery 
were excluded.  
  Reviews of interventions of any duration were included. 
Outcomes  Reviews which report synthesis of one or more of any of the 
following outcomes: weight or BMI change, change in presence 
or severity of co-morbid health conditions, change in 
cardiovascular profile, change in quality of life or mental health, 
from baseline to intervention-end or post-intervention follow-up 
were included. 
Study design  Systematic reviews and health technology assessments were 
included. 
 
6.2.3 Information sources 
A search of the following three databases within the Cochrane Library was conducted: the 
Cochrane Database of Systematic Reviews (CDSR), the Database of Abstracts and 
Reviews of Effects (DARE), and the Health Technology Assessment Database (HTAD), 
from inception to July 2014. One search was conducted using the Cochrane Library search 
manager, which retrieved records from the three databases simultaneously. 
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6.2.4 Search 
The following search strategy was used to search for review articles summarising data on 
the effectiveness of medical or behavioural weight management interventions of any 
duration for samples with extreme obesity, defined as sample mean BMI 40.0 kg/m2. 
Terms were entered as free text and MeSH (Medical Subject Heading) terms in the 
Cochrane Library search engine, which screened records obtained from the CDSR, DARE 
and HTAD. The search strategy detailing the combinations of search terms utilised is 
outlined in Table 6.2.2. Truncation of the free text terms ‘adult’ and ‘obes’ was used in 
order to include a variety of word endings such as ‘adulthood’ and ‘obesity’, thus 
maximising the number of relevant records returned. Those terms which were available as 
MeSH terms within the Cochrane Library search manager were selected using the ‘explode 
all trees’ function in order to retrieve all related terms in the search.  
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Table 6.2.2: Search strategy 
1 Adult* 
2 Overweight (MeSH) explode all trees 
3 Obesity (MeSH) explode all trees 
4 Obes* 
5 Body Mass Index (MeSH) explode all trees 
6 BMI 
7 Body Weight (MeSH) explode all trees 
8 2 or 3 or 4 or 5 or 6 or 7 
9 1 and 8 
10 Intervention 
11 Life style (MeSH) explode all trees 
12 Health Promotion (MeSH) explode all trees 
13 Health Education (MeSH) explode all trees 
14 Patient Education as Topic (MeSH) explode all trees 
15 Counseling (MeSH) explode all trees 
16 Behavior (MeSH) explode all trees 
17 Anti-Obesity Agents (MeSH) explode all trees 
18 Weight Loss (MeSH) explode all trees 
19 Diet, Reducing (MeSH) explode all trees 
20 Weight Reduction Programs (MeSH) explode all trees 
21 Exercise (MeSH) explode all trees 
22 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
23 10 and 22 
24 9 and 23 
25 24 in Cochrane Reviews (Reviews and protocols), Other Reviews and Technology 
Assessments 
 
6.2.5 Article selection 
The records retrieved following the search were exported to the EndNote programme 
(Thomson Reuters EndNote version X7.1) and a copy of the file was made for both of the 
reviewers to facilitate management of the records. Two reviewers independently screened 
the titles and abstracts using the eligibility criteria relating to population, intervention, 
outcome and study design. Those records deemed to not meet eligibility criteria were 
removed, and the number excluded at this stage was independently recorded by each 
reviewer. Once the first phase of study selection, screening by title and abstract, had been 
completed, the two reviewers met to compare selections. Discrepancies were discussed and 
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consensus was reached and the final number of reviews to be screened as full text was 
determined. A third party was to be invited to adjudicate in instances where consensus to a 
disagreement was not reached, however this was not required.  
After obtaining full text copies, the second phase of review selection, screening full 
text, was conducted by the two reviewers independently, with those not meeting the 
eligibility criteria excluded at this stage. The excluded records were then grouped by 
reason for exclusion, so that the numbers of records excluded for each reason were 
identified. The final number of reviews that were deemed to be eligible for inclusion in the 
systematic review were determined by each reviewer independently and once the second 
selection phase was complete the two reviewers again met to compare selections. The final 
number of included reviews was determined and no discrepancies in study selection were 
identified. However had it been necessary discrepancies would have been discussed and a 
third party would have been invited to adjudicate where consensus was not reached. 
Additionally, the reference lists of the included reviews would have been searched in order 
to identify any further relevant reviews, which would have been screened and subject to 
meeting eligibility criteria would subsequently have been added to the total number of 
reviews to be included in the systematic review.  
 
6.2.6 Data collection process 
The two reviewers would have independently extracted data items from the information 
provided in the full text articles, into a Microsoft Excel spreadsheet whereby each study 
would have been represented in a row of data in the spreadsheet. A detailed list of data 
items for extraction was developed with reference to the Cochrane Handbook for 
Systematic Reviews of Interventions (Version 5.1.0) (194), in order to facilitate the data 
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extraction process. A detailed list of the items specified for data extraction are outlined in 
Table 6.2.3, which was to be used as a point of reference when entering the data items into 
the spreadsheet. The two reviewers would have met once data extraction had taken place 
independently, in order to investigate any discrepancies, with a third party invited to 
adjudicate if required. 
 
6.2.7 Data items 
The data items specified for extraction from the included reviews are outlined in Table 
6.2.3. Following data extraction, specific items would have been selected from the 
finalised extraction spreadsheet to be used in the production of review characteristics tables 
which would have aided in the description and qualitative analysis of the included reviews. 
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Table 6.2.3: Data items to be extracted from included systematic reviews 
Field Data points to be extracted 
Review Author, 
Publication year. 
Methods 
Design (state whether systematic review, Health Technology Assessment) 
Objectives of review. 
Study 
characteristics 
Total number of included studies within review,  
Participant characteristics including range of age, gender, ethnicity, co-morbid health 
conditions, across studies, 
Range of mean baseline weight of the primary studies, 
Range of mean baseline BMI of the primary studies. 
Intervention 
 
Range of intervention types: i.e. pharmaceutical/behavioural/combination,  
Range of number of intervention groups,  
Range of intervention settings (where intervention is delivered),  
Range of delivery personnel type (if healthcare professional specify which, researcher, 
lay public),  
Range of delivery personnel training (detail of training in intervention delivery 
received),  
Range of duration of interventions (number and duration of contact time, including 
face to face sessions, email, telephone or other contact), 
Intensity of interventions (frequency of sessions and contact), 
Theoretical basis of interventions (e.g. self-management, cognitive behavioural) 
Range of numbers of participants entering intervention group,  
Range of numbers of participants completing intervention/presenting for data 
collection,  
Range of reported loss to follow-up rate in intervention groups across primary studies. 
Comparator 
 
Range of numbers of comparator groups across primary studies,  
Descriptions of comparator or usual care,  
Range of numbers of participants entering comparator group,  
Range of numbers of participants completing comparator group/presenting for data 
collection,  
Range of reported loss to follow-up rate in comparator groups across primary studies.  
Outcomes 
Mean effect size, weighted effect size,  
Mean difference, standardised mean difference, weighted mean difference and p values 
between intervention and control groups for the following outcomes of interest: 
 Change in weight or BMI,  
 Change in presence or severity of co-morbid health conditions,  
 Change in cardiovascular profile,  
 Change in quality of life or mental health. 
For reviews not reporting quantitative data synthesis: 
Range of effects across primary studies and main conclusions of review. 
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6.2.8 Risk of bias in individual reviews 
The included reviews would have been appraised for methodological quality using the 
Assessment of multiple systematic reviews (AMSTAR) measurement tool (195) as 
outlined in Table 6.2.4. The tool would have been used to assess the methodological 
quality according to the following criteria; reporting of an a priori design, duplication of 
study selection and data extraction, whether a comprehensive literature search is performed 
and whether publication status determines eligibility for inclusion, reporting of included 
and excluded studies and characteristics of the included studies, the assessment, reporting 
and use of scientiﬁc quality of the included studies, use of appropriate methods to combine 
study ﬁndings, and the reporting of potential publication bias and conflicts of interest. Each 
of the criteria specified in the AMSTAR tool would have been assessed and a judgement 
would have been made of ‘yes’, ‘no’, ‘can’t answer’ or ‘not applicable’. The quality 
assessment procedure would have been undertaken by both reviewers independently, with 
each included systematic review appraised. The appraisals of both reviewers would then 
have been compared and discrepancies discussed. 
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Table 6.2.4: Criteria for judging the quality systematic reviews using the AMSTAR 
tool 
1 Was an 'a priori' 
design provided?  
 
The research question and inclusion criteria should be established before the conduct of 
the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori 
published research objectives to score a “yes.”   
2 Was there duplicate 
study selection and 
data extraction?  
There should be at least two independent data extractors and a consensus procedure for 
disagreements should be in place. Note: 2 people do study selection, 2 people do data 
extraction, consensus process or one person checks the other’s work. 
3 Was a 
comprehensive 
literature search 
performed?  
 
At least two electronic sources should be searched. The report must include years and 
databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH 
terms must be stated and where feasible the search strategy should be provided. All 
searches should be supplemented by consulting current contents, reviews, textbooks, 
specialized registers, or experts in the particular field of study, and by reviewing the 
references in the studies found. Note: If at least 2 sources + one supplementary strategy 
used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search 
counts as supplementary).  
4 Was the status of 
publication (i.e. grey 
literature) used as an 
inclusion criterion?  
 
The authors should state that they searched for reports regardless of their publication 
type. The authors should state whether or not they excluded any reports (from the 
systematic review), based on their publication status, language etc. Note: If review 
indicates that there was a search for “grey literature” or “unpublished literature,” indicate 
“yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all 
considered grey for this purpose. If searching a source that contains both grey and non-
grey, must specify that they were searching for grey/unpublished lit.  
5 Was a list of studies 
(included and 
excluded) provided?  
A list of included and excluded studies should be provided. Note: Acceptable if the 
excluded studies are referenced. If there is an electronic link to the list but the link is 
dead, select “no.”  
6 Were the 
characteristics of the 
included studies 
provided?  
 
In an aggregated form such as a table, data from the original studies should be provided 
on the participants, interventions and outcomes. The ranges of characteristics in all the 
studies analysed e.g., age, race, sex, relevant socioeconomic data, disease status, 
duration, severity, or other diseases should be reported. Note: Acceptable if not in table 
format as long as they are described as above.  
7 Was the scientific 
quality of the included 
studies assessed and 
documented?  
 
'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the 
author(s) chose to include only randomized, double-blind, placebo controlled studies, or 
allocation concealment as inclusion criteria); for other types of studies alternative items 
will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad 
scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some 
kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies 
scored “low” and which scored “high”; a summary score/range for all studies is not 
acceptable).  
8 Was the scientific 
quality of the included 
studies used 
appropriately in 
formulating 
conclusions?  
The results of the methodological rigor and scientific quality should be considered in the 
analysis and the conclusions of the review, and explicitly stated in formulating 
recommendations. Note: Might say something such as “the results should be interpreted 
with caution due to poor quality of included studies.” Cannot score “yes” for this 
question if scored “no” for question 7.  
9 Were the methods 
used to combine the 
findings of studies 
appropriate?  
 
For the pooled results, a test should be done to ensure the studies were combinable, to 
assess their homogeneity (i.e., Chi-squared test for homogeneity, I
2
). If heterogeneity 
exists a random effects model should be used and/or the clinical appropriateness of 
combining should be taken into consideration (i.e., is it sensible to combine?). Note: 
Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they 
cannot pool because of heterogeneity/variability between interventions.  
10 Was the likelihood 
of publication bias 
assessed?  
 
An assessment of publication bias should include a combination of graphical aids (e.g. 
funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, 
Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if 
mentions that publication bias could not be assessed because there were fewer than 10 
included studies.   
11 Was the conflict of 
interest included?  
Potential sources of support should be clearly acknowledged in both the systematic 
review and the included studies. Note: To get a “yes,” must indicate source of funding or 
support for the systematic review AND for each of the included studies.  
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6.2.9 Synthesis of results 
Qualitative analysis would have been undertaken in order to provide a narrative summary 
of the findings of the individual included systematic reviews for each of the outcomes of 
interest, with data presented in review characteristics tables. Qualitative analysis would 
also have provided a summary of the methodological quality of the included reviews and 
any potential impact on the findings of each of the constituent reviews, and potential 
impact on the overall conclusions of the systematic review. Additionally, the findings of 
the qualitative analysis would have informed recommendations for the conduct and 
reporting of future reviews. 
The quantitative findings of the reviews would have been illustrated using forest 
plots without summary statistics for each of the following outcomes of interest: weight 
change, BMI change, change in co-morbidity presence, change in co-morbidity severity, 
quality of life change, mental health change and cardiovascular change following weight 
management intervention. The forest plots would have been used to illustrate mean 
difference in continuous measures such as weight or BMI change, and odds ratios for 
dichotomous variables such as presence of symptoms of anxiety disorder.  
 
6.2.10 Risk of bias across reviews 
Following the assessment of methodological quality of each of the included reviews using 
the AMSTAR tool, evaluation summaries would have been made across reviews and 
domains. The quality assessment information would have been used to inform the 
interpretation of the findings of each of the included reviews, with consideration of 
potential methodological factors which could introduce bias to review findings. If 
appropriate, recommendations to improve the methodological and reporting quality of 
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future reviews would have been made, highlighting areas of limitation where improvement 
may have been required.  
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6.3 RESULTS 
 
6.3.1 Article selection 
The search retrieved a total of 365 records. No duplicates were identified and 358 records 
were excluded after screening by title and abstract. Seven full text records were screened 
and all seven records were excluded as they did not meet the eligibility criteria of reporting 
intervention effectiveness in BMI ≥40.0kg/m2 individuals. Therefore no articles were 
identified as eligible for inclusion in the systematic review. The flow diagram (Figure 6.1) 
illustrates the number of records retrieved and the subsequent process of selection, as 
outlined in the PRISMA statement (192). The seven full text records which were screened 
are detailed in Table 6.3.1. Due to the fact that no systematic reviews eligible for inclusion 
were identified, there are no further results to report regarding review characteristics, risk 
of bias and analyses.  
 
Table 6.3.1: Details of the seven reviews excluded after full text screening 
Review first author 
and date of 
publication 
Title of review 
Anderson, 2004  
(196) 
Structured weight-loss programs: Meta-analysis of weight loss at 
24 weeks and assessment of effects of intervention intensity 
Hebden, 2012  
(197) 
Lifestyle intervention for preventing weight gain in young adults: 
a systematic review and meta-analysis of RCTs 
Hutchesson, 2013 
(198) 
Weight management interventions targeting young women: a 
systematic review 
Lepe, 2011  
(199) 
Long-term efficacy of high-protein diets: a systematic review 
Perez, 2013 
(200) 
Evidence-based obesity treatment interventions for Latino adults 
in the U.S. A systematic review 
Seo, 2008 
 (201) 
A meta-analysis of psycho-behavioral obesity interventions 
among US multi-ethnic and minority adults 
Witham, 2010  
(202) 
Interventions to achieve long-term weight loss in obese older 
people. A systematic review and meta-analysis 
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Figure 6.1: Flow diagram outlining the identification of included reviews 
 
 
  
Number of records screened
365
Number of records excluded
358
Number of full text articles 
assessed for eligibility
7
Number of reviews included 
in qualitative synthesis
0
Number of reviews included 
in quantitative synthesis
0
Number of full text articles 
excluded
7
Reason: Did not include 
population of BMI 
≥40.0kg/m2: N= 7
Number identified 
through included 
reviews
0
Number of records after duplicates removed
365
Number identified 
through database 
searching
365
  
240 
 
6.4 DISCUSSION 
 
6.4.1 Summary of evidence 
The present systematic review has identified that there were no systematic reviews 
examining the efficacy of medical and behavioural weight management interventions for 
extreme obese BMI ≥40.0kg/m2 populations eligible for inclusion. The review has 
highlighted that there is a gap in the literature and indicates that there is a need for a 
systematic review of primary research examining the efficacy of medical and behavioural 
weight management interventions within extreme obese samples. 
 The phenomenon of empty systematic reviews, that is reviews which contain no 
records eligible for inclusion, has been examined in a study assessing the number of empty 
systematic reviews published in the Cochrane Database of Systematic Reviews (CDSR) 
(203). At the time of publication (August, 2010) the investigators reported a total of 376 
empty reviews, which equated to 8.7% of reviews within the CDSR which reported that 
there were no records eligible for inclusion. The authors highlighted the fact that observed 
absences of evidence may help to stimulate the initiation of primary research, providing 
potential directions for targeted research, thus resulting in empty reviews being updated 
with eligible newly published studies.  
 It is likely that the present systematic review yielded no reviews eligible for 
inclusion due to the fact that the management of extreme obesity is a relatively new field, 
which has emerged recently with the increasing prevalence of the condition  (15, 17). Thus 
it is possible that there is not yet a significant body of evidence to be synthesised in a 
systematic review of the literature.  
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6.4.2 Limitations 
The systematic review was limited by the fact that the information sources which were 
searched were restricted to three databases within the Cochrane Library. There is potential 
for the possibility that the systematic review did not capture systematic reviews of medical 
and behavioural weight management interventions that were published in alternative 
databases. However within the scope of this body of work, the adopted approach was 
deemed sufficient to provide a reliable representation of the evidence for the efficacy of 
weight management interventions for extreme obesity within the body of literature. The 
present systematic review was strengthened by the duplication of the study selection 
process, which was conducted independently by two reviewers and was also strengthened 
by the use of a standardised protocol.  
 
6.4.3 Conclusions  
The results of the systematic review indicate that there is a gap in the literature, as no 
eligible systematic reviews summarising data from primary studies of the effectiveness of 
medical and behavioural weight management interventions for extreme obese populations 
have been published in the CDSR, DARE and HTA databases of the Cochrane Library. 
Given the observed increase in prevalence of extreme obesity in the UK over recent years 
(15, 17), and the fact that current levels are expected to rise (25), it is imperative that the 
efficacy of weight management interventions for the extreme obese population are 
established, thus enabling the best opportunity for affected individuals to achieve weight 
loss. The efficacy of medical or behavioural weight management interventions for extreme 
obesity remains unestablished, thus a systematic review of primary studies examining 
intervention efficacy within extreme obese populations is warranted.  
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CHAPTER SEVEN 
 
7.0 MEDICAL AND BEHAVIOURAL WEIGHT MANAGEMENT 
INTERVENTIONS FOR EXTREME OBESITY:                                                            
A SYSTEMATIC REVIEW OF PRIMARY STUDIES 
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7.1 INTRODUCTION 
 
7.1.1 Rationale 
The increasing prevalence of obesity and the associated detrimental impacts on 
individuals’ health and quality of life, have led to the development of a variety of weight 
management programmes delivered across primary (29, 31, 32, 173)  and specialist 
healthcare settings (174, 175), as well as commercial (36, 181) and research settings (73).  
Chapter four has highlighted the efficacy of such weight management interventions 
primarily among obese ≥30.0kg/m2 populations, with the majority of the weight 
management programmes demonstrating modest weight losses. As such, these weight 
management interventions may not be sufficient to produce the clinically significant 
improvements to health that are required among extreme obese individuals. Furthermore 
whilst specialist weight management services have been demonstrated to produce modest 
weight losses among extreme obese (BMI ≥40.0kg/m2) samples (174, 175), these studies 
have used non-controlled observational designs. Thus there is a lack of good quality 
evidence assessing the effectiveness of weight management interventions in facilitating 
weight loss for individuals with extreme obesity. 
The findings of the systematic review described in Chapter six indicate a gap in the 
body of research literature, with no eligible systematic reviews summarising data from 
primary studies of the effectiveness of medical and behavioural weight management 
interventions for extreme obese populations identified. The limited evidence base has 
meant that the variation in weight management service provision for extreme obese 
individuals in the UK and internationally is continuing. However, the increasing 
prevalence of obesity and subsequent demand for services means that establishing the 
  
244 
 
effectiveness of weight management services is essential in order to ensure that individuals 
are given the best opportunity at achieving weight loss.  
To address the identified gap in the literature and provide an additional contribution 
to the evidence base, this systematic review will search for primary studies examining the 
effectiveness of medical and behavioural weight management interventions within extreme 
obese (BMI ≥40kg/m2) samples. The systematic review will summarise data from included 
studies, additionally assessing the quality of studies, and generating recommendations for 
future research. 
 
7.1.2 Objectives 
The specific objectives of the systematic review are: 
 To summarise the effectiveness of medical or behavioural weight management 
interventions for adults with extreme obesity (defined as baseline BMI ≥40.0kg/m2) 
on weight change, including if appropriate a meta-analysis of the effect of 
interventions on weight and BMI change. 
 The secondary objectives are to examine the impact of these interventions on 
psychological profile (incorporating quality of life and mental health) and 
cardiovascular profile (incorporating blood pressure and lipids), with a meta-
analysis if appropriate, of the effect of interventions on psychological and 
cardiovascular factors. 
 To analyse study quality and provide a summary of the best evidence available. 
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The systematic review question was formulated using the PICOS framework as illustrated 
in Table 7.1.1. The explicit question which will be answered by the systematic review is: 
‘What is the effectiveness of medical and behavioural weight management interventions 
for extreme obesity?’ 
 
Table 7.1.1: Development of systematic review question using PICOS framework 
Population Adults with extreme obesity, defined as mean baseline BMI of 
40.0kg/m2. 
Intervention Medical or behavioural weight management (any non-surgical 
intervention which encompasses behavioural modification, 
medical or pharmaceutical components) of any duration. 
Comparators Control arm comprising usual care. 
Outcomes Primary outcome: Weight and BMI change at post-intervention 
follow-up or at intervention-end where follow-up is not 
available. 
Secondary outcome: Quality of life, mental health, and 
cardiovascular (blood pressure, lipids) change at post-
intervention follow-up or at intervention-end where follow-up is 
not available. 
Study design Randomised Controlled Trials (RCTs), controlled non-
randomised studies, controlled observational studies (prospective 
and retrospective cohort studies with concurrent controls). 
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7.2 METHODS 
 
7.2.1 Protocol and registration 
This systematic review was conducted according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (192). A systematic review 
protocol was produced for use as a reference to aid the two reviewers and ensure 
consistency in the conduct of the review (Appendix two). The systematic review was 
registered on the PROSPERO international database of prospectively registered systematic 
reviews in health and social care, with registration number CRD42014010473. 
 
7.2.2 Eligibility criteria 
The eligibility for inclusion in the systematic review was determined by the criteria 
outlined in Table 7.2.1. The criteria for inclusion in the systematic review incorporated 
primary studies in adult extreme obese populations, excluding those studies examining the 
efficacy of interventions in child and adolescent populations, and those which focused on 
populations recruited solely on the basis of health conditions other than obesity. As such 
the review focussed on the general extreme obese population, excluding those studies 
examining the effectiveness of interventions specifically among samples of individuals 
receiving treatment for other diagnosed health conditions.  
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Table 7.2.1: Eligibility criteria 
Domain Criteria 
Population  Studies reporting intervention effectiveness in BMI ≥40.0kg/m2 
populations were included, incorporating separate BMI 
≥40.0kg/m2 subgroup samples and overall study samples. 
  Studies where included study populations were adult (≥18 years) 
were included. 
  Studies including study populations based on health conditions 
other than obesity were excluded, for instance samples including 
solely individuals with heart disease, type 2 diabetes, cancer, or 
schizophrenia. 
Interventions  Studies of non-surgical interventions providing medical and or 
behavioural support incorporating pharmaceutical therapies, 
counselling, education, and lifestyle modification incorporating 
diet and physical activity were included. 
 Studies including bariatric procedures or surgery were excluded.  
  Studies which incorporated interventions of any duration were 
included. 
Outcomes  Studies reporting weight and or BMI measures at baseline and at 
intervention-end, or weight and or BMI change scores were 
included. 
 Studies reporting baseline characteristics data without post-
intervention follow-up or intervention-end weight or BMI 
outcome data were excluded. 
Study design  RCTs, controlled non-randomised studies, and controlled 
observational studies (prospective and retrospective cohort 
studies with concurrent controls) were included.  
 Study designs further down the hierarchy of evidence, such as 
observational studies without concurrent control groups were 
excluded.  
 Studies published up to and including July 2014 were included. 
 Peer reviewed studies and conference abstracts published in any 
language were included. 
 Review articles, editorials, commentaries and letters were 
excluded. 
 
7.2.3 Information sources 
A search of the following electronic databases was conducted: MEDLINE (Ovid), 
EMBASE (Ovid), CINAHL (Ebsco host), and Cochrane Central Register of Controlled 
Trials (CENTRAL) database, from inception to July 2014. In addition, grey literature 
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including conference abstracts and doctoral theses were searched using the OpenGrey and 
Zetoc databases, and reference lists of papers included in the review were hand-searched. 
 
7.2.4 Search 
The following search strategy was used to search for primary studies examining the 
efficacy of medical or behavioural weight management interventions of any duration for 
samples with extreme obesity, defined as sample mean BMI 40.0kg/m2. Terms were 
entered as free text and MeSH (Medical Subject Heading) terms in the MEDLINE, 
EMBASE, CINAHL, and CENTRAL databases. The search strategy detailing the 
combinations of search terms utilised in each database search are outlined in Tables 7.2.2 - 
7.2.5. Truncation of the free text terms ‘adult’ and ‘obes’ was used in order to include a 
variety of word endings such as ‘adulthood’ and ‘obesity’, thus maximising the number of 
relevant records returned. Those terms which were available as MeSH terms within each 
database were selected using the ‘explode all trees’ function in order to retrieve all related 
terms in the search. When searching the EMBASE and MEDLINE databases MeSH and 
free text terms were entered into multi-purpose (.mp) searches. The CINAHL database was 
searched by entering MeSH terms as exact major subject headings (MM), and free text 
terms as words in major subject headings (MJ). Limits were applied to the searches in the 
MEDLINE, EMBASE and CINAHL databases using the clinical query function. 
Specifically, the ‘therapy (maximises sensitivity)’ and ‘therapy- high sensitivity’ limits 
were selected in order to encompass a broad search and ensure that no relevant studies 
were omitted. Additionally, a ‘human’ limiter was applied in order to omit studies adopting 
animal model designs.  
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 The following free text terms were entered into the OpenGrey database: (morbid 
OR extrem* OR sever*) AND obes* AND intervention. The Zetoc database was searched 
using the following three separate free text searches: ‘morbid AND obes* AND 
intervention’, ‘extrem* AND obes* AND intervention’ and ‘sever* AND obes* AND 
intervention’. Truncation was used in order to capture a variety of word endings such as 
‘severely’ and ‘obesity’, thus maximising the number of relevant records returned. 
 
Table 7.2.2: Search strategy for MEDLINE database 
1 Adult*.mp 
2 Overweight/ dh, dt, rh, th, nu (MeSH) 
3 Obesity/ dh, dt, rh, th, nu (MeSH) 
4 Obes*.mp 
5 Body Mass Index/ (MeSH) explode all trees 
6 BMI.mp 
7 Body Weight.mp 
8 2 or 3 or 4 or 5 or 6 or 7 
9 1 and 8 
10 Intervention.mp 
11 Life style/ (MeSH) explode all trees 
12 Health Promotion/ (MeSH) explode all trees 
13 Health Education/ (MeSH) explode all trees 
14 Patient Education as topic/ (MeSH) explode all trees 
15 Counseling/ (MeSH) explode all trees 
16 Behavior/ (MeSH) explode all trees 
17 Anti-obesity Agents/ (MeSH) explode all trees 
18 Weight Reduction Programs/ (MeSH) explode all trees 
19 Diet, Reducing/ (MeSH) explode all trees 
20 Weight Loss/ (MeSH) explode all trees 
21 Exercise (MeSH) explode all trees 
22 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
23 10 and 22 
24 9 and 23 
25 Limit 24 to humans 
26 Limit 25 to “therapy (maximizes sensitivity)” 
27 Control*.mp 
28 25 and 27 
29 26 or 28 
.mp= title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword. 
dh= diet therapy, dt= drug therapy, rh= rehabilitation, th= therapy, nu= nursing.  
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Table 7.2.3: Search strategy for EMBASE database 
1 Adult*.mp 
2 Overweight*.mp 
3 Obesity/ dm, dt, rh, th (MeSH) 
4 Obes*.mp 
5 Body Mass/ (MeSH) explode all trees 
6 BMI.mp 
7 Body Weight/ co, dt, th (MeSH) 
8 2 or 3 or 4 or 5 or 6 or 7 
9 1 and 8 
10 Intervention.mp 
11 Life style/ (MeSH) explode all trees 
12 Health Promotion/ (MeSH) explode all trees 
13 Health Education/ (MeSH) explode all trees 
14 Patient Education as topic/ (MeSH) explode all trees 
15 Counseling/ (MeSH) explode all trees 
16 Behavior/ dt, rh, th (MeSH) 
17 Antiobesity Agent/ ct, dt (MeSH) 
18 Diet Restriction/ (MeSH) explode all trees 
19 Weight Reduction/ dt, th (MeSH) 
20 Exercise/ (MeSH) explode all trees 
21 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
22 10 and 21 
23 9 and 22 
24 Limit 23 to humans 
25 Limit 24 to “therapy (maximizes sensitivity)” 
26 Control*.mp 
27 24 and 26 
28 25 or 27 
mp= title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword. 
dm= disease management, dt= drug therapy, rh= rehabilitation, th= therapy, co= complication, ct= clinical 
trial. 
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Table 7.2.4: Search strategy for CINAHL database 
1 MJ Adult* 
2 MJ Overweight 
3 MM Obesity/ dh, dt, rh, th, nu (MeSH) 
4 MJ Obes* 
5 MM Body Mass Index/ (MeSH) explode all trees 
6 MJ BMI 
7 MM Body Weight (MeSH) explode all trees 
8 2 or 3 or 4 or 5 or 6 or 7 
9 1 and 8 
10 MJ Intervention 
11 MM Life style/ (MeSH) explode all trees 
12 MM Health Promotion/ (MeSH) explode all trees 
13 MM Health Education/ (MeSH) explode all trees 
14 MM Patient Education/ (MeSH) explode all trees 
15 MM Counseling/ (MeSH) explode all trees 
16 MM Behavior/ (MeSH) explode all trees 
17 MM Antiobesity Agents/ (MeSH) explode all trees 
18 MM Weight Reduction Programs/ (MeSH) explode all trees 
19 MM Diet, Reducing/ (MeSH) explode all trees 
20 MM Weight Loss/ dh, dt, th (MeSH) 
21 MM Exercise (MeSH) explode all trees 
22 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
23 10 and 22 
24 9 and 23 
25 Limiters to 24- Human 
26 Limiters to 24- Clinical Queries: Therapy- High Sensitivity; Human 
27 MJ Control* 
28 25 and 27 
29 26 or 28 
MM= Exact Major Subject Headings, MJ= Word in Major Subject Headings. 
dh= diet therapy, dt= drug therapy, rh= rehabilitation, th= therapy, nu= nursing.  
 
 
  
  
252 
 
Table 7.2.5: Search strategy for CENTRAL database 
1 Adult* 
2 Overweight (MeSH) explode all trees 
3 Obesity (MeSH) explode all trees 
4 Obes* 
5 Body Mass Index (MeSH) explode all trees 
6 BMI 
7 Body Weight (MeSH) explode all trees 
8 2 or 3 or 4 or 5 or 6 or 7 
9 1 and 8 
10 Intervention 
11 Life style (MeSH) explode all trees 
12 Health Promotion (MeSH) explode all trees 
13 Health Education (MeSH) explode all trees 
14 Patient Education as Topic (MeSH) explode all trees 
15 Counseling (MeSH) explode all trees 
16 Behavior (MeSH) explode all trees 
17 Anti-Obesity Agents (MeSH) explode all trees 
18 Weight Loss (MeSH) explode all trees 
19 Diet, Reducing (MeSH) explode all trees 
20 Weight Reduction Programs (MeSH) explode all trees 
21 Exercise (MeSH) explode all trees 
22 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
23 10 and 22 
24 9 and 23 
25 24 in Trials 
 
7.2.5 Study selection 
The records were exported to the EndNote programme (Thomson Reuters EndNote version 
X7.1) to facilitate management of the records by both reviewers. Two reviewers 
independently screened the titles and abstracts using the eligibility criteria relating to 
population, intervention, comparator, outcome and study design. Those records deemed to 
not meet eligibility criteria were removed, and the number excluded at this stage was 
independently recorded by each reviewer. Once the first phase of study selection, screening 
by title and abstract was complete, the selection of the two reviewers was compared. 
Discrepancies were discussed, consensus was reached and the final number of studies to be 
screened as full text was determined.  
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The second phase of study selection involved obtaining full text copies of each 
study and screening the full text, which was conducted by the two reviewers 
independently. Those studies which were judged to not meet the eligibility criteria were 
excluded at this stage, with the excluded records grouped by reason for exclusion. The 
final number of studies that were deemed to be eligible for inclusion in the systematic 
review were determined by each reviewer independently and once the second selection 
phase was complete the two reviewers again met to compare selection. After discussion the 
final number of included studies was determined and there were no discrepancies in 
agreement. The reference lists of the included studies were subsequently searched in order 
to identify any further relevant primary studies, which were screened against eligibility 
criteria.  
 
7.2.6 Data collection process 
Data items were extracted from the information provided in the full text articles 
independently by the two reviewers, into a Microsoft Excel spreadsheet whereby each 
study was represented in a row of data in the spreadsheet. A detailed list of data items for 
extraction was developed with reference to the Cochrane Handbook for Systematic 
Reviews of Interventions (Version 5.1.0) (194), in order to facilitate the data extraction 
process. A detailed list of the items specified for data extraction is outlined in Table 7.2.6, 
which was used as a point of reference when entering the data items into the spreadsheet. 
The two reviewers met once data extraction had taken place independently, and 
discrepancies were discussed. 
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7.2.7 Data items 
The data items specified for data extraction from the included studies are outlined in Table 
7.2.6. Following data extraction, specific data items were selected from the finalised data 
extraction spreadsheet and were used in the production of study characteristics tables to 
facilitate the description and qualitative analysis of the included studies. 
 
Table 7.2.6: Data items to be extracted from included studies 
Field 
 
Data points to be extracted 
 
Review 
Author, 
Publication year, 
Country (including city or region). 
Methods 
Design, (RCT, controlled non-randomised, controlled observational: prospective or 
retrospective cohort with concurrent control), 
Objectives, 
Randomisation method (detail method if used), 
Study duration (from point of recruitment to last data collection). 
Study 
characteristics 
Total number recruited,  
Location of recruitment (e.g. healthcare clinic/hospital, community organisation/group, 
specified region of healthcare organisation such as primary or specialist care), 
Recruitment/referral criteria,  
Age (mean and standard deviation years) and age range of study sample, 
Gender (number and proportion male and female), 
Ethnicity (number and proportion of each ethnic group), 
Weight (baseline mean and standard deviation), 
BMI (baseline mean and standard deviation),  
Whether participant data is for whole study sample (i.e. mean study sample baseline 
BMI is 40.0kg/m2) or for a BMI 40.0kg/m2 subgroup. 
Intervention 
 
Nature of intervention (i.e. behavioural, medical, education, pharmaceutical, Low 
Energy Liquid Diet, other, or a combination), 
Number of intervention groups,  
Intervention setting (where intervention is delivered), 
Delivery personnel type (if healthcare professional, researcher, lay public),  
Delivery personnel training (detail of training in intervention delivery received),  
Duration of intervention (number and duration of contact time, including face to face 
sessions, email, telephone or other contact), 
Intensity of intervention (frequency of sessions and contact), 
Theoretical basis of intervention (e.g. self-management, cognitive behavioural), 
Number of participants assigned/randomised to intervention group,  
Number of participants entering intervention group,  
Number of participants completing intervention at intervention-end, 
Number of participants completing intervention or presenting at time of last data 
collection, 
Loss to follow-up rate (number randomised-number completing/number randomised), 
Any significant differences identified between participants completing and those lost to 
follow-up. 
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Table 7.2.6 Continued: Data items to be extracted from included studies 
Field 
 
Data points to be extracted 
 
Comparator 
 
Number of comparator groups,  
Description of usual care,  
Number of participants assigned/randomised to comparator group,  
Number of participants entering comparator group,  
Number of participants completing comparator group at intervention-end, 
Number of participants completing comparator group or presenting at time of last data 
collection, 
Loss to follow-up rate (number randomised-number completing/number randomised), 
Any significant differences identified between participants completing and those lost to 
follow-up. 
Outcomes 
Primary outcomes (using available case or LOCF data):  
Weight change from baseline at last point of data collection (including mean and 
standard deviation, and time point at which obtained),  
BMI change from baseline at last point of data collection data (including mean and 
standard deviation), and time point at which obtained),  
Weight change from baseline at intervention-end (including mean and standard 
deviation),  
BMI change from baseline at intervention-end (including mean and standard 
deviation), 
Proportion losing weight (any amount), proportion losing 5% baseline weight at last 
point of data collection,  
Proportion losing weight (any amount), proportion losing 5% baseline weight at 
intervention-end,  
Secondary outcomes: 
Quality of life change from baseline to last point of data collection, 
Quality of life change from baseline to intervention-end,  
Detail quality of life measure used and report change for all if more than 1 measure, 
Mental health change from baseline to last point of data collection, 
Mental health change from baseline to intervention-end,  
State mental health measure used and report change for all if more than 1 measure, 
Systolic and diastolic blood pressure change from baseline to last point of data 
collection, 
Systolic and diastolic blood pressure change from baseline to intervention-end,  
HDL-, LDL- and total cholesterol change from baseline to last point of data collection, 
HDL-, LDL- and total cholesterol change from baseline to intervention-end,  
For all outcomes include description of confounders where adjusted-estimates are 
reported and include category boundaries where continuous variables are categorized. 
 
7.2.8 Risk of bias in individual studies 
The included studies were appraised for methodological quality using the Cochrane 
Collaboration’s tool for assessing risk of bias, version 5.1.0 (204). Studies adopting both 
randomised and non-randomised controlled designs were assessed using the tool. However 
the random sequence generation domain was not completed for studies of non-randomised 
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design. The tool assessed the following dimensions; sequence generation, allocation 
concealment, blinding of participants, personnel, outcome assessment, incomplete outcome 
data, selective reporting, and other sources of bias. Thus the quality appraisal provided an 
estimate of the level of internal validity and therefore the level of risk of bias, for each 
study. Furthermore, the quality of reporting of RCTs was assessed with the CONSORT 
checklist (205), and the reporting quality of the controlled non-randomised study was 
assessed using the STROBE checklist (206). 
 
7.2.9 Synthesis of results 
In order for the data to be entered into meta-analyses, the outcome data were extracted as 
means and standard deviations. However where data were reported as standard errors and 
95% confidence intervals rather than standard deviations, the data were transformed 
according to guidelines in the Cochrane handbook section 7.7.3.2 ‘Obtaining standard 
deviations from standard errors and confidence intervals for group means’ (194). To 
calculate standard deviations (SD) from standard errors (SE), the following formula was 
used: 
SD = SE x √Sample size 
To calculate standard deviations from confidence intervals (CIs), the divisor was 
calculated using a t distribution, as the sample sizes were relatively small for both the 
intervention and control groups. The standard deviations were calculated using the 
following formula: 
SD = [√Sample size x (upper 95% CI limit – lower limit)] / [2 x t value] 
 Once the mean and standard deviation data were obtained, they were entered in to 
the RevMan package for meta-analyses. Meta-analysis was conducted on only one 
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outcome measure, weight change from baseline to intervention-end, whereby a random-
effects model was selected due to clinical heterogeneity between the studies. It was not 
possible to conduct meta-analyses for the other outcomes of interest; BMI, blood pressure, 
cholesterol and quality of life, due to inconsistencies in data collection and reporting 
between the included studies. 
 
7.2.10 Risk of bias across studies 
The quality assessment was used to inform the interpretation of the findings of the review, 
guiding the level of confidence in the study findings. The quality assessment provided 
evaluation summaries which were made across studies and domains, of the quality of the 
body of literature. This highlighted areas of strength and weakness, and facilitated the 
generation of recommendations for the improvement of the quality for future primary 
studies. 
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7.3 RESULTS 
 
7.3.1 Study selection 
The database search retrieved a total of 9,077 studies, 2,313 of which were retrieved from 
CENTRAL, 1,869 from CINAHL, 2,286 from EMBASE, and 2,609 from MEDLINE. The 
search of additional sources which included the Zetoc and OpenGrey databases and 
reference lists of included studies, yielded a total of 141 studies. A total of 1,907 studies 
were identified as duplicates and removed, and 7,311 studies were screened by title and 
abstract, with 7,232 excluded at this stage. Seventy-nine full text studies were screened and 
76 studies were excluded as they did not meet the eligibility criteria. Therefore three 
studies were identified as eligible for inclusion in the systematic review. The flow diagram 
(Figure 7.1) illustrates the number of studies retrieved and the subsequent process of 
selection, as outlined in the PRISMA statement (192). The reasons for exclusion of the 76 
full text records are detailed in Tables 7.3.1 and 7.3.2. The most common reason for 
exclusion was that the study did not include a population of extreme obese (BMI ≥40.0 
kg/m
2
) individuals.  
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Figure 7.1: Flow diagram outlining the identification of included studies 
 
 
 
  
Number of records screened
7,311
Number of records excluded
7,232
Number of full text articles 
assessed for eligibility
79
Number of studies included 
in qualitative synthesis
3
Number of studies included 
in quantitative synthesis
2
Number of full text articles 
excluded
76
Population not mean BMI 
≥40.0kg/m2: N= 62
Usual care comparator 
absent: N= 9
Weight/BMI absent: N= 4
Study design review: N= 1
Number identified 
through other 
sources
141
Number of records after duplicates removed
7,311
Number identified 
through database 
searching
9,077
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Table 7.3.1: Full text studies excluded due to not including extreme obese populations 
Review first author and date of publication  
Abbenhardt, 2013 (207) Greenway, 2009 (208) 
Admiraal, 2013 (209) Greenway, 2010 (210) 
Aggel-Leijssen, 2002 (211) Hardcastle, 2008 (212) 
Arciero, 2006 (213) Hardcastle, 2013 (214) 
Aubertin-Leheudre, 2007 (215) Ho, 2012 (216) 
Bakris, 2002 (217) Joo, 2011 (218) 
Barak, 2008 (219) Kalter-Leibovici, 2010 (220) 
Bartfield , 2011 (221) Kerksick, 2009 (222) 
Berteus Forslund, 2008 (223) Knowler, 2009 (224) 
Bhutani, 2013 (225) Lutes, 2008 (226) 
Bhutani, 2013 (227) Madsen, 2008 (228) 
Blum, 2009 (229) Martin, 2011 (230) 
Brekke, 2003 (231) Meekums, 2012 (232) 
Brekke, 2005 (233) Miller, 2002 (234) 
Broom, 2002 (235) Moore, 2013 (236) 
Buscemi, 2011 (237) Pi-Sunyer, 2006 (238) 
Butsch, 2007 (239) Poston, 2003 (240) 
Cakmakçi, 2011 (241) 
Research group of the Rome project of coronary 
heart disease prevention, 1986 (242) 
Cayir, 2014 (243) Ross, 2012 (244) 
Craigie, 2011(245) Sarsan, 2006 (246) 
Davidson, 1999 (247) Smith, 2011 (248) 
Davis Martin, 2006 (249) Sniehotta, 2011 (250) 
Desouza, 2012 (251) Stolley, 2009 (252) 
Dutton, 2007 (253) Tanco, 1998 (254) 
Eiben, 2006 (255) Tapper, 2009 (256) 
Esposito, 2003 (257) Tiikkainen, 2004 (258) 
Fitzgibbon, 2010 (259) Tsai, 2010 (260) 
Folta, 2009 (261) Tsai, 2007 (262) 
Garcia, 2006 (263) Tumiati, 2008 (264) 
Gohner, 2012 (265) Wadden, 2011 (266) 
Goulis, 2004 (267) Yancey, 2006 (268) 
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Table 7.3.2: Full text studies excluded due to other study factors 
Review first author and date of 
publication 
Reason for exclusion 
Gantz, 2007 (269) Mean BMI not reported (range 30-43) 
Carels, 2008 (270) 
Mean BMI not reported. Mean weight suggests BMI <30.0kg/m
2
 based 
on estimation of average height 
Byrne, 2012 (271) 
Mean BMI not reported (range 30-56). Weight or BMI change not 
reported 
Beresford, 1997 (272) 
Mean BMI and weight not reported at baseline. Weight or BMI change 
not reported 
Allison, 2012 (273) Usual care comparator absent 
Annesi, 2010 (274) Usual care comparator absent 
Cooper, 2012 (275) Usual care comparator absent 
Due, 2007 (276) Usual care comparator absent 
Ettinger, 2003 (277) Usual care comparator absent 
Summerbell, 1998 (278) Usual care comparator absent 
Annesi, 2013 (279) Usual care comparator absent. Weight or BMI change not reported 
Berger, 2010 (280) Usual care comparator absent. BMI <40.0 kg/m
2
 
Donnelly, 1994 (281) Usual care comparator absent. BMI <40.0 kg/m
2
 
Ioannides-Demos, 2005  (282) Study design was review 
 
7.3.2 Study characteristics 
The characteristics of the three included studies are summarised in Table 7.3.3. All three 
studies assessed the efficacy of lifestyle interventions which adopted different approaches, 
and included a residential inpatient lifestyle programme promoting diet, physical activity 
and cognitive changes such as coping strategies, goal setting, and problem solving (283), a 
programme promoting physical activity (284), and a medical intervention incorporating a 
Low Energy Liquid Diet (LELD), pharmaceutical therapy, and a behavioural group 
support programme (285). Interventions also varied in duration from 10-14 weeks (283), to 
24 months (285). Two of the studies were conducted in the United States of America (US), 
with the remaining study taking place in Norway. 
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Table 7.3.3: Study characteristics table 
Study 
(location) 
Design Participants Intervention Comparator Outcome 
measures 
Main findings 
Danielsen, 
2013 
(Norway) 
(283) 
Study design: Non-
randomised, controlled, 
clinical trial. 
Setting: NIMI Ringerike 
Obesity clinic. 
Aim: To examine the 
efficacy of a 10-14wk 
inpatient Intensive 
Lifestyle Intervention 
(ILI) in severely obese 
adults. 
Duration: 18 months, 
September 2010 to 
March 2012. 
Referral/recruitment: 
BMI ≥40.0kg/m2 or BMI 
≥35.0 kg/m2 with co-
morbidities. 
Aged 18-65 and capable 
of walking slowly for 
20mins. 
N= 139 
 
Intervention: 
N= 100 
Mean age at baseline= 
45.2yrs (9.5).  
Females: 59.2%. 
Mean baseline weight= 
128.9kg (19.4).  
Mean baseline BMI= 
42.8kg/m
2
 (4.6). 
Number entering 
intervention= 100 
Number completing 
intervention= 71 
Intervention loss to 
follow up rate= 29% 
Control:  
N= 39 
Mean age at baseline= 
38.5yrs (9.8). 
Females 63.6%. 
Mean baseline weight= 
127.1kg (21.6). 
Mean baseline BMI= 
42.8kg/m
2
 (6.3).  
Number entering 
control= 39. 
Number completing 
control= 33. 
Control loss to follow up 
rate= 15% 
Intervention group receive 
Intensive Lifestyle 
Intervention (ILI). Inpatient 
residential programme 
lasting 10-14 weeks 
followed by phone and email 
communication up to 6 
months. 
Duration and intensity of 
physical activity increased 
from 2-3 45minute sessions 
per week. Energy and 
nutrient intake was adjusted, 
portion sizes restricted to 
1900kcal/day for males and 
1600 kcal/day for females, 
with additional individual 
dietary nutritional 
consultations. Intervention 
was a behavioural, lifestyle 
intervention, incorporating 
diet, physical activity, and 
cognitive components 
(coping strategies, goal 
setting, problem solving). 
Intervention delivered by 
multi-disciplinary team 
(MDT) including a 
physician, psychologist, 
clinical nutritionist, and 
nurses, exercise scientists, 
and physiotherapists. 
Comparator 
group 
received no 
intervention, 
and were 
recruited 
from a 
waiting list 
to receive 
the 
intervention. 
 
 
 
 
 
Intervention:  
Weight and BMI 
change at 
intervention-end 
(10-14weeks), 
Weight and BMI 
change at 12 
months, 
Systolic and 
diastolic blood 
pressure change at 
12 months, 
HDL-, LDL-, and 
total cholesterol 
change at 12 
months. 
 
Control: Weight 
and BMI change at 
intervention-end 
(10-14weeks). 
 
Mean weight change at 
intervention-end= 
Intervention: -17.5kg 
(6.1), Control: -0.5kg 
(2.8). Between group 
difference= -17.0kg (-18.7 
- -15.3) p <0.001. 
 
Mean weight change at 12 
months=  
Intervention: -20.3 (-23.3 
- -17.3) p <0.001. 
Control not reported. 
 
Mean BMI change at 
intervention-end= 
Intervention: -5.8kg/m
2
 
(1.8), Control: -0.2kg/m
2
 
(1.0). Between group 
difference= -5.6kg/m
2
 
(-6.2 - -5.1) p <0.001. 
 
Mean BMI change at 12 
months=  
Intervention: -6.7kg/m
2
 
(-7.6 - -5.7) p <0.001. 
Control not reported. 
Data are means and standard deviations or 95% confidence intervals. HDL= high density lipoprotein, LDL= low density lipoprotein.  
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Table 7.3.3 Continued: Study characteristics table 
Study 
(location) 
Design Participants Intervention Comparator Outcome 
measures 
Main findings 
Rimmer, 
2009 
(Chicago, 
US) (284) 
Study design: 
Randomised 
Controlled Trial 
Setting: Outpatient 
internal medicine clinic 
Aim:  
To examine the 
efficacy of a 
personalised exercise 
programme using two 
treatment intensities, 
on increasing physical 
activity and improving 
health outcomes, 
relative to a minimal 
intervention. 
Duration:  
Enrolment over a 24 
month period. Total 
study duration not 
reported. 
Referral/recruitment:  
BMI >27 and receiving 
primary care at site.  
Aged ≥18 years. 
Sedentary with no 
regular physical 
activity in last 6 
months and self-
reported mobility 
difficulty (walking a 
block or more/use of 
mobility aid). 
Total N= 96 
Intervention 
‘Lower’/‘Higher’: 
N= 31 / 30 
Mean age at baseline= 
58.6yrs (12.0) / 59.1yrs 
(10.7). 
Females: 94% / 97%. 
Mean baseline weight= 
129.3kg (no sd) / 135.8kg (no 
sd). 
Mean baseline BMI= 
48.5kg/m
2
 (10.7) / 51.5kg/m
2
 
(12.1). 
Number entering 
intervention= 31 / 30 
Number completing 
intervention= 28 / 27 
Intervention loss to follow up 
rate= 9.7% / 10% 
Control: N= 31 
Mean age at baseline= 
58.7yrs (12.2). 
Females: 94% 
Mean baseline weight= 
118.9kg (no sd).  
Mean baseline BMI= 
43.6kg/m
2
 (10.9). 
Number entering control= 31 
Number completing control= 
23 
Control loss to follow up 
rate= 25.8% 
Two intervention groups 
receiving 6-month 
personalised exercise 
programmes with either 
higher or lower support. 
‘Lower’ support group 
receive recommendation to 
exercise from physician, 
educational brochure, 
device to monitor activity, 
monthly newsletter, weekly 
5-35minute telephone 
consultations to develop 
physical activity by tailored 
goal-setting, and activities. 
‘Higher’ support group 
received above plus 
monthly 90minute exercise 
support group involving 
participation in physical 
activity, encouragement 
from facilitator, peer 
discussion, education, 
overcoming barriers to 
exercise. Intervention 
delivered by qualified 
fitness professionals. 
Intervention was a 
behavioural, lifestyle 
intervention promoting 
physical activity. 
 
Control group 
received 
recommend-
ation to 
exercise from 
physician, 
educational 
brochure, and 
device to 
monitor 
activity. 
Control group 
received no 
contact or 
support over 6 
month 
intervention 
period.  
 
All study 
arms:  
 
Weight and 
BMI (no sd) at 
baseline and 
intervention-
end. 
 
Quality of life 
(Quality of 
Well-Being 
QWB) scale at 
baseline and 
intervention-
end. 
 
Systolic and 
diastolic blood 
pressure at 
baseline and 
intervention-
end. 
 
HDL-, LDL-, 
and total 
cholesterol at 
baseline and 
intervention-
end. 
Mean weight change at 
intervention-end= 
‘Lower’ intervention: 129.3 
to 128.2kg, p= 0.89 
‘Higher’ intervention: 
135.8 to 125.6kg, p <0.01. 
Control: 118.9 to 120.5kg, 
p= 0.89. 
 
Mean BMI change at 
intervention-end= 
‘Lower’ intervention: 48.5 
to 48.6kg/m
2
, p= 0.97. 
‘Higher’ intervention: 
51.5 to 47.7kg/m
2
, p <0.01. 
Control: 43.6 to 44.3kg/m
2
, 
p= 0.85. 
 
Data are means and standard deviations. HDL= high density lipoprotein, LDL= low density lipoprotein.  
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Table 7.3.3 Continued: Study characteristics table 
Study 
(location) 
Design Participants Intervention Comparator Outcome 
measures 
Main findings 
Ryan, 
2010 
(Louisiana, 
US) (285) 
Study design: 
Randomised Controlled 
'pragmatic clinical' Trial 
 
Setting: Primary care 
practices 
 
Aim:  
To examine efficacy of a 
primary care practice 
intervention on weight 
loss in extreme obese 
individuals, relative to 
usual care at 2 years. 
 
Duration:  
2.5yrs: July 2005 to 
January 2008 
 
Referral/recruitment: 
BMI ≥40 up to and 
including  BMI 60. Aged 
20 to 60. Enrolled in 
programmes of the 
Louisiana state 
employees group 
benefits office.  
N= 390 
 
Intervention: 
N= 200 
Mean age at baseline= 
47.2yrs (0.6)*.  
Females: 83.5% 
Mean baseline weight= 
126.2kg (23.2) †.  
Mean baseline BMI= 
45.6kg/m
2
 (7.9) †.  
Number entering 
intervention= 200 
Number completing 
intervention= 101 
Intervention loss to follow 
up rate= 49.5% 
Control: 
 N= 190 
Mean age at baseline= 
47.1yrs (0.6)*. 
Females: 83.7% 
Mean baseline weight= 
128.4kg (28.6) † 
Mean baseline BMI= 
46.6kg/m
2
 (8.5) †.   
Number entering control= 
190 
Number completing 
control= 86 
Control loss to follow up 
rate= 54.7% 
Intervention group receiving 
Intensive Medical 
Intervention (IMI) for 24 
months. Intervention 
comprised 3 phases: Phase 1 
comprised Low Energy 
Liquid Diet (LELD) for 12 
weeks. Phases 2 and 3 
comprised calorie restricted 
diet with prescription of 
weight loss medication and 
weekly then bi-weekly 
behavioural 60minute group 
sessions, with continued 
meal replacement as 
required. Phases 2 lasted 
from 3 to 8 months, and 
phase 3 from 8 to 24 
months. 
Intervention was medical 
incorporating supervised 
meal replacement and 
pharmaceutical components 
as well as behavioural 
lifestyle components.  
Control group 
received 
instruction in 
the use of 
mayo clinic 
weight 
management 
web site. 
Control group 
received no 
contact or 
support over 
24 month 
intervention 
period (except 
assessment at 
1yr and 2yrs). 
 
 
Both arms: 
Mean weight 
change from 
baseline to 
intervention-end 
using available 
case and LOCF 
data.  
Proportion losing 
≥5% weight at 
intervention-end 
(using available 
case and LOCF 
data). 
Mean BMI 
change not 
reported. 
Mean change in 
systolic and 
diastolic blood 
pressure from 
baseline to 
intervention-end. 
Mean change in 
HDL-, and LDL- 
cholesterol from 
baseline to 
intervention-end. 
All secondary 
measures reported 
using available 
case data. 
Mean weight change 
at intervention end using 
available case data:  
Intervention: -12.7kg 
(1.7)*.  
Control: -0.5 (0.9)*. 
Between arms 
comparison p <0.001. 
 
Mean weight change 
percentage at 
intervention end using 
LOCF data:  
Intervention: -8.3% 
(0.8)* 
Control: 0.0% (0.4)*. 
Between arms 
comparison p <0.001. 
 
Mean weight change 
percentage at 
intervention end using 
available case data: 
Intervention: -9.7% 
(1.3)* 
Control: -0.4% (0.7)*. 
Between arms 
comparison p <0.001. 
 
 
Data are mean and standard error (SE)*. Data are median & IQR †. LOCF= Last observation carried forward, HDL= high density lipoprotein, 
LDL= low density lipoprotein.
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7.3.3 Risk of bias within studies 
The included studies were appraised for quality using the Cochrane Collaboration’s tool 
for assessing risk of bias, version 5.1.0 (204), with findings displayed in Table 7.3.4. There 
was a high risk of bias for several domains in two of the included studies, with Danielsen, 
2013 (283) scoring high risk across four domains and Rimmer, 2009 (284), in three 
domains. The remaining study, Ryan, 2010 (285) scored high risk for only two domains, 
and low risk for three domains.  
The key areas affected by risk of bias in the Danielsen, 2013 study (283) are the 
concealment of allocation and blinding of participants, personnel and outcome assessment, 
which are plausible in the evaluation of an intervention of this nature, and were similar 
across all studies. However there was also a high risk of bias due to the incomplete 
reporting of outcome data, with follow-up measures obtained for the intervention and not 
control arm of the study. This was a major flaw in the study design, however this was pre-
specified as a study aim to investigate the long-term impact of the intervention arm only, 
and so consequently the selective reporting of outcomes was judged to be at low risk of 
bias. Rimmer, 2009 (284) was judged to be at high risk of bias in the selective reporting 
domain, due to the fact that measures of distribution were not reported. The incomplete 
reporting of such data means that as a consequence the outcomes cannot be entered into the 
meta-analyses. In contrast, Ryan, 2010 (285) scored as low risk for both of these domains, 
but scored as high risk for the blinding of participants, personnel and outcome assessment.  
The assessment indicates that two of the studies were deemed to be at moderate risk 
of bias, although this included the performance and detection bias domains which are not 
necessarily pertinent to evaluations of interventions of this nature, whilst the remaining 
study demonstrated less risk of bias. 
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Table 7.3.4: Assessment of risk of bias 
 Selection bias Performance 
bias 
Detection bias Attrition bias Reporting bias Other bias 
Study Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
assessment 
Incomplete outcome 
data 
Selective 
reporting 
Other sources 
of bias 
Danielsen, 
2013 
(283) 
N/A 
 
High risk of bias: 
Participants and 
investigators 
could foresee 
assignment as 
control arm on 
waiting list for 
intervention. 
High risk of 
bias: 
No blinding of 
participants or 
personnel 
High risk of bias 
(all outcomes): 
No blinding of 
outcome 
assessment 
 
High risk of bias (all 
outcomes): 
Outcomes not collected 
for control group 
beyond intervention 
end, whilst intervention 
group followed up at 6 
and 12 months with 
greater range of 
measures.  
Low risk of bias: 
The outcomes of 
interest were pre-
specified, and aim 
identified. 
Low risk of bias: 
The study 
appears to be 
free from other 
sources of bias. 
Rimmer, 
2009 
(284) 
Low risk of bias: 
Participants given 
numbered 
brochure outlining 
study arm 
assignment. 
High risk of bias: 
No indication that 
numbered 
brochures were 
concealed. 
High risk of 
bias: 
No blinding of 
participants or 
personnel. 
Unclear risk of 
bias (all 
outcomes): 
Personnel 
conducting 
assessments not 
involved in 
intervention, but 
use of blinding 
unknown. 
 
Low risk of bias (all 
outcomes): 
Outcome data reported 
for all pre-specified 
measures as pre- and 
post- intervention 
means (however 
standard deviations, 
standard errors or 
confidence intervals 
not reported). 
High risk of bias: 
Outcomes of 
interest are 
missing standard 
deviations, 
standard errors or 
confidence 
intervals) thus 
cannot be entered 
into a meta-
analysis.  
Low risk of bias: 
The study 
appears to be 
free from other 
sources of bias. 
Ryan, 
2010 
(285) 
Unclear risk of 
bias: 
Minimisation 
allocation applied 
stratified by age, 
sex, BMI. 
Unclear risk of 
bias: 
Insufficient 
information to 
determine whether 
allocation was 
concealed. 
High risk of 
bias: 
No blinding of 
participants or 
personnel. 
High risk of bias 
(all outcomes): 
No blinding of 
outcome 
assessment 
Low risk of bias (all 
outcomes): 
No missing outcome 
data. Weight outcomes 
reported using 
available cases, LOCF 
and BOCF approaches. 
Low risk of bias: 
The outcomes of 
interest were pre-
specified, and 
analyses 
conducted and 
reported. 
Low risk of bias: 
The study 
appears to be 
free from other 
sources of bias. 
N/A: Not applicable as the study was not a randomised controlled trial. 
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7.3.4 Results of individual studies 
 
Effect of intervention on weight and BMI 
All three included studies reported change in weight from baseline to intervention-end, the 
results of which are displayed in Table 7.3.5. The greatest weight loss was observed in the 
Danielsen, 2013 inpatient intervention (283), achieving a significant mean loss of -17.5kg 
(p <0.001), compared to the Ryan, 2010 medical intervention  (285) which yielded a mean 
loss of -12.7kg (significance not reported), and the Rimmer, 2009 exercise intervention 
(284)  with a significant mean loss of -10.2kg (p <0.01) in the higher support programme 
and a non-significant loss of -1.1kg (p =0.89) for the lower support programme, from 
baseline. 
 
Table 7.3.5: Change in weight (kg) at intervention-end for included studies 
 Intervention Control 
Study Baseline 
Intervention
-end 
Change Baseline 
Intervention
-end 
Change 
Danielsen, 
2013 
128.9 (19.4) NR -17.5 (6.1) 127.1 (21.6). NR -0.5 (2.8) 
Rimmer, 
2009 
‘Lower’: 
129.3 
‘Higher’: 
135.8 
‘Lower’: 
128.2 
‘Higher’: 
125.6 
NR 118.9 120.5 NR 
Ryan,  
2010 
126.2 (23.2) 
† 
NR 
-12.7 (1.7*) 
(17.1) ≠ 
128.4 (28.6) 
† 
NR 
-0.5 (0.9*) 
(8.3) ≠ 
Data are means and standard deviations or standard errors (*) 
† Data are median & IQR 
NR= Data not reported ‘Lower’= Lower support intervention, ‘Higher’= Higher support intervention 
Standard deviation calculated by transforming 95% CI or standard error (≠). 
 
The mean change in BMI from baseline to post-intervention was reported in two studies 
and results are summarised in Table 7.3.6. Similar to the weight change findings reported 
in Table 7.3.5, the greatest loss of BMI was obtained through the Danielsen, 2013 inpatient 
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intervention (283) which yielded a significant loss of -5.8kg/m
2
 (p <0.001). The Rimmer, 
2009 higher support exercise programme (284) also yielded a significant mean loss of 
-3.8kg/m
2
 (p <0.01), whilst the lower support programme resulted in a non-significant gain 
of 0.1kg/m
2
 (p =0.97). 
 
Table 7.3.6: Change in BMI at intervention-end for included studies 
 Intervention Control 
Study Baseline 
Intervention
-end 
Change Baseline 
Intervention
-end 
Change 
Danielsen, 
2013 
42.8 (4.6) NR -5.8 (1.8) 42.8 (6.3) NR -0.2 (1.0) 
Rimmer, 
2009 
‘Lower’:  
48.5 (10.7) 
‘Higher’: 
51.5 (12.1) 
‘Lower’:  
48.6 
‘Higher’: 
47.7 
NR 43.6 (10.9) 44.3 NR 
Ryan,  
2010 
45.6 (7.9) † NR NR 46.6 (8.5) † NR NR 
Data are means and standard deviations 
† Data are median & IQR 
NR= Data not reported, ‘Lower’= Lower support intervention, ‘Higher’= Higher support intervention. 
 
Only one study (Danielsen, 2013) (283) reported changes in weight and BMI at post-
intervention follow-up, which was obtained at 12 months post-baseline on completion of 
the 10-14 week inpatient programme. However this was only reported for the intervention 
group, with follow-up measures not obtained for the control group. The reporting of ≥5% 
weight loss as shown in Table 7.3.7, was also limited, with one study (Ryan, 2010)  (285) 
reporting proportions losing ≥5% weight loss for the intervention arm only, one study 
(Danielsen, 2013) (283) reporting the proportion at intervention-end only, and the 
remaining study not reporting any indication of ≥5% weight loss. 
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Table 7.3.7: Proportion of individuals in included studies achieving ≥5% weight loss 
 Intervention Control  
Study Intervention-end Follow-up Intervention-end Follow-up 
Danielsen, 
2013 
100% 91.5% NR NR 
Rimmer, 
2009 
NR NR NR NR 
Ryan,  
2010 
61% NR 20% NR 
Data are percentages 
NR= Data not reported, ‘Lower’= Lower support intervention, ‘Higher’= Higher support intervention. 
 
Effect of intervention on quality of life 
Only one study (Rimmer, 2009) (284) assessed the impact of the intervention on quality of 
life, with findings displayed in Table 7.3.8. The Quality of Well-Being (QWB) (286) 
31-item self-report measure was used to assess quality of life before and after the 
intervention. The investigators stated that both the higher and lower support intervention 
groups experienced an improvement in quality of life, however the change was not 
significant for either group (p= 0.79) and (p= 0.24), respectively. The control group 
reported a mean decrease in quality of life which was also not significant (p= 0.66). 
Interestingly, the use of the QWB scale in the manner reported by the investigators is not 
the conventional way that the measure is used, as the scale authors advise that the measure 
should yield scores ranging between 0 to 1, whereby 0 represents death and 1 represents 
optimum functioning (286).  
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Table 7.3.8: Change in quality of life at intervention-end for included studies 
 Intervention Control 
Study Baseline 
Intervention
-end 
Change Baseline 
Intervention
-end 
Change 
Danielsen, 
2013 
NR NR NR NR NR NR 
Rimmer, 
2009 
‘Lower’:  
2.4  
‘Higher’: 
 2.2 
‘Lower’:  
2.5  
‘Higher’:  
2.3 
NR 2.3 2.0 NR 
Ryan,  
2010 
NR NR NR NR NR NR 
Data are mean scores on QWB scale 
NR= Data not reported, ‘Lower’= Lower support intervention, ‘Higher’= Higher support intervention. 
 
Effect of intervention on blood pressure 
All three included studies reported either mean change in systolic and diastolic blood 
pressure or reported pre- and post- intervention measures and results are summarised in 
Tables 7.3.9 and 7.3.10. One study (Ryan, 2010)  (285) reported mean percentage change 
in blood pressure, with both the intervention and control arms experiencing a reduction in 
systolic and diastolic blood pressure between baseline and intervention-end, with no 
significant difference between the study arms in the mean percentage reduction for both 
systolic (p =0.09) and diastolic (p =0.60) blood pressure. However, the study did not report 
whether the reduction from baseline was significant. No significant change in mean 
systolic and diastolic blood pressure for each of the study arms of the Rimmer, 2009 
exercise intervention (284) were reported. Whilst the inpatient intervention (Danielsen, 
2013) (283) reported a significant -6.4mmHg reduction of systolic blood pressure 
(p <0.001), and a non-significant -1.3mmHg reduction of diastolic blood pressure 
(p =0.175). 
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Table 7.3.9: Change in systolic blood pressure at intervention-end for included 
studies 
 Intervention Control 
Study Baseline 
Intervention
-end 
Change Baseline 
Intervention
-end 
Change 
Danielsen, 
2013 
132 (11) NR 
-6.4 (-9.1, -
3.7) (11.4) ≠ 
NR NR NR 
Rimmer, 
2009 
‘Lower’:  
133 
‘Higher’:  
130 
‘Lower’:  
127 
‘Higher’:  
133 
NR 130 137 NR 
Ryan,  
2010 
131 (1) NR 
-14.7 (2.4)* 
(24.1) ≠ 
132 (1) NR 
-8.6 (2.6)* 
(24.1) ≠ 
Data are means and standard deviations or mean percentages with standard errors (*) 
Standard deviation calculated by transforming 95% CI or standard error (≠) 
NR= Data not reported, ‘Lower’= Lower support intervention, ‘Higher’= Higher support intervention. 
 
Table 7.3.10: Change in diastolic blood pressure at intervention-end for included 
studies 
 Intervention Control 
Study Baseline 
Intervention
-end 
Change Baseline 
Intervention
-end 
Change 
Danielsen, 
2013 
83.7 (6.1) NR 
-1.3 (-3.2, 
0.6) (8.0) ≠ 
NR NR NR 
Rimmer, 
2009 
‘Lower’:  
73.0  
‘Higher’:  
75.0 
‘Lower’:  
69.0  
‘Higher’: 
74.2 
NR 72.6 71.8 NR 
Ryan,  
2010 
79.6 (0.7) NR 
-4.4 (1.8)* 
(18.1) ≠ 
80.3 (0.7) NR 
-3.2 (1.5)* 
(13.9) ≠ 
Data are means and standard deviations or mean percentages with standard errors (*) 
Standard deviation calculated by transforming 95% CI or standard error (≠) 
NR= Data not reported, ‘Lower’= Lower support intervention, ‘Higher’= Higher support intervention. 
 
Effect of intervention on cholesterol 
The effect of the interventions on HDL-, LDL-, and total cholesterol are summarised in 
Tables 7.3.11, 7.3.12, and 7.3.13. The medical intervention (Ryan, 2010) (285) reported 
percentage increases in HDL- and LDL-cholesterol, although did not report whether the 
increases from baseline were significant. However the 7.9% increase in HDL-cholesterol 
observed in the intervention arm was significantly greater than the increase of 1.5% 
observed for the control arm (p <0.05). The inpatient intervention (Danielsen, 2013) (283) 
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also reported an increase in HDL-cholesterol, with the slight increase of 0.1mmol/l 
representing a significant increase from baseline level (p <0.05). The study examining the 
exercise intervention (Rimmer, 2009) (284), yielded no significant changes between 
baseline and post-intervention in HDL-, LDL- or total cholesterol levels, for the 
intervention and control arms (p >0.05). 
 
Table 7.3.11: Change in HDL-cholesterol at intervention-end for included studies 
 Intervention Control 
Study Baseline 
Intervention
-end 
Change Baseline 
Intervention
-end 
Change 
Danielsen, 
2013 
1.1mmol/l 
(0.3) 
NR 
0.1 mmol/l 
(0.0, 0.1) 
(0.2) ≠ 
NR NR NR 
Rimmer, 
2009 
‘Lower’: 
53.3mg/dl 
‘Higher’: 
46.0mg/dl 
‘Lower’: 
46.3mg/dl 
‘Higher’: 
43.1mg/dl 
NR 49.7mg/dl 42.8mg/dl NR 
Ryan,  
2010 
52.4mg/dl 
(1.0) 
NR 
7.9 (1.8)* 
(18.1) ≠ 
50.6mg/dl 
(0.9) 
NR 
1.5 (1.8)* 
(16.7) ≠ 
Data are means and standard deviations or mean percentages with standard errors (*) 
Standard deviation calculated by transforming 95% CI or standard error (≠) 
NR= Data not reported, ‘Lower’= Lower support intervention, ‘Higher’= Higher support intervention 
1mg/dl= 0.0259 mmol/l. 
 
Table 7.3.12: Change in LDL-cholesterol at intervention-end for included studies 
 Intervention Control 
Study Baseline 
Intervention
-end 
Change Baseline 
Intervention
-end 
Change 
Danielsen, 
2013 
2.9mmol/l 
(0.9) 
NR 
-0.2mmol/l  
(-0.3, -0.1) 
(0.4) ≠ 
NR NR NR 
Rimmer, 
2009 
‘Lower’: 
123mg/dl 
‘Higher’: 
100mg/dl 
‘Lower’: 
116mg/dl 
‘Higher’: 
97mg/dl 
NR 112mg/dl 114.0mg/dl NR 
Ryan,  
2010 
119mg/dl  
(2) 
NR 
1.8 (2.4)* 
(24.1) ≠ 
116mg/dl  
(2) 
NR 
0.7 (2.4)* 
(22.3) ≠ 
Data are means and standard deviations or mean percentages with standard errors (*) 
Standard deviation calculated by transforming 95% CI or standard error (≠) 
NR= Data not reported, ‘Lower’= Lower support intervention, ‘Higher’= Higher support intervention 
1mg/dl= 0.0259 mmol/l. 
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Table 7.3.13: Change in total cholesterol at intervention-end for included studies 
 Intervention Control 
Study Baseline 
Intervention
-end 
Change Baseline 
Intervention
-end 
Change 
Danielsen, 
2013 
4.7mmol/l 
(1.1) 
NR 
-0.1mmol/l  
(-0.3, 0.0) 
(0.6) ≠ 
NR NR NR 
Rimmer, 
2009 
‘Lower’: 
191mg/dl 
‘Higher’: 
160mg/dl 
‘Lower’: 
179mg/dl 
‘Higher’: 
164mg/dl 
NR 182mg/dl 176mg/dl NR 
Ryan,  
2010 
202mg/dl  
(3) 
NR NR 
199mg/dl  
(3) 
NR NR 
Data are means and standard deviations 
Standard deviation calculated by transforming 95% CI or standard error (≠) 
NR= Data not reported, ‘Lower’= Lower support intervention, ‘Higher’= Higher support intervention 
1mg/dl= 0.0259 mmol/l. 
 
7.3.5 Synthesis of results 
Meta-analysis was conducted on only one outcome measure, weight change from baseline 
to intervention-end. Figure 7.2 illustrates the mean change in weight from baseline to 
intervention-end for two studies, Danielsen, 2013 (283) and Ryan, 2010 (285). The 
remaining study, Rimmer, 2009 (284) could not be included in the meta-analysis due to the 
fact that standard deviations or standard errors were not reported.  
Both studies reported statistically and clinically significant weight losses from 
baseline to intervention-end. The pooled mean change in weight was -14.91kg (-19.57 - 
-10.24), however heterogeneity between the studies was very high (Q= 5.17, df= 1, 
p= 0.02, I
2
= 81%. Both studies reported lifestyle interventions conducted in medical 
settings, however they utilised differing intensities, with Danielsen, 2013 (283) reporting a 
10-14 week intervention, whilst Ryan, 2010 reported a 24-month intervention. Due to this 
clinical heterogeneity between the studies, a random-effects model was utilised. 
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Figure 7.2: Mean change in weight from baseline to intervention-end 
 
 
Due to inconsistencies between the three studies in data collection and reporting, meta-
analyses were not possible for the other outcomes of interest; BMI, blood pressure, 
cholesterol and quality of life. 
 
7.3.6 Risk of bias across studies 
The domain which was consistently at a high risk of bias was the performance bias, 
blinding of participants and personnel domain. However, this is plausible and reflects the 
nature of the studies which all examined medical and or behavioural interventions, thus are 
less pertinent to evaluations of interventions of this nature, for instance relative to 
pharmaceutical interventions.  
Most of the information reported in two of the included studies, Danielsen, 2013 
(283) and Rimmer, 2009 (284), is at moderately high risk of bias, whilst the remaining 
study, Ryan, 2010 is at a low to moderate risk of bias. Thus the proportion of information 
from all included studies is not deemed sufficient to affect the interpretation of the results 
of the systematic review. The quality assessment has highlighted the specific areas of 
limitation as the incomplete and selective reporting of outcome data.  
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7.3.7 Quality assessment of studies 
The quality of reporting of the two studies adopting RCT designs, Rimmer, 2009 (284) and 
Ryan, 2010 (285) was assessed with the CONSORT checklist (205), and the reporting 
quality of the Danielsen, 2013 (283) controlled non-randomised study was assessed using 
the STROBE checklist (206). The assessment indicated that the reporting quality was 
acceptable for all studies, and the reporting forms used in the quality assessment are 
included in Appendix three, Tables 1-3. 
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7.4 DISCUSSION 
 
7.4.1 Summary of evidence 
The meta-analysis indicated that both included studies reported statistically and clinically 
significant weight losses from baseline to intervention-end, with a pooled mean reduction 
in weight of -14.9kg (-19.6 - -10.2). However heterogeneity between the studies was very 
high and only two studies were included due to selective outcome reporting in the 
remaining study (Rimmer, 2009) (284). Furthermore, the quality assessment highlighted 
that the incomplete and selective reporting of outcome measures was an area of limitation 
among the studies included in the review, and that future primary studies should improve 
on these specific domains in order to improve study quality and enable greater confidence 
in study findings. Analyses of secondary outcomes were also limited by the incomplete 
reporting of outcomes and between study heterogeneity in reporting. One of the aims of the 
systematic review was to explore the impact of interventions on psychological factors 
including quality of life and mental health. However, only one study (Rimmer, 2009) (284) 
included the use of a psychological measure, and the use of the Quality of Well-Being 
scale (QWB) (286) was non-conventional. This indicates that the inclusion of 
psychological outcomes is an area which also requires further attention. Indeed, the 
impacts of interventions on improvement of mental health and quality of life following 
intervention are an important indicator of intervention efficacy which should be assessed.  
The review also highlighted the absence of long-term measures of outcomes. Only 
one of the included studies (Danielsen, 2013) (283) reported outcome measures obtained at 
post-intervention follow-up, which were obtained at 12 months post-baseline subsequent to 
the 10-14 week inpatient intervention. However these measures were obtained only for the 
intervention and not control arm of the study, thus comparison of the longer-term impacts 
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of the intervention could not be compared to the control arm. The remaining studies, 
Rimmer, 2009 (284) and Ryan, 2010 (285), reported outcome measures only at 
intervention-end, with no follow-up measures reported. This highlights an important area 
for improvement as it is essential that the long-term impacts of interventions are 
established. Additionally the imputation of outcome data using a LOCF approach is widely 
used to deal with the problem of missing outcome data in RCTs (186), however only the 
Ryan, 2010 study (285) reported LOCF outcomes, thus further limiting the analyses. Thus 
future primary studies should report outcome measures after a post-intervention follow-up 
period as well as at intervention-end, using both LOCF and available case data.  
The literature search identified a substantial number of studies which assessed the 
efficacy of interventions in extreme obese samples which were not eligible for inclusion 
due to the use of observational non-controlled study designs. This included predominantly 
head to head study designs, examining for instance dietary interventions in comparison to 
dietary plus physical activity interventions (275, 287), behavioural interventions in 
comparison to behavioural interventions plus Low Energy Liquid Diet (LELD) (288, 289), 
comparisons of dietary interventions (278, 290, 291), and comparisons of behavioural 
programmes (292, 293). Additionally, several studies examined the impact of 
pharmaceutical interventions in extreme obese samples, however none of which included a 
usual care comparator and so were also not eligible for inclusion (273, 277, 294). In 
summary, the systematic review has highlighted that the methodological quality of the 
literature examining the effectiveness of interventions for extreme obesity is predominantly 
relatively low in the hierarchy of evidence. Thus the quality of evidence would be 
improved by the inclusion of studies adopting controlled study designs.  
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7.4.2 Limitations 
The systematic review was limited by the fact that only three studies were identified which 
were eligible for inclusion. The fact that so few studies were included meant that the 
analyses and summaries of evidence were restricted. The limited body of literature 
highlights the need for a greater number of high quality primary studies. Indeed, the 
management of extreme obesity is a relatively new field, which is growing with the 
increasing prevalence of the condition  (15, 17). This is supported by the fact that the 
included studies were published between 2009 and 2013, all within the last five years. 
Indeed, there is evidence that the body of literature is growing, as the search also identified 
the publication in 2013 of a study protocol for an upcoming pragmatic randomised 
controlled 2-arm trial of an intervention for extreme obese individuals awaiting bariatric 
surgery, the EVOLUTION trial (295). Thus it is possible that whilst there is not yet a 
significant body of evidence, the conduct of primary studies is ongoing, and an update of 
the review will be required in order to identify and incorporate the findings of newly 
published primary studies.  
The present review was also limited by between study heterogeneity in the 
reporting of outcome measures. This restricted the quantitative analyses and as a result, 
only one measure was available for meta-analysis. The incomplete and selective reporting 
of outcome measures was a substantial flaw in the included studies and as such has been 
targeted as a direction for improvement. Despite these limitations, the present systematic 
review was strengthened by the duplication of the study selection, data extraction and 
quality assessment processes by two independent reviewers. Additionally the use of a 
standardised protocol also strengthened the methodology of the review.  
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7.4.3 Conclusions 
The findings of the systematic review indicate that the body of literature is limited, with 
only three primary studies examining the effectiveness of medical and behavioural weight 
management interventions for extreme obese populations eligible for inclusion. Whilst the 
meta-analysis suggests that intensive medically-led lifestyle interventions can yield 
clinically and statistically significant weight loss for individuals with extreme obesity, the 
efficacy of these interventions remains largely unestablished. In order to establish the 
efficacy of weight management interventions for the extreme obese population, the 
conduct of further primary studies examining intervention efficacy within extreme obese 
populations is required. Future primary studies should use controlled designs, thoroughly 
report outcome measures for all study arms at intervention-end and after post-intervention 
follow-up using both LOCF and available case data, and also incorporating measures to 
assess the potential psychological impact of interventions.  
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CHAPTER EIGHT 
 
8.0 THESIS SUMMARY 
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8.1 SUMMARY OF FINDINGS 
 
This thesis has investigated weight management interventions for extreme obesity, 
specifically evaluating the efficacy of two treatment pathways within a currently operating 
Specialist Weight Management Service, as well as reviewing the summarised evidence and 
primary studies evaluating medical and behavioural interventions within extreme obese 
populations. This work has provided a detailed profile of the characteristics of a sample of 
extreme obese individuals entering the service, thus enhancing current understanding of 
individuals attending the service and more broadly of individuals with extreme obesity. 
Specifically, the poor sleep quality and poor quality of life experienced by individuals, as 
well as the widespread prevalence of physical and psychological co-morbid health 
conditions including symptoms of anxiety and depression were highlighted. Further in 
depth analyses examining the association between psychological characteristics and 
adiposity indicated a complex relationship, whereby increasing adiposity was associated 
with a reduction in several areas of quality of life, but was not significantly associated with 
prevalence of anxiety and depression. 
This work has demonstrated the value of the Specialist Weight Management 
Service in the care of individuals with extreme obesity, with both the CWMS 
community-based service and SLiM group education programme achieving clinically 
significant weight loss outcomes. Indeed a substantial proportion of individuals attending 
both treatment pathways achieved weight losses ≥5% baseline body weight which have 
been demonstrated to reduce the risk of cardiovascular disease and overall mortality. In 
addition, both pathways were able to facilitate greater weight losses than demonstrated by 
other specialist weight management services and several but not all commercial and 
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primary care-led programmes. A substantial gap in the weight management literature was 
identified by a systematic review which demonstrated that there were no existing reviews 
examining the efficacy of medical and behavioural weight management interventions for 
extreme obese populations. Subsequently, a systematic review of primary research 
examining the efficacy of medical and behavioural weight management interventions 
within extreme obese samples was conducted, which identified the limited body of good 
quality research. However, the review synthesised the results of two studies which 
demonstrated the value of medically-supported behavioural weight management 
programmes in facilitating statistically and clinically significant weight loss for individuals 
with extreme obesity.  
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8.2 RECOMMENDATIONS 
 
Recommendations have been generated from the findings of this work, including those 
aimed at improving both service provision and the quality of research evaluating weight 
management interventions.  
 
8.2.1 Recommendations for service provision 
A summary of the clinically-focussed recommendations to improve service provision is 
outlined in Figure 8.1. When considering the implementation of any weight management 
service it is essential that both the costs and outcomes associated with the service are taken 
into consideration. Specifically within the Specialist Weight Management Service, the 
nature of the CWMS and SLiM treatment pathways greatly differed in terms of duration 
and intensity of support. The CWMS was associated with a greater number and expertise 
of staff, and a greater number of individuals attending the CWMS pathway, thus making it 
a more expensive option relative to the SLiM pathway. The two treatment pathways both 
yielded clinically significant weight loss outcomes within the measured time period, thus 
indicating that the SLiM pathway is likely to be the more cost-effective of the two 
approaches. However, the longer-term weight loss outcomes of the pathways were not 
assessed in the present study, and would need to be taken into consideration when making 
conclusive recommendations regarding the cost-effectiveness of each of the treatment 
pathways.  
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Figure 8.1: Summary of recommendations for service provision 
 Consider both the outcomes and costs of a weight management service:  
 The multidisciplinary team (MDT) approach provided by the CWMS is more intensive and 
therefore more expensive (estimated at £75 per individual per week) than the SLiM 
programme (estimated at £31 per individual per week) 
 Both treatment pathways yielded clinically significant weight loss outcomes within the 
measured time period 
 The CWMS approach offers longer-term provision of support for individuals (minimum 12 
months), relative to the SLiM programme (6 months) 
 The longer-term outcomes need to be assessed, ideally after a 12 month follow-up period, in 
order to make conclusive cost-effectiveness recommendations for each of the pathways 
 Address the complex medical and psychological needs experienced by those attending the service 
 Incorporate support in managing the mental and physical co-morbidities of extreme obesity 
into multi-disciplinary care 
 Provide support through tailored pilot interventions focusing on:  
 enhancing overall mental health and well-being 
 improving self-esteem 
 managing specific co-morbidities such as type 2 diabetes or OSA 
 coping with multiple co-morbidities and threats to health 
 Provide enhanced support for those potentially less likely to achieve weight loss; younger 
individuals at lower levels of baseline weight reporting better quality of life 
 Improve accessibility of the service for employed individuals by potentially piloting ‘out of hours’ 
sessions held during evenings or weekends 
 Consider piloting additional commencement approaches to increase access such as: 
 Providing awareness events to increase access to the service among minority ethnicity 
communities 
 Providing informal information sessions on referral to the service, dealing with individuals’ 
concerns and queries 
 Increasing contact with those who do not respond to initial communication on referral to the 
service, through follow-up telephone calls 
 
Recommendations also include addressing the complex medical and psychological 
needs experienced by those attending the service, by incorporating support in managing the 
mental as well as physical co-morbidities of extreme obesity into multi-disciplinary care. 
Specifically, support should be provided through tailored interventions which focus on 
enhancing mental health and well-being, with a specific emphasis on improving self-
esteem, as this was an area of great impairment. Those with co-morbid health conditions 
such as type 2 diabetes or OSA which may potentially affect individuals’ ability to achieve 
weight loss may also benefit from further support. A potential need was also identified for 
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the provision of further support for those younger individuals entering the service at lower 
levels of baseline weight and reporting relatively better quality of life, in order to help 
these individuals to achieve weight loss during attendance at the service. Tailoring of the 
interventions for the different needs of the individuals could be achieved by ensuring that 
the sessions are relevant to those attending by considering their specific priorities and 
resources as well as the socio-economic, religious, cultural, family and environmental 
factors which influence weight loss efforts. For instance sessions could focus on 
addressing socio-economic barriers to health through providing low-cost healthy food 
suggestions and recipes and providing information on local free to access physical activity 
opportunities. Indeed programmes tailored for low-income groups have been demonstrated 
to be effective in promoting healthy dietary and physical activity behaviours (296), as have 
those adapted to be culturally sensitive (297). For instance sessions could also be tailored 
at relevant times of the year coinciding with religious and cultural festivals through 
providing support and developing coping strategies to maintain healthy food and activity 
choices during more potentially challenging times where relapse to less healthy behaviours 
may be more likely to occur. Additionally the content of programmes should be modified 
to address specific issues highlighted by the individuals attending, so that targeted 
information can be provided and  group discussion facilitated on the most relevant and 
important areas of concern for individuals.  
 In addition to the modification of support that is provided to individuals, the 
modification of existing service referral processes may also be beneficial. New approaches 
such as the provision of outreach sessions held in local communities, informal information 
sessions and additional follow-up communication during referral could be employed in 
pilot trials to assess their impacts. It is anticipated that through the adoption of improved 
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approaches to the service referral process that the service will be accessible to a greater 
number of individuals of all backgrounds, thus increasing inclusivity and maximising the 
opportunity for weight loss. 
 
8.2.2 Recommendations for future research 
A summary of the recommendations to improve future research is outlined in Figure 8.2. 
The primary recommendation is that the currently limited evidence base for the efficacy of 
weight management interventions within extreme obese samples needs to be expanded 
through the conduct of further research.  
 
Figure 8.2: Summary of recommendations for future research 
 Conduct of further research is required in order to expand the currently limited evidence base for the 
efficacy of weight management interventions within extreme obese samples 
 Collect demographic and clinical information and self-report measures in order to: 
 Understand the specific population attending the service 
 Identify those individuals who may require additional support 
 Utilise methodologically rigorous designs such as controlled studies and RCTs 
 Report outcome measures fully: 
 Include LOCF data as well as available case data for outcomes so that comparisons between 
services can be made 
 Include outcomes for intervention and control arms 
 Include sufficient detail to enable data to be combined in a quantitative synthesis 
 Include an assessment of potential differences between those withdrawing and those completing 
weight management interventions, in order to aid interpretation of findings and minimise the 
potential for withdrawal bias 
 Include quality of life and mental health outcome measures in order to assess the potential 
psychological impacts of services 
 Include the assessment of  long-term outcomes ideally obtained after a 12 month follow-up period, 
in order to determine the impacts of the service beyond intervention-end 
 
Future studies should incorporate the collection of a range of demographic and 
clinical information as well as self-report measures in order to better understand the patient 
population, as undertaken in the present study. The collection of such detailed measures 
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may potentially help to identify those individuals who require additional support in order 
to fully benefit from attendance at the service and have the greatest opportunity to achieve 
weight loss success. Additionally, future studies should also employ methodologically 
rigorous controlled designs such as RCTs, as well as fully reporting outcome measures by 
including LOCF as well as available case data for all study arms. Psychological outcome 
measures should also be included when assessing the impact of interventions, as the effects 
on individuals’ quality of life and mental health are important yet lesser studied factors. 
Finally, it is imperative that studies include long-term outcome measures obtained after a 
follow-up period in order to determine any potential impacts beyond intervention-end. 
Through the expansion of the evidence base with the conduct of further research 
employing such study designs it will be possible to conclusively determine the efficacy of 
weight management services and interventions among extreme obese populations. 
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8.3 CONCLUDING REMARKS 
 
This thesis has made a unique contribution to the limited body of research investigating 
weight management interventions for extreme obesity. The work has enhanced current 
understanding of the extreme obese population, and demonstrated the substantial 
psychological burden of extreme obesity. This work has investigated weight management 
interventions for the lesser-researched extreme obese population, through demonstrating 
the efficacy of two currently operating medically-supported interventions and synthesising 
the evidence in the body of literature. Thus the findings presented in this thesis represent a 
significant addition to the existing evidence base. Recommendations generated from this 
work have been made in order to improve service provision and research of weight 
management interventions. Through the adoption of the clinical and research 
recommendations, it is hoped that the efficacy of weight management services can be 
improved and understanding of specialist weight management services and their patient 
populations can be enhanced. This will ensure that these individuals are given the greatest 
opportunity to achieve weight loss and diminish the negative physical and psychological 
impacts of extreme obesity.   
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APPENDIX ONE 
 
1.0 PROTOCOL FOR THE SYSTEMATIC REVIEW OF SYSTEMATIC 
REVIEWS 
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MEDICAL AND BEHAVIOURAL WEIGHT MANAGEMENT INTERVENTIONS 
FOR EXTREME OBESITY: 
A PROTOCOL FOR A SYSTEMATIC REVIEW OF SYSTEMATIC REVIEWS 
 
Rationale 
Several reviews have examined the impact of non-surgical medical and behavioural weight 
management interventions within obese populations, including a narrative review 
focussing specifically on weight management services in the UK (189), a review and meta-
analysis of interventions delivered solely to male samples (190) and a comprehensive  
Health Technology Assessment including a systematic review of 84 Randomised 
Controlled Trials (RCTs) of obesity treatments (191). The numerous reviews of weight 
management interventions reflect the extensive body of primary studies investigating the 
impact of weight management interventions in obese samples. However, the body of 
literature examining the efficacy of weight management interventions within extreme 
obese (BMI ≥40kg/m2) samples is relatively limited. As such it is anticipated that the 
synthesis of data from primary studies investigating the impact of interventions in extreme 
obese samples within reviews, will consequently also be limited. Given the increasing 
prevalence of extreme obesity and the associated detrimental impacts on the health and 
quality of life of individuals (82), it is important to examine the effectiveness of treatment 
pathways such as medical and behavioural interventions which have been widely adopted 
in the care of individuals with extreme obesity.  
This systematic review will search for systematic reviews examining the 
effectiveness of medical or behavioural weight management interventions within 
exclusively extreme obese (BMI ≥40kg/m2) samples. This systematic review will 
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summarise data from included systematic reviews, and if the systematic reviews identified 
are deemed to be of poor quality or in need of updating due to the accumulation of new 
primary research since publication, then a systematic review of primary studies examining 
intervention effectiveness within extremely obese populations will be conducted in order to 
fill the gap in the body of the literature. The systematic review protocol is registered on the 
PROSPERO international database of prospectively registered systematic reviews in health 
and social care, with registration number CRD42014012988. 
 
Objectives 
The specific objectives of the systematic review are: 
 To produce a systematic review of systematic reviews and health technology 
assessments which have examined the effectiveness of medical and behavioural 
weight management interventions for adults with extreme obesity (defined as 
baseline BMI ≥40.0kg/m2) on change in weight or BMI, change in presence or 
severity of co-morbid health conditions, change in cardiovascular profile, change in 
quality of life or change in mental health. 
 To produce a summary of the evidence of the effectiveness of medical and 
behavioural weight management interventions for extreme obesity.  
 To analyse the quality of the reviews and provide a summary of the best evidence 
available. 
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Research question 
The systematic review question was formulated using the PICOS format: 
Population: Adults with extreme obesity, defined as mean baseline BMI of all included 
primary studies 40.0kg/m2. 
Intervention: Medical or behavioural weight management (any non-surgical intervention 
which encompasses behavioural modification, medical or pharmaceutical components) of 
any duration. 
Comparators: The reviews may incorporate a range of comparator groups including but 
not limited to control not receiving intervention, control receiving usual care, or alternative 
non-surgical intervention.  
Outcomes: Weight and BMI change, change in presence and severity of co-morbid health 
conditions, change in cardiovascular profile, change in quality of life and mental health. 
Study design: Systematic reviews and health technology assessments. 
 
This gave rise to the following question to be answered by the systematic review: ‘What is 
the summarised evidence for the effectiveness of medical and behavioural weight 
management interventions for extreme obesity?’ 
 
Eligibility criteria  
 Population: 
o Reviews reporting intervention effectiveness exclusively in BMI 
≥40.0kg/m2 populations will be included. 
o Reviews reporting intervention effectiveness in broader overweight and 
obese BMI ≥30.0kg/m2 populations will be excluded. 
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o Reviews where included study populations are adult (≥18 years) will be 
included. 
o Reviews including study populations based on health conditions other than 
obesity will be excluded, for instance samples including solely individuals 
with type 2 diabetes, stroke, cancer, and schizophrenia. 
 Interventions: 
o Reviews of non-surgical interventions providing medical and or behavioural 
support incorporating pharmaceutical therapies, counselling, education, and 
lifestyle modification incorporating diet and exercise will be included. 
o Reviews which include interventions of any duration will be included. 
 Outcomes: 
o Reviews which report synthesis of any of the following outcomes: weight or 
BMI change, change in presence or severity of co-morbid health conditions, 
change in cardiovascular profile, change in quality of life or mental health, 
from baseline to intervention-end or post-intervention follow-up will be 
included. 
 Study design: 
o Systematic reviews and health technology assessments will be included.  
 
Information sources 
A search of the following databases within the Cochrane Library will be conducted: the 
Cochrane Database of Systematic Reviews (CDSR), the Database of Abstracts and 
Reviews of Effects (DARE), and the Health Technology Assessment Database (HTAD), 
from inception to time of search. In addition, the reference lists of reviews included in the 
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systematic review will be hand-searched. A flow diagram as outlined in figure 1 will be 
used to demonstrate the process of study identification, as outlined in the PRISMA 
statement (192). 
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Figure 1: Flow diagram outlining the identification of included reviews 
 
 
 
Number identified 
through included 
reviews 
XXXXX 
Number of records after duplicates removed 
XXXXX 
Number of records screened 
XXXXX 
Number identified 
through database 
searching 
XXXXX 
Number of records excluded 
XXXXX 
Number of full text articles 
assessed for eligibility 
XXXXX 
Number of reviews included 
in qualitative synthesis 
XXXXX 
Number of reviews included 
in quantitative synthesis 
XXXXX 
Number of full text articles 
excluded 
XXXXX 
Reason 1: N= XXX 
Reason 2: N= XXX 
Reason 3: N= XXX 
Reason 4: N= XXX 
Reason 5: N= XXX 
Reason 6: N= XXX 
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Search strategy 
The following search strategy will be used to search for review articles that summarise data 
on the effectiveness of medical or behavioural weight management interventions of any 
duration, for samples with extreme obesity, defined as sample mean BMI 40.0 kg/m2. 
Terms will be entered as free text and MeSH term searches in the Cochrane Library search 
engine, screening records obtained from the CDSR, DARE and HTAD. 
 
Search terms 
1. Adult* 
2. Overweight (MeSH) explode all trees 
3. Obesity (MeSH) explode all trees 
4. Obes* 
5. Body Mass Index (MeSH) explode all trees 
6. BMI 
7. Body Weight (MeSH) explode all trees 
8. 2 or 3 or 4 or 5 or 6 or 7 
9. 1 and 8 
10. Intervention 
11. Life style (MeSH) explode all trees 
12. Health Promotion (MeSH) explode all trees 
13. Health Education (MeSH) explode all trees 
14. Patient Education as Topic (MeSH) explode all trees 
15. Counseling (MeSH) explode all trees 
16. Behavior (MeSH) explode all trees 
17. Anti-Obesity Agents (MeSH) explode all trees 
18. Weight Loss (MeSH) explode all trees 
19. Diet, Reducing (MeSH) explode all trees 
20. Weight Reduction Programs (MeSH) explode all trees 
21. Exercise (MeSH) explode all trees 
22. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
23. 10 and 22 
24. 9 and 23 
25. 24 in Cochrane Reviews (Reviews and protocols), Other Reviews and Technology 
Assessments 
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Article selection 
The number of records retrieved will be recorded in the flow diagram as illustrated in 
figure 1 and the records will be exported to be managed using EndNote software. The 
number of duplicate records will be recorded and duplicate records will then be removed. 
The remaining records will first be screened by title and abstract, to assess if the records 
meet the eligibility criteria relating to population, intervention, outcome and study design, 
with those records that are judged to not meet eligibility criteria removed, and the number 
excluded at this stage will be recorded.  
The process of review selection will be conducted independently by two reviewers 
who will meet once the first phase of selection (screening by title and abstract) is complete. 
Discrepancies will be discussed and where consensus to a disagreement is not reached a 
third party will be invited to adjudicate on whether full text copies of reviews should be 
screened, after which the final number of reviews to be screened as full text will be 
determined.  
After obtaining full text copies, the second phase of review selection (screening full 
text) will be conducted the reviewers, with those not meeting the eligibility criteria at this 
stage excluded and the excluded records will be grouped by reason for exclusion, so that 
the number of records excluded for each reason can be identified. The final number of 
reviews included in the systematic review will be recorded and the reference lists of these 
reviews will be searched to identify any further relevant reviews, which will then be 
screened and if they meet eligibility criteria will subsequently be added to the total number 
of reviews to be included in the systematic review of reviews. The two reviewers will meet 
once the second selection phase is complete. Discrepancies will be discussed and where 
consensus to a disagreement is not reached a third party will be invited to adjudicate on 
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whether reviews should be included, after which the final number of included reviews will 
be determined. 
 
Data extraction 
The two reviewers will independently extract data items from the information provided in 
the full text articles, into an Excel spreadsheet whereby each study will be represented in a 
row of data in the spreadsheet. Accompanying notes displayed in Table 1 were developed 
for use in the present review with reference to the Cochrane Handbook for Systematic 
Reviews of Interventions (Version 5.1.0) (194), which will provide further detail and be 
used as a reference when entering the data items into the spreadsheet. The two reviewers 
will meet once data extraction has taken place independently, and any discrepancies will be 
investigated, with a third party invited to adjudicate where consensus is not reached. Data 
items from the finalised data extraction spreadsheet will then be used to produce review 
characteristics tables as illustrated in Table 2, which will be used in qualitative analysis. 
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Table 1: Accompanying notes for data extraction 
Field 
 
Data points to be extracted 
 
Review 
Author, 
Publication year. 
Methods 
Design (state whether systematic review, Health Technology Assessment) 
Objectives of review. 
Study 
characteristics 
Total number of included studies within review,  
Participant characteristics including range of age, gender, ethnicity, co-morbid health 
conditions, across studies, 
Range of mean baseline weight of the primary studies, 
Range of mean baseline BMI of the primary studies. 
Intervention 
 
Range of intervention types: i.e. pharmaceutical/behavioural/combination,  
Range of number of intervention groups,  
Range of intervention settings (where intervention is delivered),  
Range of delivery personnel type (if healthcare professional specify which, researcher, 
lay public),  
Range of delivery personnel training (detail of training in intervention delivery 
received),  
Range of duration of interventions (number and duration of contact time, including 
face to face sessions, email, telephone or other contact), 
Intensity of interventions (frequency of sessions and contact), 
Theoretical basis of interventions (e.g. self-management, cognitive behavioural) 
Range of numbers of participants entering intervention group,  
Range of numbers of participants completing intervention/presenting for data 
collection,  
Range of reported loss to follow-up rate in intervention groups across primary studies. 
Comparator 
 
Range of numbers of comparator groups across primary studies,  
Descriptions of comparator or usual care,  
Range of numbers of participants entering comparator group,  
Range of numbers of participants completing comparator group/presenting for data 
collection,  
Range of reported loss to follow-up rate in comparator groups across primary studies.  
Outcomes 
Mean effect size, weighted effect size,  
Mean difference, standardised mean difference, weighted mean difference and p values 
between intervention and control groups for the following outcomes of interest: 
 Change in weight or BMI,  
 Change in presence or severity of co-morbid health conditions,  
 Change in cardiovascular profile,  
 Change in quality of life or mental health. 
For reviews not reporting quantitative data synthesis: 
Range of effects across primary studies and main conclusions of review. 
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Table 2: Review characteristics table 
Review Methods  Participants Intervention Comparator Outcomes 
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Quality assessment 
Included reviews will be appraised for methodological quality using the ‘Assessment of 
multiple systematic reviews’ (AMSTAR) measurement tool (195) as illustrated in table 3. 
The tool will be used to assess the methodological quality according the following criteria; 
reporting of an a priori design, duplication of study selection and data extraction, whether a 
comprehensive literature search is performed and whether publication status determines 
eligibility for inclusion, reporting of included and excluded studies and characteristics of 
the included studies, the assessment, reporting and use of scientiﬁc quality of the included 
studies, use of appropriate methods to combine study ﬁndings, and the reporting of 
potential publication bias and conflicts of interest. 
Following the assessment of each of the included reviews, evaluation summaries 
will be made across reviews and domains. The quality assessment information will be used 
to inform the interpretation of the findings of each of the included reviews, with 
consideration of potential methodological factors which could introduce bias to review 
findings, which will be highlighted. If appropriate, recommendations to improve the 
methodological and reporting quality of future reviews will be made, highlighting areas of 
current limitation where improvement is required. 
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Table 3: AMSTAR tool 
1. Was an 'a priori' 
design provided?  
 
The research question and inclusion criteria should be established before the 
conduct of the review. 
Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori 
published research objectives to score a “yes.”  
□ Yes  
□ No  
□ Can't answer  
□ Not applicable  
2. Was there 
duplicate study 
selection and data 
extraction?  
 
There should be at least two independent data extractors and a consensus procedure 
for disagreements should be in place. 
Note: 2 people do study selection, 2 people do data extraction, consensus process 
or one person checks the other’s work.  
□ Yes  
□ No  
□ Can't answer  
□ Not applicable  
3. Was a 
comprehensive 
literature search 
performed?  
 
At least two electronic sources should be searched. The report must include years 
and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or 
MESH terms must be stated and where feasible the search strategy should be 
provided. All searches should be supplemented by consulting current contents, 
reviews, textbooks, specialized registers, or experts in the particular field of study, 
and by reviewing the references in the studies found.  
Note: If at least 2 sources + one supplementary strategy used, select “yes” 
(Cochrane register/Central counts as 2 sources; a grey literature search counts as 
supplementary).  
□ Yes  
□ No  
□ Can't answer  
□ Not applicable  
4. Was the status of 
publication (i.e. grey 
literature) used as an 
inclusion criterion?  
 
The authors should state that they searched for reports regardless of their 
publication type. The authors should state whether or not they excluded any reports 
(from the systematic review), based on their publication status, language etc.  
Note: If review indicates that there was a search for “grey literature” or 
“unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference 
proceedings, and trial registries are all considered grey for this purpose. If 
searching a source that contains both grey and non-grey, must specify that they 
were searching for grey/unpublished lit.  
□ Yes  
□ No  
□ Can't answer  
□ Not applicable  
5. Was a list of 
studies (included and 
excluded) provided?  
 
A list of included and excluded studies should be provided.  
Note: Acceptable if the excluded studies are referenced. If there is an electronic 
link to the list but the link is dead, select “no.”  
□ Yes  
□ No  
□ Can't answer  
□ Not applicable  
6. Were the 
characteristics of the 
included studies 
provided?  
 
In an aggregated form such as a table, data from the original studies should be 
provided on the participants, interventions and outcomes. The ranges of 
characteristics in all the studies analysed e.g., age, race, sex, relevant 
socioeconomic data, disease status, duration, severity, or other diseases should be 
reported.  
Note: Acceptable if not in table format as long as they are described as above.  
□ Yes  
□ No  
  
323 
 
□ Can't answer  
□ Not applicable  
7. Was the scientific 
quality of the 
included studies 
assessed and 
documented?  
 
'A priori' methods of assessment should be provided (e.g., for effectiveness studies 
if the author(s) chose to include only randomized, double-blind, placebo controlled 
studies, or allocation concealment as inclusion criteria); for other types of studies 
alternative items will be relevant.  
Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk 
of bias, sensitivity analysis, etc., or a description of quality items, with some kind 
of result for  
EACH study (“low” or “high” is fine, as long as it is clear which studies scored 
“low” and which scored “high”; a summary score/range for all studies is not 
acceptable).  
□ Yes  
□ No  
□ Can't answer  
□ Not applicable  
8. Was the scientific 
quality of the 
included studies used 
appropriately in 
formulating 
conclusions?  
 
The results of the methodological rigor and scientific quality should be considered 
in the analysis and the conclusions of the review, and explicitly stated in 
formulating recommendations.  
Note: Might say something such as “the results should be interpreted with caution 
due to poor quality of included studies.” Cannot score “yes” for this question if 
scored “no” for question 7.  
□ Yes  
□ No  
□ Can't answer  
□ Not applicable  
9. Were the methods 
used to combine the 
findings of studies 
appropriate?  
 
For the pooled results, a test should be done to ensure the studies were combinable, 
to assess their homogeneity (i.e., Chi-squared test for homogeneity, I
2
). If 
heterogeneity exists a random effects model should be used and/or the clinical 
appropriateness of combining should be taken into consideration (i.e., is it sensible 
to combine?).  
Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain 
that they cannot pool because of heterogeneity/variability between interventions.  
□ Yes  
□ No  
□ Can't answer  
□ Not applicable  
10. Was the 
likelihood of 
publication bias 
assessed?  
 
An assessment of publication bias should include a combination of graphical aids 
(e.g. funnel plot, other available tests) and/or statistical tests (e.g., Egger regression 
test, Hedges-Olken).  
Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions 
that publication bias could not be assessed because there were fewer than 10 
included studies.  
□ Yes  
□ No  
□ Can't answer  
□ Not applicable  
11. Was the conflict 
of interest included?  
 
Potential sources of support should be clearly acknowledged in both the systematic 
review and the included studies.  
Note: To get a “yes,” must indicate source of funding or support for the systematic 
review AND for each of the included studies.  
□ Yes  
□ No  
□ Can't answer  
□ Not applicable  
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Data synthesis and analysis 
Qualitative analysis will provide a narrative summary of the findings of the individual 
included reviews for each of the outcomes of interest, with data presented in review 
characteristics tables. Qualitative analysis will also provide a summary of the 
methodological quality of the included reviews and any potential impact on the findings of 
each of the reviews, and potential impact on the conclusions of the overview of systematic 
reviews. Additionally qualitative analysis will be used to inform recommendations for the 
conduct and reporting of future reviews. 
The quantitative findings of the reviews will be illustrated using forest plots 
without summary statistics for each of the following outcomes of interest: weight change, 
BMI change, change in co-morbidity presence, change in co-morbidity severity, quality of 
life change, mental health change and cardiovascular change for BMI ≥40.0kg/m2 samples.  
A detailed report of the findings of the overview of systematic reviews will be 
written as a thesis chapter. The findings will be reported utilising the PRISMA 27-item 
checklist and flow-diagram illustrating the flow of information through the phases of the 
systematic review (192). The use of the PRISMA statement will enhance reporting by 
facilitating explicit description of the systematic review. 
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APPENDIX TWO 
 
2.0 PROTOCOL FOR THE SYSTEMATIC REVIEW OF PRIMARY STUDIES 
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MEDICAL AND BEHAVIOURAL WEIGHT MANGEMENT INTERVENTIONS 
FOR EXTREME OBESITY: 
A PROTOCOL FOR A SYTEMATIC REVIEW OF PRIMARY STUDIES 
 
Rationale  
The prevalence of obesity among adults, and in particular extreme obesity, has risen 
rapidly over previous decades (82). Levels of extreme obesity (BMI ≥40kg/m2) in the US 
have increased 70% over the last decade (2000 - 2010), with the prevalence reaching 6.6% 
(24). Indeed, recent estimates predict the prevalence of extreme obesity to reach 9% in the 
US by 2030 and 5% in the UK by 2033 (25). The increasing prevalence of extreme obesity 
and associated diseases has created increased demand for weight management services in 
the UK. The National Institute for Health and Care Excellence (NICE) has recommended 
the development of multidisciplinary care teams in the management of obesity and its co-
morbid complications (14). Indeed, NICE has recommended management in a specialist 
obesity service for a minimum period of 6 months before bariatric surgery is considered as 
a treatment option (14). 
The increasing prevalence of obesity and the associated detrimental impacts on 
individuals’ health and quality of life, have led to the development of a variety of weight 
management programmes delivered across primary and specialist healthcare settings, as 
well as commercial and research settings.  However, there is a lack of consensus as to 
which weight management interventions are effective in facilitating weight loss in 
individuals with extreme obesity who have complex care needs. A narrative review of 
weight management services in the UK published in 2012, details the efficacy of services 
delivered to individuals with BMI ≥30kg/m2 (189). The review encompassed a range of 
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programmes and services including the Counterweight primary care model of weight 
management (29), the Specialist Glasgow and Clyde weight management service (174) as 
well as the multi-arm Lighten-Up trial which incorporated commercial and primary care 
interventions (34). The review demonstrated that studies with a minimum of 12-month 
outcome data were few and that evidence is lacking for services delivered to individuals at 
the extreme end of the obesity spectrum. One of the studies included in the review reported 
data from an audit of primary care referral to the Slimming World intervention (37), which 
since publication of the narrative review published the findings of further analysis of the 
same population in an extreme obese BMI ≥40kg/m2 subgroup (179).  
Whilst the narrative review demonstrated an overall representation and summary of 
the evidence for interventions for obese individuals in the UK, it did not however advance 
understanding about the effectiveness of interventions specifically in the extreme obese 
population. Furthermore, a comprehensive  Health Technology Assessment published in 
2004 included a systematic review of 84 Randomised Controlled Trials (RCTs) of weight 
loss interventions for obese individuals with BMI ≥30 kg/m2 (191), which again provided a  
synthesis of the evidence and recommendation in the treatment and care of obese 
individuals with no focus on extreme obesity.  
A scoping exercise has revealed that the evidence base for medical and behavioural 
weight management interventions for extreme obesity is limited, and furthermore there are 
no protocols or review questions regarding interventions for this population registered in 
the Cochrane library or Prospero database. The limited evidence base has meant that the 
variation in weight management service provision available for extreme obese individuals 
in the UK and internationally is continuing. However, the increasing prevalence of obesity 
and subsequent demand for services means that establishing the effectiveness of weight 
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management services is essential in order to ensure that individuals are given the best 
opportunity at achieving weight loss. A systematic review will be conducted in order to 
provide an additional contribution to the evidence base, as there are no published 
systematic reviews specifically addressing interventions for extreme obesity. The 
systematic review protocol is registered on the PROSPERO international database of 
prospectively registered systematic reviews in health and social care, with registration 
number CRD42014010473. 
 
Objectives 
The specific objectives of the systematic review are: 
 To summarise the effectiveness of medical and behavioural weight management 
interventions for adults with extreme obesity (defined as baseline BMI ≥40.0kg/m2) 
on weight change, including if appropriate a meta-analysis of the effect of 
interventions on weight and BMI change. 
 The secondary objectives are to examine the impact of these interventions on 
psychological profile (incorporating quality of life and mental health) and 
cardiovascular profile (incorporating blood pressure and lipids), with a meta-
analysis if appropriate, of the effect of interventions on psychological and 
cardiovascular factors. 
 To analyse study quality and provide a summary of the best evidence available. 
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Research question 
The systematic review question was formulated using the PICOS format: 
Population: Adults with extreme obesity, defined as BMI 40.0kg/m2  
Intervention:  Medical and behavioural weight management (any non-surgical 
intervention which encompasses behavioural modification, medical or 
pharmaceutical components) of any duration. 
Comparators: Control arm comprising usual care. 
Outcomes:  Primary outcome: Weight and BMI change at post-intervention follow-up, 
or at intervention-end where follow-up is not available. 
Secondary outcomes: Quality of life, mental health, and biomedical (blood pressure, lipids) 
change at post-intervention follow-up, or at intervention-end where follow-
up is not available. 
Study design: Randomised Controlled Trials (RCTs), controlled non-randomised studies, 
controlled observational studies (prospective or retrospective cohort studies 
with concurrent controls). 
 
This gave rise to the following question to be answered by the systematic review: ‘What is 
the effectiveness of medical and behavioural weight management interventions for extreme 
obesity?’ 
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Eligibility criteria  
 Population: 
o Study samples of adults, defined as aged ≥18 years will be included. 
o Samples of individuals with extreme obesity (mean baseline BMI 
≥40.0kg/m2), will be included, incorporating separate BMI ≥40.0kg/m2 sub-
group samples and overall study samples. 
 
 Interventions: 
o Interventions providing medical and or behavioural support, incorporating 
pharmaceutical therapies, counselling, education, and lifestyle modification 
including diet and exercise will be included. 
o Interventions of any duration will be included. 
o Studies which include surgical intervention will be excluded. 
 Comparator: 
o Control arm receiving usual care or receiving no intervention.  
 Outcomes: 
o Studies reporting weight and or BMI measures at baseline and at 
intervention-end, or weight and or BMI change scores will be included. 
o Studies which report baseline characteristics data without post-intervention 
follow-up or intervention-end weight or BMI outcome data will be 
excluded.  
 Study design: 
o RCTs, controlled non-randomised studies, and controlled observational 
studies (prospective and retrospective cohort studies with concurrent 
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controls) will be included. Study designs further down the hierarchy of 
evidence, such as observational studies without concurrent control groups 
will be excluded.  
o Studies published up to and including June 2014 will be included. 
o Studies published in any language will be included. 
o Review articles, editorials, commentaries and letters will be excluded. 
 
Information sources 
A search will be conducted in the area of medical and behavioural management of extreme 
obesity using the following electronic databases: MEDLINE (Ovid), EMBASE (Ovid), 
CINAHL (Ebsco host), and Cochrane Central Register of Controlled Trials (CENTRAL) 
database, from inception to time of search. In addition, grey literature including conference 
abstracts and doctoral theses will be searched using the OpenGray and Zetoc databases, 
and reference lists of papers included in the review will be hand-searched. A flow diagram 
as outlined in figure 1 will be used to demonstrate the process of study identification, as 
outlined in the PRISMA statement (192). 
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Figure 1: Flow diagram of the identification of included studies 
 
 
 
Number identified 
through other 
sources 
XXXXX 
Number of records after duplicates removed 
XXXXX 
Number of records screened 
XXXXX 
Number identified 
through database 
searching 
XXXXX 
Number of records excluded 
XXXXX 
Number of full text articles 
assessed for eligibility 
XXXXX 
Number of studies included 
in qualitative synthesis 
XXXXX 
Number of studies included 
in quantitative synthesis 
XXXXX 
Number of full text articles 
excluded 
XXXXX 
Reason 1: N= XXX 
Reason 2: N= XXX 
Reason 3: N= XXX 
Reason 4: N= XXX 
Reason 5: N= XXX 
Reason 6: N= XXX 
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Search strategy 
The following search strategy will be used to search for articles that detail medical or 
behavioural weight management interventions of any duration, to samples with extreme 
obesity, defined as mean BMI 40.0kg/m2. When searching the EMBASE and MEDLINE 
databases MeSH and free text terms will be entered into multi-purpose (.mp) searches. The 
CINAHL database will be searched by entering MeSH terms as exact major subject 
headings (MM), and free text terms as words in major subject headings (MJ). In the 
Cochrane CENTRAL database terms will be entered as MeSH and free text terms, where 
relevant MeSH terms are not available. 
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Search terms: EMBASE 
1. Adult*.mp 
2. Overweight*.mp 
3. Obesity/ dm, dt, rh, th (MeSH) 
4. Obes*.mp 
5. Body Mass/ (MeSH) explode all trees 
6. BMI.mp 
7. Body Weight/ co, dt, th (MeSH) 
8. 2 or 3 or 4 or 5 or 6 or 7 
9. 1 and 8 
10. Intervention.mp 
11. Life style/ (MeSH) explode all trees 
12. Health Promotion/ (MeSH) explode all trees 
13. Health Education/ (MeSH) explode all trees 
14. Patient Education as topic/ (MeSH) explode all trees 
15. Counseling/ (MeSH) explode all trees 
16. Behavior/ dt, rh, th (MeSH) 
17. Antiobesity Agent/ ct, dt (MeSH) 
18. Diet Restriction/ (MeSH) explode all trees 
19. Weight Reduction/ dt, th (MeSH) 
20. Exercise/ (MeSH) explode all trees 
21. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
22. 10 and 21 
23. 9 and 22 
24. Limit 23 to humans 
25. Limit 24 to “therapy (maximizes sensitivity)” 
26. Control*.mp 
27. 24 and 26 
28. 25 or 27 
 
mp= title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword. 
dm= disease management, dt= drug therapy, rh= rehabilitation, th= therapy, co= 
complication, ct= clinical trial. 
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Search terms: MEDLINE 
1. Adult*.mp 
2. Overweight/ dh, dt, rh, th, nu (MeSH) 
3. Obesity/ dh, dt, rh, th, nu (MeSH) 
4. Obes*.mp 
5. Body Mass Index/ (MeSH) explode all trees 
6. BMI.mp 
7. Body Weight.mp 
8. 2 or 3 or 4 or 5 or 6 or 7 
9. 1 and 8 
10. Intervention.mp 
11. Life style/ (MeSH) explode all trees 
12. Health Promotion/ (MeSH) explode all trees 
13. Health Education/ (MeSH) explode all trees 
14. Patient Education as topic/ (MeSH) explode all trees 
15. Counseling/ (MeSH) explode all trees 
16. Behavior/ (MeSH) explode all trees 
17. Anti-obesity Agents/ (MeSH) explode all trees 
18. Weight Reduction Programs/ (MeSH) explode all trees 
19. Diet, Reducing/ (MeSH) explode all trees 
20. Weight Loss/ dt, th (MeSH) 
21. Exercise (MeSH) explode all trees 
22. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
23. 10 and 22 
24. 9 and 23 
25. Limit 24 to humans 
26. Limit 25 to “therapy (maximizes sensitivity)” 
27. Control*.mp 
28. 25 and 27 
29. 26 or 28 
.mp= title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword. 
dh= diet therapy, dt= drug therapy, rh= rehabilitation, th= therapy, nu= nursing 
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Search terms: CINAHL 
1. MJ Adult* 
2. MJ Overweight 
3. MM Obesity/ dh, dt, rh, th, nu (MeSH) 
4. MJ Obes* 
5. MM Body Mass Index/ (MeSH) explode all trees 
6. MJ BMI 
7. MM Body Weight (MeSH) explode all trees 
8. 2 or 3 or 4 or 5 or 6 or 7 
9. 1 and 8 
10. MJ Intervention 
11. MM Life style/ (MeSH) explode all trees 
12. MM Health Promotion/ (MeSH) explode all trees 
13. MM Health Education/ (MeSH) explode all trees 
14. MM Patient Education as topic/ (MeSH) explode all trees 
15. MM Counseling/ (MeSH) explode all trees 
16. MM Behavior/ (MeSH) explode all trees 
17. MM Anti-obesity Agents/ (MeSH) explode all trees 
18. MM Weight Reduction Programs/ (MeSH) explode all trees 
19. MM Diet, Reducing/ (MeSH) explode all trees 
20. MM Weight Loss/ dh, dt, th (MeSH) 
21. MM Exercise (MeSH) explode all trees 
22. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
23. 10 and 22 
24. 9 and 23 
25. Limiters to 24- Human 
26. Limiters to 24- Clinical Queries: Therapy- High Sensitivity; Human 
27. MJ Control* 
28. 25 and 27 
29. 26 or 28 
MM= Exact Major Subject Headings, MJ= Word in Major Subject Headings. 
dh= diet therapy, dt= drug therapy, nu= nursing, rh= rehabilitation, th= therapy.  
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Search terms: Cochrane Central Register of Controlled Trials (CENTRAL) 
26. Adult* 
27. Overweight (MeSH) explode all trees 
28. Obesity (MeSH) explode all trees 
29. Obes* 
30. Body Mass Index (MeSH) explode all trees 
31. BMI 
32. Body Weight (MeSH) explode all trees 
33. 2 or 3 or 4 or 5 or 6 or 7 
34. 1 and 8 
35. Intervention 
36. Life style (MeSH) explode all trees 
37. Health Promotion (MeSH) explode all trees 
38. Health Education (MeSH) explode all trees 
39. Patient Education as Topic (MeSH) explode all trees 
40. Counseling (MeSH) explode all trees 
41. Behavior (MeSH) explode all trees 
42. Anti-Obesity Agents (MeSH) explode all trees 
43. Weight Loss (MeSH) explode all trees 
44. Diet, Reducing (MeSH) explode all trees 
45. Weight Reduction Programs (MeSH) explode all trees 
46. Exercise (MeSH) explode all trees 
47. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
48. 10 and 22 
49. 9 and 23 
50. 24 in Trials 
 
Study selection 
The number of records retrieved will be recorded in the flow diagram as illustrated in 
figure 1 and the records will be exported to be managed using EndNote software. The 
number of duplicate records will be recorded and duplicate records will then be removed. 
The remaining records will first be screened by title and abstract, to assess if the records 
meet the eligibility criteria relating to population, intervention, outcome and study design, 
with those records that are judged to not meet eligibility criteria removed, and the number 
excluded at this stage will be recorded.  
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The process of study selection will be conducted independently by two reviewers 
who will meet once the first phase of selection (screening by title and abstract) is complete. 
Discrepancies will be discussed and where consensus to a disagreement is not reached a 
third party will be invited to adjudicate on whether full text copies of studies should be 
screened, after which the final number of studies to be screened as full text will be 
determined.  
After obtaining full text copies, the second phase of study selection (screening full 
text) will be conducted the reviewers, with those not meeting the eligibility criteria at this 
stage excluded and the excluded records will be grouped by reason for exclusion, so that 
the number of records excluded for each reason can be identified. The final number of 
studies included in the systematic review will be recorded and the reference lists of these 
studies will be searched to identify any further relevant studies, which will then be 
screened and if they meet eligibility criteria will subsequently be added to the total number 
of studies to be included in the systematic review. The two reviewers will meet once the 
second selection phase is complete. Discrepancies will be discussed and where consensus 
to a disagreement is not reached a third party will be invited to adjudicate on whether 
studies should be included, after which the final number of included studies will be 
determined. 
 
Data extraction 
The two reviewers will independently extract data items from the information provided in 
the full text articles, into an Excel spreadsheet whereby each study will be represented in a 
row of data in the spreadsheet. Accompanying notes displayed in Table 1 were developed 
for use in the present review with reference to the Cochrane Handbook for Systematic 
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Reviews of Interventions (Version 5.1.0) (194), which will provide further detail and be 
used as a reference when entering the data items into the spreadsheet. The two reviewers 
will meet once data extraction has taken place independently, and any discrepancies will be 
investigated, with a third party invited to adjudicate where consensus is not reached. 
Relevant data items from the finalised data extraction spreadsheet will then be transferred 
to RevMan software for quantitative analysis and will be used to produce study 
characteristics tables as illustrated in Table 2, which will be used in qualitative analysis. 
 
Table 1: Accompanying notes for data extraction 
Field 
 
Data items to be extracted into Excel spreadsheet 
 
Study 
 Author, 
 Publication year, 
 Country (including city or region) 
Methods 
 Design, (specify RCT, controlled non-randomised, controlled 
observational: prospective cohort with concurrent or historical control, 
retrospective cohort with concurrent control) 
 Objectives, 
 Randomisation method, (detail method or state not used) 
 Study duration (from point of recruitment to last data collection) 
Participants 
 
 Total number recruited,  
 Location of recruitment (e.g. healthcare clinic/hospital, community 
organisation/group, specified region of healthcare organisation such as 
specific Primary Care Trust), 
 Recruitment/referral criteria,  
 Age (mean and standard deviation years) and age range study sample, 
 Gender (number and proportion male and female), 
 Ethnicity (number and proportion of each ethnic group), 
 Weight (baseline mean and standard deviation), 
 BMI (baseline mean and standard deviation),  
 State whether participant data is for whole study sample (i.e. mean study 
sample baseline BMI is 40.0kg/m2) or for a BMI 40.0kg/m2 subgroup. 
Intervention 
 
 Nature of intervention: (i.e. behavioural, medical, education, 
pharmaceutical, very low calorie diet, other, or a combination), 
 Number of intervention groups,  
 Intervention setting (where intervention is delivered), 
 Delivery personnel type (if healthcare professional specify which, 
researcher, lay public),  
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 Delivery personnel training (detail of training in intervention delivery 
received),  
 Duration of intervention (number and duration of contact time, including 
face to face sessions, email, telephone or other contact), 
 Intensity of intervention (frequency of sessions and contact), 
 Theoretical basis of intervention (e.g. self-management, cognitive 
behavioural) 
 Number of participants assigned/randomised to intervention group,  
 Number of participants entering intervention group,  
 Number of participants completing intervention at intervention-end, 
 Number of participants completing intervention or presenting at time of 
last data collection, 
 Loss to follow-up rate: (number randomised-number completing/number 
randomised), 
 Any significant differences identified between participants completing 
and those lost to follow-up (detail which factors differ, state none for 
specified factors if authors report this, or state not reported). 
Comparator 
 
 Number of comparator groups,  
 Description of comparator or usual care,  
 Number of participants assigned/randomised to comparator group,  
 Number of participants entering comparator group,  
 Number of participants completing comparator group at intervention-
end, 
 Number of participants completing comparator group or presenting at 
time of last data collection, 
 Loss to follow-up rate: (number randomised-number completing/number 
randomised), 
 Any significant differences identified between participants completing 
and those lost to follow-up (detail which factors differ, state none for 
specified factors if authors report this, or state not reported). 
Outcomes 
Primary outcomes using LOCF data:  
 Weight change from baseline at last point of data collection calculated 
using last observation carried forward (LOCF) data (include mean and 
standard deviation, state time point at which obtained),  
 BMI change from baseline at last point of data collection calculated 
using last observation carried forward (LOCF) data (include mean and 
standard deviation), state time point at which obtained),  
 Weight change from baseline at intervention-end calculated using last 
observation carried forward (LOCF) data (include mean and standard 
deviation),  
 BMI change from baseline at intervention-end calculated using last 
observation carried forward (LOCF) data (include mean and standard 
deviation), 
 Proportion losing weight (any amount), proportion losing 5% baseline 
weight at last point of data collection calculated using last observation 
carried forward (LOCF) data,  
 Proportion losing weight (any amount), proportion losing 5% baseline 
weight at intervention-end calculated using last observation carried 
forward (LOCF) data,  
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Primary outcomes using available case data:  
 Weight change from baseline at last point of data collection calculated 
using available case data (include mean and standard deviation, state 
time point at which obtained),  
 BMI change from baseline at last point of data collection calculated 
using available case data (include mean and standard deviation), state 
time point at which obtained),  
 Weight change from baseline at intervention-end calculated using 
available case data (include mean and standard deviation),  
 BMI change from baseline at intervention-end calculated using available 
case data (include mean and standard deviation), 
 Proportion losing weight (any amount), proportion losing 5% baseline 
weight at last point of data collection calculated using available case 
data,  
 Proportion losing weight (any amount), proportion losing 5% baseline 
weight at intervention-end calculated using available case data.  
 
Secondary outcomes: 
 Quality of life change from baseline to last point of data collection, 
 Quality of life change from baseline to intervention-end,  
 State quality of life measure used and report change for all if >1 used, 
 Mental health change from baseline to last point of data collection, 
 Mental health change from baseline to intervention-end,  
 State mental health measure used and report change for all if >1 used, 
 Systolic and diastolic blood pressure change from baseline to last point 
of data collection, 
 Systolic and diastolic blood pressure change from baseline to 
intervention-end,  
 HDL-, LDL- and total cholesterol change from baseline to last point of 
data collection, 
 HDL-, LDL- and total cholesterol change from baseline to intervention-
end,  
 
For all outcomes include description of confounders where adjusted-estimates 
are reported and include category boundaries where continuous variables are 
categorized. 
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Table 2: Study characteristics table 
Study Methods  Participants Intervention Comparator Outcomes 
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Quality assessment 
It is anticipated that the review will encompass a variety of study designs, such as RCTs, 
controlled non-randomised studies, and controlled observational studies including 
prospective and retrospective cohort studies with concurrent controls. For this reason, 
studies adopting an RCT design will be assessed using the Cochrane Collaboration’s tool 
for assessing risk of bias, version 5.1.0 (204) as illustrated in Table 3. Studies adopting 
controlled non-randomised designs, or controlled observational designs will also be 
assessed using the Cochrane Collaboration’s tool for assessing risk of bias, version 5.1.0, 
however the random sequence generation domain will not be completed. Furthermore, the 
quality of reporting of RCTs will be assessed with the CONSORT checklist (205), and the 
reporting quality of studies adopting controlled non-randomised designs, and controlled 
observational designs will be assessed using the STROBE checklist (206). 
Included studies will be appraised for quality, in order to provide an estimate of the 
level of internal validity and therefore the level of risk of bias, for each outcome of interest. 
The quality assessment will also be used to guide the interpretation of the findings of the 
review, for instance the level of confidence in the study findings, the explanation of 
heterogeneity of study findings with quality factors, or possible associations between study 
quality and study findings. Furthermore, the quality assessment information will be used to 
provide evaluation summaries which will be made across studies and domains, of the 
quality of the body of literature, highlighting areas of strength and limitation, and if 
appropriate, recommendations for the improvement of the quality of primary studies will 
be made. 
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Table 3: Reporting form for Cochrane Collaboration’s tool for assessing risk of bias 
 STUDY: 
DOMAIN SUPPORT FOR JUDGEMENT JUDGEMENT 
Selection bias   
Random sequence 
generation 
  
Allocation concealment   
Performance bias   
Blinding of participants and 
personnel 
  
Detection bias   
Blinding of outcome 
assessment 
  
Attrition bias   
Incomplete outcome data   
Reporting bias   
Selective reporting   
Other bias   
Other sources of bias   
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Data synthesis and analysis 
Qualitative analysis will provide a narrative summary of the findings of the included 
studies including detail of the primary weight and BMI change outcomes and the 
secondary outcomes of changes in quality of life, mental health and cardiovascular factors. 
The qualitative analysis will also provide a summary of the methodological quality and the 
reporting quality of the included studies and their impact on the findings of the review, and 
additionally making recommendations for the conduct and reporting of future primary 
studies. 
Quantitative analysis will be used to illustrate the findings of the studies using 
forest plots for the following outcomes: weight change, BMI change, quality of life 
change, mental health change and cardiovascular change. The forest plots will be grouped 
in order to reduce methodology and clinical heterogeneity caused by the differences 
between studies, with specific subgroup analyses conducted by study design, intervention 
type, intervention duration, intervention intensity, outcome measures, use of intention to 
treat, and length of follow-up. A judgement will be made for each subgroup regarding the 
clinical and methodological heterogeneity, and if the studies within the subgroup are 
deemed to measure the same true effect of an intervention, a fixed effects model will be 
used in the meta-analysis and pooled overall estimates of the effect of the weight 
management interventions will be reported. Alternatively, if there is deemed to be 
substantial clinical or methodological heterogeneity, whereby studies represent a 
distribution of possible effects, a random-effects model will be used. However, the 
heterogeneity will be further examined using the I
2
 statistic, according to the guideline of I
2
 
values representing low levels of heterogeneity at 25%, moderate at 50% and high at 75% 
(298). If the level of heterogeneity between the studies is deemed to be significant then a 
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pooled summary statistic will either not be reported, or will be reported with emphasis on 
the fact that it is included for demonstration of direction of effect only and should not be 
interpreted as a meaningful result. 
Caution will be taken in the interpretation of the findings of the meta-analysis 
particularly in the subgroup analyses of observational studies due to the absence of 
randomisation and in the analyses of subgroups based on intervention type, as the 
likelihood of finding a significant result increases with the number of subgroup analyses 
performed. Through the careful interpretation of the analyses, a summary of the best 
evidence available for the effectiveness of medical and behavioural weight management 
interventions for adults with extreme obesity will be produced. 
A detailed report of the findings of the systematic review and meta-analysis will be 
written as a thesis chapter. The findings will be reported utilising the PRISMA 27-item 
checklist and flow-diagram illustrating the flow of information through the phases of the 
systematic review (192). The use of the PRISMA statement will enhance reporting by 
facilitating explicit description of the systematic review and meta-analysis.  
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APPENDIX THREE 
 
3.0 QUALITY ASSESSMENT FORMS COMPLETED FOR STUDIES INCLUDED 
IN SYSTEMATIC REVIEW  
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Table 1: CONSORT checklist for Ryan, 2010 study 
Section /Topic 
Item 
No 
Checklist item 
Page 
No 
Title and abstract 
 1a Identification as a randomised trial in the title - 
 1b Structured summary of trial design, methods, results, and 
conclusions (for specific guidance see CONSORT for 
abstracts) 
1 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 2 
 2b Specific objectives or hypotheses 2 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) 
including allocation ratio 
2, 3 
 3b Important changes to methods after trial commencement 
(such as eligibility criteria), with reasons 
- 
Participants 4a Eligibility criteria for participants 2 
 4b Settings and locations where the data were collected 4 
Interventions 5 The interventions for each group with sufficient details to 
allow replication, including how and when they were 
actually administered 
2, 3 
Outcomes 6a Completely defined pre-specified primary and secondary 
outcome measures, including how and when they were 
assessed 
3 
 6b Any changes to trial outcomes after the trial commenced, 
with reasons 
- 
Sample size 7a How sample size was determined - 
 7b When applicable, explanation of any interim analyses and 
stopping guidelines 
- 
Randomisation:    
Sequence generation 8a Method used to generate the random allocation sequence 3 
 8b Type of randomisation; details of any restriction (such as 
blocking and block size) 
3 
Allocation  
concealment 
mechanism 
9 Mechanism used to implement the random allocation 
sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until 
interventions were assigned 
3 
Implementation 10 Who generated the random allocation sequence, who 
enrolled participants, and who assigned participants to 
interventions 
- 
Blinding 11a If done, who was blinded after assignment to interventions 
(for example, participants, care providers, those assessing 
outcomes) and how 
N/A 
 11b If relevant, description of the similarity of interventions 2, 3 
Statistical methods 12a Statistical methods used to compare groups for primary and 
secondary outcomes 
3, 4 
 12b Methods for additional analyses, such as subgroup analyses 
and adjusted analyses 
3, 4 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were 
randomly assigned, received intended treatment, and were 
analysed for the primary outcome 
3 
 13b For each group, losses and exclusions after randomisation, 
together with reasons 
3, 4 
Recruitment 14a Dates defining the periods of recruitment and follow-up 1, 2 
 14b Why the trial ended or was stopped N/A 
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Table 1 Continued: CONSORT checklist for Ryan, 2010 study 
Section /Topic 
Item 
No 
Checklist item 
Page 
No 
Baseline data 15 A table showing baseline demographic and clinical 
characteristics for each group 
4 
Numbers analysed 16 For each group, number of participants (denominator) 
included in each analysis and whether the analysis was by 
original assigned groups 
7 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each 
group, and the estimated effect size and its precision (such 
as 95% confidence interval) 
7 
 17b For binary outcomes, presentation of both absolute and 
relative effect sizes is recommended 
- 
Ancillary analyses 18 Results of any other analyses performed, including subgroup 
analyses and adjusted analyses, distinguishing pre-specified 
from exploratory 
6 
Harms 19 All important harms or unintended effects in each group (for 
specific guidance see CONSORT for harms) 
5 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses 
6 
Generalisability 21 Generalisability (external validity, applicability) of the trial 
findings 
6 
Interpretation 22 Interpretation consistent with results, balancing benefits and 
harms, and considering other relevant evidence 
6-8 
Other information 
Registration 23 Registration number and name of trial registry 1 
Protocol 24 Where the full trial protocol can be accessed, if available - 
Funding 25 Sources of funding and other support (such as supply of 
drugs), role of funders 
3, 8 
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Table 2: CONSORT checklist for Rimmer, 2009 study 
Section /Topic 
Item 
No 
Checklist item 
Page 
No 
Title and abstract 
 1a Identification as a randomised trial in the title - 
 1b Structured summary of trial design, methods, results, and 
conclusions (for specific guidance see CONSORT for 
abstracts) 
1 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 1, 2 
 2b Specific objectives or hypotheses 2 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) 
including allocation ratio 
2, 4 
 3b Important changes to methods after trial commencement 
(such as eligibility criteria), with reasons 
- 
Participants 4a Eligibility criteria for participants 2 
 4b Settings and locations where the data were collected 2 
Interventions 5 The interventions for each group with sufficient details to 
allow replication, including how and when they were 
actually administered 
2, 3 
Outcomes 6a Completely defined pre-specified primary and secondary 
outcome measures, including how and when they were 
assessed 
3, 4 
 6b Any changes to trial outcomes after the trial commenced, 
with reasons 
- 
Sample size 7a How sample size was determined 4 
 7b When applicable, explanation of any interim analyses and 
stopping guidelines 
- 
Randomisation:    
Sequence generation 8a Method used to generate the random allocation sequence 2 
 8b Type of randomisation; details of any restriction (such as 
blocking and block size) 
- 
Allocation  
concealment 
mechanism 
9 Mechanism used to implement the random allocation 
sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until 
interventions were assigned 
2 
Implementation 10 Who generated the random allocation sequence, who 
enrolled participants, and who assigned participants to 
interventions 
2 
Blinding 11a If done, who was blinded after assignment to interventions 
(for example, participants, care providers, those assessing 
outcomes) and how 
N/A 
 11b If relevant, description of the similarity of interventions 2, 3 
Statistical methods 12a Statistical methods used to compare groups for primary and 
secondary outcomes 
4 
 12b Methods for additional analyses, such as subgroup analyses 
and adjusted analyses 
4 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were 
randomly assigned, received intended treatment, and were 
analysed for the primary outcome 
4 
 13b For each group, losses and exclusions after randomisation, 
together with reasons 
4 
Recruitment 14a Dates defining the periods of recruitment and follow-up 2 
 14b Why the trial ended or was stopped N/A 
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Table 2 Continued: CONSORT checklist for Rimmer, 2009 study 
Section /Topic 
Item 
No 
Checklist item 
Page 
No 
Baseline data 15 A table showing baseline demographic and clinical 
characteristics for each group 
4, 5 
Numbers analysed 16 For each group, number of participants (denominator) 
included in each analysis and whether the analysis was by 
original assigned groups 
4, 5 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each 
group, and the estimated effect size and its precision (such 
as 95% confidence interval) 
- 
 17b For binary outcomes, presentation of both absolute and 
relative effect sizes is recommended 
- 
Ancillary analyses 18 Results of any other analyses performed, including subgroup 
analyses and adjusted analyses, distinguishing pre-specified 
from exploratory 
5 
Harms 19 All important harms or unintended effects in each group (for 
specific guidance see CONSORT for harms) 
- 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses 
6 
Generalisability 21 Generalisability (external validity, applicability) of the trial 
findings 
6 
Interpretation 22 Interpretation consistent with results, balancing benefits and 
harms, and considering other relevant evidence 
6 
Other information 
Registration 23 Registration number and name of trial registry - 
Protocol 24 Where the full trial protocol can be accessed, if available - 
Funding 25 Sources of funding and other support (such as supply of 
drugs), role of funders 
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Table 3: STROBE checklist for Danielsen, 2013 study 
Section /Topic 
Item 
No 
Checklist item 
Page 
No 
Title and abstract 
 1  a) Indicate the study’s design with a commonly used term in 
the title or the abstract 
1 
  b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
1 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
1, 2 
Objectives 3 State specific objectives, including any pre-specified 
hypotheses 
2 
Methods 
Study design 4 Present key elements of study design early in the paper 2 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
2, 3 
Participants 6 a) Give the eligibility criteria, and the sources and methods 
of selection of participants. Describe methods of follow-up 
2-4 
  b) For matched studies, give matching criteria and number 
of exposed and unexposed  
2, 3 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, 
if applicable 
2-4 
Data sources/ 
measurement 
8* For each variable of interest, give sources of data and details 
of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than 
one group 
4 
Bias 9 Describe any efforts to address potential sources of bias - 
Study size 10 Explain how the study size was arrived at 4 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were 
chosen and why 
4 
Statistical methods 12 a) Describe all statistical methods, including those used to 
control for confounding 
4 
  b) Describe any methods used to examine subgroups and 
interactions 
4 
  c) Explain how missing data were addressed 4 
  d) If applicable, explain how loss to follow-up was 
addressed  
3, 4 
  e) Describe any sensitivity analyses 4 
Results 
 13* a) Report numbers of individuals at each stage of study, e.g. 
numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-
up, and analysed 
3 
  b) Give reasons for non-participation at each stage 3 
  c) Consider use of a flow diagram 3 
Descriptive data 14* 
 
a) Give characteristics of study participants (e.g. 
demographic, clinical, social) and information on exposures 
and potential confounders 
5 
  b) Indicate number of participants with missing data for each 
variable of interest 
- 
  c) Summarise follow-up time (e.g. average and total 
amount) 
6, 7 
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Table 3 Continued: STROBE checklist for Danielsen, 2013 study 
Section /Topic 
Item 
No 
Checklist item 
Page 
No 
Outcome data 15* Report numbers of outcome events or summary measures 
over time 
6-10 
Main results 16 a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (e.g., 95% confidence 
interval). Make clear which confounders were adjusted for 
and why they were included 
6-10 
  (b) Report category boundaries when continuous variables 
were categorized 
7 
  (c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
- 
Other analyses 17 Report other analyses done, e.g. analyses of subgroups and 
interactions, and sensitivity analyses 
8 
Discussion 
Key results 18 Summarise key results with reference to study objectives 10 
Limitations 19 Discuss limitations of the study, taking into account sources 
of potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
10 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence. 
5-10 
Generalisability 21 Discuss the generalisability (external validity) of the study 
results 
- 
Other information 
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on 
which the present article is based. 
- 
*Give information separately for exposed and unexposed groups in cohort studies. 
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Abstract  
Objectives: To explore the cross-sectional association between adiposity, mental well-
being, and quality of life in extreme obese individuals entering a UK specialist weight 
management service prior to treatment commencement. 
Methods: The sample comprised 263 extreme obese individuals who were referred to the 
service as a result of having a body mass index (BMI) 40 kg/m2 or 35 kg/m2 with a co-
morbid health condition. In a retrospective analysis, routinely collected baseline clinical 
examination data and self-report questionnaires (Impact of Weight on Quality of Life: 
IWQOL-Lite, EQ5D-3L, and Hospital Anxiety and Depression Scale: HADS) were 
analysed to examine the cross-sectional association between adiposity and quality of life. 
Results: The sample was predominantly female (74.8%) with mean BMI 47.0±7.9 kg/m
2
.  
Increasing adiposity was significantly negatively associated with quality of life, with an 
increase of 1 BMI unit associated with decreases of 1.93 in physical function 
(95% CI -2.86 - -1.00, p<0.001), 1.62 in self-esteem (95% CI -2.67 - -0.57, p<0.05), 2.69 
in public distress (95% CI -3.75 - -1.62, p<0.001), 1.33 in work (95% CI -2.63 - -0.02, 
p<0.05), and 1.79 in total IWQOL-Lite scores (95% CI -2.65 - -0.93, p<0.001). Adiposity 
was associated with significantly increased risk of problems in mobility (OR=3.44, 95% CI 
1.47-8.05), and performing usual activities (OR=2.45, 95% CI 1.10-5.46) in highest 
relative to lowest BMI tertile. The prevalence of experience of symptoms of anxiety 
(70.3%) and depression (66.2%) as measured by HADS was consistently high.  
Conclusions: We identified a high prevalence of psychological co-morbidity, including 
widespread experience of symptoms of anxiety and depressive disorders and reduced 
quality of life among these extreme obese individuals seeking weight management 
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treatment. Clinical implications include the need for the incorporation of strategies to 
improve mental well-being into multi-disciplinary weight management interventions.  
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Introduction 
The prevalence of obesity among adults, and in particular extreme obesity, has risen 
rapidly over previous decades (1). Current levels of extreme obesity (BMI ≥40 kg/m2) in 
the US have increased 70% over the last decade between 2000 and 2010, with the 
prevalence rate reaching 6.6% (2), whilst current UK prevalence rates of extreme obesity 
are 3% for females and 2% for males (3). Indeed, recent estimates predict the rate of 
extreme obesity to reach 5% in the UK by 2033 and 9% in the US by 2030 (4). The 
physical co-morbidities of extreme obesity are well documented and research suggests that 
there are also substantial negative impacts of adiposity on depression (5), anxiety (6) and 
reduced quality of life (7). However, there are inconsistencies in the literature, with several 
reviews reporting studies demonstrating no association between adiposity and 
psychological health (5, 6, 8). In the extreme obese current understanding is limited as 
studies have focused on those individuals specifically seeking bariatric surgery (9), and 
have not included a range of assessments of putative psychological co-morbidities. In order 
to improve service provision for patients with extreme obesity, it is important to 
understand the extent of psychological co-morbidity and the impact on quality of life. 
Baseline data from treatment-seeking individuals at a community-based UK specialist 
weight management service were analysed in order to test the null hypothesis that there is 
no association between adiposity and psychological health.  
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Materials and Methods 
 
Participants  
This cross-sectional service evaluation study included a consecutive sample of 262 
individuals with extreme obesity entering a specialist community-based weight 
management service (CWMS) in the West Midlands, UK. Eligible participants were 
referred to the CWMS by their general practitioner (GP) as a result of fulfilling the criteria 
of having a body mass index (BMI) ≥40 kg/m2, or alternatively a BMI ≥35 kg/m2 with a 
co-morbid health condition, such as type 2 diabetes mellitus or hypertension. Patient 
referral required previous unsuccessful weight loss attempts in primary care and 
commercial weight loss programmes. The participants entered the service between 
February 2008 and August 2012, with those included in the evaluation selected at random 
from an opportunity sample. Baseline data including adiposity, quality of life, and mental 
well-being were routinely collected prior to the initiation of treatment.  
Demographic information 
As part of routine clinical care, demographic and health details were collected including 
participants’ age, gender, ethnicity, waist circumference, smoking status, and alcohol 
consumption. Details of participants’ co-morbid health conditions including cardiovascular 
disease, hypertension, diabetes, obstructive sleep apnoea and arthritis were also recorded.  
Clinical assessment 
Within the CWMS, all participants underwent a comprehensive clinical history and 
examination by a consultant physician and specialist dietitian. A psychologist provided 
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further support in the service. Participants’ initial weight and height data were recorded at 
baseline, and BMI was calculated by dividing participants’ weight in kg by height in 
meters squared.  
Quality of life and mental health measures 
Questionnaires were routinely collected as part of the comprehensive clinical assessment. 
Quality of life and mental health were assessed using three measures, the Impact of Weight 
on Quality of Life (IWQOL-Lite) questionnaire, which is an obesity-specific quality of life 
measure, the EQ5D-3L, which is a general quality of life measure, and the Hospital 
Anxiety and Depression Scale (HADS) which is a screening tool widely used in both 
clinical and research settings. The IWQOL-Lite consists of 31 items measuring the impact 
of obesity on physical function, self-esteem, sexual life, public distress and work (10). 
Respondents are asked to rate the extent to which a series of statements is applicable to 
them using a Likert scale ranging from 5 ‘Always true’ to 1 ‘Never true’. Responses to the 
questionnaire items yield a total impact of weight on quality of life score as well as 
individual scores for each of the five domains, with maximum scores of 100 on each 
subscale indicating optimum quality of life. 
The EQ5D-3L consists of five questions relating to five dimensions of health; 
‘mobility’, ‘self-care’, ‘usual activities’, ‘pain and discomfort’ and ‘anxiety and 
depression’ (11). Respondents indicate which of a possible three statements best describe 
their current health state for each dimension. A ‘level 1’ response indicates that the 
respondent has no problem in the specific dimension, a ‘level 2’ response indicates some 
problems, and a ‘level 3’ response indicates extreme problems. Respondents are asked to 
repeat this process for the five dimensions by indicating one level for each dimension, 
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giving rise to scores ranging from 1 to 3, with scores of 3 on each dimension indicating the 
most severe impairment. Binary variables were computed for each dimension 
dichotomising the levels into ‘No problems’ (level 1) and ‘Problems’ (levels 2 and 3). 
Perceived current health state is measured by asking respondents to indicate their current 
health state on a Visual Analogue Scale (VAS) with endpoints labelled 0 ‘Worst 
imaginable health state’ and 100 ‘Best imaginable health state’.  
The Hospital Anxiety and Depression Scale (HADS) comprises 14 items, 7 relating 
to anxiety, and 7 relating to depression (12).  Respondents rate the extent to which a series 
of statements represents how they currently feel using a Likert scale ranging from 0 to 3.  
The scale yields individual anxiety and depression scores as well as an overall HADS 
score. Individual subscale for anxiety and depressive symptom scores range from 0 to 21, 
with a score of 8 established as a cut-point for identifying symptoms of anxiety and 
depressive disorders and scores of 11 established as a cut-point for identifying more severe 
symptoms (13). Whilst the HADS scale is widely used in clinical practice to identify the 
experience of symptoms of anxiety and depression, it cannot provide a confirmatory 
diagnosis of anxiety and depressive disorders. 
Statistical analysis 
All data were analysed using SPSS (version 19.0). T-tests, cross-tabulation, chi
2
 and 
analysis of variance (ANOVA) calculations were conducted to compare the BMI tertile 
groups: first BMI tertile ≤42.99; second BMI tertile 43.00 - 48.61; third BMI tertile 48.62 
kg/m
2
. Linear regression coefficients were calculated to assess the relationship between 
BMI and quality of life as measured by IWQOL-Lite scores (continuous) and in separate 
analyses between BMI and overall perceived health status as measured by EQ5D-3L VAS. 
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Analyses were conducted for the whole sample and repeated in gender-stratified sub-
groups.  
Logistic regression models were constructed to assess the association between BMI 
and experience of symptoms of anxiety and depressive disorder as measured by HADS, 
and presence of problems in mobility, self-care and performing usual activities as 
measured by EQ5D-3L, with the first BMI tertile group as the reference. The odds ratios 
(ORs) and 95% confidence intervals (CIs) for three hierarchical models are presented: 
crude; adjusting for age and sex; and additionally adjusting for the co-morbidities; 
diabetes, hypertension, arthritis, obstructive sleep apnoea and cardiovascular disease. 
 
Ethics statement 
This was a retrospective analysis of routinely collected data to evaluate the psychological 
and quality of life burden of extreme obesity. Data were anonymised prior to any data 
analysis. The anonymised data were analysed as part of the specialist weight management 
service evaluation at the Heart of England NHS Foundation Trust, requiring no specific 
research ethics approval as recommended by the UK National Research Ethics Service 
(14). The analysis was registered with and approved by the local governance audit 
department. 
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Results 
Demographic and clinical characteristics 
The participants were aged 19 to 76 years, with a mean age of 43.1±11.8 years and a mean 
BMI of 47.0±7.9 kg/m
2
. Table 1 shows that in those with increasing levels of adiposity, 
there were significantly more problems in mobility, self-care and performing usual 
activities, and weight was reported to have a greater impact on physical function, causing 
public distress, ability to work, and overall quality of life. Those with increasing BMI were 
also more likely to have type 2 diabetes mellitus, hypertension, obstructive sleep apnoea 
(OSA) and cardiovascular disease (CVD). There were no significant differences in HADS 
anxiety and depression scores, with prevalence of anxiety and depressive symptoms 
consistently high across the BMI groups, with data for the combined sample indicating 
prevalence rates of anxiety symptoms (70.3%) and depressive symptoms (66.2%), which 
are far greater than the UK general population rates of 33.0% for anxiety disorders and 
11.4% for depressive disorders (15). Indeed, levels of severe anxiety and depressive 
symptoms defined by the higher cut-point scores of ≥11 are also substantial, with severe 
anxiety symptoms experienced by 48.3% of the sample and 40.4% of the sample 
experiencing symptoms of severe depressive disorders. 
Data indicate that quality of life is impaired, with sample mean IWQOL-Lite scores 
ranging from 26.2 (self-esteem) to 51.2 (work), whereby 100 represents optimum quality 
of life. Perceived health status was also poor with a sample mean of 44.0, whereby 100 
represents best possible health state; which is considerably worse than the UK general 
population mean score of 82.8 (16). There were no significant gender differences in 
EQ5D-3L. However there were gender differences in HADS anxiety, but not depression 
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and total scores, and gender differences in the IWQOL-Lite total and subscales self-esteem 
and sexual life, with significantly poorer quality of life in females (data not shown). 
Linear regression: BMI, IWQOL-Lite and perceived health status 
The IWQOL-Lite total measure and the subscales physical function, self-esteem, public 
distress and work were significantly negatively associated with increasing BMI (Table 2). 
Increasing BMI was associated with decreasing quality of life across the domains of 
physical function (1.93, p<0.001), self-esteem (1.62, p<0.05), public distress (2.69, 
p<0.001), work (1.33, p<0.05) and total score (1.79, p<0.001). Stratification by gender 
revealed that BMI was more strongly negatively associated with these measures in males. 
Interestingly, BMI was not significantly associated with the sexual life IWQOL-Lite 
subscale and the perceived health status measure (EQ5D-3L VAS). 
Logistic regression: BMI, EQ5D-3L and HADS anxiety and depression 
Table 3 shows the logistic regression analyses of the EQ5D-3L subscales ‘mobility’, ‘self-
care’ and ‘usual activities’, which were significantly associated with BMI. The fully 
adjusted model revealed an increased risk of mobility problems with increased BMI, with 
the odds ratios of 1.64 (0.78 - 3.44) and 3.44 (1.47 - 8.05) for second and third BMI tertile 
groups (P for trend <0.05) respectively, compared to those in the first BMI tertile group. 
There was a non-significant increased risk of self-care problems, with the odds ratios of 
0.89 (0.41 - 1.96) and 1.87 (0.86 - 4.09) for second and third BMI tertile groups (P for 
trend =0.104) respectively. However the fully adjusted model remained significant 
demonstrating increased risk of self-care problems in the continuous BMI model 1.05 (1.00 
- 1.09). The fully adjusted model also revealed an increased risk of problems performing 
usual activities, with the odds ratios of 2.04 (0.98 - 4.26) and 2.45 (1.10 - 5.46) for second 
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and third BMI tertile groups (P for trend <0.05) respectively, compared to those in the first 
BMI tertile group. Interestingly, the logistic regression analyses of anxiety and depressive 
symptoms as defined as HADS subscale score ≥8 revealed that anxiety and depressive 
symptoms were not significantly associated with BMI across the range encountered in the 
sample. 
  
Discussion 
The findings of the present evaluation demonstrated that quality of life was markedly 
impaired in this sample of extreme obese individuals entering a specialist community-
based weight management service having not succeeded with previous efforts at weight 
loss. Furthermore, we observed that the prevalence of anxiety and depressive symptoms 
was very high. Whilst much of the research investigating the complex association between 
adiposity and quality of life and mental well-being has incorporated individuals across the 
spectrum of obesity, the present study is of particular importance as it focuses on the 
escalating extreme obese population (4).  
We observed a significant negative association between increasing adiposity at 
these extreme levels and quality of life, specifically in the areas of physical function, self-
esteem, public distress and work, with increased adiposity associated with reduced quality 
of life as measured by IWQOL-Lite score. The association between adiposity and weight-
specific quality of life as measured by IWQOL-Lite has been established, with findings 
indicating that BMI accounts for approximately 28% of the variance in total IWQOL-Lite 
scores (7). Previous research has shown that scores vary with degree of adiposity and 
treatment status, with those with higher BMI and those seeking treatment reporting 
significantly worse quality of life (7). In addition, changes in IWQOL-Lite score from 
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baseline to post-intervention have been shown to correlate significantly with weight loss 
(17). The results obtained in the present study show a similar level of impairment in quality 
of life to those obtained in a study of bariatric surgery-seeking individuals, which reported 
scores ranging from 40.4 (work) to 46.2 (self-esteem) across IWQOL-Lite subscales (7). 
Interestingly, the present study reported one subscale which was not shown to be 
significantly associated with adiposity; sexual life. This is consistent with findings from a 
comparison of white and African American US women, whereby white women scored 
significantly lower on sexual life compared to their African American counterparts, in both 
class II and III obesity, and BMI was significantly  associated with sexual life in the white 
sub-group but not in the African American sub-group (18). A similar pattern of results 
whereby significant association was not observed between BMI and sexual life has also 
been reported in a sample of over 400 bariatric surgery-seeking extreme obese individuals 
(18).  The investigators concluded that the lack of observed association is due to the high 
level of co-morbidities, which may diminish the association between quality of life and 
BMI at the level of extreme obesity. However, the results of the present study show that 
the association between BMI and quality of life remains when controlling for co-morbid 
health conditions, suggesting that obesity negatively affects quality of life, independently 
of these conditions.  This lack of association indicates that there are additional factors 
outside of those measured, which contribute to the reduced level of quality of life in these 
specific domains. Indeed, the substantial impairments in sexual quality of life in this 
population have been greatly under-researched (19) and are thought to be associated with 
the broader aspects of stigmatisation and discrimination (20) as well as negative perceived 
body image (19, 21) experienced by this patient population. 
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Likewise, significant associations were observed between adiposity and some, but 
not all, of the EQ5D-3L subscales. Adiposity was associated with experience of problems 
in mobility, self-care, and performing usual activities, with those in the third BMI tertile 
more likely to experience problems in these areas. Whilst the fully adjusted models 
remained significant for the mobility and performing usual activities analyses, the self-care 
model was no longer significant when fully adjusted in the BMI tertile model. These 
findings are consistent with the limited previous studies which have shown that general 
quality of life as measured by EQ5D-3L is poorest for individuals with class III obesity, 
compared to class I and II obese groups, as well as overweight and underweight groups, 
relative to those of normal weight where quality of life scores are optimum (22, 23). 
Notably, the present study reported two subscale scores, which were not shown to be 
significantly associated with adiposity, ‘pain and discomfort’ and ‘anxiety and 
depression’(data shown in Table 1). This is in contrast to previous research which has 
identified that obese individuals are at greater odds of experiencing anxiety and depressive 
disorders (5, 6), and pain (OR=1.94) relative to normal weight counterparts (23). The 
results of the present study indicate that individuals reported the greatest amount of 
problems in these domains. Likewise, no significant association between adiposity and 
perceived health status (EQ5D-3L VAS) was observed. Together, these findings suggest a 
possible ceiling effect for the EQ5D-3L tool being unable to detect differences within such 
a homogeneous group as the present sample in which the quality of life is consistently low. 
An additional aspect is the absence of normal weight individuals, which truncates the BMI 
range, reducing the opportunity to identify an association. There was a non-significant 
trend whereby perceived health status was highest for the first BMI tertile group (47.4) and 
lowest for the third BMI tertile group (42.9) supporting the above contentions. Unlike the 
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present study, previous studies have demonstrated that perceived health status significantly 
decreases with increasing adiposity, and is poorest for individuals with class III obesity, 
relative to those of normal weight (23); it is likely that the expected significant negative 
association was not observed in the present study due to the homogeneity in adiposity of 
this exclusively extreme obese sample.  
The expected significant associations between adiposity and symptoms of anxiety 
and depressive disorder as measured by HADS were also not observed in the present study. 
However, it was evident that the prevalence of symptoms of psychological co-morbidities 
was high across the sample (anxiety, 70.3%; depression, 66.2%) and is far greater than the 
UK general population rates of 33.0% for anxiety and 11.4% for depressive disorder (15). 
The relationship between depressive disorders and obesity has been widely documented in 
the literature, with results from prospective studies indicating that obesity is associated 
with future incidence of depression and cross-sectional studies revealing significant 
positive associations between adiposity and depression, particularly in females (5). No 
significant variation in prevalence of anxiety and depressive symptoms was observed 
across the levels of adiposity in the current sample, probably due to the truncated BMI 
range and the overall high prevalence of anxiety and depressive symptoms. However, data 
from the NHANES (National Health and Nutrition Examination Survey) study 
demonstrated a dose-response relationship between depression and adiposity, with class III 
obese individuals having greater odds of experiencing lifetime major depression 
(OR=2.60), recurrent major depression (OR=2.28), depression in the past month 
(OR=4.98) and past year (OR=2.92) than the class I and II obesity groups relative to those 
of normal BMI (24).  
  
373 
 
Whilst much research has demonstrated evidence for an association between 
adiposity and both depressive and anxiety disorders (6, 24, 25) it is important to note that 
some studies have reported no significant association  (8) or have reported non-significant 
trends (26-29). A systematic review and meta-analysis of the association between obesity 
and anxiety has concluded that there is evidence in support of a positive association 
between obesity and anxiety, with pooled cross-sectional data indicating that obese 
individuals are more likely to experience anxiety (OR=1.4) (6). It is also of interest that the 
findings of the present work indicate that anxiety was more prevalent in this sample than 
depression.  
The mechanism of the association between adiposity, impairment in quality of life 
and presence of anxiety and depressive disorders is not yet established, with several 
proposed pathways through which obesity may lead to psychological co-morbidity and 
vice versa. Firstly, through the multiple health threats associated with obesity acting as 
stressors, and secondly through the negative effects of stigma and weight-related 
discrimination. Indeed frequency of stigmatisation and inability to adopt effective coping 
strategies have been shown to result in depressed mood (29). The relationship between 
obesity and depression specifically, appears to be bi-directional with obesity associated 
with increased experience of depressive symptoms, and depressive episodes associated 
with further weight gain. Furthermore, obese individuals are more likely to over-eat and 
gain weight compared to non-obese individuals during an episode of depression (30). A 
systematic review of the relationship between depression and adiposity reported that the 
majority of evidence was cross-sectional and thus causality could not be established (5). 
Previous research has been criticised for the inclusion of only one measure of 
quality of life (23), and as such the inclusion of several quality of life measures is a novel 
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aspect of the present evaluation. Previous studies have utilised either general measures 
such as the EQ5D-3L (22, 23) and the Medical Outcomes Study Short Form Health Survey 
(SF-36) (31, 32) or condition specific measures such as the Obesity Adjustment Survey 
(OAS) (33) and the Obesity Related Well-being (ORWELL 97) questionnaire  (34); 
however the IWQOL-Lite measure is the most widely used weight-specific measure  (35). 
Present findings suggest that in the assessment of quality of life within extreme obesity, 
both weight-specific and general quality of life measures are effective. Notably, the 
IWQOL-Lite, EQ5D-3L and HADS measures all contained subscales which were not 
associated with adiposity indicating that each of the tools may have limitations in 
capability of identifying differences in extreme adiposity. The specific domains which 
were not associated with adiposity; pain and discomfort, anxiety and depression and sexual 
life were in fact the more severely affected aspects of life. Likewise, none of the 
components of the HADS mental health screening tool were associated with adiposity. 
However, the tool was shown to be effective in determining prevalence of symptoms of 
anxiety and depressive disorders in an extreme obese sample. Future studies should utilise 
several quality of life measures, including those that are weight specific and general in 
order to establish the validity of the measures in this patient group (36), as well as enabling 
deeper understanding of the additional factors which may influence the complex 
relationship between adiposity, quality of life and mental well-being. 
A key strength of the present study is that it demonstrates that the negative impact 
on quality of life associated with increasing BMI remains even when controlling for the 
presence of obesity related co-morbid health conditions commonly experienced by the 
extreme obese population. Previous studies have concluded that the association between 
adiposity and quality of life is mediated by health co-morbidities such as pain, 
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cardiovascular disease and type 2 diabetes mellitus (37-39); however the present study 
supports that the association is independent, and that the role of co-morbidities in the 
relationship may have previously been over-estimated, and the impact of adiposity, 
underestimated. 
An additional strength of the present study is that it improves understanding of the 
characteristics of this less-researched extreme obese population. However, the present 
work has several limitations. The individuals characterised in the sample are those that had 
sought assistance in managing their weight and as a consequence it may not be appropriate 
to extrapolate these findings to the general extreme obese population, as evidence suggests 
that non-treatment-seeking obese individuals do not experience the same psychological co-
morbidities (40) and impairment in quality of life (7) as those seeking treatment. 
Furthermore, the fact that these findings are obtained from a single weight management 
service may limit their generalizability to other UK specialist weight management settings. 
The cross-sectional design of the present study means that it is not possible to confirm a 
causal relationship between adiposity and quality of life. The present work also adopted a 
service evaluation approach aiming to understand the psychological and quality of life 
burden of obesity to improve service provision, which means that it is not possible to 
compare the characteristics of the extreme obese treatment-seeking group, with a non-
obese control group or an extreme obese non-treatment-seeking group for comparison. As 
such the findings of the present work should be interpreted with caution and future studies 
adopting a controlled design comprising a control group of extreme obese non-treatment-
seeking individuals should be utilised in further investigation of the psychological co-
morbidities of extreme obesity. 
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In conclusion, we observed that among this sample of treatment-seeking extreme 
obese individuals there is a high prevalence of symptoms of psychological co-morbidity, 
including experience of anxiety and depressive disorder symptoms and reduced quality of 
life. Increasing adiposity was associated with a reduction in several areas of quality of life, 
but was not significantly associated with symptoms of anxiety and depressive disorders. 
These findings are of clinical importance indicating that the impairment in quality of life 
and mental health challenges faced by these individuals must be addressed and 
incorporated into the multi-disciplinary care of these patients, in order to provide tailored 
weight management interventions.  
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 Table 1: Demographic and clinical characteristics of the sample across BMI tertiles. 
 
Whole 
sample 
1
st
 BMI 
tertile 
≤ 42.99 
2
nd
 BMI 
tertile 
43.00 - 48.61 
3
rd
 BMI 
tertile 
 48.62 
P 
N 262 87 87 88  
Age (years) 43.1±11.8 43.0±13.2 41.7±10.2 44.7±11.8 0.234 
Sex (% female) 74.8 72.4 77.0 75.0 0.783 
Ethnicity (%)     0.585 
White European 90.8 90.0 95.5 87.9  
Asian 5.6 5.0 2.3 8.6  
Black African/Caribbean 2.8 2.5 2.3 3.4  
Other 0.7 2.5 0.0 00  
Weight (kg) 132.1±24.7 112.6±14.7 129.1±15.6 154.2±22.3 <0.001 
Body mass index (BMI, kg/m
2
) 47.0±7.9 39.4±2.6 45.8±1.6 55.8±6.6 <0.001 
Waist circumference (cm) 131.6±14.5 123.8±11.8 128.6±12.7 142.4±12.5 <0.001 
Systolic blood pressure (mmHg) 140.9±17.7 136.0±14.5 140.4±17.0 146.4±20.0 0.009 
Diastolic blood pressure (mmHg) 85.2±11.7 83.3±9.7 85.5±11.4 86.9±13.6 0.263 
Diabetes (%) 26.3 24.1 18.4 36.4 0.022 
Hypertension (%) 34.4 31.0 26.4 45.5 0.022 
Arthritis (%) 24.0 21.8 19.5 30.7 0.190 
Obstructive sleep apnoea (OSA, %) 25.6 16.1 26.4 34.1 0.024 
Cardiovascular disease (CVD, %) 11.1 9.2 5.7 18.2 0.026 
Smoking (%) 25.5 31.7 23.0 22.2 0.655 
Alcohol consumption (%) 64.7 62.9 81.0 52.9 0.004 
IWQOL-Lite (%) Total 39.5±22.1 49.0±23.3 38.5±19.9 32.1±20.2 <0.001 
Physical function 42.4±25.3 54.1±24.9 40.4±23.6 34.1±23.7 <0.001 
Self-esteem 26.2±27.5 30.4±30.5 24.1±24.4 24.5±27.5 0.286 
Sexual life 41.9±35.9 47.3±36.9 43.5±35.6 35.2±34.7 0.128 
Public distress 40.5±28.9 56.6±31.5 38.9±25.2 27.7±22.7 <0.001 
Work 51.2±30.3 61.6±30.4 46.1±27.4 47.1±31.3 0.003 
Mobility problems % 66.7 55.9 63.0 80.3 0.006 
Self care problems % 35.7 29.9 27.2 50.0 0.006 
Anxiety/depression problems % 75.3 73.1 75.6 77.0 0.864 
Pain/discomfort problems % 85.3 80.0 86.3 89.3 0.272 
Usual activities problems % 69.0 58.0 70.4 77.6 0.036 
Perceived health status 44.0±20.1 47.4±19.4 42.4±19.0 42.9±21.8 0.303 
HADS Total score 19.6±7.7 19.0±7.6 20.2±7.8 19.6±7.9 0.654 
HADS anxiety score 10.4±4.5 10.5±4.3 10.7±4.8 10.2±4.5 0.780 
HADS depression score 9.1±4.0 8.6±4.0 9.3±3.9 9.3±4.1 0.436 
Anxiety symptoms ≥8 (%)  70.3 74.0 68.7 68.8 0.716 
Depression symptoms ≥8 (%)  66.2 62.3 72.5 63.2 0.333 
Severe anxiety symptoms ≥11 (%) 48.3 50.7 48.2 46.3 0.860 
Severe depression symptoms ≥11 (%)  40.4 33.3 42.5 44.7 0.338 
Data are percentages and means ± standard deviations. HADS= Hospital anxiety and depression scale
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Table 2: Linear regression of BMI predicting IWQOL-Lite subscale and total scores and perceived health status (EQ5D-3L VAS) in whole sample and 
stratified by gender. 
 
Univariate  Model 1  Model 2  
U.B. S.E. S.B U.B. S.E. S.B U.B. S.E. S.B 
Physical function  -0.83** 0.20 -0.26 -1.95** 0.48 -0.62 -1.93** 0.47 -0.61 
Male † -1.66* 0.54 -0.37 -1.92* 0.53 -0.43 -2.00** 0.50 -0.44 
Female † -0.66* 0.21 -0.23 -0.56* 0.20 -0.19 -0.51* 0.21 -0.18 
Self esteem -0.34 0.22 -0.10 -1.53* 0.53 -0.44 -1.62* 0.53 -0.47 
Male † -1.80* 0.63 -0.35 -1.39* 0.60 -0.27 -1.19 0.63 -0.23 
Female † 0.01 0.22 -0.00 -0.06 0.22 -0.02 -0.11 0.22 -0.04 
Sexual life -0.56 0.32 -0.12 -1.55* 0.77 -0.34 -1.45 0.79 -0.31 
Male † -1.47 0.75 -0.25 -1.55* 0.76 -0.27 -1.21 0.81 -0.21 
Female † -0.33 0.35 -0.08 -0.27 0.35 -0.06 -0.29 0.36 -0.07 
Public distress -1.44** 0.22 -0.40 -2.82** 0.53 -0.77 -2.69** 0.54 -0.74 
Male † -3.00** 0.49 -0.62 -2.76** 0.48 -0.57 -2.48** 0.51 -0.51 
Female † -1.14** 0.24 -0.34 -1.19** 0.24 -0.35 -1.18** 0.25 -0.35 
Work -0.83* 0.25 -0.22 -1.34* 0.65 -0.35 -1.33* 0.66 -0.35 
Male † -1.39* 0.67 -0.28 -1.23 0.68 -0.25 -1.22 0.73 -0.25 
Female † -0.70* 0.27 -0.20 -0.70* 0.28 -0.20 -0.68* 0.28 -0.19 
IWQOL-Lite total  -0.79** 0.17 -0.28 -1.84** 0.43 -0.66 -1.79** 0.44 -0.65 
Male † -1.82** 0.44 -0.47 -1.78** 0.45 -0.46 -1.60* 0.46 -0.42 
Female † -0.56* 0.19 -0.22 -0.54* 0.19 -0.22 -0.52* 0.19 -0.21 
Perceived health status -0.17 0.18 -0.07 -0.12 0.49 -0.05 -0.07 0.49 -0.03 
Male † -0.12 0.48 -0.04 -0.11 0.50 -0.03 -0.08 0.50 -0.03 
Female † -0.18 0.19 -0.07 -0.18 0.20 -0.07 -0.12 0.20 -0.05 
U.B. =Unstandardised Beta, S.E. =Standard error, S.B =Standardised Beta.  
*P<0.05, **P<0.001 
Model 1 adjusting for age, gender and interaction between BMI and gender.  
† Model 1 and 2 adjusting for age only. Model 2 additionally adjusting for diabetes, hypertension, arthritis, obstructive sleep apnoea, cardiovascular disease.
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Table 3: Logistic regression of presence of problems in mobility, self care and usual activities (EQ5D) and presence of anxiety and depression (HADS) by 
BMI tertiles and by continuous BMI. 
 
1
st
 tertile 
( ≤ 42.99) 
2
nd
 tertile 
(43.00 - 48.61) 
3
rd
 tertile 
(  48.62) 
P for linear trend Continuous BMI 
 Odds ratio (95% CI)   
Mobility problems 
Univariate 1.00 1.25 (0.64 – 2.44) 2.95 (1.40 – 6.22)* 0.004 1.07 (1.02 – 1.12)* 
Model 1 1.00 1.32 (0.66 – 2.63) 2.83 (1.31 – 6.15)* 0.008 1.07 (1.02 – 1.12)* 
Model 2 1.00 1.64 (0.78 – 3.44) 3.44 (1.47 – 8.05)* 0.009 1.08 (1.03 – 1.13)* 
Self-care  problems  
Univariate 1.00 0.84 (0.41 – 1.72) 2.19 (1.09 – 4.39)* 0.018 1.05 (1.01 – 1.09)* 
Model 1 1.00 0.88 (0.42 – 1.88) 2.05 (0.98 – 4.27) 0.044 1.05 (1.01 – 1.10)* 
Model 2 1.00 0.89 (0.41 – 1.96) 1.87 (0.86 – 4.09) 0.104 1.05 (1.00 – 1.09)* 
Problems 
performing usual 
activities  
Univariate 1.00 1.71 (0.86 – 3.37) 2.65 (1.27 – 5.52)* 0.008 1.05 (1.01 – 1.10)* 
Model 1 1.00 1.73 (0.86 – 3.44) 2.48 (1.17 – 5.23)* 0.016 1.05 (1.01 – 1.10)* 
Model 2 1.00 2.04 (0.98 – 4.26) 2.45 (1.10 – 5.46)* 0.040 1.05 (1.00 – 1.10)* 
Anxiety 
Univariate 1.00 0.75 (0.37 – 1.51) 0.73 (0.36 – 1.45) 0.409 0.98 (0.95 – 1.02) 
Model 1 1.00 0.68 (0.33 – 1.42) 0.74 (0.35 – 1.54) 0.460 0.98 (0.94 – 1.01) 
Model 2 1.00 0.71 (0.34 – 1.50) 0.81 (0.37 – 1.74) 0.633 0.98 (0.95 – 1.02) 
Depression 
Univariate 1.00 1.57 (0.78 – 3.15) 1.00 (0.51 – 1.98) 0.958 1.00 (0.96 – 1.03) 
Model 1 1.00 1.59 (0.79 – 3.20) 1.06 (0.53 – 2.11) 0.910 1.00 (0.96 – 1.03) 
Model 2 1.00 1.65 (0.80 – 3.40) 1.26 (0.61 – 2.62) 0.550 1.00 (0.97 – 1.04) 
Presence of problems defined as level 2 (some problems) and level 3 (extreme problems) scores on EQ5D-3L; Presence of anxiety and depression defined as HADS 
anxiety subscale score 8.  
* P<0.05, **P<0.001 
Model 1 adjusting for age and sex. Model 2 additionally adjusting for diabetes, hypertension, arthritis, obstructive sleep apnoea, cardiovascular disease.   
